<SEC-DOCUMENT>0001655759-22-000016.txt : 20220506
<SEC-HEADER>0001655759-22-000016.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505163757
ACCESSION NUMBER:		0001655759-22-000016
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARVINAS, INC.
		CENTRAL INDEX KEY:			0001655759
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472566120
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38672
		FILM NUMBER:		22897046

	BUSINESS ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-535-1456

	MAIL ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS INC.
		DATE OF NAME CHANGE:	20181001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS HOLDING COMPANY, LLC
		DATE OF NAME CHANGE:	20151015
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arvn-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:966c8cdd-8d85-475a-b79b-8010015adf33,g:b9593e04-7343-4e88-918f-c5a2cc011d89,d:5f8d406ab3aa45be82590782b0fe2e1d--><html xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:arvn="http://www.arvinas.com/20220331" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arvn-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80L2ZyYWc6NzVlYmYxOWE1ODA2NGJjOTkxMTU2YTk1Njc5NTIzY2QvdGFibGU6NzdhNWMyZTllYWRkNGI2MGIxZmY1M2NhMDEzZWRjMWMvdGFibGVyYW5nZTo3N2E1YzJlOWVhZGQ0YjYwYjFmZjUzY2EwMTNlZGMxY18yLTEtMS0xLTIwODM3_8a648472-c68f-4329-925b-6864536a481a">false</ix:nonNumeric><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80L2ZyYWc6NzVlYmYxOWE1ODA2NGJjOTkxMTU2YTk1Njc5NTIzY2QvdGFibGU6NzdhNWMyZTllYWRkNGI2MGIxZmY1M2NhMDEzZWRjMWMvdGFibGVyYW5nZTo3N2E1YzJlOWVhZGQ0YjYwYjFmZjUzY2EwMTNlZGMxY18zLTEtMS0xLTIwODM3_afe56cf2-48de-4d16-91fc-d561ad737fd9">2022</ix:nonNumeric><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80L2ZyYWc6NzVlYmYxOWE1ODA2NGJjOTkxMTU2YTk1Njc5NTIzY2QvdGFibGU6NzdhNWMyZTllYWRkNGI2MGIxZmY1M2NhMDEzZWRjMWMvdGFibGVyYW5nZTo3N2E1YzJlOWVhZGQ0YjYwYjFmZjUzY2EwMTNlZGMxY180LTEtMS0xLTIwODM3_f5342113-e18b-4bf8-8e78-c5589c497420">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80L2ZyYWc6NzVlYmYxOWE1ODA2NGJjOTkxMTU2YTk1Njc5NTIzY2QvdGFibGU6NzdhNWMyZTllYWRkNGI2MGIxZmY1M2NhMDEzZWRjMWMvdGFibGVyYW5nZTo3N2E1YzJlOWVhZGQ0YjYwYjFmZjUzY2EwMTNlZGMxY181LTEtMS0xLTIwODM3_5f3c7dbd-6fff-42ac-8690-1d951f52a660">0001655759</ix:nonNumeric><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80L2ZyYWc6NzVlYmYxOWE1ODA2NGJjOTkxMTU2YTk1Njc5NTIzY2QvdGFibGU6NzdhNWMyZTllYWRkNGI2MGIxZmY1M2NhMDEzZWRjMWMvdGFibGVyYW5nZTo3N2E1YzJlOWVhZGQ0YjYwYjFmZjUzY2EwMTNlZGMxY182LTEtMS0xLTIwODM3_cd6e7184-9a7f-440a-bdd1-0c48da238327">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="id1a386ef91f34522865c79b14ea0b285_I20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfMS0xLTEtMS0yMDgzNw_6375aae0-27d1-4f54-8417-90e64372bcae">9</ix:nonNumeric><ix:nonNumeric contextRef="ie20688dc77174b7f82b8e1f0419169f7_I20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfMi0xLTEtMS0yMDgzNw_bab45435-a7df-450e-a878-2d14b023e52b">1</ix:nonNumeric><ix:nonNumeric contextRef="i2aa7f1a0cfca4e97964f782ad3f98919_I20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfMy0xLTEtMS0yMDgzNw_d6b795df-ed92-42e6-a514-11678be91fca">1</ix:nonNumeric><ix:nonNumeric contextRef="i102061bc526443889b82c4150e2f488c_I20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfNC0xLTEtMS0yMDgzNw_b8f8c67d-b006-4032-b917-2cd9ca2ab2e7">1</ix:nonNumeric><ix:nonNumeric contextRef="i882466d699264682b0f4ba252c12d5e5_I20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfNS0xLTEtMS0yMDgzNw_9032550b-3bca-4f78-95c7-1474270b4f02">1</ix:nonNumeric><ix:nonNumeric contextRef="i4345a91c389b4360afb19c57116d7ac2_I20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfNi0xLTEtMS0yMDgzNw_33cd66c6-0f27-41f6-bfae-768ad3b8aff5">1</ix:nonNumeric><ix:nonNumeric contextRef="i310b023a39314b88848d936e4457d7e7_I20220331" xsi:nil="true" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfNy0xLTEtMS0yMDgzNw_d4fea663-e22f-4a4a-9e2e-3bea1e3d6421"></ix:nonNumeric><ix:nonNumeric contextRef="ibc8c5780bba44a3ea641915dda767963_D20180301-20180331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNDkwNA_c8db3740-5782-4c3e-b75d-6ff6aad14517">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arvn-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i298bddf478094dbe96ea9820c24d31b6_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i25a3253dc54e4eac92fd34e0a563037a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9805af17bb1e4148957b4b787a17b462_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325b2c55e24f4d3085397ec2a20a3663_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia371b6c494bd486eba4eb8f874aac24d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic08ce866c4b94f27be498b6f213dedf4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdded53975a5429895fe70fedb812866_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64cdb93492594796ae0fafa8520ff6ef_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e87a608f4fe4e9fba87219c47ddd422_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i466a50b5c0114bcea592e1b1334a0324_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ab3a4e1902404387845f936fedb097_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3d030a19ea49da95e47ac71dec2969_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69f4662e8e8448abec08c5f3b291024_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a46859c40274bc9b50db4b08d11374e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c768bfb30f454d8c3b8dedd536434c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife15238ba3aa438e92145e6ce7fce7e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79edb451b83c41328adf8b4f80baea6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i695ecd5938c4493b80a441194c7f13f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e39a8922e54876b257e31ace35e9dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6bd9ddc02dc48188e9e3137a9f8178d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5dd562c52e04ac296e9718c72c905ce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c6e27ac8b742a493910e355bca12b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e38918aafc24219a8eb691051421674_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc3521706e841c982eab94aeac4cc7b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia234f753bb3e4302ab5a9e1282401b5e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b8bae6e224e4a98adadcf7e3210eb8f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f6edb80919d4576ac9bb041310aa949_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i431cda9cb00645c88fdbc954baf2ad13_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2998b237d8c4cc5b5cfbfbbe55bd80a_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8cc818798e540e78ab7b7c156e4fbc2_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryAndSalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf1b8a28931b4231b16a210b71e519f8_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa2e9fa2922c461da7d579a31613e064_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4532b7b853b44517abe2e4b76db69a39_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68c017139446444892ba5b5141397092_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0da6cc0567c949ee99cc3823d7769be9_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i961fd92786d94a7bb50d58b8ec7d663f_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8f6a7fb4f9d4e3dba2515d41bb60d59_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7429a91425d84698be06a86197d0ffc8_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8bc2b78c234516bd399c4cb1c0fb36_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id06d955e966b4215b1e8175bf00c3521_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18bd65fbf8f4463899c17a0bdfe66d8d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i179e7109d53d425a903964aede9fad1f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae46787668d404b9768ffd8422cf730_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ff207795b444585941a6e4f1d28bb9b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b01340ddf614d96910de55cc1e88eab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i489172a8ff124366a130239025bbf1c6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0348777d704a5a973250876179db45_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e203cfdd5884e8d9b9a0ab5f0fabd0d_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>arvn:Target</xbrli:measure></xbrli:unit><xbrli:context id="i06908e112e7d405b9415d441e9bdb200_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab85607423a442d5a33914e00073dd49_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36dff9a96749481b9449da6624996bb1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if28802bd397f467aaea1a72ce7ce0c76_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0638c95ee09d4cd68aeefe4b785026d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a386ef91f34522865c79b14ea0b285_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20688dc77174b7f82b8e1f0419169f7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aa7f1a0cfca4e97964f782ad3f98919_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i102061bc526443889b82c4150e2f488c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i882466d699264682b0f4ba252c12d5e5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4345a91c389b4360afb19c57116d7ac2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i310b023a39314b88848d936e4457d7e7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed48a9634a74706aa50054bf2177c4f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25cf701d1374c4c9ab79f7036a6ab1e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95d305fe2172466ab61fdf2e1b9c22b3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ca9825bcc0c4b3cba9688ebc7c3599c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57a0f6dd7ca44f28ac6939f93d4228da_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife24052b16484996b2ccebc986eefddf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i248d829d7548451dae53a9e40b3985ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic556a60245544ecf94e8f539795821fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e68c26befb7440a88ac95a1480a49a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e17a2a0dd9d408188b1eea507950135_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd25500d0c7946cab2bb104a0d38fbdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c11d105fc7e43e8abf3b8464ed2b242_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2432c4a5e7ba4d1ea0e0080e009e226b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e050c23b5444aae82eec5a8826e74b9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea03b274b37a4adb984dd693b64b3f6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d23fd19f97f40e78883b6aa5fea051f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib57b0b1255a54112b386652ff3e4aa50_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i209db759fd014857b8ce446bc1b613a2_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i3ea0fe2f906848acb4fdf90217135445_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a11df340c6411ab9d44c8a5bdca3b6_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie80d3e8623984738bd827627643f522d_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib76a16c4b82e4fc1afb937c6900e150c_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4935b90c90e34bf6b3aed0f1df6f02ee_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73790ff93f1f4e57acc10cab17dc2e89_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd70cc9b901409ab550af0ec999338f_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i060bd9cd585847318e2f9ad13a0d80e6_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cddce78d1d948c5b583d717cd77e28a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45363eaf411f4c0fa67bd782a95bcb4c_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib22a7c97a95649208e3e16626fb046fa_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i102371b1a4f74f1989575feb5349c7e8_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d11b00f18034e2faf571d32e08733be_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6baa8537a2484bdcbd212331111a5ab2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283e92babacf44249b5ac15c0401dae2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fcf33d6545f49979c8996508f1dafdc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic72afe64f6d942ceaec3f2bcea014191_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc8c5780bba44a3ea641915dda767963_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ed2e413afc4936a46c5ae2d54150a8_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i135de9f10c6a4846ba8e3bd9311c3aaf_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6380e9eea75f4e87923e1958591b5177_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4075817b88149f4ad4be9a0e24f00bd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i671442cf18e9459a9ae011753dc2baf4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i676daf315860494fae1a0db23d870397_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a028511c76147dfa9eea3ef963d7391_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22436d4d6b37470dae576ae029c13e17_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i433048cb8a22434c9c966ee4a08d5783_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61acd713861543de9a324e7901c946b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b128b20436420eb6e8f593916c4d49_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0183429203148f5b51f86ce4175b9db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i671f93d65ec949f6a09add626b9cc77d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfe72e9e1d7f4ef38b63abc9e9247aa6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4067c8a18e3a462ab80648a7b2f71e05_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6884606b15a4b1c92ccbbd8551ca251_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i649860d7edd84bfdb3be6ff127c824e6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98d32989f98049b98b156c00b715a0f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d56097cbd64f55a89cefb5e23f4fdd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a949a59544846bea32da66debdc0f5c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20769d0f7ab420fb3b232e6d0b967fe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e513085eec343c4b787da47473ad4c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ebb09ff5e84d1aa19beee9d199a829_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i726c996b1f294aea83f7646f6c212dd2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07f988855484455ab096cd4c3443153c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf87072bef5a4f5cbbe0ef6ae8aee71b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b1f35859d641bd8934d7229fc923b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a02298ba683464096a7a075d1fbb1bb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e55da3f43bb49b19eed56be6d2f98be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i834d98020bdd4bcca28aae792703f6b0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870a90a229974cd0bf199bf46c04b252_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i300ed13406744d99b22892681909ed10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f56e3363e742a0b334906ca508739d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c01ec64eb01468487ce85da6539107d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333e000cdba54a2482be61ecd1dd9dbb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3073ab7967df4bf8a4f22af60b4b3306_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f17d29e95941cbb2f7dfbf46b84035_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTUx_4064c2f0-c694-4691-a96b-2b321ff9e870">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6OWQ1OGRmZTY4YzcwNGQ2NDk4NmEwOWFkMzA4MjczN2IvdGFibGVyYW5nZTo5ZDU4ZGZlNjhjNzA0ZDY0OTg2YTA5YWQzMDgyNzM3Yl8wLTAtMS0xLTIwODM3_0d5f0a45-abc7-4004-938a-8ec8b79b9a81">&#253;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25.5pt;text-align:left;text-indent:-24.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8xNjQ5MjY3NDQzODU1_95d2c6b1-de55-49ff-9cfb-304e1b36d8d9">March 31, 2022</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NjZkMzc3OGQ5MTAzNGJjMmFiNWFiYmRkYzJmOTg2YzIvdGFibGVyYW5nZTo2NmQzNzc4ZDkxMDM0YmMyYWI1YWJiZGRjMmY5ODZjMl8wLTAtMS0xLTIwODM3_173628a6-ea0f-42f5-abae-73cfd3303494">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTQ2_4ea6d77d-b805-4212-842a-8579e8cc59c1">001-38672</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTUy_9ef89422-2c2c-402c-9401-bbd6ad0ebf38">ARVINAS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8wLTAtMS0xLTIwODM3_64c4369b-adfe-43e0-9d86-a581f2dcb64e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8wLTEtMS0xLTIwODM3_adafb64f-6abc-4426-8809-383fd364e195">47-2566120</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">incorporation or organization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8yLTAtMS0xLTIwODM3L3RleHRyZWdpb246NDA1MDc2ZjVhMDFhNDUzYzllNjViYTA0ZTE1ZmViMTNfNQ_7e42c30c-979f-4f2c-b9f7-e194064d039e">5 Science Park</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8yLTAtMS0xLTIwODM3L3RleHRyZWdpb246NDA1MDc2ZjVhMDFhNDUzYzllNjViYTA0ZTE1ZmViMTNfOQ_a225eef4-c23d-4d0e-9db4-49e130fd6bbb">395 Winchester Ave</ix:nonNumeric>. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8yLTAtMS0xLTIwODM3L3RleHRyZWdpb246NDA1MDc2ZjVhMDFhNDUzYzllNjViYTA0ZTE1ZmViMTNfMTQ_b4e33654-40b8-4dae-9145-f8c14bde3edd">New Haven</ix:nonNumeric>, <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8yLTAtMS0xLTIwODM3L3RleHRyZWdpb246NDA1MDc2ZjVhMDFhNDUzYzllNjViYTA0ZTE1ZmViMTNfMTg_35e28594-2939-407e-b9cf-14b5ef04b530">Connecticut</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8yLTEtMS0xLTIwODM3_42c9aff9-8a27-4376-9d1f-6b93afcbb9f7">06511</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTUz_cfcc814c-423d-45da-951f-edb3bd46b64e">203</ix:nonNumeric>) <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTQ3_d5225101-d1eb-4853-a598-e2b18374af3e">535-1456</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:39.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ODQ0NjJjZDA2Nzg4NDY2NzlhYzE1NDg3OTAxYjI3MWMvdGFibGVyYW5nZTo4NDQ2MmNkMDY3ODg0NjY3OWFjMTU0ODc5MDFiMjcxY18xLTAtMS0xLTIwODM3_9cb9a92c-6d52-4391-8f00-671b5e507bee">Common stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ODQ0NjJjZDA2Nzg4NDY2NzlhYzE1NDg3OTAxYjI3MWMvdGFibGVyYW5nZTo4NDQ2MmNkMDY3ODg0NjY3OWFjMTU0ODc5MDFiMjcxY18xLTItMS0xLTIwODM3_5b9395b0-b9fb-4634-a782-4ea1e8135524">ARVN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ODQ0NjJjZDA2Nzg4NDY2NzlhYzE1NDg3OTAxYjI3MWMvdGFibGVyYW5nZTo4NDQ2MmNkMDY3ODg0NjY3OWFjMTU0ODc5MDFiMjcxY18xLTQtMS0xLTIwODM3_f2257590-e464-4715-8307-2f2ebdba96df"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Nasdaq </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Market LLC</span></ix:nonNumeric></div></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8xNjQ5MjY3NDQzOTI0_21f1838f-c0fb-412b-ba3a-ae652c519fc0">Yes</ix:nonNumeric> </span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8xNjQ5MjY3NDQzOTI1_11233275-596c-4a51-bea7-75ab7b3c9373">Yes</ix:nonNumeric> </span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ZmJkNGNjNjBmMzFlNDM1NDlkNmI2MTc2NTk4ZjMzMTEvdGFibGVyYW5nZTpmYmQ0Y2M2MGYzMWU0MzU0OWQ2YjYxNzY1OThmMzMxMV8wLTAtMS0xLTIwODYy_3cfe9a70-9de1-47ab-8613-17b6b4438d0f">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#253;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ZmJkNGNjNjBmMzFlNDM1NDlkNmI2MTc2NTk4ZjMzMTEvdGFibGVyYW5nZTpmYmQ0Y2M2MGYzMWU0MzU0OWQ2YjYxNzY1OThmMzMxMV8xLTMtMS0xLTIwODM3_1509dbb4-c00b-4684-bae3-e6ad032476f4">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ZmJkNGNjNjBmMzFlNDM1NDlkNmI2MTc2NTk4ZjMzMTEvdGFibGVyYW5nZTpmYmQ0Y2M2MGYzMWU0MzU0OWQ2YjYxNzY1OThmMzMxMV8yLTMtMS0xLTIwODM3_2dd5e6cb-733a-4710-892d-0daf2f9ba23c">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTQ4_75e801ca-41e2-4b90-b14d-dba9e143a26c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of April&#160;29, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i298bddf478094dbe96ea9820c24d31b6_I20220429" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8xNjQ5MjY3NDQzODcz_8cad88b1-afe9-4529-8046-c19312a2bfa5">53,165,962</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_13">PART I.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_16">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_22">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.15pt;text-indent:-0.15pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_28">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_34">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_82">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_82">16</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_103">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_103">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_103">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_106">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_106">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_106">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_109">PART II.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_109">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_109">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_112">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_112">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_112">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_115">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_115">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_115">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_118">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_118">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_118">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_121">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_121">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_121">30</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_124">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5f8d406ab3aa45be82590782b0fe2e1d_124">31</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;goals,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the initiation, timing, progress and results of our current and future clinical trials of  bavdegalutamide, ARV-471 and ARV-766, including statements regarding the period during which the results of the clinical trials will become available;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of, and our ability to obtain, marketing approval of  bavdegalutamide, ARV-471 and ARV-766, and the ability of bavdegalutamide, ARV-471, ARV-766 and our other product candidates to meet existing or future regulatory standards;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the potential achievement of milestones and receipt of payments under our collaborations, including our collaboration with Pfizer Inc., or Pfizer, entered into in July 2021, or the ARV-471 Collaboration;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our plans to pursue research and development of other product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the potential advantages of our platform technology and our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the extent to which our scientific approach and platform technology may potentially address a broad range of diseases and disease targets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the potential receipt of revenue from future sales of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the rate and degree of market acceptance and clinical utility of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our estimates regarding the potential market opportunity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our sales, marketing and distribution capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our ability to establish and maintain arrangements for manufacture of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our ability to enter into additional collaborations with third parties;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our intellectual property position;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the impact of COVID-19 on our business and operations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the impact of government laws and regulations; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our competitive position.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 28, 2022, and this Quarterly Report on Form 10-Q, particularly in the &#8220;Risk Factors&#8221; sections, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements except as required by applicable law.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;Arvinas,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; except where the context requires otherwise, refer to Arvinas, Inc. and its consolidated subsidiaries, or any one or more of them as the context may require, and &#8220;our board of directors&#8221; refers to the board of directors of Arvinas, Inc.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use Arvinas, the Arvinas logo, and other marks as trademarks in the United States and other countries. This Quarterly Report on Form 10-Q contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Quarterly Report on Form 10-Q, including logos, artwork and other visual displays, may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_16"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_19"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMy0xLTEtMS0yMDgzNw_19556ade-b602-4295-8b3b-ab93d651b845">62.3</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMy0zLTEtMS0yMDgzNw_0f75a892-8622-49c6-993f-26a4dac23f60">108.3</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNC0xLTEtMS0yMDgzNw_8245f05f-1f1d-45eb-954a-50782d57e913">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNC0zLTEtMS0yMDgzNw_d4a69809-c777-428e-9c71-fe3cb9e6e393">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Marketable securities</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNS0xLTEtMS0yMDgzNw_51fd8a4b-8a0a-4205-a29a-10bdfd17277a">1,366.1</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNS0zLTEtMS0yMDgzNw_c0271a52-c991-4b2c-8465-e2196f2f5c47">1,394.3</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNi0xLTEtMS0yMDgzNw_4683b266-5f18-4237-9130-8897efdb2f94">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNi0zLTEtMS0yMDgzNw_d783c23c-bdec-41f4-891a-f4ec92cf89d4">15.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other receivables</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNy0xLTEtMS0yMDgzNw_206d05a6-bbc3-4720-87bd-d9f73ac8974f">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNy0zLTEtMS0yMDgzNw_0b7f3516-56fd-40a3-a128-b7cab1d80c89">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfOC0xLTEtMS0yMDgzNw_c1428128-cbdb-40f4-861d-c41098766a56">17.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfOC0zLTEtMS0yMDgzNw_e1c74dcd-62a7-4961-8e2d-ba9a1652303d">19.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfOS0xLTEtMS0yMDgzNw_350668d2-d6ab-4679-b6c7-6703e735c56f">1,457.0</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfOS0zLTEtMS0yMDgzNw_07413802-a565-47de-815c-9c2e946ec85f">1,552.5</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTAtMS0xLTEtMjA4Mzc_6b764d39-be0e-472d-9064-86dab06866a7">13.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTAtMy0xLTEtMjA4Mzc_ac618b18-9c7e-4aca-816f-ac399ee46871">12.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTEtMS0xLTEtMjA4Mzc_78470bc0-96cd-43fb-b3d3-4af95397f6ef">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTEtMy0xLTEtMjA4Mzc_1742eeae-2042-4853-ae60-5ca8a923c26b">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Collaboration contract asset and other assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTItMS0xLTEtMjA4Mzc_670f9d1f-9ad1-41ac-b924-e79525a3dc06">12.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTItMy0xLTEtMjA4Mzc_ee7a8cd7-e210-4520-99fd-b8459cca364d">12.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total assets</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTMtMS0xLTEtMjA4Mzc_44bba137-60bd-4f45-944b-2dae958981f7">1,488.3</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTMtMy0xLTEtMjA4Mzc_6d7f4884-b0f4-4c1d-b5ba-569a4ac9cf13">1,581.6</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Liabilities and stockholders' equity</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTYtMS0xLTEtMjA4Mzc_436ec88c-2c64-42cd-904f-f158cb2fb933">8.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTYtMy0xLTEtMjA4Mzc_5dc4c07f-9673-464a-bbd8-d3b74870c381">31.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTctMS0xLTEtMjA4Mzc_b79def8e-8370-4e8f-86c0-51eef9e112c1">30.2</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTctMy0xLTEtMjA4Mzc_6e0f3ec2-1d3a-47aa-8bcc-dfd2c99cc480">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTgtMS0xLTEtMjA4Mzc_de8936c0-3845-4af9-aa3c-d08b38d2476d">197.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTgtMy0xLTEtMjA4Mzc_84f8a1a1-65d3-4dd6-bbbb-471003026439">206.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTktMS0xLTEtMjA4Mzc_fa513f25-756f-4a55-9880-f169181d35b8">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTktMy0xLTEtMjA4Mzc_d1d791f0-5b70-474f-8a01-233861bb5d8b">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current liabilities</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjAtMS0xLTEtMjA4Mzc_33aac8a4-358b-496b-9191-4081e0c17e96">238.0</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjAtMy0xLTEtMjA4Mzc_5398c1ca-9e75-427e-a7fb-2d04d05b51c1">261.7</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjEtMS0xLTEtMjA4Mzc_8bb82385-acb9-45a1-94e6-7f3849e9255a">521.9</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjEtMy0xLTEtMjA4Mzc_b8ed97a8-8d77-4ed5-bc9c-c1bfcf58435d">534.3</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjItMS0xLTEtMjA4Mzc_edcfd2cc-0b69-4cbb-8472-08737ff750ff">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjItMy0xLTEtMjA4Mzc_16d2dc54-6b8f-42e8-8ac5-a66ad3146dd0">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liability</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjMtMS0xLTEtMjA4Mzc_7e4c11b4-a2b1-4d17-9aae-1dc926f88833">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjMtMy0xLTEtMjA4Mzc_abfa783c-59ff-4a44-b044-b9da61e9f958">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjQtMS0xLTEtMjA4Mzc_6d72adc0-f72c-4f7e-ad29-e3b8a0513223">765.0</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjQtMy0xLTEtMjA4Mzc_4ea89b10-21d8-4619-a78a-1ee10521f902">799.9</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and Contingencies</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjUtMS0xLTEtMjA4Mzc_57f32fd3-2ace-4b9d-80c8-bdbe42aa7baa"></ix:nonFraction></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjUtMy0xLTEtMjA4Mzc_55231700-288f-47b3-8726-8d6a4ad4bde1"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Stockholders&#8217; equity:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl8xOQ_06f810a6-c1f1-46dd-94aa-9a3589976d4b"><ix:nonFraction unitRef="usdPerShare" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl8xOQ_2513f3c0-3dc5-4dd6-b55e-e42266508b21">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl85MzQ1ODQ4ODM2MjI2_423cf8bf-0e8e-46ad-bf31-61897b665563"><ix:nonFraction unitRef="shares" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl85MzQ1ODQ4ODM2MjI2_a814da7d-4e13-4c44-af54-d20616e21d29">53.1</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl85MzQ1ODQ4ODM2MjIy_a0b920a3-834f-4d88-9b90-4c5ad251c483"><ix:nonFraction unitRef="shares" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl85MzQ1ODQ4ODM2MjIy_f79464a7-a5b9-4d87-bd8f-83ec4dbf3f64">53.0</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMS0xLTEtMjA4Mzc_0e5001df-e6b9-4a9e-949a-2c080a3658ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMy0xLTEtMjA4Mzc_8dce893e-11f5-4ad8-8844-2a5456db4ebe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjgtMS0xLTEtMjA4Mzc_2e502757-d5d9-4e0b-a47a-3ea0c962aee5">746.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjgtMy0xLTEtMjA4Mzc_565423bd-faca-4258-976b-157b3d495c1d">682.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjktMS0xLTEtMjA4Mzc_f82f4eff-7ce1-439a-83c7-4ac31b566011">1,488.3</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjktMy0xLTEtMjA4Mzc_f8031ed5-98ce-464c-9e71-84307cc84916">1,469.2</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzAtMS0xLTEtMjA4Mzc_d814cece-6acd-4d67-b887-4b3cb6583176">18.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzAtMy0xLTEtMjA4Mzc_7f2a267a-f7f2-463c-a04f-33e1fc803190">4.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzEtMS0xLTEtMjA4Mzc_7a048b3d-bd6a-40f7-8833-37b9c4f46314">723.3</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzEtMy0xLTEtMjA4Mzc_d19d032d-b140-4940-9f1f-cf6714dba1c1">781.7</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities and stockholders&#8217; equity</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzItMS0xLTEtMjA4Mzc_267865d6-b093-442a-be45-c1b64773d52a">1,488.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzItMy0xLTEtMjA4Mzc_09096e78-fa91-4185-ad39-47ca8de0c658">1,581.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Condensed Consolidated Statements of Operations</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMi0xLTEtMS0yMDgzNw_d5891d75-b3f5-44cb-9c3f-900839b52016">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMi0zLTEtMS0yMDgzNw_3ed0d905-e673-4ea7-a3d0-2c5ac51fbf30">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNC0xLTEtMS0yMDgzNw_b3992245-996b-434e-aba8-1a0548fa2477">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNC0zLTEtMS0yMDgzNw_6652b330-fc7d-4e5c-9d00-c9e929ecae41">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNS0xLTEtMS0yMDgzNw_ff343dd6-4ee3-46ff-8db2-07fdf61c90ae">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNS0zLTEtMS0yMDgzNw_554ae67c-a508-4744-a34b-ea7865d5cccb">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNi0xLTEtMS0yMDgzNw_d8fe1056-3445-426f-9fd6-931e21146646">84.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNi0zLTEtMS0yMDgzNw_78930013-8617-4197-8338-e8939bda5436">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNy0xLTEtMS0yMDgzNw_660e54a8-b7cc-4658-9fb9-2f2a556eb24b">60.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNy0zLTEtMS0yMDgzNw_abc6e002-071e-4050-9f3d-7da55185ebb4">41.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other income (expenses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfOS0xLTEtMS0yMDgzNw_4db02d9e-6444-41d3-a446-8735fc0609d2">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfOS0zLTEtMS0yMDgzNw_df24ca16-ff53-4482-98ec-c3ed252a7131">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTAtMS0xLTEtMjA4Mzc_7983560f-9cef-4d0b-9782-147d050ccfbd">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTAtMy0xLTEtMjA4Mzc_3ef3a033-c824-4298-a1bf-c3077e81a532">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTItMS0xLTEtMjA4Mzc_56a5c81d-4e43-4643-a175-8871cd5fd0d0">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTItMy0xLTEtMjA4Mzc_458890d1-1040-4bbe-bf13-ec109d8eba3a">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTMtMS0xLTEtMjU1NTA_a5c006d8-0f94-4b7b-b864-4a563bbfd4e5">58.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeLossAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTMtMy0xLTEtMjU1NTA_722841dc-24d0-4a0d-a173-2c35dce1dfe4">41.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMS0xLTEtMjU1NTA_337b7fbc-8f9f-4001-8e3b-ec42f2ef993c">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMy0xLTEtMjU1NTA_9a593ea8-6f3c-4a70-a780-2237775d41db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTMtMS0xLTEtMjA4Mzc_f00d7240-6f2d-4b28-aaba-ff9889341130">63.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTMtMy0xLTEtMjA4Mzc_aad210f9-10b6-432d-87fd-d7adb57d59a0">41.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss per common share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMS0xLTEtMjA4Mzc_89df1570-a9cd-4bca-9ddd-c7dbd0486877"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMS0xLTEtMjA4Mzc_b2979a19-9b0e-43d8-9981-ed56442e5a05">1.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMy0xLTEtMjA4Mzc_99d3f1aa-cea6-4cd3-841a-1e607dd0195f"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMy0xLTEtMjA4Mzc_f7079a8d-1643-4de1-96f9-a02611f53a60">0.84</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted average common shares outstanding, basic and diluted</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTUtMS0xLTEtMjA4Mzc_85ac847a-f618-4930-8c8c-a0f7e26d9e23"><ix:nonFraction unitRef="shares" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTUtMS0xLTEtMjA4Mzc_e95a855f-fe3b-4271-a553-308a1750f667">53.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTUtMy0xLTEtMjA4Mzc_2b21cf41-e740-4d03-9902-9258e56b0341"><ix:nonFraction unitRef="shares" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTUtMy0xLTEtMjA4Mzc_37ba2093-ab35-4d99-8c26-e1cb56e5880c">48.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_25"></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Condensed Consolidated Statements of Comprehensive Loss</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfMi0xLTEtMS0yMDgzNw_e275535b-0ab7-433f-96cb-63b54baa6ba5">63.4</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfMi0zLTEtMS0yMDgzNw_0be15ac7-4b2e-4e03-b65f-6404384bd4a2">41.0</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other comprehensive loss:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfNC0xLTEtMS0yMDgzNw_3d870d01-203d-4d03-b0ed-bc98eae205aa">14.1</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfNC0zLTEtMS0yMDgzNw_31856354-8d36-4c68-9912-569994269636">0.8</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Comprehensive loss</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfNS0xLTEtMS0yMDgzNw_e72f7f7b-eeb1-498c-8d5d-528d2e5ba9ad">77.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfNS0zLTEtMS0yMDgzNw_e43ab475-9bad-4f28-bebb-c5f269701dad">41.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.027%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Common</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Accumulated <br/>Other <br/>Comprehensive <br/>(Loss) Income </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Total <br/>Stockholders' <br/>Equity </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i325b2c55e24f4d3085397ec2a20a3663_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi0xLTEtMS0yMDgzNw_61f86174-d022-444b-816b-d082a98a3e1a">53.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i325b2c55e24f4d3085397ec2a20a3663_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi0zLTEtMS0yMDgzNw_6e793bd8-01c6-426b-ad2c-4da3c252d3f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia371b6c494bd486eba4eb8f874aac24d_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi01LTEtMS0yMDgzNw_474d2488-ebb9-4293-a282-eb535aaa4e8b">682.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic08ce866c4b94f27be498b6f213dedf4_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi03LTEtMS0yMDgzNw_44644f1c-376d-41de-b5ae-a93bb9a89450">1,469.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ibdded53975a5429895fe70fedb812866_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi05LTEtMS0yMDgzNw_2fae3b10-f489-4460-986d-315447e8a4ef">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi0xMS0xLTEtMjA4Mzc_9d04acc3-b9e0-4599-bb99-e80d6f43a864">781.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i64cdb93492594796ae0fafa8520ff6ef_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMy03LTEtMS0yMDgzNw_2a9d7ebf-0d1f-4448-a64f-7e70dc98ff49">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMy0xMS0xLTEtMjA4Mzc_839103b6-528c-4d73-877d-b884733e216e">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8e87a608f4fe4e9fba87219c47ddd422_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfNC01LTEtMS0yMDgzNw_4bc50ddd-6a17-4db0-bb0d-986cb8d969b2">63.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfNC0xMS0xLTEtMjA4Mzc_3f5160a9-2560-4984-9b1e-efe9a698b421">63.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i466a50b5c0114bcea592e1b1334a0324_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfNi0xLTEtMS0yMDgzNw_c8914daa-b23c-45d9-b4e9-ffe8a8dab473">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i64cdb93492594796ae0fafa8520ff6ef_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfNi03LTEtMS0yMDgzNw_67a3e8c8-4f15-4b7b-b3e1-32aa52ada126">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfNi0xMS0xLTEtMjA4Mzc_ddab3603-2567-41a8-841b-83a6769c5b87">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22.22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie9ab3a4e1902404387845f936fedb097_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOC05LTEtMS0yMDgzNw_909c9b69-53b4-4293-a21a-25dab4e24345">14.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOC0xMS0xLTEtMjA4Mzc_f13428c1-4949-468a-b6ea-9c4c976f39aa">14.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i3a3d030a19ea49da95e47ac71dec2969_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS0xLTEtMS0yMDgzNw_69e8a440-cb53-49d4-9f7b-262c61c99d56">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3a3d030a19ea49da95e47ac71dec2969_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS0zLTEtMS0yMDgzNw_03447c35-668f-440c-853f-e2395828de68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib69f4662e8e8448abec08c5f3b291024_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS01LTEtMS0yMDgzNw_39e2caca-f27f-4ec6-b964-fc846784ae7b">746.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1a46859c40274bc9b50db4b08d11374e_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS03LTEtMS0yMDgzNw_0293485e-a039-4af1-be92-1ca0d7f13334">1,488.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4c768bfb30f454d8c3b8dedd536434c_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS05LTEtMS0yMDgzNw_6d3275d9-4c9c-4861-b403-3c9d406a56f1">18.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS0xMS0xLTEtMjA4Mzc_fdb9e445-e724-4fe7-a561-c3ce211dca10">723.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ife15238ba3aa438e92145e6ce7fce7e7_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTAtMS0xLTEtMjA4Mzc_3a544740-500f-4f04-a5e1-db2a6daa85a1">48.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i79edb451b83c41328adf8b4f80baea6f_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTAtNS0xLTEtMjA4Mzc_7ce559d7-d163-485c-8975-137041629b12">491.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i695ecd5938c4493b80a441194c7f13f6_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTAtNy0xLTEtMjA4Mzc_e945a221-c555-410b-866d-197330a426bd">1,133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i41e39a8922e54876b257e31ace35e9dd_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTAtOS0xLTEtMjA4Mzc_9b3556bb-fc1a-4d4e-ae9a-5464b21109f0">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTAtMTEtMS0xLTIwODM3_f3d9e4dd-c079-4da2-b222-1d7346f3ef54">642.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if6bd9ddc02dc48188e9e3137a9f8178d_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTEtNy0xLTEtMjA4Mzc_6179b880-a732-4d99-b11f-ec9d1fa4ab7a">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTEtMTEtMS0xLTIwODM3_fbd9df9e-9424-4f45-b43e-829e42bec6e7">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id5dd562c52e04ac296e9718c72c905ce_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTItNS0xLTEtMjA4Mzc_36fcf1a1-decd-4287-a82f-a4b0f3ce1672">41.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTItMTEtMS0xLTIwODM3_d7f676a6-7dbb-4a3f-8266-e9a5b45782a9">41.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Restricted stock vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i99c6e27ac8b742a493910e355bca12b4_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTMtMS0xLTEtMjA4Mzc_fe3724d8-b6ef-4d4e-9f17-c1e8c3572d63">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTMtMTEtMS0xLTIwODM3_8376ce46-169a-4187-ab04-b7f54d75ef6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i99c6e27ac8b742a493910e355bca12b4_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTQtMS0xLTEtMjA4Mzc_8f071e93-a1bd-417e-b852-4489e9eae8b6">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if6bd9ddc02dc48188e9e3137a9f8178d_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTQtNy0xLTEtMjA4Mzc_14901a27-a665-42a1-83d3-aaeb270e6a83">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTQtMTEtMS0xLTIwODM3_e5b370ce-7427-4295-b1cf-0e1cd3d8a8a9">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8e38918aafc24219a8eb691051421674_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTYtOS0xLTEtMjA4Mzc_f9559f71-9087-46bb-a78a-00814c8de891">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTYtMTEtMS0xLTIwODM3_4fb6ef44-84f7-47eb-8fa9-7519c8a25fbf">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6bc3521706e841c982eab94aeac4cc7b_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctMS0xLTEtMjA4Mzc_fa7f0508-8afa-448c-b8d0-1260afab85e6">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6bc3521706e841c982eab94aeac4cc7b_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctMy0xLTEtMjA4Mzc_599bcc6e-d028-4892-9ac5-03a12aca55b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia234f753bb3e4302ab5a9e1282401b5e_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctNS0xLTEtMjA4Mzc_7c14911c-995b-477d-ac88-640c6cab799e">532.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6b8bae6e224e4a98adadcf7e3210eb8f_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctNy0xLTEtMjA4Mzc_eb70b3d8-a6c7-4fda-8af1-dcee2a8d85aa">1,148.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i4f6edb80919d4576ac9bb041310aa949_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctOS0xLTEtMjA4Mzc_26e222c0-b316-46c4-857a-806fb649bbd8">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i431cda9cb00645c88fdbc954baf2ad13_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctMTEtMS0xLTIwODM3_5a97c28b-a5e4-4e63-93f0-32c9d3a8bc71">615.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMy0xLTEtMS0yMDgzNw_79e45f39-7137-48c5-8702-23405a946a0e">63.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMy0zLTEtMS0yMDgzNw_a3d7de30-3fb5-40e9-9de2-b493966f4631">41.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfNS0xLTEtMS0yMDgzNw_89bc87b8-4432-4d96-9820-56aba0381c90">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfNS0zLTEtMS0yMDgzNw_36cb332c-39ee-4f74-8fbe-bac40994c908">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net accretion of bond discounts/premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfNi0xLTEtMS0yMDgzNw_196b766d-833c-4633-9f21-5122357f4d30">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfNi0zLTEtMS0yMDgzNw_52aa1c23-0df9-4ff7-bc1c-e3d2f44db8ee">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfOS0xLTEtMS0yMDgzNw_3683cb03-b5c3-442b-ab60-539c4ce5c8d7">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfOS0zLTEtMS0yMDgzNw_b4aff522-66a3-4844-8807-e086efa2963d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amortization of collaboration contract asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTAtMS0xLTEtMjA4Mzc_f10b934e-f183-41d2-b118-ad0e8fca4e0e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTAtMy0xLTEtMjA4Mzc_af9cc870-ae5b-4a7a-8659-66f7167547ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTEtMS0xLTEtMjA4Mzc_a1b4c41f-f98c-4bd7-aa56-20e31c3c4b91">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTEtMy0xLTEtMjA4Mzc_ff750bdf-5364-44c1-8626-264201e78fcc">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTMtMS0xLTEtMjA4Mzc_c8552dab-56e1-480c-850c-2bdf4887fc58">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTMtMy0xLTEtMjA4Mzc_8cbd306e-21f5-4320-8a12-795896b9f3c8">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTQtMS0xLTEtMjA4Mzc_ea02efa9-91e4-436a-be3d-9fcef5543f84">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTQtMy0xLTEtMjA4Mzc_a39fa2b8-1809-4a37-86e1-51d65dedd1dd">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTUtMS0xLTEtMjA4Mzc_b36375f4-03cb-4b37-9e3d-aa92c8402c25">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTUtMy0xLTEtMjA4Mzc_e44a2d06-e07d-44ab-b88a-e950f936067b">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTctMS0xLTEtMjA4Mzc_81dabe16-fd47-4815-bfe8-29c88f681aef">22.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTctMy0xLTEtMjA4Mzc_1439129d-153a-4c8c-9010-817bd84418f8">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTgtMS0xLTEtMjA4Mzc_3742d2e9-d488-4550-90a0-a2294efa4477">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTgtMy0xLTEtMjA4Mzc_b4c7d91a-05a2-43a8-99ae-84977569ec42">10.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="arvn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTktMS0xLTEtMjA4Mzc_8ee22207-8b8c-44c0-86e1-fd547d88cbe6">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="arvn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTktMy0xLTEtMjA4Mzc_d1e96950-72f1-497d-b878-8925632945e7">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjAtMS0xLTEtMjA4Mzc_64c1f53a-316f-4958-a329-7bfcade8398b">21.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjAtMy0xLTEtMjA4Mzc_f9d87955-6431-416c-bb56-3f05f90d5277">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjEtMS0xLTEtMjA4Mzc_94ec76d1-299f-4f16-af28-d41d0bdc81b0">57.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjEtMy0xLTEtMjA4Mzc_52fcb070-de2d-4608-92f9-1ffca6f94ed6">39.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjMtMS0xLTEtMjA4Mzc_22c8830d-2772-4d0e-b966-1a387cdb0321">263.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjMtMy0xLTEtMjA4Mzc_f50c0fbe-c000-4f1a-a3cb-a06830ce371f">240.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjQtMS0xLTEtMjA4Mzc_ae7658f1-e679-4a1f-9233-ec3ca8406cf9">273.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjQtMy0xLTEtMjA4Mzc_240c3bec-691c-4419-ac86-479c52ff98b6">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Purchases of property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjYtMS0xLTEtMjA4Mzc_8327ec0c-adde-4ab8-987a-69fd476bf3d6">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjYtMy0xLTEtMjA4Mzc_935245e1-13cf-4fd9-9315-79f7c3097197">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjctMS0xLTEtMjA4Mzc_52607cd7-a790-40c6-96f5-b618dc7ac2b3">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjctMy0xLTEtMjA4Mzc_09fd6629-8078-4721-a0b6-795ea59afc8f">207.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzEtMS0xLTEtMjA4Mzc_e75a7107-c55b-425e-b855-9769776b921b">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzEtMy0xLTEtMjA4Mzc_412819bf-9e20-4bf4-b6c2-28a348db0199">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzItMS0xLTEtMjA4Mzc_41d9e580-6967-4e8d-8260-732bfe86186e">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzItMy0xLTEtMjA4Mzc_e796d469-ed16-4507-85ad-8b0b2a55d3d9">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzMtMS0xLTEtMjA4Mzc_8f41d036-cf91-49a5-9740-f5a647be61d5">46.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzMtMy0xLTEtMjA4Mzc_c2c6a69c-d89b-4e2a-b75c-b86d247fa36b">242.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzQtMS0xLTEtMjA4Mzc_816ec28b-b124-4080-a83d-e7f210b5d260">112.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzQtMy0xLTEtMjA4Mzc_ac970c30-7c8c-47f9-ba04-a86621f23efc">588.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzUtMS0xLTEtMjA4Mzc_49881344-93b3-4bb3-8d0b-87e751ea024c">66.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i431cda9cb00645c88fdbc954baf2ad13_I20210331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzUtMy0xLTEtMjA4Mzc_3e904089-c704-4d8e-8154-6772188a1742">346.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Purchases of property, equipment and leasehold improvements </span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">unpaid at period end</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzctMS0xLTEtMjA4Mzc_19e1d7f8-bf01-40dd-ba9a-9f3a6aed1734">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzctMy0xLTEtMjA4Mzc_41b14733-0e09-4b5b-9316-35ec84fa29c0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zNy9mcmFnOmM2NDk3NGFkNDlmMjQ5NmQ4NDVjNDg5MDllODhiYjZhL3RleHRyZWdpb246YzY0OTc0YWQ0OWYyNDk2ZDg0NWM0ODkwOWU4OGJiNmFfMjk3Ng_e2ba13bc-833d-4e37-8021-d6f8991bd19c" continuedAt="i563740fba9e14de99c9a7e2cb30c4f0c" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i563740fba9e14de99c9a7e2cb30c4f0c"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and subsidiaries (&#8220;Arvinas&#8221; or &#8220;the Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (&#8220;SEC&#8221;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from Arvinas&#8217; audited consolidated financial statements at that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, forming part of Arvinas&#8217; 2021 Annual Report on Form 10-K filed with the SEC on February&#160;28, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products, and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future.  The Company has financed its operations primarily through sales of equity interests, proceeds from collaborations, grant funding and debt financing. The Company had cash, cash equivalents, restricted cash and marketable securities totaling $<ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-8" name="arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zNy9mcmFnOmM2NDk3NGFkNDlmMjQ5NmQ4NDVjNDg5MDllODhiYjZhL3RleHRyZWdpb246YzY0OTc0YWQ0OWYyNDk2ZDg0NWM0ODkwOWU4OGJiNmFfOTM0NTg0ODg0MDYyMQ_19d04983-0691-4d1a-a453-4491019363b4">1.4</ix:nonFraction> billion as of March&#160;31, 2022.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of the Coronavirus (&#8220;COVID-19&#8221;) Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, many companies have experienced disruptions in their operations and in the markets they serve. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company&#8217;s financial position and results of operations as of and for the three months ended March&#160;31, 2022. The full extent of the future impacts of COVID-19 on the Company&#8217;s operations remains uncertain. A prolonged outbreak could have a material adverse impact on the Company's financial results and business operations, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance its preclinical pipeline.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80MC9mcmFnOjk4ZjdiMTRjZWU2NTQ4NDU5OTViYzBlZTAwNGM3YWQwL3RleHRyZWdpb246OThmN2IxNGNlZTY1NDg0NTk5NWJjMGVlMDA0YzdhZDBfMzY5_97db9182-1aba-4123-a236-7b7ade6c2c6b" continuedAt="idb4b82be82ec4162ae1c663894a03f25" escape="true">Accounting Pronouncements and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="idb4b82be82ec4162ae1c663894a03f25"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviews</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new accounting standards as issued. As of March&#160;31, 2022, the Company has not identified any new standards that it believes will have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2022.</span></div></ix:continuation><div id="i5f8d406ab3aa45be82590782b0fe2e1d_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzYwNA_c912e438-ed6f-45fb-8d2b-249e8c5bc4ba" continuedAt="i9c1d41abba11416fa010f796bc9afc1f" escape="true">Research Collaboration and License Agreements </ix:nonNumeric></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"><ix:continuation id="i9c1d41abba11416fa010f796bc9afc1f" continuedAt="ida00f56e6d88479c8c01f9854e5d80d4"> </ix:continuation></span></div><ix:continuation id="ida00f56e6d88479c8c01f9854e5d80d4" continuedAt="ie88fbe74cc8e42569b924a186ea73456"><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARV-471 Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) (the &#8220;ARV-471 Collaboration Agreement&#8221;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#8217;s proprietary compound ARV-471 (the &#8220;Licensed Products&#8221;). Under the ARV-471 Collaboration Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="ia2998b237d8c4cc5b5cfbfbbe55bd80a_I20210731" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNTEw_697c860d-0322-4998-8e19-56d7b12bbf37">650.0</ix:nonFraction> million. In addition, the Company will be eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="if8cc818798e540e78ab7b7c156e4fbc2_I20210731" decimals="-8" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNTg3_04f2f260-f838-4555-b192-12fad2199185">1.4</ix:nonFraction> billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $<ix:nonFraction unitRef="usd" contextRef="icf1b8a28931b4231b16a210b71e519f8_I20210731" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzMw_a2cb6b97-f19d-48b4-9c8d-f4db0d300e36">400.0</ix:nonFraction> million in regulatory milestones are related to marketing approvals and $<ix:nonFraction unitRef="usd" contextRef="iaa2e9fa2922c461da7d579a31613e064_I20210731" decimals="-8" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzk3_f56bfbe3-da59-4f5b-885d-fcc15320c97d">1.0</ix:nonFraction> billion are related to sales-based milestones.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Pfizer will share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the ARV-471 Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $<ix:nonFraction unitRef="usd" contextRef="i4532b7b853b44517abe2e4b76db69a39_D20220101-20220331" decimals="-5" name="arvn:DirectAndIncrementalCostsIncurredToObtainTheContract" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfMzU2OQ_87933076-fbd3-49f8-af37-5693e11f05cc">12.9</ix:nonFraction> million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $<ix:nonFraction unitRef="usd" contextRef="i68c017139446444892ba5b5141397092_I20220331" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfMzY2OQ_474f6617-45f7-4170-b21f-2beda1f8827b">12.9</ix:nonFraction> million in collaboration contract asset and other assets on the condensed consolidated balance sheet at inception of the agreement, which is being amortized as general and administrative expense over the total estimated period of performance under the ARV-471 Collaboration Agreement.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the &#8220;Bayer Collaboration Agreement&#8221;) setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC&#174; targeted protein degraders, that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="i0da6cc0567c949ee99cc3823d7769be9_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNDQ4Nw_08f72825-a3e0-4241-bcf2-c99d68d6556c">17.5</ix:nonFraction> million in exchange for the use of the Company&#8217;s technology license. Bayer is committed to fund an additional $<ix:nonFraction unitRef="usd" contextRef="i961fd92786d94a7bb50d58b8ec7d663f_I20231231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNDYzOA_dc124a69-cc30-48f6-8109-637736108095">12.0</ix:nonFraction> million through 2023, of which of $<ix:nonFraction unitRef="usd" contextRef="if8f6a7fb4f9d4e3dba2515d41bb60d59_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzODc1Mw_bccdeee7-de2d-4518-84ab-145c13635d75">10.5</ix:nonFraction>&#160;million was received through March&#160;31, 2022. These payments are being recognized over the total estimated period of performance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i7429a91425d84698be06a86197d0ffc8_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzMDg0MQ_ccbaa29b-0310-4bb7-9ce2-a279133affc4">197.5</ix:nonFraction> million in development milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="ibb8bc2b78c234516bd399c4cb1c0fb36_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzMDg4OQ_f5de40aa-e6d7-4aee-9651-71290ac614a0">490.0</ix:nonFraction> million in sales-based milestone payments for all designated targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were <ix:nonFraction unitRef="usd" contextRef="id06d955e966b4215b1e8175bf00c3521_D20220101-20220331" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzMTE3Mw_0f8e8b3b-c77f-4ea9-8b8c-0c1a55f4ac17"><ix:nonFraction unitRef="usd" contextRef="i18bd65fbf8f4463899c17a0bdfe66d8d_D20220101-20220331" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzMTE3Mw_b1933677-45fc-4879-b008-12b357fdc8e4">no</ix:nonFraction></ix:nonFraction> development or sales-based milestone payments or royalties received as of March&#160;31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><ix:continuation id="ie88fbe74cc8e42569b924a186ea73456" continuedAt="ibbea6255f3144911bcb5cf933182fc41"><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Research Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the &#8220;Pfizer Research Collaboration Agreement&#8221;). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $<ix:nonFraction unitRef="usd" contextRef="i179e7109d53d425a903964aede9fad1f_D20180101-20181231" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNTkyNA_7977e394-1d1b-4d76-8095-74c2e1b2f30e">28.0</ix:nonFraction> million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="ieae46787668d404b9768ffd8422cf730_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNTkyOA_38ab3c76-fe74-4ff5-a5d8-3b3fe4fa78df">37.5</ix:nonFraction> million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="i9ff207795b444585941a6e4f1d28bb9b_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNjExMQ_5e390f24-165e-4f66-af39-42912e820ed7">225.0</ix:nonFraction> million in development milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="i7b01340ddf614d96910de55cc1e88eab_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNjE1OQ_c7f1273f-c2bc-4687-91f1-7c3e6b84adeb">550.0</ix:nonFraction> million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. During the three months ended March&#160;31, 2022, the Company received payments totaling $<ix:nonFraction unitRef="usd" contextRef="i489172a8ff124366a130239025bbf1c6_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNjkzNw_0635062f-e757-417f-8b45-ea8ba0dccc57">3.5</ix:nonFraction> million, which was included in accounts receivable at December 31, 2021, for an additional target and additional services which are being recognized as revenue over the total period of performance. There were <ix:nonFraction unitRef="usd" contextRef="i3b0348777d704a5a973250876179db45_D20220101-20220331" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNTE1Mw_d7b8006d-fcb9-4718-84bf-fefe6a4353db">no</ix:nonFraction> sales-based milestone payments or royalties received as of March&#160;31, 2022.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genentech Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the &#8220;Genentech Modification&#8221;) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement. Under the Genentech Modification, the Company received additional upfront, non-refundable payments of $<ix:nonFraction unitRef="usd" contextRef="i9e203cfdd5884e8d9b9a0ab5f0fabd0d_D20171101-20171130" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNjgzOQ_e80410e2-2b22-4da3-87ef-6882c5262128">34.5</ix:nonFraction> million (in addition to $<ix:nonFraction unitRef="usd" contextRef="i9e203cfdd5884e8d9b9a0ab5f0fabd0d_D20171101-20171130" decimals="-5" name="arvn:AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNjg1OA_c1884c27-e5e0-4419-b507-32078149c41c">11.0</ix:nonFraction> million received under the previous agreement) to fund Genentech-related research. Under the Genentech Modification, Genentech has the right to designate up to <ix:nonFraction unitRef="target" contextRef="i9e203cfdd5884e8d9b9a0ab5f0fabd0d_D20171101-20171130" decimals="INF" name="arvn:NumberOfMaximumDesignatedTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzAxMw_10921100-830d-4b0e-a079-3ff7e7b72a8e">ten</ix:nonFraction> targets. The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i06908e112e7d405b9415d441e9bdb200_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNzU4NQ_8ac610db-61c7-4344-b46d-9cf48ea364d8">27.5</ix:nonFraction> million in additional expansion target payments if Genentech exercises its options on all remaining targets. Upfront non-refundable payments are recognized as revenue over the total estimated period of performance. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="iab85607423a442d5a33914e00073dd49_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNzgzOA_85603980-5305-42d0-b98f-0e1e226598ed">44.0</ix:nonFraction> million per target in development milestone payments, $<ix:nonFraction unitRef="usd" contextRef="i36dff9a96749481b9449da6624996bb1_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNzg4OA_22bf7b8f-fe39-49e0-ae33-5139f3463d80">52.5</ix:nonFraction> million in regulatory milestone payments and $<ix:nonFraction unitRef="usd" contextRef="if28802bd397f467aaea1a72ce7ce0c76_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNzkyOQ_a88c370c-5567-4526-9fe9-2ea6c9381ded">60.0</ix:nonFraction> million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were <ix:nonFraction unitRef="usd" contextRef="i0638c95ee09d4cd68aeefe4b785026d6_D20220101-20220331" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzODAzNg_20c4b72e-a630-4865-b2d0-d00161e4acc4">no</ix:nonFraction> development, regulatory or commercial milestone payments or royalties received as of March&#160;31, 2022.</span></div><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzYwMg_24969c73-7936-4dca-834a-c6ca7f82b6cb" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about changes in the Company's contract balances for the three months ended March&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMi0xLTEtMS0zNDc1Mw_d783c23c-bdec-41f4-891a-f4ec92cf89d4">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMi0zLTEtMS0zNDk3MA_b339aebe-fb9e-41a1-8a22-cb6607b94b18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMy0xLTEtMS0zNDk3Mw_237790ad-1743-46ad-929b-05bbe8e6c892">15.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMy0zLTEtMS0zNDk3MA_5bda23ff-24e0-4291-906f-ac44e83d43a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNC0xLTEtMS0zNDk3Mw_2c4d387f-4683-4576-b48b-a7ac35cc040f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i431cda9cb00645c88fdbc954baf2ad13_I20210331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNC0zLTEtMS0zNDk3MA_79e204a6-7d44-4d5a-8d44-f245aa88997d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNi0xLTEtMS0zNDk3NQ_0828d1e8-0791-4550-9802-c440736234bc">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNi0zLTEtMS0zNDk3NQ_542f575d-c98e-4cd8-8c2c-9bed31589a04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="arvn:CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNy0xLTEtMS0zNDc4Ng_801555be-405c-4542-ae44-a1158fb08054">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNy0zLTEtMS0zNDk3NQ_57a8ea7e-18ef-4e25-8f43-2145797a77d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfOC0xLTEtMS0zNDk3NQ_6038fc88-93d9-45c1-8100-d0d138e94cab">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i431cda9cb00645c88fdbc954baf2ad13_I20210331" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfOC0zLTEtMS0zNDk3NQ_a97151b5-b4a4-468a-9372-16783d80a851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMS0xLTEtMS0zNDY3Nw_556827c7-58ff-453f-81c7-500368045f2f">740.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMTAtMy0xLTEtMzQ5Nzc_ec258c9b-40b1-42a0-9b51-9743fc1ab6e9">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMi0xLTEtMS0zNDY4MA_e4111376-01c6-4749-b27a-2c46fb0325b6">24.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMTEtMy0xLTEtMzQ5Nzc_67fc0d73-ac4d-47f8-991a-cba18c77315c">5.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMy0xLTEtMS0zNDY4Ng_73bdf976-88d8-4224-b8c1-14e3cd197829">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMTItMy0xLTEtMzQ5Nzc_b75eb012-c869-41a8-9f97-1cf490effbe7">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNC0xLTEtMS0zNDY5Ng_e955cef7-b32d-4ecb-9b19-28e3f76dcc7c">719.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i431cda9cb00645c88fdbc954baf2ad13_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMTMtMy0xLTEtMzQ5Nzc_c7efa5eb-8510-448b-81f7-f623ad88559a">42.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><ix:continuation id="ibbea6255f3144911bcb5cf933182fc41"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzYwMw_75d2d12e-7370-434b-8683-066580fc3f9a" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of March&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzA0MDY3MQ_537dec3d-b734-400e-bacb-2a51515db046">719.4</ix:nonFraction> million, which is expected to be recognized in the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id1a386ef91f34522865c79b14ea0b285_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfMC0xLTEtMS0yMDgzNw_aa98d425-f892-443e-b1fe-0a5a1bbe2858">150.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie20688dc77174b7f82b8e1f0419169f7_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfMS0xLTEtMS0yMDgzNw_c4b16414-d34f-4297-989c-db9413a593af">190.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2aa7f1a0cfca4e97964f782ad3f98919_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfMi0xLTEtMS0yMDgzNw_0631c054-128f-4e85-b9df-565d1b5c8143">136.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i102061bc526443889b82c4150e2f488c_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfMy0xLTEtMS0yMDgzNw_752bc1e8-b42b-4270-8e93-863718c5f35a">100.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i882466d699264682b0f4ba252c12d5e5_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfNC0xLTEtMS0yMDgzNw_90a382c7-5187-4ab2-a589-b6a89b4415d1">63.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4345a91c389b4360afb19c57116d7ac2_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfNS0xLTEtMS0yMDgzNw_8ed69761-4350-44fb-8b15-36ead46c6403">34.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310b023a39314b88848d936e4457d7e7_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfNi0xLTEtMS0yMDgzNw_8c5e8898-96af-4ae9-837e-24ab44fd0ef7">44.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfNy0xLTEtMS0yMDgzNw_fd473969-e6ca-4848-9492-f50d5cc3f028">719.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5f8d406ab3aa45be82590782b0fe2e1d_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RleHRyZWdpb246MWJiNWNmMjFkZmNlNDMyMWJkNjkxM2M2MGY0MmM3NzZfMzEzNg_c21f88eb-a8d9-4bd4-92bf-a140f82c7ee0" continuedAt="i16e65f5abb6c408e990bd50562c53404" escape="true">Marketable Securities and Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="i16e65f5abb6c408e990bd50562c53404"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities consist of corporate bonds and government securities which are adjusted to fair value at each balance sheet date based on quoted prices, which are considered Level 2 inputs. </span></div><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RleHRyZWdpb246MWJiNWNmMjFkZmNlNDMyMWJkNjkxM2M2MGY0MmM3NzZfMzEzNw_f6de12f4-0836-436a-87e7-7f019cc090ae" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities measured at fair value on a recurring basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 - 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3ed48a9634a74706aa50054bf2177c4f_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMi00LTEtMS0yMDgzNw_7d77eb7a-8d38-4b80-af3c-ba896436dc95">797.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3ed48a9634a74706aa50054bf2177c4f_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMi02LTEtMS0yMDgzNw_9760dae9-b5ff-4b38-9674-dfdca6fcc17e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i3ed48a9634a74706aa50054bf2177c4f_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMi04LTEtMS0yMDgzNw_2a62743f-bc17-4665-8116-4cc427368801">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3ed48a9634a74706aa50054bf2177c4f_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMi0xMC0xLTEtMjA4Mzc_98247007-1e86-4f50-88f3-a4c70ed57c75">793.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic25cf701d1374c4c9ab79f7036a6ab1e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMy00LTEtMS0yMDgzNw_c599ab41-405d-4de3-8e4c-0b9dc99f2d49">525.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic25cf701d1374c4c9ab79f7036a6ab1e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMy02LTEtMS0yMDgzNw_1d70262d-b462-4bb4-8d7a-46880cdf3bde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic25cf701d1374c4c9ab79f7036a6ab1e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMy04LTEtMS0yMDgzNw_b3c8d716-ca27-461c-9c14-21de951ec45e">14.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic25cf701d1374c4c9ab79f7036a6ab1e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMy0xMC0xLTEtMjA4Mzc_63499a26-2b2e-434d-9dc2-bf047bc3330d">511.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 - 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i95d305fe2172466ab61fdf2e1b9c22b3_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC02LTEtMS0yOTQ5MA_8ad598c5-36fe-4efd-be27-8d39e4611d87">41.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i95d305fe2172466ab61fdf2e1b9c22b3_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC04LTEtMS0yOTQ5MA_058110fd-a070-44e5-b32f-3ae93ae54be5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i95d305fe2172466ab61fdf2e1b9c22b3_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC0xMC0xLTEtMjk0OTA_01260710-407f-466c-875a-56bc0e701ed1">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i95d305fe2172466ab61fdf2e1b9c22b3_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC0xMi0xLTEtMjk0OTA_7238106e-d19f-47cc-99de-7e72d4e30487">41.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2ca9825bcc0c4b3cba9688ebc7c3599c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC00LTEtMS0yMDgzNw_61f2013b-3b6e-4c38-95e7-913b4d124eb6">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2ca9825bcc0c4b3cba9688ebc7c3599c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC02LTEtMS0yMDgzNw_f9edea6d-2711-44da-af6f-2469f5c713f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2ca9825bcc0c4b3cba9688ebc7c3599c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC04LTEtMS0yMDgzNw_bc4e0bb7-24dd-4de2-be09-2458931cda18">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2ca9825bcc0c4b3cba9688ebc7c3599c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC0xMC0xLTEtMjA4Mzc_06c119ad-9ec8-4579-88df-1762e5f94842">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i57a0f6dd7ca44f28ac6939f93d4228da_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNS00LTEtMS0yMDgzNw_faa3ecaa-160a-42dd-a1c3-19450a644161">1,384.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i57a0f6dd7ca44f28ac6939f93d4228da_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNS02LTEtMS0yMDgzNw_dc30ddb9-d54c-4e13-a077-47eb496a1de4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i57a0f6dd7ca44f28ac6939f93d4228da_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNS04LTEtMS0yMDgzNw_0ffea319-dd1b-44dc-afa0-953b7516e839">18.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i57a0f6dd7ca44f28ac6939f93d4228da_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNS0xMC0xLTEtMjA4Mzc_d3d4410e-8ece-45df-b74b-1939aa472502">1,366.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ife24052b16484996b2ccebc986eefddf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMi00LTEtMS0yMDgzNw_fbe1e186-e43f-4572-82eb-0344d8d528c6">784.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ife24052b16484996b2ccebc986eefddf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMi02LTEtMS0yMDgzNw_62117d34-d7fb-4989-b6e8-16b6a389d04f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ife24052b16484996b2ccebc986eefddf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMi04LTEtMS0yMDgzNw_d17f55d8-5063-48e1-bd11-c586d3512db6">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ife24052b16484996b2ccebc986eefddf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMi0xMC0xLTEtMjA4Mzc_eaf5e57b-666b-4502-85a3-2f4a6960f554">783.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i248d829d7548451dae53a9e40b3985ca_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy02LTEtMS0yNzA4NQ_216f16fd-a410-4016-98fa-34d36cfbb9ab">582.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i248d829d7548451dae53a9e40b3985ca_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy04LTEtMS0yNzA4NQ_4591feb6-7162-4ce0-9772-d47c47b3ddfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i248d829d7548451dae53a9e40b3985ca_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy0xMC0xLTEtMjcwODU_dc7e8b1a-ab31-4c4a-88f7-22a3508600f1">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i248d829d7548451dae53a9e40b3985ca_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy0xMi0xLTEtMjcwODU_e292948a-c11e-448e-a10f-a9bd44d63f26">578.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic556a60245544ecf94e8f539795821fb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfNC02LTEtMS0yNzA4NQ_3fd59dc6-e6cc-4219-9bca-31e1163ffd1e">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic556a60245544ecf94e8f539795821fb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfNC04LTEtMS0yNzA4NQ_4e8cb840-9855-4bc5-bd13-95eda2ade568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic556a60245544ecf94e8f539795821fb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfNC0xMC0xLTEtMjcwODU_547bebba-e9fc-44d1-8c7e-bb018f07fb3c">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic556a60245544ecf94e8f539795821fb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfNC0xMi0xLTEtMjcwODU_5cc8fcb7-b7bf-4cab-8119-80bb8c5bdb89">32.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4e68c26befb7440a88ac95a1480a49a3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy00LTEtMS0yMDgzNw_c4682c15-2391-4ca6-818b-d14471275007">1,398.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4e68c26befb7440a88ac95a1480a49a3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy02LTEtMS0yMDgzNw_1ec7b02c-b5e8-4ae2-98a0-c33e35b06c92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i4e68c26befb7440a88ac95a1480a49a3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy04LTEtMS0yMDgzNw_6cd375dc-9702-4bce-9f58-5144f82988cb">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4e68c26befb7440a88ac95a1480a49a3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy0xMC0xLTEtMjA4Mzc_3c25aa33-4b88-40f3-b75a-67676f05a3c1">1,394.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts receivable, accounts payable and accrued expenses approximate their </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values due to the short-term nature of these assets and liabilities.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RleHRyZWdpb246MWIwMmIzYTk1NDBhNDllYjg0NjFmNzRlM2YxZTQ3ZDJfMzAz_c2d95188-bb3c-48ef-ab3c-e4295f908e48" continuedAt="i1827d761ce8645dd8d9e33ccc32a2d05" escape="true">Property, Equipment and Leasehold Improvements </ix:nonNumeric></span></div><ix:continuation id="i1827d761ce8645dd8d9e33ccc32a2d05"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RleHRyZWdpb246MWIwMmIzYTk1NDBhNDllYjg0NjFmNzRlM2YxZTQ3ZDJfMzA0_009cfa53-13dc-416c-ab0b-e4e894711280" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following at:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9e17a2a0dd9d408188b1eea507950135_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMS0xLTEtMS0yMDgzNw_b14b0320-8af4-49d5-9526-0749e02d0fdf">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="idd25500d0c7946cab2bb104a0d38fbdb_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMS0zLTEtMS0yMDgzNw_2fbb42c8-522b-4be9-812e-d5f64e331bc2">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5c11d105fc7e43e8abf3b8464ed2b242_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMi0xLTEtMS0yOTQ1OQ_6df727c6-1bf8-4cdd-af0c-5b4dbe04408e">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2432c4a5e7ba4d1ea0e0080e009e226b_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMi0zLTEtMS0yOTQ1OQ_a74b0332-91e7-47c8-859f-3737300c6edf">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6e050c23b5444aae82eec5a8826e74b9_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMi0xLTEtMS0yMDgzNw_9fa1dfa2-7b2e-46d5-b477-24fb1a51caed">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iea03b274b37a4adb984dd693b64b3f6c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMi0zLTEtMS0yMDgzNw_15e6b4bb-48fa-40b1-ad94-92d88a7e7e78">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNC0xLTEtMS0yMDgzNw_59dff922-3f65-49ca-8715-5281f284c291">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNC0zLTEtMS0yMDgzNw_516516f8-7b52-48bd-9db3-a38e8fc66068">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNS0xLTEtMS0yMDgzNw_c32ca116-dae6-4ff6-8096-de6085ac7ed2">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNS0zLTEtMS0yMDgzNw_fad593b8-8e1d-4eac-ab1b-f26f627a780e">10.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNi0xLTEtMS0yMDgzNw_68e8405b-02da-4050-8f3b-2715c27e39d0">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNi0zLTEtMS0yMDgzNw_ac2d5422-c583-425a-89d0-605ad2db15b6">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RleHRyZWdpb246MWIwMmIzYTk1NDBhNDllYjg0NjFmNzRlM2YxZTQ3ZDJfMTgw_dbb33da8-bad2-41db-97f5-d061a862de0b">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RleHRyZWdpb246MWIwMmIzYTk1NDBhNDllYjg0NjFmNzRlM2YxZTQ3ZDJfMTg3_35a8ff41-781f-40ed-9bcf-d87affaeed11">1.1</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div id="i5f8d406ab3aa45be82590782b0fe2e1d_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjEwOQ_7b0681fa-2edb-4d98-8e6f-0a99961f69f1" continuedAt="ic7924806a00c4e12b237011d0858a7c4" escape="true">Right-of-Use Assets and Liabilities</ix:nonNumeric></span></div><ix:continuation id="ic7924806a00c4e12b237011d0858a7c4" continuedAt="i08767b22f7194d768d19313e51d35d9d"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate ranges from <ix:nonFraction unitRef="number" contextRef="i5d23fd19f97f40e78883b6aa5fea051f_I20220331" decimals="3" name="arvn:PercentageOfIncrementalBorrowingForLeasePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfODY2_6891fada-a55c-4d52-89cc-ccd29a9a1f27">3.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ib57b0b1255a54112b386652ff3e4aa50_I20220331" decimals="3" name="arvn:PercentageOfIncrementalBorrowingForLeasePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfODcw_8849e24f-ef6f-4fcb-988d-f6b2a5654ef4">4.1</ix:nonFraction>%. Lease expense is recognized on a straight-line basis over the lease term. Some of the Company&#8217;s leases include options to extend or terminate the lease. The Company includes these options in the recognition of the Company&#8217;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise such options.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a lease for approximately <ix:nonFraction unitRef="sqft" contextRef="i209db759fd014857b8ce446bc1b613a2_I20210531" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjE5OTAyMzI1NzcyMw_7bee4d18-1be9-45e6-b66c-c31b73f5b819">160,000</ix:nonFraction> square feet of laboratory and office space to be occupied in 2024. In connection with the signing of the lease, and at the Company&#8217;s election to increase the landlord&#8217;s contribution to the tenant improvement allowance, the Company issued a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="i209db759fd014857b8ce446bc1b613a2_I20210531" decimals="-5" name="us-gaap:PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMTUyNg_fc6eec26-af89-4a56-84b4-d148d11e9232">4.5</ix:nonFraction> million, collateralized by a certificate of deposit in the same amount, which is presented as restricted cash at March&#160;31, 2022. Once occupied, the base rent will range from $<ix:nonFraction unitRef="usd" contextRef="i3ea0fe2f906848acb4fdf90217135445_D20210501-20210531" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMTY4Mw_eba7eeae-6498-4a2d-a800-f329e1275208">7.7</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i44a11df340c6411ab9d44c8a5bdca3b6_D20210501-20210531" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMTY4OQ_17684a47-91e2-48e9-a403-3295c42ede89">8.8</ix:nonFraction> million annually over a <ix:nonNumeric contextRef="ie80d3e8623984738bd827627643f522d_D20210501-20210531" name="arvn:BaseLeaseRentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjExMA_2aceb46a-781b-47f0-b6c0-0d7edb294139">ten-year</ix:nonNumeric> lease term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than January&#160;31, 2026. The leases have a weighted average remaining term of <ix:nonNumeric contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMTkwMQ_6c779a8f-590a-43fb-9eed-7d420ef239ca">3.1</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjEwNg_7969f479-3215-4af2-bd81-33a72ef28883" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOmM1ODdmY2RiYjNmODQ5M2Y5YjVhOGFiZjM3ZTEyNzc2L3RhYmxlcmFuZ2U6YzU4N2ZjZGJiM2Y4NDkzZjliNWE4YWJmMzdlMTI3NzZfMi0xLTEtMS0yMDgzNw_3ece09da-9f9b-4ae8-82f4-4f60037697bd">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOmM1ODdmY2RiYjNmODQ5M2Y5YjVhOGFiZjM3ZTEyNzc2L3RhYmxlcmFuZ2U6YzU4N2ZjZGJiM2Y4NDkzZjliNWE4YWJmMzdlMTI3NzZfMi0zLTEtMS0yMDgzNw_a26050f5-99b6-496c-a045-a9e69b164480">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><ix:continuation id="i08767b22f7194d768d19313e51d35d9d"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjEwNw_79ad83ad-e705-4306-ba95-d0d06a8a9d2d" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjU4NTdjODE4N2UwZjRmZjI4OThjMDc1NjFlZWZjZmFmL3RhYmxlcmFuZ2U6NTg1N2M4MTg3ZTBmNGZmMjg5OGMwNzU2MWVlZmNmYWZfMy0xLTEtMS0yMDgzNw_c051f1f4-e303-4279-bbac-27b45ee55fa7">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjU4NTdjODE4N2UwZjRmZjI4OThjMDc1NjFlZWZjZmFmL3RhYmxlcmFuZ2U6NTg1N2M4MTg3ZTBmNGZmMjg5OGMwNzU2MWVlZmNmYWZfMy0zLTEtMS0yMDgzNw_de5eecbf-c400-4061-8595-af393798e9c5">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjU4NTdjODE4N2UwZjRmZjI4OThjMDc1NjFlZWZjZmFmL3RhYmxlcmFuZ2U6NTg1N2M4MTg3ZTBmNGZmMjg5OGMwNzU2MWVlZmNmYWZfNS0xLTEtMS0yMDgzNw_bb4fed26-97e9-47c4-abbb-318e97ce67ec">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjU4NTdjODE4N2UwZjRmZjI4OThjMDc1NjFlZWZjZmFmL3RhYmxlcmFuZ2U6NTg1N2M4MTg3ZTBmNGZmMjg5OGMwNzU2MWVlZmNmYWZfNS0zLTEtMS0yMDgzNw_e7d01a7a-ebeb-45c9-9935-b4383fb847ab">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjEwOA_d3a990dc-0154-4a29-aa23-ab303bfa31d5" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for operating leases as of March&#160;31, 2022, are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfMC0xLTEtMS0yMDgzNw_3e14dc75-737b-4db8-9c3a-fa9be4a90e73">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfMS0xLTEtMS0yMDgzNw_29878eac-c58b-497b-92ce-ee220f2351f9">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfMi0xLTEtMS0yMDgzNw_0a8bb6b2-a054-4208-b7c6-0779d41b4335">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfMy0xLTEtMS0yMDgzNw_f8248cc8-2c04-46be-8c21-8a9219fd5e8f">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfNS0xLTEtMS0yNjcyMw_f70c1561-2bed-42f3-9947-6eb0efdda9c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfNC0xLTEtMS0yMDgzNw_cc01028a-de0f-4ee1-8cf4-e5106ae59d72">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfNS0xLTEtMS0yMDgzNw_0b1fb4cc-c9c5-4521-9f60-ce98a62822e8">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfNi0xLTEtMS0yMDgzNw_2ea4b78b-e579-4ec4-9a3b-77f1485faa89">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5f8d406ab3aa45be82590782b0fe2e1d_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RleHRyZWdpb246MmZmOTUwODRkOTdiNDk1MDlkOTFkOGMyOWZlZWU3MjNfNzE_3e42d362-682b-474a-8dde-34a490c046c3" continuedAt="i48b3246b2054430ca798034fffa5621c" escape="true">Accrued Expenses </ix:nonNumeric></span></div><ix:continuation id="i48b3246b2054430ca798034fffa5621c"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RleHRyZWdpb246MmZmOTUwODRkOTdiNDk1MDlkOTFkOGMyOWZlZWU3MjNfNzI_dbb7865b-16f2-4622-9331-ac729ecc42e9" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMi0xLTEtMS0yMDgzNw_f4a56a51-4650-4a62-bd9c-180aa60197c5">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMi0zLTEtMS0yMDgzNw_23bcf969-9988-4492-b4d2-23b201bcc5ae">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0xLTEtMS0zMTE4NA_0d06b265-3fa3-4588-8557-94fc0f046644">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0zLTEtMS0zMTE4NA_47eeee58-805c-45e4-b0de-fdef6a7b7d1a">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0xLTEtMS0zMzQ5Ng_9a2b52ad-a981-4be7-ae0d-9bc90a127391">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0zLTEtMS0zMzQ5Ng_fc801133-54f8-42ab-b41e-3df0b836ea3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:AccruedProfessionalFeesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0xLTEtMS0yMDgzNw_20439d2e-b730-45c5-b0b0-2320147a9b98">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:AccruedProfessionalFeesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0zLTEtMS0yMDgzNw_26634b13-7c22-4e27-9187-850c018ee89b">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfNC0xLTEtMS0yMDgzNw_041f3859-0ed7-4867-9d22-86be5abb082a">30.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfNC0zLTEtMS0yMDgzNw_65a010d5-642d-47ac-ab76-e10a8213852e">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5f8d406ab3aa45be82590782b0fe2e1d_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfMjA0Mw_27fac540-037e-4ed9-a749-901760420e1e" continuedAt="i20a5d82ca5fb4c4ab6d7b047b020a9f7" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="i20a5d82ca5fb4c4ab6d7b047b020a9f7" continuedAt="i38790ffd00844b79b0b1f56dc031b752"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into an additional Assistance Agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed $<ix:nonFraction unitRef="usd" contextRef="ib76a16c4b82e4fc1afb937c6900e150c_I20180930" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDE4MA_a9df2d12-179c-4dbf-a812-2a2ddf4701d8">2.0</ix:nonFraction> million under the 2018 Assistance Agreement in September 2018, of which $<ix:nonFraction unitRef="usd" contextRef="i4935b90c90e34bf6b3aed0f1df6f02ee_D20180901-20180930" decimals="-5" name="arvn:DebtInstrumentLoanForgiveness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDE5Ng_1eb4fa51-85f6-4598-a09a-082a30ef0ece">1.0</ix:nonFraction> million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of <ix:nonFraction unitRef="number" contextRef="ib76a16c4b82e4fc1afb937c6900e150c_I20180930" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDIwNQ_d033ab47-3736-4846-8490-fa89b2d2442d">3.25</ix:nonFraction>% per annum, with interest-only payments required for the first <ix:nonNumeric contextRef="i4935b90c90e34bf6b3aed0f1df6f02ee_D20180901-20180930" name="arvn:DebtInstrumentInterestPaymentsTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDIxNw_b3b79ff8-b1b8-4088-a582-5e3995971573">60</ix:nonNumeric> months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through 2028, with a default penalty of repayment of the full original funding amount of $<ix:nonFraction unitRef="usd" contextRef="ib76a16c4b82e4fc1afb937c6900e150c_I20180930" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDIzMw_6bc352db-8c11-4dc4-9b0e-971df28895c2">2.0</ix:nonFraction> million plus liquidated damages of <ix:nonFraction unitRef="number" contextRef="i4935b90c90e34bf6b3aed0f1df6f02ee_D20180901-20180930" decimals="3" name="arvn:PercentageOfLiquidatedDamages" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDI0MA_96c5b243-c7be-4cfa-b011-51385ba86d8e">7.5</ix:nonFraction>% of the total amount of funding received. At March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MTcyMw_edcfd2cc-0b69-4cbb-8472-08737ff750ff">1.0</ix:nonFraction> million remains outstanding under the 2018 Assistance Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an Assistance Agreement with the State of Connecticut entered into in 2014 (the &#8220;2014 Assistant Agreement&#8221;) under which all the borrowings by the Company were forgiven, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $<ix:nonFraction unitRef="usd" contextRef="i73790ff93f1f4e57acc10cab17dc2e89_I20141231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MjE0Mw_08aa2143-5f62-43ef-8e22-b3841d760be0">2.5</ix:nonFraction> million plus liquidated damages of <ix:nonFraction unitRef="number" contextRef="i0dd70cc9b901409ab550af0ec999338f_D20140101-20141231" decimals="3" name="arvn:PercentageOfLiquidatedDamages" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MjE3NA_67b052a9-13b0-42b0-b2c0-d4d685925441">7.5</ix:nonFraction>%. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><ix:continuation id="i38790ffd00844b79b0b1f56dc031b752"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfMjA0NA_e49eda8d-86ec-4c4c-af25-f662be915399" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt for the years ending December&#160;31 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMC0xLTEtMS0yNjUyNA_85f4ba4c-8ec2-4b47-bc28-869c7a87256b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMC0xLTEtMS0yMDgzNw_3f4cb524-aac1-43a2-8986-5293f0ffa1c8">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMS0xLTEtMS0yMDgzNw_d63be136-a011-41b1-a836-21bdeb2e09e9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMy0xLTEtMS0yNjUyNA_57ca97b5-07de-4114-8e8b-a8f5de5b4d5a">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfNC0xLTEtMS0yNjUyNA_312c940a-5602-4437-98e4-7fc14bcae32c">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="arvn:LongTermDebtMaturityYearSix" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMi0xLTEtMS0yMDgzNw_6fb6e77c-f670-4978-87be-84783560eb73">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMy0xLTEtMS0yMDgzNw_da44f74e-0171-4bc0-b6a9-9fbeb7941794">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, interest expense was immaterial.</span></div></ix:continuation><div id="i5f8d406ab3aa45be82590782b0fe2e1d_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODE3Mg_3fbd2812-f2c3-4410-92ff-d3c401bff37f" continuedAt="i94f17ee2166e42d2aa1be871ed144476" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="i94f17ee2166e42d2aa1be871ed144476" continuedAt="i64987c9b6c8e43c788b7b3f46ea382f1"><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Distribution Agreements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp; Company (&#8220;Piper Sandler&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $<ix:nonFraction unitRef="usd" contextRef="i060bd9cd585847318e2f9ad13a0d80e6_I20210831" decimals="-5" name="arvn:MaximumAggregateOfferingPriceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzMDU0Mg_bfbe808b-0855-4728-9707-939a0e556c5b">300.0</ix:nonFraction> million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the common stock registered under the Company's universal shelf registration statement pursuant to one or more &#8220;at-the-market" offering. During the quarter ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i5cddce78d1d948c5b583d717cd77e28a_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfMTU1NQ_7e2103ab-eee1-412d-8979-8dc3a703b59c">no</ix:nonFraction> shares have been issued under this agreement.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the &#8220;2018 ESPP&#8221;), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i45363eaf411f4c0fa67bd782a95bcb4c_I20180930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfMjYyMA_01a8d0c8-453b-4506-afac-16f1ab7b0191">311,850</ix:nonFraction> shares of the Company&#8217;s common stock. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2018 ESPP increase, pursuant to the terms of the 2018 ESPP, by additional shares equal to <ix:nonFraction unitRef="number" contextRef="ib22a7c97a95649208e3e16626fb046fa_D20200101-20200101" decimals="2" name="arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfMjgzMQ_3face9f5-16f6-4a10-8563-fde84bf18f01"><ix:nonFraction unitRef="number" contextRef="i102371b1a4f74f1989575feb5349c7e8_D20220101-20220101" decimals="2" name="arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfMjgzMQ_4c78b31c-d150-4728-94c2-de0878a2b28e"><ix:nonFraction unitRef="number" contextRef="i9d11b00f18034e2faf571d32e08733be_D20210101-20210101" decimals="2" name="arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfMjgzMQ_99079aa0-b239-4179-9bff-2641f34b99df">1</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company&#8217;s then-outstanding common stock, effective as of January 1 of each year. As of March&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i6baa8537a2484bdcbd212331111a5ab2_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzMjA3Nw_b1723404-4997-45c0-a84e-14de6c3ad014">2,005,714</ix:nonFraction> shares remained available for purchase. During the three months ended March&#160;31, 2022 and 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i283e92babacf44249b5ac15c0401dae2_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzMjMyOQ_284b57c6-ddc2-4d27-bdbd-322631512c26">5,749</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2fcf33d6545f49979c8996508f1dafdc_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzOTE3MQ_cf452139-469e-4d61-a322-2d7615560743">12,050</ix:nonFraction> shares, respectively, of common stock under the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incentive Share Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Fourth Amendment to the Company&#8217;s Incentive Share Plan (the &#8220;Incentive Plan&#8221;) adopted in March 2018, the Company was authorized to issue up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic72afe64f6d942ceaec3f2bcea014191_I20180331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNDY5Nw_2748640b-53a0-4beb-9620-7e33392bd5db">6,199,477</ix:nonFraction> incentive units pursuant to the terms of the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNDkwNA_c8db3740-5782-4c3e-b75d-6ff6aad14517">one</span> to <ix:nonNumeric contextRef="i49ed2e413afc4936a46c5ae2d54150a8_D20180301-20180331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNDkxMA_beda9855-ee29-4ad6-ba95-da6b73e14174">four years</ix:nonNumeric>. The Incentive Plan was terminated in September 2018. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Stock Incentive Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s board of directors adopted, and the Company&#8217;s stockholders approved, the 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s initial public offering. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) <ix:nonFraction unitRef="shares" contextRef="i135de9f10c6a4846ba8e3bd9311c3aaf_I20180930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNTMyMg_c0edac75-03f3-4d1f-8dce-8ff6b5857f04">4,067,007</ix:nonFraction> shares of common stock; plus (2) the number of shares of common stock (up to <ix:nonFraction unitRef="shares" contextRef="i6380e9eea75f4e87923e1958591b5177_I20180930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNTQwMg_f5377291-84f3-455e-a0ed-aae48fb487d6">1,277,181</ix:nonFraction>) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement expired, terminated or were otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><ix:continuation id="i64987c9b6c8e43c788b7b3f46ea382f1" continuedAt="i7f151bea14794c7abf3cb183be2249fb"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and including, the fiscal year ending December 31, 2028, equal to the lesser of <ix:nonFraction unitRef="shares" contextRef="if4075817b88149f4ad4be9a0e24f00bd_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNTk1Nw_ed2bead3-6e50-47df-bbe7-c98ad0a34330">4,989,593</ix:nonFraction> shares of the Company&#8217;s common stock, <ix:nonFraction unitRef="number" contextRef="i671442cf18e9459a9ae011753dc2baf4_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNTk5OA_cbb5ad14-28ca-4776-b182-2c6d83e861da">4</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the year or an amount determined by the Company&#8217;s board of directors. As of March&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i676daf315860494fae1a0db23d870397_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzNDcwMw_c89d250c-e8dd-4903-a6ef-ba2bd22c17b5">2,849,537</ix:nonFraction> shares remained available for issuance under the 2018 Plan. Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or canceled without having been fully exercised or are forfeited in whole or in part shall be available for future grants of awards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, the Company recognized compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i2a028511c76147dfa9eea3ef963d7391_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNjU4NA_6ac96fb8-2c09-48e5-b67e-f553fa914054">16.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i22436d4d6b37470dae576ae029c13e17_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNjU5MQ_322ecf09-2968-4edb-a16e-f2a9a822c29f">10.3</ix:nonFraction> million, respectively, relating to the issuance of incentive awards. At March&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i433048cb8a22434c9c966ee4a08d5783_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNjc4Mg_e5506459-e027-44ed-9183-0b40528a7668">93.1</ix:nonFraction> million of unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately <ix:nonNumeric contextRef="i2a028511c76147dfa9eea3ef963d7391_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNjkwMw_55ecd2fa-82ae-4364-9247-da9738979e5d">two years</ix:nonNumeric>.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODE3Mw_50452851-08f7-47e7-a8b9-3b9e6d79d87a" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during the three months ended March&#160;31, 2022 and 2021 was determined using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMS0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmM5MTFlY2ZlYjJhNzRhNGFhMGI0ZTgzNjZmODdlOGY4XzQ_4b3a2696-536e-46ad-8aff-55085677380f">73.2</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMS0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmM5MTFlY2ZlYjJhNzRhNGFhMGI0ZTgzNjZmODdlOGY4Xzk_a815f8d2-9f0d-45bc-8b21-140ff8e98f59">76.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMS0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjcwMjFhY2RhNjE3MjRiN2JhYjBhMDUwZmFjZjYzYTc4XzQ_f56098d9-68a9-4f7c-b9b3-45b9ab332ecf">77.4</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMS0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjcwMjFhY2RhNjE3MjRiN2JhYjBhMDUwZmFjZjYzYTc4Xzk_cd0bc2a2-3dda-405d-a53a-7e19d6449ad0">78.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i61acd713861543de9a324e7901c946b2_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMi0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjJlNDUyZDk5NmM4MTQ1MTdiYmNmNjA5Yjg4MjM0Y2RhXzQ_39ad28a4-8441-480b-8246-6b1da62e4bdb">5.6</ix:nonNumeric> - <ix:nonNumeric contextRef="i89b128b20436420eb6e8f593916c4d49_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMi0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjJlNDUyZDk5NmM4MTQ1MTdiYmNmNjA5Yjg4MjM0Y2RhXzk_10ae2479-0937-497c-ab12-8fabc2389094">7.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ic0183429203148f5b51f86ce4175b9db_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMi0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmFjOThiZjdmMWViMTRhYzQ5NDE2YTFmM2E4Y2JhMjk2XzQ_a4c1510a-4e32-4a6f-8053-d54182688c16">5.6</ix:nonNumeric> - <ix:nonNumeric contextRef="i671f93d65ec949f6a09add626b9cc77d_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMi0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmFjOThiZjdmMWViMTRhYzQ5NDE2YTFmM2E4Y2JhMjk2Xzk_e383f357-1965-4289-831d-bb7c36566f03">7.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMy0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmFjNmY1NTU0NmUzYzQ5YjFiYzM1NWNlYzkyYjc1YTdmXzQ_08c98ea6-0e16-4a49-83be-138dd2b2bff3">1.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMy0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmFjNmY1NTU0NmUzYzQ5YjFiYzM1NWNlYzkyYjc1YTdmXzk_5a0b15e6-61e6-4f31-b757-6c7811d8d284">2.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMy0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjhjZjliMmY2ZTYxODRkYjQ5NTYwMjRhOGU0MTY4YzliXzQ_1b25f2e9-15da-4690-aacc-2040d0478aed">0.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMy0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjhjZjliMmY2ZTYxODRkYjQ5NTYwMjRhOGU0MTY4YzliXzk_31e1e481-7e88-4efe-9ada-0d8b1d6b8fc8">1.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNC0xLTEtMS0yMDgzNw_19344529-b014-4224-bd1e-b4b1f9a15529">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNC0zLTEtMS0yMDgzNw_afc0ca15-7e14-4684-bb0b-7723c2da4608">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idfe72e9e1d7f4ef38b63abc9e9247aa6_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNS0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmZmYjdkODVjNTU4MjRhMjdhYTM4ZTIzNjA2OGNhNzRjXzQ_718f5640-a28e-4bc6-a661-cef2df58b98e">64.19</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i4067c8a18e3a462ab80648a7b2f71e05_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNS0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmZmYjdkODVjNTU4MjRhMjdhYTM4ZTIzNjA2OGNhNzRjXzk_4eea3042-83b2-445a-9c87-70be83e2e830">78.91</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id6884606b15a4b1c92ccbbd8551ca251_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNS0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjc3NTc1NjY3Nzc1MDQ4YWI4NThjZGEyYTQ5OWZmNTcxXzQ_308567c7-0c50-4210-98f9-142df61f68de">77.51</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i649860d7edd84bfdb3be6ff127c824e6_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNS0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjc3NTc1NjY3Nzc1MDQ4YWI4NThjZGEyYTQ5OWZmNTcxXzk_0890b9b4-a7d4-43ca-9136-004bdd3b078f">82.21</ix:nonFraction></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the Company&#8217;s common stock has not been trading for a sufficient period of time, the Company calculates volatility of its common stock by utilizing a weighted average of a collection of peer company volatilities and its own common stock volatility. The expected term is calculated utilizing the simplified method. </span></div><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODE2OQ_b043fc85-09ed-43b8-bd05-23f169bd8756" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Options </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Term (Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i98d32989f98049b98b156c00b715a0f0_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMS0yLTEtMS0yMDgzNw_d1d15104-b152-48eb-a4c9-26017efdc710">5,343,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98d32989f98049b98b156c00b715a0f0_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMS00LTEtMS0yMDgzNw_c2fea9be-ab77-4c5e-9ded-da4e268af4bb">44.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMi0yLTEtMS0yMDgzNw_cf209888-8e07-4d5a-b93a-4d4b1aa34328">1,234,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMi00LTEtMS0yMDgzNw_d72c4de3-5923-41e4-906f-4ca86136ad7a">65.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMy0yLTEtMS0yMDgzNw_16ed894b-8e57-45cf-bdf2-fd3915a6c100">117,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMy00LTEtMS0yMDgzNw_1bbcd5e9-e316-4a5c-ae86-a6626ffdac8f">17.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNC0yLTEtMS0yMDgzNw_61d37977-c064-4dfb-b2ba-60fafd7a93dd">101,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNC00LTEtMS0yMDgzNw_f0ca702e-9ccd-43fd-9f78-5f6e35df7496">57.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i676daf315860494fae1a0db23d870397_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNS0yLTEtMS0yMDgzNw_6ffa6281-92f0-4292-a403-6583cb05dd4b">6,359,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i676daf315860494fae1a0db23d870397_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNS00LTEtMS0yMDgzNw_9336cb0a-3324-4b30-9d58-2b7a1539967e">49.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNS02LTEtMS0yMDgzNw_065181d2-c4d7-4f28-a00a-54f10f90852d">8.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i676daf315860494fae1a0db23d870397_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNS04LTEtMS0yMDgzNw_6685627e-cd09-4024-8714-46b24f850b3f">137.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exercisable at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i676daf315860494fae1a0db23d870397_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNi0yLTEtMS0yMDgzNw_09b0e345-ab0c-4aaa-8501-2e9ccd78953c">2,739,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i676daf315860494fae1a0db23d870397_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNi00LTEtMS0yMDgzNw_b1a9e251-5d13-4e6c-84d7-9d38a2f68011">31.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNi02LTEtMS0yMDgzNw_c79329b6-0013-44ca-8413-d389adc3fba9">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i676daf315860494fae1a0db23d870397_I20220331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNi04LTEtMS0yMDgzNw_827e12b6-1b5b-44d2-b345-4195ecec2d68">103.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><ix:continuation id="i7f151bea14794c7abf3cb183be2249fb"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzNzEzMg_76a6f1ce-04b9-4e92-9e3d-11994f2afd4c">43.02</ix:nonFraction>. The total intrinsic value of options exercised during the three months ended March&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzNzIwNg_9cb6ebd0-4110-42c2-8a23-6c7eb6f5fbc5">5.9</ix:nonFraction> million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i676daf315860494fae1a0db23d870397_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzNjE3Mg_9c2adfde-6d0b-4c8e-bedb-32efed6f6cbd">5,995,790</ix:nonFraction> stock options under the 2018 Plan that have vested or are expected to vest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODE3MA_389ccf2a-7982-49f2-b9a1-01b6ad82c79b" continuedAt="i1dda6b5c53704d72a10f367ab17a11e3" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock award activity under the Incentive Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include restricted stock granted to employees, directors and consultants.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i28d56097cbd64f55a89cefb5e23f4fdd_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMS0yLTEtMS0yMDgzNw_cd6a2cea-34fd-4a8e-b88b-c298bab507e7">30,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28d56097cbd64f55a89cefb5e23f4fdd_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMS00LTEtMS0yMDgzNw_bd60f215-b36d-46ca-b1e7-b67ab9d396d1">16.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i3a949a59544846bea32da66debdc0f5c_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMi0yLTEtMS0yMDgzNw_f54c02d0-c92b-42f5-bb5e-cc56cacf7fdc">23,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a949a59544846bea32da66debdc0f5c_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMi00LTEtMS0yMDgzNw_b31da503-4b33-495b-bb59-3b8d02cb72d0">16.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i3a949a59544846bea32da66debdc0f5c_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMy0yLTEtMS0yODExMQ_b677f457-2ce0-4c14-9df8-9137836e6a72">1,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a949a59544846bea32da66debdc0f5c_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMy00LTEtMS0yODExMQ_4ae194a8-06b1-4101-9173-004613b957fd">16.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id20769d0f7ab420fb3b232e6d0b967fe_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMy0yLTEtMS0yMDgzNw_0c3f6a67-04ea-4672-bf3f-00f3306f2547">5,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="id20769d0f7ab420fb3b232e6d0b967fe_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMy00LTEtMS0yMDgzNw_34ff549e-a0e7-414f-ba0c-ad5f7a3f7687">16.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i8e513085eec343c4b787da47473ad4c0_I20220331" decimals="INF" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzNTkyNA_35ce34fa-fb37-4889-9931-c6fd636a9e44">5,810</ix:nonFraction> restricted shares under the Incentive Plan that are expected to vest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><ix:continuation id="i1dda6b5c53704d72a10f367ab17a11e3"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity under the 2018 Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include restricted stock units granted to employees. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock units at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i70ebb09ff5e84d1aa19beee9d199a829_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMS0yLTEtMS0yMDgzNw_fc05b851-c223-4bbb-b08f-91ce6391b366">88,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i70ebb09ff5e84d1aa19beee9d199a829_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMS00LTEtMS0yMDgzNw_8fe25adc-08fb-40cd-aff7-b258f74944f8">20.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMi0yLTEtMS0yODE3MQ_38482701-d4e5-435b-bb95-c16bb50d536b">167,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMi00LTEtMS0yODE3MQ_848954f0-2304-4039-b778-9d8295f74a2e">64.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMi0yLTEtMS0yMDgzNw_95357865-8d1a-46e8-807d-e4c8b876721f">38,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMi00LTEtMS0yMDgzNw_9338a975-1c63-4a6e-b59c-b3eab7baf09d">19.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMy0yLTEtMS0yMDgzNw_d2e553ed-3b04-493d-b8c8-4baae3871724">3,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMy00LTEtMS0yMDgzNw_b1610d51-395d-45e9-8349-34c22ab65cf4">21.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock units at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i726c996b1f294aea83f7646f6c212dd2_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfNC0yLTEtMS0yMDgzNw_55afa567-2633-45e6-be52-a95326e65776">214,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i726c996b1f294aea83f7646f6c212dd2_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfNC00LTEtMS0yMDgzNw_8290b76e-b9a1-4cf5-b789-197fc080493f">55.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i676daf315860494fae1a0db23d870397_I20220331" decimals="INF" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODA4OQ_9b6ad4cc-2638-4220-8f4a-0c5f4e84e6cf">174,335</ix:nonFraction> restricted stock units under the 2018 Plan that have vested or are expected to vest.</span></div></ix:continuation><div id="i5f8d406ab3aa45be82590782b0fe2e1d_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfMTAwMQ_f9a8e097-eb96-44e0-a183-7fca7239aad1" continuedAt="ia754f84608a54e5abb6dc59060cdf061" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="ia754f84608a54e5abb6dc59060cdf061" continuedAt="ie28b5dfe31ce4b15850db4dfc1eb803f"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate was <ix:nonFraction unitRef="number" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfOTM0NTg0ODgzNzEwMQ_4ed53fb9-70a6-47ae-88b2-b2f6560c66aa">7.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfNjA_00df6d9b-942b-4fb6-8768-e5441ac02fe2">0.0</ix:nonFraction>% for the three months ended March&#160;31, 2022 and 2021, respectively. The primary reconciling items between the federal statutory rate of <ix:nonFraction unitRef="number" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfOTM0NTg0ODgzNzYxOA_09457a69-0270-4df8-bba7-79d8b726dc2e">21.0</ix:nonFraction>% for the three months ended March&#160;31, 2022 and the Company&#8217;s overall effective tax rate of <ix:nonFraction unitRef="number" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfODc5NjA5MzAyNDA5Ng_2bf39c95-f074-4617-aae0-6524d1297d38">7.6</ix:nonFraction>% was the effect of equity compensation, deferred state income taxes and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of <ix:nonFraction unitRef="number" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfOTM0NTg0ODgzNzUyOQ_559862ba-0586-40cb-9922-3cb3c6b7516d">21.0</ix:nonFraction>% for the three months ended March&#160;31, 2021 and the Company&#8217;s overall effective tax rate of <ix:nonFraction unitRef="number" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfODc5NjA5MzAyNDEwNA_58d7c678-089e-4c8e-92b5-8e2dd63823ea">0.0</ix:nonFraction>% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company is expecting to have net taxable income for the current year, resulting in current income tax expense for the period, and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div><ix:continuation id="ie28b5dfe31ce4b15850db4dfc1eb803f" continuedAt="ia9b8d219710f44a48aab430ce6dd3ac4"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expects to fully utilize its net operating loss and credit carryforwards during the year. This is primarily due to revenue recognition for tax purposes from the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ARV-471 Collaboration Agreement</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ia9b8d219710f44a48aab430ce6dd3ac4"> and the capitalization of qualified research and development expenses incurred on or after January 1, 2022. Under the Tax Cuts and Jobs Act of 2017, qualified research expenses incurred after 2021 are no longer immediately deductible for tax purposes and instead must be amortized over at least five years for tax purposes. A valuation allowance has been established against the Company&#8217;s net deferred tax assets, including the deferred tax liabilities resulting from the deferred revenue and deferred tax assets associated with the capitalization of research and development expenses for tax, since the Company expects to incur tax losses again after the current year.</ix:continuation> </span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RleHRyZWdpb246ZWYxYWE4ZmEwMTQ5NGVlYThiODViZmVmMTBjZjUyODVfMTA2_13b09cf3-0757-4de0-9af7-55193d638ba6" continuedAt="if351b3f0549845a0ba1cb6209843dbfe" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="if351b3f0549845a0ba1cb6209843dbfe"><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RleHRyZWdpb246ZWYxYWE4ZmEwMTQ5NGVlYThiODViZmVmMTBjZjUyODVfMTA3_4ed24ece-1d55-4f05-8640-0cbbbc265fe1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMi0xLTEtMS0yMDgzNw_4bd91451-9a29-4b35-b799-51276d67d205">63.4</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMi0zLTEtMS0yMDgzNw_c65d1faa-c3dd-4dc6-a548-d1a93e5ef1aa">41.0</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average number of common shares outstanding</span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;- basic and diluted</span></div></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMy0xLTEtMS0yMDgzNw_2a941460-aeeb-409f-9b39-3a027cff81e0"><ix:nonFraction unitRef="shares" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMy0xLTEtMS0yMDgzNw_f61c4c1b-5862-4ee8-94e3-8391c4d5b33f">53.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMy0zLTEtMS0yMDgzNw_c60912e3-2467-4d1d-add7-57bbaf71edc3"><ix:nonFraction unitRef="shares" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMy0zLTEtMS0yMDgzNw_e46a9766-55cc-42ef-b162-bf1ecdb7abc7">48.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net loss per common share </span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">-  basic and diluted</span></div></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfNC0xLTEtMS0yMDgzNw_0c49f434-4cdf-4450-ab01-b5390ad8b622"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfNC0xLTEtMS0yMDgzNw_ed672c4c-e4ea-498b-b9de-79488343167c">1.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfNC0zLTEtMS0yMDgzNw_055e3030-ab73-4804-92bc-8c6dec52789f"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfNC0zLTEtMS0yMDgzNw_6cac20e5-71c4-46e6-8558-8c0f0fac708e">0.84</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RleHRyZWdpb246ZWYxYWE4ZmEwMTQ5NGVlYThiODViZmVmMTBjZjUyODVfMTY0OTI2NzQ0MjA5MQ_b15f0545-c36a-48d5-b935-f629b329d109" escape="true"><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the three months ended March&#160;31, 2022 and 2021, and therefore excluded all stock options, restricted stock awards and restricted stock units from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07f988855484455ab096cd4c3443153c_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfMi0xLTEtMS0yNjExMg_f700e9c5-47c1-4705-9849-1ed969c02fb2">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf87072bef5a4f5cbbe0ef6ae8aee71b_D20210101-20210331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfMi0xLTEtMS0yNjAzNw_74a78d6c-47ab-4912-8e08-2ee2c9497c1b">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0b1f35859d641bd8934d7229fc923b5_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfMy0xLTEtMS0yNjExMg_70c6fef8-e3e8-4ba4-9f15-247d5654999c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a02298ba683464096a7a075d1fbb1bb_D20210101-20210331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfMy0xLTEtMS0yNjAzNw_8e1a026b-6f24-4c1a-9693-69a0ef37c0ec">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e55da3f43bb49b19eed56be6d2f98be_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfNC0xLTEtMS0yNjExMg_16e93b7c-0a70-4bb6-9173-f7466aaa508a">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i834d98020bdd4bcca28aae792703f6b0_D20210101-20210331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfNC0xLTEtMS0yNjAzNw_19dcadd0-7d70-4637-9cd1-aeda1773edaa">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfNS0xLTEtMS0yNjExMg_ae737539-3875-41ea-be6e-68a7b7d2712c">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfNS0zLTEtMS0yNjExMg_724725e8-6338-4efb-a609-228b1a74e9c7">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5f8d406ab3aa45be82590782b0fe2e1d_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfMTA2MQ_f5fcb2a0-6e01-47ba-a3a8-7be42878b4bd" continuedAt="i0984f5464d8347eba1acd5ac0b4ccfed" escape="true">Equity Method Investments</ix:nonNumeric></span></div><ix:continuation id="i0984f5464d8347eba1acd5ac0b4ccfed"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company and Bayer CropScience LP (&#8220;Bayer LP&#8221;) formed a joint venture, Oerth Bio LLC (&#8220;Oerth&#8221;), to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. As Oerth is jointly controlled by the Company and Bayer LP, the Company accounts for its <ix:nonFraction unitRef="number" contextRef="i870a90a229974cd0bf199bf46c04b252_I20190731" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfMzY3_a27b8ec8-ef27-4904-bcef-15cd0802e18c">50</ix:nonFraction>% interest using the equity method of accounting.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides to Oerth compensated research and development services and administrative services through a separate agreement. The services rendered by the Company during the three months ended March&#160;31, 2022 and 2021 were immaterial.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses and net loss of Oerth for the three months ended March&#160;31, 2022 and 2021 totaled $<ix:nonFraction unitRef="usd" contextRef="i300ed13406744d99b22892681909ed10_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfNzM0_97888492-b65c-480a-8d96-22cd82b30f0e"><ix:nonFraction unitRef="usd" contextRef="i300ed13406744d99b22892681909ed10_D20220101-20220331" decimals="-5" name="arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfNzM0_f0429ecf-fca1-41f0-94ea-b758dabb1414">4.9</ix:nonFraction></ix:nonFraction> million</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i32f56e3363e742a0b334906ca508739d_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfNzQx_3012a966-cc73-4648-a823-9215b62bf3a7"><ix:nonFraction unitRef="usd" contextRef="i32f56e3363e742a0b334906ca508739d_D20210101-20210331" decimals="-5" name="arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfNzQx_6a6efdc5-7301-48d5-8765-8678fb8d4311">2.6</ix:nonFraction></ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he investment has been reduced to <ix:nonFraction unitRef="usd" contextRef="i4c01ec64eb01468487ce85da6539107d_I20210331" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfOTI0_0fe1a905-d8f6-4cd0-9cc3-c132d7165e83"><ix:nonFraction unitRef="usd" contextRef="i333e000cdba54a2482be61ecd1dd9dbb_I20220331" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfOTI0_5a28484b-f626-4673-8441-e20d7fcdaea1">zero</ix:nonFraction></ix:nonFraction> and, as a result, <ix:nonFraction unitRef="usd" contextRef="i3073ab7967df4bf8a4f22af60b4b3306_D20220101-20220331" decimals="INF" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfOTQ1_1d001570-6d65-4a24-9ca7-432474c2d39e"><ix:nonFraction unitRef="usd" contextRef="ia7f17d29e95941cbb2f7dfbf46b84035_D20210101-20210331" decimals="INF" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfOTQ1_9434cf96-8155-415a-b699-9ccfc8f70872">no</ix:nonFraction></ix:nonFraction> additional losses were recorded against the carrying value of the investment during the three months ended March&#160;31, 2022 and 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and the related notes and discussion and analysis of financial condition and results of operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed on February&#160;28, 2022. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February&#160;28, 2022, our actual results may differ materially from those anticipated in or implied by these forward-looking statements. </span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_85"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. We use our PROTAC Discovery Engine, proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body&#8217;s own natural protein disposal system to selectively remove disease-causing proteins. We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. Our small molecule PROTAC technology has the potential to address a broad range of intracellular disease targets, including those representing up to the 80% of proteins that currently cannot be addressed by existing small molecule therapies, commonly referred to as &#8220;undruggable&#8221; targets. We are using our PROTAC Discovery Engine to build an extensive pipeline of protein degradation product candidates to target diseases in oncology (including immuno-oncology), neuroscience, and other therapeutic areas. Our three lead product candidates are bavdegalutamide, ARV-471, and ARV-766.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bavdegalutamide</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing bavdegalutamide, an investigational orally bioavailable PROTAC protein degrader targeting the androgen receptor protein, or AR, for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC. We initiated a Phase 1 clinical trial of bavdegalutamide designed to assess the safety, tolerability and pharmacokinetics of bavdegalutamide, which also includes measures of anti-tumor activity as secondary endpoints, including reduction in prostate specific antigen, or PSA, a well-recognized biomarker of prostate cancer progression. We received fast track designation for bavdegalutamide for mCRPC in May 2019. We have completed dose escalation in the Phase 1 clinical trial. In the fourth quarter of 2020, we initiated ARDENT, the Phase 2 single agent expansion portion of the bavdegalutamide clinical trial. In the fourth quarter of 2021, we initiated a Phase 1b clinical trial with bavdegalutamide in combination with abiraterone for the treatment of men with mCRPC. In the second quarter of 2022, we intend to initiate discussions with the U.S. Food and Drug Administration, or FDA, about the potential for an accelerated approval pathway with bavdegalutamide in molecularly defined mCRPC and finalize a partnership for a companion diagnostic. In the second half of 2022, we plan to initiate a pivotal trial for patients with AR T878/H875 tumor mutations. We anticipate that future studies will be planned to explore the potential to treat earlier-line patients with AR-dependent tumors who may benefit from bavdegalutamide therapy. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-471</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing ARV-471, an investigational orally bioavailable PROTAC protein degrader targeting the estrogen receptor protein, or ER, for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. We initiated a Phase 1 clinical trial of ARV-471 designed to assess the safety, tolerability and pharmacokinetics of ARV-471, which also includes measures of anti-tumor activity as secondary endpoints. In the fourth quarter of 2020, we initiated a Phase 1b cohort expansion of ARV-471 in combination with Ibrance&#174; (palbociclib). We have completed dose escalation in the Phase 1 clinical trial. In the first quarter of 2021, we initiated VERITAC, the Phase 2 single agent expansion cohort of the ARV-471 clinical trial. In July 2021, we entered into a collaboration agreement with Pfizer Inc., or Pfizer, pursuant to which we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted Pfizer worldwide coexclusive rights to develop and commercialize ARV-471. In December 2021, we presented data from the dose escalation portion of the Phase 1/2 clinical trial at the San Antonio Breast Cancer Symposium. In </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the second half of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, we plan to present data from the VERITAC Phase 2 dose expansion (with patients dosed at 200 and 500 mg) and present safety data from the Phase 1b combination study with palbociclib. Additionally, in 2022, we plan to initiate a Phase 1b clinical trial with ARV-471 in combination with everolimus in patients with metastatic breast cancer, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiate a Phase 1b combination trial with cyclin-dependent kinase, or CDK, inhibitors or other targeted therapies, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiate a Phase 2 clinical trial in patients with early breast cancer in the neoadjuvant setting and initiate two Phase 3 clinical trials in patients with metastatic breast cancer as a monotherapy and in combination.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-766</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing ARV-766, an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. In preclinical studies, ARV-766 degraded all tested resistance-driving point mutations of AR, including L702H, a mutation associated with treatment with abiraterone and other AR-pathway therapies, which bavdegalutamide did not degrade in preclinical studies. In 2021, we initiated a Phase 1 clinical trial for ARV-766 designed to assess the safety, tolerability and pharmacokinetics of ARV-766, which also includes measures of anti-tumor activity as secondary endpoints, including reduction in PSA. In the second half of 2022, we plan to present Phase 1 dose escalation data and initiate a Phase 2 expansion trial for the treatment of men with mCRPC.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bavdegalutamide, ARV-471 and ARV-766 have all demonstrated potent and selective protein degradation in our preclinical studies. We believe favorable clinical trial results in these initial oncology programs would provide validation of our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins regardless of therapeutic area. </span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, many companies have experienced disruptions in their operations and in the markets they serve. We have instated some and may take additional precautionary measures intended to help ensure our employees&#8217; well-being and minimize business disruption. We temporarily shut down our laboratories in mid-March 2020 and initiated work with biology contract research organizations, or CROs, but have since reopened our laboratories and our office-based employees are working in a hybrid of remote and in-person work. We considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on our results of operations and financial position as of March&#160;31, 2022. The full extent of the future impacts of COVID-19 on our operations remains uncertain. A prolonged outbreak could have a material adverse impact on our financial results and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business operations, including the timing and our ability to complete certain clinical trials and other efforts required to advance our preclinical pipeline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced operations in 2013. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and clinical trials and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests, proceeds from our collaborations, grant funding and debt financing. Since inception through March&#160;31, 2022, we raised approximately $1.3&#160;billion in gross proceeds from the sale of equity instruments and the exercise of stock options and had received an aggregate of $780.5&#160;million in payments primarily from collaboration partners.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage company. Bavdegalutamide and ARV-471 are each in Phase 1/2 clinical trials, ARV-766 is in a Phase 1 clinical trial and our other drug discovery activities are at the research and preclinical development stages. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Since inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our net loss was $63.4 million for the three months ended March&#160;31, 2022. As of March&#160;31, 2022, we had an accumulated deficit of $746.3 million. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total operating expenses were $84.2 million for the three months ended March&#160;31, 2022. We anticipate that our expenses will increase substantially due to costs associated with our ongoing and anticipated clinical activities for bavdegalutamide, ARV-471, and ARV-766, development activities associated with our other product candidates, research activities in oncology, neurological and other disease areas to expand our pipeline, hiring additional personnel in research, clinical trials, quality and other functional areas, increased expenses incurred with contract manufacturing organizations, or CMOs, to supply us with product for our preclinical and clinical studies and CROs for the synthesis of compounds in our pre-clinical development activities, as well as other associated costs including the management of our intellectual property portfolio. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate revenue from sales of any product for many years, if ever. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research or product development programs or any future commercialization efforts, or to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.</span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_88"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. Our revenues to date have been generated through research collaboration and license agreements. Revenue is recognized ratably over our expected performance period under each agreement. We expect that any revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not received any sales-based milestone payments or royalties under any of the collaboration agreements. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we entered into an Option and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, collectively referred to as Genentech, focused on PROTAC targeted protein degrader discovery and research for target proteins, or Targets, based on our proprietary platform technology, other than excluded Targets as described below. This collaboration was expanded in November 2017 through an Amended and Restated Option, License and Collaboration Agreement, which we refer to as the Restated Genentech Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Genentech Agreement, Genentech has the right to designate up to ten Targets for further discovery and research utilizing our PROTAC platform technology. Genentech may designate as a Target any protein to which a PROTAC targeted protein degrader, by design, binds to achieve its mechanism of action, subject to certain exclusions. Genentech also has the right to remove a Target from the collaboration and substitute a different Target that is not an excluded Target at any time prior to us commencing research on such Target or in certain circumstances following commencement of research by us.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time we entered into the original agreement with Genentech we received an upfront payment of $11.0 million, and at the time we entered into the Restated Genentech Agreement, we received an additional $34.5 million in upfront and expansion target payments. We are eligible to receive up to an aggregate of $27.5 million in additional expansion target payments if Genentech exercises its options for all remaining Targets. We are also eligible to receive payments aggregating up to $44.0 million per Target upon the achievement of specified development milestones; payments aggregating up to $52.5 million per Target (assuming approval of two indications) subject to the achievement of specified regulatory milestones; and payments aggregating up to $60.0 million per PROTAC targeted protein degrader directed against the applicable Target, subject to the achievement of specified sales milestones. These milestone payments are subject to reduction if we do not have a valid patent claim covering the licensed PROTAC targeted protein degrader at the time the milestone is achieved. We are also eligible to receive, on net sales of licensed PROTAC targeted protein degraders, mid-single digit royalties, which may be subject to reductions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into a Research Collaboration and License Agreement with Pfizer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets, using our proprietary platform technology that are identified in the agreement or subsequently selected by Pfizer, subject to certain exclusions. We refer to this agreement as the Pfizer Research Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pfizer Research Collaboration Agreement, Pfizer has designated a number of initial Targets. For each identified Target, we and Pfizer will conduct a separate research program pursuant to a research plan. Pfizer may make substitutions for any of the initial Target candidates, subject to the stage of research for such Target. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2018, we received an upfront non-refundable payment and certain additional payments totaling $28.0 million in exchange for use of our technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. We are eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. We are also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as mid- to high-single digit tiered royalties, which may be subject to reductions, on net sales of PROTAC targeted protein degrader-related products. We received payments totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.5 million in the quarter ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, and $1.2 million and $4.4 million in the years ended December 31, 2021 and 2020, respectively, for additional targets and services.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we entered into a Collaboration and License Agreement, or the Bayer Collaboration Agreement, with Bayer AG, or, together with its controlled affiliates, Bayer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets, using our proprietary platform technology, that are selected by Bayer, subject to certain exclusions and limitations. The Bayer Collaboration Agreement became effective in July 2019. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Bayer Collaboration Agreement, we and Bayer conduct a research program pursuant to separate research plans mutually agreed to by us and Bayer and tailored to each Target selected by Bayer. Bayer may make substitutions for any such initial Target candidates, subject to certain conditions and based on the stage of research for such Target. During the term of the Bayer Collaboration Agreement, we are not permitted, either directly or indirectly, to design, identify, discover or develop any small molecule pharmacologically-active agent whose primary mechanism of action is, by design, directed to the inhibition or degradation of any Target selected or reserved by Bayer, or grant any license, covenant not to sue or other right to any third party in the field of human disease under the licensed intellectual property for the conduct of such activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Bayer Collaboration Agreement, we received an aggregate upfront non-refundable payment of $17.5 million. Bayer is committed to fund a total of $12.0 million in research funding payments through 2023, of which $10.5 million was received through March&#160;31, 2022, subject to potential increases if our costs for research activities exceed the research funding payments allocated to a Target and certain conditions are met. We are also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, we are eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer ARV-471 Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into we entered into a collaboration agreement with Pfizer, or the ARV-471 Collaboration Agreement, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound ARV-471, or the Licensed Products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ARV-471 Collaboration Agreement, we received an upfront, non-refundable payment of $650.0 million. In addition, we are eligible to receive up to an additional $1.4 billion in contingent payments </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on specified regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer will share equally (50/50) all development costs (including costs for conducting any clinical trials) for the Licensed Products, subject to certain exceptions. Except for certain regions described below, we will also share equally (50/50) all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be the marketing authorization holder and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. We will determine with Pfizer which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of all profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the ARV-471 Collaboration Agreement will expire on a Licensed Product-by-Licensed Product and country-by-country basis when such Licensed Products are no longer commercialized or developed for commercialization in such country. Pfizer may terminate the ARV-471 Collaboration Agreement for convenience in its entirety or on a region-by-region basis subject to certain notice periods. Either party may terminate the ARV-471 Collaboration Agreement for the other party&#8217;s uncured material breach or insolvency. Subject to applicable terms of the ARV-471 Collaboration Agreement, including certain payments to Pfizer upon termination for our uncured material breach, effective upon termination of the ARV-471 Collaboration Agreement, we are entitled to retain specified licenses to be able to continue to exploit the Licensed Products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to specified exceptions, we and Pfizer have each agreed not to directly or indirectly research, develop, or commercialize any competing products outside of the ARV-471 Collaboration Agreement anywhere in the world during the term of the ARV-471 Collaboration Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">expenses incurred under agreements with third parties, including CROs and other third parties that conduct research and preclinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the costs of laboratory supplies and developing preclinical studies and clinical trial materials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">third-party licensing fees. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use our employee and infrastructure resources across our development programs, and as such, do not track all of our internal research and development expenses on a program-by-program basis. The following table summarizes our research and development expenses for our AR program, which includes bavdegalutamide and ARV-766, ER program, which includes ARV-471, and all other platform and exploratory research and development costs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AR program development costs</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.1&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.2&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ER program development costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development costs</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33.1&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22.1&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development costs</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we conduct clinical trials for bavdegalutamide, ARV-471 and ARV-766, including our ongoing Phase 1/2 clinical trials for bavdegalutamide and ARV-471 and our ongoing Phase 1 clinical trial for ARV-766, and continue to discover and develop additional product candidates. Research and development expenses related to ARV-471 are shared equally with Pfizer from July 22, 2021, the effective date of the ARV-471 Collaboration Agreement. The ER program development costs in the table above reflect the cost sharing with Pfizer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot reasonably estimate or determine with certainty the duration and costs of future clinical trials of bavdegalutamide, ARV-471 and ARV-766 or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">successful completion of preclinical studies; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">successful initiation of clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">successful patient enrollment in and completion of clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">receipt and related terms of marketing approvals from applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">obtaining and maintaining third-party coverage and adequate reimbursement; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">maintaining a continued acceptable safety profile of the products following approval; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">effectively competing with other therapies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the U.S. Food and Drug Administration, or the FDA, or another regulatory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support increased research and development activities relating to our product candidates. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with the Nasdaq Stock Market and Securities and Exchange Commission requirements; director and officer insurance costs; and investor and public relations costs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since our inception in 2013, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our federal or state earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. As of December&#160;31, 2021, we had federal net operating loss carryforwards of $373.6&#160;million, which begin to expire in 2033, state and local net operating loss carryforwards of $346.9&#160;million, and federal and state research and development tax credit carryforwards of $15.2&#160;million and $4.5&#160;million, respectively, which begin to expire in 2033 and 2036, respectively. We expected to fully utilize these net operating loss and credit carryforwards in the current year due to taxable income resulting from revenue recognition for tax purposes from our ARV-471 Collaboration Agreement and the capitalization of qualified research and development expenses incurred on or after January 1, 2022. The revenue recognition and capitalization of research expenses are timing differences for tax purposes and deferred tax assets were established. We have provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon our earnings history, it is more likely than not that the benefits will not be realized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, Arvinas, Inc. had four wholly-owned subsidiaries organized as C-corporations: Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., and Arvinas Winchester, Inc. Prior to December 31, 2018, these subsidiaries were separate filers for federal tax purposes.</span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_91"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no material changes to our critical accounting estimates from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the Securities and Exchange Commission on February&#160;28, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Three Months Ended March&#160;31, 2022 and 2021</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the three months ended March&#160;31, 2022 totaled $24.2&#160;million, as compared to $5.5&#160;million for the three months ended March&#160;31, 2021. The increase of $18.7&#160;million was due to revenue from the ARV-471 Collaboration Agreement with Pfizer entered into during the third quarter of 2021.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three months ended March&#160;31, 2022 totaled $64.0&#160;million, compared with $34.9&#160;million for the three months ended March&#160;31, 2021. The increase of $29.1&#160;million was primarily due to an increase in our continued investment in our platform and exploratory programs of $11.0&#160;million as well as increases in expenses related to our AR and ER programs of $8.9&#160;million and $9.2&#160;million, respectively. The increase in spending over all of our programs was primarily due to increased personnel and personnel costs utilized across all of our programs of $9.2 million, including $3.4 million related to stock compensation expense. Clinical trial costs and related drug manufacturing costs increased by $15.6 million as we expanded our AR and ER programs into additional clinical studies. Direct expenses related to our platform and exploratory targets increased by $3.6 million as we continued to expand the number of protein targets in the exploratory and lead optimization phases and continued to make investments into our platform discovery efforts.</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses totaled $20.2&#160;million for the three months ended March&#160;31, 2022, compared with $12.3&#160;million for the three months ended March&#160;31, 2021. The increase of $7.9&#160;million was primarily due to an increase of personnel and facility related costs of $5.5&#160;million, including $2.3&#160;million related to stock compensation expense, and insurance, taxes and professional fees of $2.4&#160;million.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income totaled $1.1&#160;million for the three months ended March&#160;31, 2022, compared with $0.7&#160;million for the three months ended March&#160;31, 2021. The increase of $0.4&#160;million was primarily due to higher interest income of $0.7&#160;million from marketable security investments as compared to prior year due to higher interest rates, offset in part by lower refundable research and development credits from the State of Connecticut of $0.3 million. The Company is no longer eligible to receive a cash refund for the research and development credits in the State of Connecticut.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense totaled $4.5&#160;million for the three months ended March&#160;31, 2022, compared with zero for the three months ended March&#160;31, 2021, primarily due to current income taxes resulting from revenue recognition for tax purposes from our ARV-471 Collaboration Agreement and the capitalization of research and development expenses incurred on or after January 1, 2022. Under the Tax Cuts and Jobs Act of 2017, qualified </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research expenses incurred after 2021 are no longer immediately deductible for tax purposes and instead must be amortized over 5 years for tax purposes. As a result of these items, we expect to fully utilize our federal net operating loss and credit carryforwards in the current year, resulting in current income tax expense for the period.</span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_97"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of equity interests and through payments from collaboration partners, grant funding and loans from the State of Connecticut. Since inception through March&#160;31, 2022, we had received an aggregate of $780.5&#160;million in payments from collaboration partners, grant funding and forgivable and partially forgivable loans from the State of Connecticut, and raised approximately $1.3&#160;billion in gross proceeds from the sale of equity interests and the exercise of stock options, including: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">October 2018: our initial public offering in which we issued an aggregate of 7,700,482 shares of common stock, for aggregate gross proceeds of $123.2 million before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">July 2019: the sale of 1,346,313 shares of common stock to Bayer AG for aggregate gross proceeds of $32.5 million; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">November 2019: completion of a follow-on offering in which we issued 5,227,273 shares of common stock for aggregate gross proceeds of $115.0 million before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">September &#8211; December 2020: sale of 2,593,637 shares of common stock in an &#8220;at-the-market offering&#8221; for aggregate gross proceeds of $65.6 million before fees and expenses;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">December 2020: completion of a follow-on offering in which we issued 6,571,428 shares of common stock for aggregate gross proceeds of $460.0 million before fees and expenses; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">September 2021: issuance of 3,457,815 shares of common stock to Pfizer for aggregate gross proceeds of $350.0 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into a lease for approximately 160,000 square feet of laboratory and office space to be occupied in 2024. In connection with the signing of the lease, and at our election to increase the landlord&#8217;s contribution to the tenant improvement allowance, we issued a letter of credit for $4.5 million, collateralized by a certificate of deposit in the same amount. Once occupied, the base rent will range from $7.7 million to $8.8 million annually over a ten-year lease term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into an Equity Distribution Agreement with Piper Sandler &amp; Company and Cantor Fitzgerald &amp; Co., as agents, pursuant to which we may offer and sell from time to time, through the agents, up to $300.0 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the common stock registered under our universal shelf registration statement pursuant to one or more &#8220;at-the-market" offering. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, no shares have been issued under this agreement.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents, restricted cash and marketable securities totaled $1.4 billion as of March&#160;31, 2022 and $1.5 billion as of December&#160;31, 2021. We had an outstanding loan balance of $1.0 million as of each of March&#160;31, 2022 and December&#160;31, 2021. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for the period presented: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(57.1)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(39.0)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(207.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(46.0)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(242.3)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2022 totaled $57.1 million, primarily due to our net loss of $63.4 million, a net reduction in accrued expenses and accounts payable of $15.6 million and a reduction in deferred revenue of $21.2 million, partially offset by non-cash charges of $22.3 million and a decrease in account and other receivables of $19.1 million. Non-cash charges included stock compensation expense of $16.6 million, net accretion of bond discounts/premiums of $3.3 million, and depreciation and amortization of $1.5 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2021 totaled $39.0 million, primarily due to our net loss of $41.0 million, a net reduction in accrued expenses and accounts payable of $9.1 million and a reduction in deferred revenue of $2.5 million, partially offset by non-cash charges of $12.7 million and a decrease in account and other receivables of $3.3 million. Non-cash charges were primarily stock compensation expense of $10.3 million, depreciation and amortization of $1.1 million and net accretion of bond discounts/premiums of $1.0 million.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March&#160;31, 2022 totaled $8.6 million, attributable to maturities of marketable securities in excess of purchases of $10.7 million, offset by purchases of property and equipment of $2.1 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March&#160;31, 2021 totaled $207.8 million, attributable to purchases of marketable securities in excess of the maturities of marketable securities of $206.8 million and purchases of property and equipment of $1.0 million.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2022 totaled $2.5 million, attributable to the proceeds from the exercise of stock options. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2021 totaled $4.5 million, attributable to the proceeds from the exercise of stock options.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. In addition, we expect to continue to incur additional costs associated with operating as a public company. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we anticipate that our expenses will increase substantially if, and as we:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.02pt">continue a Phase 1/2 clinical trial of our product candidate bavdegalutamide and a Phase 1b clinical trial of bavdegalutamide in combination with abiraterone for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiate one or more additional </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1b clinical expansions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bavdegalutamide</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with standard of care agents, in men with mCRPC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continue a Phase 1/2 clinical trial of our product candidate ARV-471 and a Phase 1b clinical trial of ARV-471 in combination with palbociclib, and initiate an additional Phase 1b cohort expansion in combination with a standard of care agent, each in patients with locally advanced or metastatic ER positive / HER2 negative breast cancer and initiate a window of opportunity study in early breast cancer;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continue a Phase 1 clinical trial of our product candidate ARV-766 in men with mCRPC, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and initiate a planned Phase 2 cohort expansion trial in 2022;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">expand the capabilities of our PROTAC Discovery Engine; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we may obtain marketing approval; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">expand, maintain and protect our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">hire additional development, including clinical and regulatory, and scientific personnel; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">add operational, financial and management information systems and personnel to support our research, product development and future commercialization efforts and support our operations as a public company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents, restricted cash and marketable securities totaling $1.4 billion as of March&#160;31, 2022. We believe that our cash, cash equivalents, restricted cash and marketable securities as of March&#160;31, 2022 will enable us to fund our planned operating expenses and capital expenditure requirements multiple additional years beyond 2024. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the progress, costs and results of our ongoing clinical trials for bavdegalutamide, ARV-471 and ARV-766 and any future clinical development of bavdegalutamide, ARV-471 and ARV-766; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the number of, and development requirements for, other product candidates that we pursue, including our other oncology and neurodegenerative research programs; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the success of our collaborations with Pfizer, Genentech and Bayer; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the costs, timing and outcome of regulatory review of our product candidates; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, for the development or commercialization of our product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these anticipated expenditures, we will need to obtain substantial additional financing in connection with our continuing operations. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations with Pfizer, Genentech and Bayer, we do not currently have any committed external source of funds. Adequate additional funds may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, we entered into an Assistance Agreement with the State of Connecticut, or the 2014 Assistance Agreement, under which we borrowed $2.5 million. Borrowings under the 2014 Assistance Agreement were forgivable if we maintained a minimum number of full-time jobs in the State of Connecticut for a minimum period at a minimum annual salary. Effective in March 2016, the full principal amount under the 2014 Assistance Agreement had been forgiven. While borrowings under the 2014 Assistance Agreement have been forgiven, we remain subject to an ongoing covenant to be located in the State of Connecticut through January 2024. Upon violation of this covenant, we would be required to repay the full original funding amount of $2.5 million plus liquidated damages of 7.50%. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we entered into an additional Assistance Agreement with the State of Connecticut, or the 2018 Assistance Agreement, to provide funding for the expansion and renovation of laboratory and office space.  We borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that we be located in the State of Connecticut through 2028 with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received. At March&#160;31, 2022, $1.0 million remains outstanding under the 2018 Assistance Agreement.</span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents, restricted cash and marketable securities. Interest income earned on these assets totaled $1.2 million and $0.5 million for the three months ended March&#160;31, 2022 and 2021, respectively. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. At March&#160;31, 2022, our cash equivalents consisted of bank deposits and money market funds, and our marketable securities included interest-earning securities. Our outstanding debt totaled $1.0 million as of each of March&#160;31, 2022 and December&#160;31, 2021. Our outstanding debt as of March&#160;31, 2022 carries a fixed interest rate of 3.25% per annum.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2022. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended March&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal control over financial reporting due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 pandemic on our internal controls to minimize the impact on their design and operating effectiveness.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, those risks and uncertainties discussed in &#8220;Part I, Item 1A, Risk Factors,&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">February&#160;28, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> together with all of the other information contained in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. The risk factor disclosure in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 is qualified by the information that is described in this Quarterly Report on Form 10-Q. If any of the risks described in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 actually occur, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment.</span></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any securities that were not registered under the Securities Act during the three months ended March&#160;31, 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:13.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1*&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="pfizerarvinasamendmentno2r.htm">Amendment No. 2 to Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated January 14, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.2*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvinas-formofrsuagreement.htm">Form of Restricted Stock Unit Agreement under 2018 Stock Incentive Plan</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20220331x10qex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20220331x10qex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20220331x10qex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20220331x10qex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Schema Document.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Label Linkbase Document.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104.00</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101). </span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">           </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><div id="i5f8d406ab3aa45be82590782b0fe2e1d_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">Tabl</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">e of Co</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5f8d406ab3aa45be82590782b0fe2e1d_7">ntents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Arvinas, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: May&#160;5, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ John Houston, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">John Houston, Ph.D.</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">President and Chief Executive Officer</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: May&#160;5, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Sean Cassidy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Sean Cassidy</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Chief Financial Officer and Treasurer</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>pfizerarvinasamendmentno2r.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i45b66b66b9df4a3db6ba35028360fced_1"></div><div style="min-height:105.84pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXECUTION VERSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment No. 2 to Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;Amendment No. 2&#8221;)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment No. 2 Effective Date&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">January 14, 2022</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Name of Original Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; &#160;&#160;&#160;&#160;Research Collaboration and License Agreement (the &#8220;Original Agreement,&#8221; and together with previous amendments, if any, as described below, the &#8220;Agreement&#8221;)</font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date of Original Agreement&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">December 22, 2017 (&#8220;Effective Date&#8221;)</font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Pfizer Inc. (&#8220;Pfizer&#8221;) and Arvinas Operations, Inc., f&#47;k&#47;a Arvinas, Inc. (&#8220;Arvinas&#8221;)</font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dates of Previous Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Amendment No. 1 dated December 9, 2019</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties wish to amend the terms of the Agreement regarding the use of Overages (as defined in the Agreement).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in order to accommodate the desired amendments, the Parties hereby agree as follows&#58;  </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Amendments to the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.6pt">Section 2.2.4 of the Agreement is hereby deleted in its entirety and replaced with the following&#58; </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;&#91;**&#93;.&#8221;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.6pt">Section 2.2.5 of the Agreement is hereby deleted in its entirety and replaced with the following&#58; </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;&#91;**&#93;.&#8221; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.6pt">Notwithstanding any other provision of the Agreement, the Parties agree that (i) Pfizer shall hereby be deemed to have issued a Target Substitution Notice pursuant to which &#91;**&#93; shall be replaced with &#91;**&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;**&#93; Substitute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which Arvinas accepts as a Target under the Agreement, (ii) the &#91;**&#93; Substitute &#91;**&#93;, and (iii) the Parties shall agree on the Research Plan for the &#91;**&#93; Substitute &#91;**&#93;, as applicable, in accordance with Section 3.5 of the Agreement, and Pfizer shall &#91;**&#93; for such Target no later than &#91;**&#93;. Notwithstanding Section 5.4 of the Agreement, the payment due under such Section 5.4.2 thereof &#91;**&#93; for the &#91;**&#93; Substitute pursuant to Section 2.8 thereof shall be paid on or before &#91;**&#93;, and the Parties shall cooperate as reasonably required to ensure that the corresponding invoice is issued and paid on or before such date. For clarity, in accordance with Sections 2.2.4 and 2.2.5 of the Agreement (as amended by this Amendment No. 2), any &#91;**&#93; with respect to the &#91;**&#93; Substitute may be applied by Pfizer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:105.84pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as &#91;**&#93; due under Section 5.4 of the Agreement with respect to a &#91;**&#93; made in accordance with clause (ii) of the first sentence of this Section.</font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.6pt">Notwithstanding Section 5.4 of the Agreement, the payment due under Section 5.4.3 thereof upon the &#91;**&#93; for the Target &#91;**&#93; shall be paid on or before &#91;**&#93;, and the Parties shall cooperate as reasonably required to ensure that the corresponding invoice is issued and paid on or before such date.</font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Ratification of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly set forth in Article 2 above, the Agreement shall remain unmodified and in full force and effect.  The execution, delivery and effectiveness of this Amendment No. 2 shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the parties to the Agreement, nor constitute a waiver of any provision of the Agreement.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment No. 2 may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall constitute one and the same agreement.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SIGNATURES IMMEDIATELY FOLLOWING ON NEXT PAGE</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:105.84pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the duly authorized representatives of Pfizer and Arvinas have executed this Amendment No. 2 as of the date first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.153%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arvinas Operations, Inc</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sean Cassidy&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sean Cassidy&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CFO and Treasurer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">1&#47;14&#47;2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Duly authorized)&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:7.692%;min-width:6.692%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.155%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pfizer Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Charlotte Allerton&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Charlotte Allerton&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SVP, Head Medicine Design&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">January 21, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Duly authorized)</font></div></div></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>arvinas-formofrsuagreement.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie1747162d84143819bedac015dc22f6b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) hereby grants the following restricted stock units pursuant to its 2018 Stock Incentive Plan.  The terms and conditions attached hereto are also a part hereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Grant</font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:49.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of recipient (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) granted&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number, if any, of RSUs that vest immediately on the grant date&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RSUs that are subject to vesting schedule&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Start Date&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;</font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:48.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.819%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Signature of Participant</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Street Address</font></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:19.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Officer</font></div><div style="padding-left:19.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>City&#47;State&#47;Zip Code</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 191571453v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Restricted Stock Unit Agreement </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Incorporated Terms and Conditions</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Award of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of services rendered and to be rendered to the Company, by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth in this Restricted Stock Unit Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and in the Company&#8217;s 2018 Stock Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), an award with respect to the number of restricted stock units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth in the Notice of Grant that forms part of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each RSU represents the right to receive one share of common stock, $0.001 par value per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) upon vesting of the RSU, subject to the terms and conditions set forth herein.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The RSUs shall vest in accordance with the Vesting Schedule set forth in the Notice of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Any fractional shares resulting from the application of any percentages used in the Vesting Schedule shall be rounded down to the nearest whole number of RSUs.  Upon the vesting of the RSU, the Company will deliver to the Participant, for each RSU that becomes vested, one share of Common Stock, subject to the payment of any taxes pursuant to Section 7.  The Common Stock will be delivered to the Participant as soon as practicable following each vesting date, but in any event within 30 days of such date.  Notwithstanding anything herein to the contrary, in the sole discretion of the Board, the Company may, with respect to any applicable vesting date of the RSU, deliver to the Participant cash having a fair market value equal to the number of shares of Common Stock underlying the portion of the RSU that vested on such date, payable within 30 days of the vesting date, less applicable taxes.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Forfeiture of Unvested RSUs Upon Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In the event that the Participant ceases to be an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive awards under the Plan (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eligible Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation.  The Participant shall have no further rights with respect to the unvested RSUs or any Common Stock that may have been issuable with respect thereto.  If the Participant provides services to a subsidiary of the Company, any references in this Agreement to provision of services to the Company shall instead be deemed to refer to service with such subsidiary.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictions on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively &#8220;transfer&#8221;) any RSUs, or any interest therein. The Company shall not be required to treat as the owner of any RSUs or issue any Common </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 191571453v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock to any transferee to whom such RSUs have been transferred in violation of any of the provisions of this Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Participant shall have no rights as a stockholder of the Company with respect to any shares of Common Stock that may be issuable with respect to the RSUs until the issuance of the shares of Common Stock to the Participant following the vesting of the RSUs.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Acknowledgments&#59; No Section 83(b) Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges that he or she is responsible for obtaining the advice of the Participant&#8217;s own tax advisors with respect to the award of RSUs and the Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with respect to the tax consequences relating to the RSUs.  The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#8217;s tax liability that may arise in connection with the acquisition, vesting and&#47;or disposition of the RSUs.  The Participant acknowledges that no election under Section 83(b) of the Internal Revenue Code, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is available with respect to RSUs.   </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other taxes of any kind required by law to be withheld with respect to the vesting of the RSUs.  At such time as the Participant is not aware of any material nonpublic information about the Company or the Common Stock and is permitted to do so under the Company&#8217;s insider trading policy, the Participant shall execute the instructions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Durable Automatic Sale Instructions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as the means of satisfying such tax obligation unless the Participant has existing, effective Durable Automatic Sale Instructions in place as of the date hereof.  If the Participant does not execute the Automatic Sale Instructions prior to an applicable vesting date, then the Participant agrees that if under applicable law the Participant will owe taxes at such vesting date on the portion of the award then vested the Company shall be entitled to immediate payment from the Participant of the amount of any tax required to be withheld by the Company and the Participant further agrees and acknowledges that the Company will not (and is not obligated to) deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Right to Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges and agrees that, notwithstanding the fact that the vesting of the RSUs is contingent upon his or her continued service to the Company, this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with the Company or any affiliate of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The RSUs awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section 409A of the Code and the Treasury Regulations </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 191571453v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">issued thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The delivery of shares of Common Stock on the vesting of the RSUs may not be accelerated or deferred unless permitted or required by Section 409A.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Participant&#8217;s Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges that he or she&#58;  (i) has read this Agreement&#59; (ii) has been represented in the preparation, negotiation and execution of this Agreement by legal counsel of the Participant&#8217;s own choice or has voluntarily declined to seek such counsel&#59; (iii) understands the terms and consequences of this Agreement&#59; and (iv) is fully aware of the legal and binding effect of this Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be construed, interpreted and enforced in accordance with the internal laws of the State of Delaware without regard to any applicable conflicts of laws provisions.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 191571453v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DURABLE AUTOMATIC SALE INSTRUCTION</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Durable Automatic Sale Instruction is being delivered to Arvinas, Inc. (the &#8220;Company&#8221;) by the undersigned on the date set forth below.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;I hereby acknowledge that the Company has granted, or may in the future from time to time grant, to me restricted stock units (&#8220;RSUs&#8221;) under the Company&#8217;s equity incentive plans as in effect from time to time. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I acknowledge that upon the vesting dates applicable to any such RSUs, I will have compensation income equal to the fair market value of the shares of the Company&#8217;s common stock subject to the RSU that vest on such date and that the Company is required to withhold income and employment taxes in respect of that compensation income on the applicable vesting date. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I desire to establish a process to satisfy such withholding obligation in respect of all RSUs that have been, or may in the future be, granted by the Company to me through an automatic sale of a portion of the shares of the Company&#8217;s common stock that would otherwise be issued to me on each applicable vesting date, such portion to be in an amount sufficient to satisfy such withholding obligation, with the proceeds of such sale delivered to the Company in satisfaction of such withholding obligation.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I understand that the Company has arranged for the administration and execution of its equity incentive plans and the sale of securities by plan participants thereunder pursuant to an Internet-based platform administered by a third party (the &#8220;Administrator&#8221;) and the Administrator&#8217;s designated brokerage partner.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon any vesting of my RSUs from and after the date of this Durable Automatic Sale Instruction, I hereby appoint the Administrator (or any successor administrator) to automatically sell such number of shares of the Company&#8217;s common stock issuable with respect to my RSUs that vest as is sufficient to generate net proceeds sufficient to satisfy the Company&#8217;s minimum statutory withholding obligations with respect to the income recognized by me upon the vesting of the RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income), and the Company shall receive such net proceeds in satisfaction of such tax withholding obligation.  </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I hereby appoint the Chief Executive Officer, the Chief Financial Officer and the Corporate Counsel, and any of them acting alone and with full power of substitution, to serve as my attorneys in fact to arrange for the sale of shares of common stock in accordance with these durable automatic sale instructions.  I agree to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the shares of common stock pursuant to these Durable Automatic Sale Instructions.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By signing below, I hereby represent to the Company that, as of the date hereof, I am not aware of any material nonpublic information about the Company or its common stock and that I am not prohibited from entering into these durable automatic sale instructions by the Company&#8217;s insider trading policy or otherwise.  I have structured these automatic sale instructions to constitute a &#8220;binding contract&#8221; relating to the sale of common stock, consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act.</font></div><div><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 191571453v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Print Name&#58;  _____________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58;  __________________________</font></div><div><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 191571453v.3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>arvn-20220331x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if88f0156611c46ffa602e1a845bcb2b2_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Houston, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Arvinas, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.979%"><tr><td style="width:1.0%"></td><td style="width:48.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2022</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Houston, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Houston, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>arvn-20220331x10qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i721ee274e61941a99d7a53b83d110f87_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sean Cassidy, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Arvinas, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:0.05pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2022</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sean Cassidy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sean Cassidy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer and Treasurer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>arvn-20220331x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifd88b8569752414fbe99ee1eaa0c814f_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:0.05pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.979%"><tr><td style="width:1.0%"></td><td style="width:48.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2022</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Houston, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Houston, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>arvn-20220331x10qex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i46683429155c4d07a859719b9fbc9bc8_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:0.05pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2022</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sean Cassidy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sean Cassidy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer and Treasurer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>arvn-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:966c8cdd-8d85-475a-b79b-8010015adf33,g:b9593e04-7343-4e88-918f-c5a2cc011d89-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arvn="http://www.arvinas.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arvinas.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.arvinas.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingPronouncementsandSignificantAccountingPolicies" roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Accounting Pronouncements and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreements" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements">
        <link:definition>2104103 - Disclosure - Research Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTables" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables">
        <link:definition>2305301 - Disclosure - Research Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails">
        <link:definition>2407403 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails">
        <link:definition>2408404 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1">
        <link:definition>2408404 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurements" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements">
        <link:definition>2109104 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsTables" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables">
        <link:definition>2310302 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails">
        <link:definition>2411405 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovements" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements">
        <link:definition>2112105 - Disclosure - Property, Equipment and Leasehold Improvements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsTables" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables">
        <link:definition>2313303 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails">
        <link:definition>2414406 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails">
        <link:definition>2415407 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilities" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilities">
        <link:definition>2116106 - Disclosure - Right-of-Use Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesTables" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables">
        <link:definition>2317304 - Disclosure - Right-of-Use Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails">
        <link:definition>2418408 - Disclosure - Right-of-Use Assets and Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails">
        <link:definition>2419409 - Disclosure - Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails">
        <link:definition>2420410 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>2421411 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>2421411 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.arvinas.com/role/AccruedExpenses">
        <link:definition>2122107 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.arvinas.com/role/AccruedExpensesTables">
        <link:definition>2323305 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.arvinas.com/role/AccruedExpensesDetails">
        <link:definition>2424412 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.arvinas.com/role/LongTermDebt">
        <link:definition>2125108 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.arvinas.com/role/LongTermDebtTables">
        <link:definition>2326306 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails">
        <link:definition>2427413 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails">
        <link:definition>2428414 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.arvinas.com/role/Equity">
        <link:definition>2129109 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.arvinas.com/role/EquityTables">
        <link:definition>2330307 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails">
        <link:definition>2431415 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails">
        <link:definition>2432416 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofStockOptionActivityDetails" roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails">
        <link:definition>2433417 - Disclosure - Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofRestrictedStockGrantActivityDetails" roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails">
        <link:definition>2434418 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.arvinas.com/role/IncomeTaxes">
        <link:definition>2135110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesDetails">
        <link:definition>2436419 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.arvinas.com/role/NetLossPerShare">
        <link:definition>2137111 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.arvinas.com/role/NetLossPerShareTables">
        <link:definition>2338308 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareBasicandDilutedLossperCommonShareDetails" roleURI="http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails">
        <link:definition>2439420 - Disclosure - Net Loss Per Share - Basic and Diluted Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails">
        <link:definition>2440421 - Disclosure - Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestments" roleURI="http://www.arvinas.com/role/EquityMethodInvestments">
        <link:definition>2141112 - Disclosure - Equity Method Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentsDetails" roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsDetails">
        <link:definition>2442422 - Disclosure - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arvn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" abstract="false" name="DirectAndIncrementalCostsIncurredToObtainTheContract" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_DebtInstrumentLoanForgiveness" abstract="false" name="DebtInstrumentLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_EmployeesMember" abstract="true" name="EmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" abstract="true" name="ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_ProceedsFromMaturitiesOfMarketableSecurities" abstract="false" name="ProceedsFromMaturitiesOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_TwoThousandAndFourteenAssistanceAgreementMember" abstract="true" name="TwoThousandAndFourteenAssistanceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_NumberOfMaximumDesignatedTargets" abstract="false" name="NumberOfMaximumDesignatedTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arvn_OerthBioLimitedLiabilityCorporationMember" abstract="true" name="OerthBioLimitedLiabilityCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_MaximumAggregateOfferingPriceOfCommonStock" abstract="false" name="MaximumAggregateOfferingPriceOfCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" abstract="false" name="IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_RegulatoryAndSalesBasedMilestonesMember" abstract="true" name="RegulatoryAndSalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arvn_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsTable" abstract="true" name="ResearchCollaborationAndLicenseAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_LongTermDebtMaturityYearSix" abstract="false" name="LongTermDebtMaturityYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CollaborationContractAssetAndOtherAssets" abstract="false" name="CollaborationContractAssetAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" abstract="true" name="GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PercentageOfLiquidatedDamages" abstract="false" name="PercentageOfLiquidatedDamages" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease" abstract="false" name="CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" abstract="true" name="ResearchCollaborationAndLicenseAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" abstract="true" name="ResearchCollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_EquityDistributionAgreementMember" abstract="true" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_SalesBasedMilestonePaymentsMember" abstract="true" name="SalesBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CommercialMilestonesMember" abstract="true" name="CommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ResearchFundingPaymentsMember" abstract="true" name="ResearchFundingPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_TwoThousandEighteenStockIncentivePlanMember" abstract="true" name="TwoThousandEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_RegulatoryMilestonePaymentsMember" abstract="true" name="RegulatoryMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" abstract="true" name="ChangeInCollaborationContractAssetAndOtherAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_PercentageOfIncrementalBorrowingForLeasePayments" abstract="false" name="PercentageOfIncrementalBorrowingForLeasePayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" abstract="true" name="GenentechIncorporationAndFHoffmanLaRocheLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PfizerIncorporationMember" abstract="true" name="PfizerIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" abstract="false" name="EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_BaseLeaseRentPeriod" abstract="false" name="BaseLeaseRentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arvn_DebtInstrumentInterestPaymentsTerm" abstract="false" name="DebtInstrumentInterestPaymentsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" abstract="true" name="IncomeStatementAndStatementOfComprehensiveIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_OptionPaymentsToLicenseAgreementMember" abstract="true" name="OptionPaymentsToLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PiperSandlerAndCantorMember" abstract="true" name="PiperSandlerAndCantorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" abstract="true" name="GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_TwoThousandAndEighteenAssistanceAgreementMember" abstract="true" name="TwoThousandAndEighteenAssistanceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_BayerCropScienceLPMember" abstract="true" name="BayerCropScienceLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" abstract="true" name="SupplementalNonCashInformationRelatedToLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_DevelopmentMilestonePaymentsMember" abstract="true" name="DevelopmentMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" abstract="false" name="AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" abstract="false" name="ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_EmployeesDirectorsAndConsultantsMember" abstract="true" name="EmployeesDirectorsAndConsultantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" abstract="true" name="GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AggregateIntrinsicValueAbstract" abstract="true" name="AggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>arvn-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:966c8cdd-8d85-475a-b79b-8010015adf33,g:b9593e04-7343-4e88-918f-c5a2cc011d89-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="arvn-20220331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_140e86eb-9aaf-4cc4-9169-651e31318649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_92d40221-ff89-40b8-a0d7-1ce784c06636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_140e86eb-9aaf-4cc4-9169-651e31318649" xlink:to="loc_us-gaap_CommonStockValue_92d40221-ff89-40b8-a0d7-1ce784c06636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c33b1e13-d888-4771-afd0-cf78b88656c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_140e86eb-9aaf-4cc4-9169-651e31318649" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c33b1e13-d888-4771-afd0-cf78b88656c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_89c49e70-373f-461f-9358-b686baa0e7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_140e86eb-9aaf-4cc4-9169-651e31318649" xlink:to="loc_us-gaap_AdditionalPaidInCapital_89c49e70-373f-461f-9358-b686baa0e7b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_42206399-4ce4-4770-bb3c-80fc461cc386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_140e86eb-9aaf-4cc4-9169-651e31318649" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_42206399-4ce4-4770-bb3c-80fc461cc386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a949777a-9829-4712-950e-4f37bacaa8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_554e0eb9-63fc-4415-90fe-8a6482fc8a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a949777a-9829-4712-950e-4f37bacaa8ec" xlink:to="loc_us-gaap_LiabilitiesCurrent_554e0eb9-63fc-4415-90fe-8a6482fc8a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c51eb091-8483-4000-97e1-05a5ec27cf79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a949777a-9829-4712-950e-4f37bacaa8ec" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c51eb091-8483-4000-97e1-05a5ec27cf79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_af51383e-e6a0-4207-9e25-7f8d49e0bcde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a949777a-9829-4712-950e-4f37bacaa8ec" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_af51383e-e6a0-4207-9e25-7f8d49e0bcde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83b5ee7d-7eb4-4dfb-9fd5-b3612de0b2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a949777a-9829-4712-950e-4f37bacaa8ec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83b5ee7d-7eb4-4dfb-9fd5-b3612de0b2a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7e52cc9a-db8c-48be-b5fd-1625e4005553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5648a4a8-a26f-4512-a031-b5e555cd4b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e52cc9a-db8c-48be-b5fd-1625e4005553" xlink:to="loc_us-gaap_AssetsCurrent_5648a4a8-a26f-4512-a031-b5e555cd4b9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7f9fa232-75e2-4fc8-9159-69665ec7d437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e52cc9a-db8c-48be-b5fd-1625e4005553" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7f9fa232-75e2-4fc8-9159-69665ec7d437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d7e74979-c14f-47e8-a7b7-25d0492cac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e52cc9a-db8c-48be-b5fd-1625e4005553" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d7e74979-c14f-47e8-a7b7-25d0492cac8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_dc01e019-063f-4c5a-8f03-3218db50eea9" xlink:href="arvn-20220331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e52cc9a-db8c-48be-b5fd-1625e4005553" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_dc01e019-063f-4c5a-8f03-3218db50eea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b0419f2d-6886-48fa-9a71-c718b11f5d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_391a1d0d-a248-4d16-9940-4791e07e1545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b0419f2d-6886-48fa-9a71-c718b11f5d3f" xlink:to="loc_us-gaap_Liabilities_391a1d0d-a248-4d16-9940-4791e07e1545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d17e5e86-972c-4b4b-a3bc-9e46dc101597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b0419f2d-6886-48fa-9a71-c718b11f5d3f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d17e5e86-972c-4b4b-a3bc-9e46dc101597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f47b33dd-9a14-4295-9204-f9d78c87e859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b0419f2d-6886-48fa-9a71-c718b11f5d3f" xlink:to="loc_us-gaap_StockholdersEquity_f47b33dd-9a14-4295-9204-f9d78c87e859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d61e9f4b-1b6c-489d-a5c2-f0e202f77f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44f82045-36ca-4184-b8b5-c056d22fa9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d61e9f4b-1b6c-489d-a5c2-f0e202f77f51" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44f82045-36ca-4184-b8b5-c056d22fa9e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_17afe18b-ba9f-438d-9f3f-a143fed60990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d61e9f4b-1b6c-489d-a5c2-f0e202f77f51" xlink:to="loc_us-gaap_RestrictedCashCurrent_17afe18b-ba9f-438d-9f3f-a143fed60990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1e152a30-ea1f-4212-a792-7d67c2825b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d61e9f4b-1b6c-489d-a5c2-f0e202f77f51" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1e152a30-ea1f-4212-a792-7d67c2825b06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dc258332-6c1b-401f-8196-31ea05457475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d61e9f4b-1b6c-489d-a5c2-f0e202f77f51" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dc258332-6c1b-401f-8196-31ea05457475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_58ca4f65-8c2c-4eaa-b0f8-d3d8a6d1442a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d61e9f4b-1b6c-489d-a5c2-f0e202f77f51" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_58ca4f65-8c2c-4eaa-b0f8-d3d8a6d1442a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea4ed53d-6c55-4395-a6dc-75ed8ccd4f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d61e9f4b-1b6c-489d-a5c2-f0e202f77f51" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea4ed53d-6c55-4395-a6dc-75ed8ccd4f58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1502fd8b-ec6f-465b-9f78-1dfbdb3f2d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_086d8926-bca4-4267-be8f-b77b534314c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1502fd8b-ec6f-465b-9f78-1dfbdb3f2d44" xlink:to="loc_us-gaap_AccountsPayableCurrent_086d8926-bca4-4267-be8f-b77b534314c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_28d63c22-daea-420e-805c-5134ff30b2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1502fd8b-ec6f-465b-9f78-1dfbdb3f2d44" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_28d63c22-daea-420e-805c-5134ff30b2ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_25bcf867-c0f9-46df-9038-7bece4e5acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1502fd8b-ec6f-465b-9f78-1dfbdb3f2d44" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_25bcf867-c0f9-46df-9038-7bece4e5acb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b24e3da4-5fe7-451e-9cdd-ca9766468cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1502fd8b-ec6f-465b-9f78-1dfbdb3f2d44" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b24e3da4-5fe7-451e-9cdd-ca9766468cdd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="arvn-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_4c40df17-2122-4ef0-ade1-ce2194600c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7bed8452-b283-4226-8c51-a270e9d42d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_4c40df17-2122-4ef0-ade1-ce2194600c6a" xlink:to="loc_us-gaap_OperatingIncomeLoss_7bed8452-b283-4226-8c51-a270e9d42d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2af9cbb6-6635-4a22-aebf-fc7daa719f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_4c40df17-2122-4ef0-ade1-ce2194600c6a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2af9cbb6-6635-4a22-aebf-fc7daa719f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dbc633ab-f619-4b2a-bff6-6edf33967e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8bb94138-f045-4aa2-bded-d73ad2c74bde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_dbc633ab-f619-4b2a-bff6-6edf33967e21" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8bb94138-f045-4aa2-bded-d73ad2c74bde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b3541e36-81a3-4bb7-a047-e984d9ce3dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_dbc633ab-f619-4b2a-bff6-6edf33967e21" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b3541e36-81a3-4bb7-a047-e984d9ce3dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f6180ea-584c-4eec-866b-c45727a8b238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a3cd258-1b66-461b-84cb-2031d17923e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f6180ea-584c-4eec-866b-c45727a8b238" xlink:to="loc_us-gaap_NetIncomeLoss_7a3cd258-1b66-461b-84cb-2031d17923e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f637c12a-b49f-4edd-9637-2a9285b9bf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f6180ea-584c-4eec-866b-c45727a8b238" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f637c12a-b49f-4edd-9637-2a9285b9bf2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_29dca58e-8f1a-4d16-8c25-c671d2b8aed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_33c74759-6c52-4231-8934-1780faf81579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_29dca58e-8f1a-4d16-8c25-c671d2b8aed5" xlink:to="loc_us-gaap_Revenues_33c74759-6c52-4231-8934-1780faf81579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6f684384-d02e-476f-8231-e0fba541b57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_29dca58e-8f1a-4d16-8c25-c671d2b8aed5" xlink:to="loc_us-gaap_OperatingExpenses_6f684384-d02e-476f-8231-e0fba541b57e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d54b88f4-1f41-4bf9-909f-b194f4ba966c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_4b45a7bd-c824-4f47-be4e-9cc0c9658450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d54b88f4-1f41-4bf9-909f-b194f4ba966c" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_4b45a7bd-c824-4f47-be4e-9cc0c9658450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0f1e9db4-6350-4018-b245-181c3f23bac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d54b88f4-1f41-4bf9-909f-b194f4ba966c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0f1e9db4-6350-4018-b245-181c3f23bac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_266d9dde-eabb-4783-a123-d072dbe0422c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_307292ab-5662-4ab8-bf2c-077d71ccaac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_266d9dde-eabb-4783-a123-d072dbe0422c" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_307292ab-5662-4ab8-bf2c-077d71ccaac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5aca5c22-793d-4f54-9960-6825ce965434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_266d9dde-eabb-4783-a123-d072dbe0422c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5aca5c22-793d-4f54-9960-6825ce965434" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="arvn-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_82c28d8e-df12-4464-a9f0-e94f01877570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_82c28d8e-df12-4464-a9f0-e94f01877570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ec721751-6e57-4108-89e1-4ca7e346c2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ec721751-6e57-4108-89e1-4ca7e346c2c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_09e8bf30-561c-4786-b91c-2040fc30fae5" xlink:href="arvn-20220331.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_09e8bf30-561c-4786-b91c-2040fc30fae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f2d6770c-081d-452c-a833-c4e8e105b3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f2d6770c-081d-452c-a833-c4e8e105b3cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_53a36eb1-0b95-4f42-ab84-6a3247307f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_53a36eb1-0b95-4f42-ab84-6a3247307f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_56a6b4f3-4ea7-4952-b788-cf0cb44e8eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_56a6b4f3-4ea7-4952-b788-cf0cb44e8eb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_ce9531bb-f999-40c7-a3c1-afbddbb51706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_ce9531bb-f999-40c7-a3c1-afbddbb51706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3b630148-12f8-4770-835d-00327704601c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_ShareBasedCompensation_3b630148-12f8-4770-835d-00327704601c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_06444dad-2150-4fe1-bf12-9f61288dd78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_06444dad-2150-4fe1-bf12-9f61288dd78f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6904d20d-8d3f-4fa1-9011-894c010968fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_ProfitLoss_6904d20d-8d3f-4fa1-9011-894c010968fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c9744a9e-6b8c-45bc-b2e3-7e4ed5d10d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c9744a9e-6b8c-45bc-b2e3-7e4ed5d10d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_539237ff-9cf5-464c-8ae3-a8bd260114c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_539237ff-9cf5-464c-8ae3-a8bd260114c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_edaf2ed7-5ecb-4f16-9238-9cf97a1fb4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_720115bb-1f19-47eb-b802-6970893d9900" xlink:to="loc_us-gaap_DepreciationAndAmortization_edaf2ed7-5ecb-4f16-9238-9cf97a1fb4bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f50b02ba-811c-4a12-9de7-43057915778b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_693e304a-a64e-450c-a65d-a2d1df8b4653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f50b02ba-811c-4a12-9de7-43057915778b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_693e304a-a64e-450c-a65d-a2d1df8b4653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7919ffc-3063-4fc8-b658-ed01c4c2b0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4c3c6421-aa6e-4a00-adbf-6714f3ea0928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7919ffc-3063-4fc8-b658-ed01c4c2b0f8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4c3c6421-aa6e-4a00-adbf-6714f3ea0928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b74b54ed-6d41-435a-ad24-89dc2de0c4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7919ffc-3063-4fc8-b658-ed01c4c2b0f8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b74b54ed-6d41-435a-ad24-89dc2de0c4a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b447cb0-bca9-42ed-ae3c-4b444eed131b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7919ffc-3063-4fc8-b658-ed01c4c2b0f8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b447cb0-bca9-42ed-ae3c-4b444eed131b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a64b45a3-6742-4c90-9575-f26f5a6828bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_6b9e0cf0-061a-4fc1-994e-6a0c73bfa0c3" xlink:href="arvn-20220331.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a64b45a3-6742-4c90-9575-f26f5a6828bf" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_6b9e0cf0-061a-4fc1-994e-6a0c73bfa0c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d980b9a6-7d76-45dd-9aa6-e582adfc13fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a64b45a3-6742-4c90-9575-f26f5a6828bf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d980b9a6-7d76-45dd-9aa6-e582adfc13fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a0506c2f-180a-4974-bcdf-dc42e8bfbeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a64b45a3-6742-4c90-9575-f26f5a6828bf" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a0506c2f-180a-4974-bcdf-dc42e8bfbeb8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d9f48274-434e-421a-a0f0-7a405a9f610c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9259ba41-07ae-4f72-9982-84cf59b3be10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d9f48274-434e-421a-a0f0-7a405a9f610c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9259ba41-07ae-4f72-9982-84cf59b3be10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5c9ada09-a6b1-4e69-b632-f3c228a4c702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d9f48274-434e-421a-a0f0-7a405a9f610c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5c9ada09-a6b1-4e69-b632-f3c228a4c702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_60baac89-4804-4765-8816-8ef44781c679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d9f48274-434e-421a-a0f0-7a405a9f610c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_60baac89-4804-4765-8816-8ef44781c679" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fee6228d-6a11-4784-87fa-74790215c805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_61f12b3e-0afa-4337-8f5d-c5392facec5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fee6228d-6a11-4784-87fa-74790215c805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_61f12b3e-0afa-4337-8f5d-c5392facec5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9e74a32b-0990-4fae-bc30-e86674f3547c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fee6228d-6a11-4784-87fa-74790215c805" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9e74a32b-0990-4fae-bc30-e86674f3547c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e776935-38df-4498-b6b5-997296945b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66fd8f19-5456-4af4-b539-c1e23255c25f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e776935-38df-4498-b6b5-997296945b47" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66fd8f19-5456-4af4-b539-c1e23255c25f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_09a89340-dcd7-4879-8991-52aaa0497e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e776935-38df-4498-b6b5-997296945b47" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_09a89340-dcd7-4879-8991-52aaa0497e13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6e4fb0ae-cd55-4433-97db-eded3a14bcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e776935-38df-4498-b6b5-997296945b47" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6e4fb0ae-cd55-4433-97db-eded3a14bcf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8478476b-8031-4464-bc46-35dd2ab4b89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e776935-38df-4498-b6b5-997296945b47" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8478476b-8031-4464-bc46-35dd2ab4b89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_335a5002-739c-466f-81c7-4917b92636d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e776935-38df-4498-b6b5-997296945b47" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_335a5002-739c-466f-81c7-4917b92636d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="arvn-20220331.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9607a2e1-6713-45ab-84f0-67ffc4418a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_86c8b815-afe3-49ee-a0b7-a2d6f3007e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9607a2e1-6713-45ab-84f0-67ffc4418a19" xlink:to="loc_us-gaap_OperatingLeaseLiability_86c8b815-afe3-49ee-a0b7-a2d6f3007e96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f9d7109a-b3a3-45dc-a2cb-2658d5b6b521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9607a2e1-6713-45ab-84f0-67ffc4418a19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f9d7109a-b3a3-45dc-a2cb-2658d5b6b521" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2ea60cc6-6d10-4d66-aa11-fa8a3b856fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_b00dc3c9-1e1c-4d13-b2b1-8aa96d855a00" xlink:href="arvn-20220331.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2ea60cc6-6d10-4d66-aa11-fa8a3b856fb7" xlink:to="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_b00dc3c9-1e1c-4d13-b2b1-8aa96d855a00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_5f371632-eda6-4349-9673-747320224f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2ea60cc6-6d10-4d66-aa11-fa8a3b856fb7" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_5f371632-eda6-4349-9673-747320224f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e2304ada-1bf9-46f3-a7c1-0fa5d994b7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2ea60cc6-6d10-4d66-aa11-fa8a3b856fb7" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e2304ada-1bf9-46f3-a7c1-0fa5d994b7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5d3064d-d60a-4f21-b88e-75b2b690fd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2ea60cc6-6d10-4d66-aa11-fa8a3b856fb7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5d3064d-d60a-4f21-b88e-75b2b690fd3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_36eb72c4-5450-4456-981b-ffb9d77e2fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_32257878-74b1-458c-9868-b27034b865b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_36eb72c4-5450-4456-981b-ffb9d77e2fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_32257878-74b1-458c-9868-b27034b865b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_725c0b1b-d153-4649-a9f9-5446fc61dfec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_36eb72c4-5450-4456-981b-ffb9d77e2fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_725c0b1b-d153-4649-a9f9-5446fc61dfec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e45eddeb-f666-4e0d-8449-0f2813253d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_36eb72c4-5450-4456-981b-ffb9d77e2fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e45eddeb-f666-4e0d-8449-0f2813253d66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LongTermDebtMaturityYearSix_4282aed2-7466-4305-90b5-b22ba6a4af36" xlink:href="arvn-20220331.xsd#arvn_LongTermDebtMaturityYearSix"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_36eb72c4-5450-4456-981b-ffb9d77e2fca" xlink:to="loc_arvn_LongTermDebtMaturityYearSix_4282aed2-7466-4305-90b5-b22ba6a4af36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1bff75ef-5197-4ba4-ba69-bd353d4a712d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_36eb72c4-5450-4456-981b-ffb9d77e2fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1bff75ef-5197-4ba4-ba69-bd353d4a712d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ffe1910f-8be9-405e-b0e2-b9eaf0a56e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_36eb72c4-5450-4456-981b-ffb9d77e2fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ffe1910f-8be9-405e-b0e2-b9eaf0a56e46" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>arvn-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:966c8cdd-8d85-475a-b79b-8010015adf33,g:b9593e04-7343-4e88-918f-c5a2cc011d89-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="simple" xlink:href="arvn-20220331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="extended" id="id4715e0ccc114b368fbf55f019a2afa0_CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a713aa9-ea9f-4bc7-b018-8d54dea5f5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a713aa9-ea9f-4bc7-b018-8d54dea5f5e3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_33955c3c-83e5-493c-8c32-81507ae2e8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_33955c3c-83e5-493c-8c32-81507ae2e8f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4efdd1d0-d213-46d2-82d8-ad8ebd356dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockholdersEquity_4efdd1d0-d213-46d2-82d8-ad8ebd356dbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_180900f7-b035-4e6f-9ff6-af2773cf07b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_180900f7-b035-4e6f-9ff6-af2773cf07b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_571be89a-09ba-4242-bd4e-2431b71f198e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_NetIncomeLoss_571be89a-09ba-4242-bd4e-2431b71f198e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_bdcad23c-0faa-451d-bbdd-c214b6403d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_bdcad23c-0faa-451d-bbdd-c214b6403d8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ef8a6e0d-6077-48a6-bf21-d54423bbd97f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ef8a6e0d-6077-48a6-bf21-d54423bbd97f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49150edb-f386-46e0-bbc7-6b0c78198aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49150edb-f386-46e0-bbc7-6b0c78198aad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e6316e5-68ec-4bd6-8dd3-e11f99493a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e6316e5-68ec-4bd6-8dd3-e11f99493a72" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f9ab21ef-667b-407a-bad8-2c6e55c30d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f9ab21ef-667b-407a-bad8-2c6e55c30d22" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c0fd553a-65a7-4ea7-b7b8-fe9555b47a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8a99f9d4-c0e0-4ad1-b5eb-28b6c2ef4a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8f333f3-0156-4a30-b401-7984eeff89e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4a713aa9-ea9f-4bc7-b018-8d54dea5f5e3" xlink:to="loc_us-gaap_StatementTable_e8f333f3-0156-4a30-b401-7984eeff89e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aec2afde-3618-4eb3-8e2b-7a6097f22eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e8f333f3-0156-4a30-b401-7984eeff89e5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aec2afde-3618-4eb3-8e2b-7a6097f22eca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aec2afde-3618-4eb3-8e2b-7a6097f22eca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aec2afde-3618-4eb3-8e2b-7a6097f22eca" xlink:to="loc_us-gaap_EquityComponentDomain_aec2afde-3618-4eb3-8e2b-7a6097f22eca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aec2afde-3618-4eb3-8e2b-7a6097f22eca" xlink:to="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_17618fd2-45fc-479c-9fec-7ffa0a44177e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:to="loc_us-gaap_CommonStockMember_17618fd2-45fc-479c-9fec-7ffa0a44177e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_73a5e86c-ddb4-4c2f-ace2-d9bb020c7371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:to="loc_us-gaap_RetainedEarningsMember_73a5e86c-ddb4-4c2f-ace2-d9bb020c7371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1a416517-88c6-468f-a78a-15af70368116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1a416517-88c6-468f-a78a-15af70368116" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb1e033e-e188-499b-a86d-717269ac474f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb1e033e-e188-499b-a86d-717269ac474f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended" id="ib8404f6083374129bca4f15e2c3a7878_ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_e63c6bae-3b66-4420-be10-5ff981ea1809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_e63c6bae-3b66-4420-be10-5ff981ea1809" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_9324058e-d9ff-4d61-8dfe-90d05edd6c7d" xlink:href="arvn-20220331.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_9324058e-d9ff-4d61-8dfe-90d05edd6c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_8424c9a7-0df8-40c4-b6ee-b19bce991fe3" xlink:href="arvn-20220331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_8424c9a7-0df8-40c4-b6ee-b19bce991fe3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_650ece53-194a-4831-b10d-445e154a8226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_us-gaap_ProceedsFromCollaborators_650ece53-194a-4831-b10d-445e154a8226" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_55c0a050-131f-40f1-8496-8210c85184c6" xlink:href="arvn-20220331.xsd#arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_55c0a050-131f-40f1-8496-8210c85184c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfMaximumDesignatedTargets_2919f95c-ae04-4707-af23-40cd07b2ea53" xlink:href="arvn-20220331.xsd#arvn_NumberOfMaximumDesignatedTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_arvn_NumberOfMaximumDesignatedTargets_2919f95c-ae04-4707-af23-40cd07b2ea53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_304c0e19-0341-4a14-8b38-fa62a3beb4df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:to="loc_srt_CounterpartyNameAxis_304c0e19-0341-4a14-8b38-fa62a3beb4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_304c0e19-0341-4a14-8b38-fa62a3beb4df_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_304c0e19-0341-4a14-8b38-fa62a3beb4df" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_304c0e19-0341-4a14-8b38-fa62a3beb4df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65858c4d-80ab-4132-ba40-511a1f4328c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_304c0e19-0341-4a14-8b38-fa62a3beb4df" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65858c4d-80ab-4132-ba40-511a1f4328c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_48cdd76e-ef63-42af-9c4e-99d856337755" xlink:href="arvn-20220331.xsd#arvn_PfizerIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65858c4d-80ab-4132-ba40-511a1f4328c1" xlink:to="loc_arvn_PfizerIncorporationMember_48cdd76e-ef63-42af-9c4e-99d856337755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember_5c0886c9-90f3-412f-b66b-988673721af6" xlink:href="arvn-20220331.xsd#arvn_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65858c4d-80ab-4132-ba40-511a1f4328c1" xlink:to="loc_arvn_BayerAGMember_5c0886c9-90f3-412f-b66b-988673721af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_e4e9fcaf-0832-4450-8f20-4d777f57eddf" xlink:href="arvn-20220331.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65858c4d-80ab-4132-ba40-511a1f4328c1" xlink:to="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_e4e9fcaf-0832-4450-8f20-4d777f57eddf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0c5b9b09-4216-4f39-a714-c82000c1fd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0c5b9b09-4216-4f39-a714-c82000c1fd01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c5b9b09-4216-4f39-a714-c82000c1fd01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0c5b9b09-4216-4f39-a714-c82000c1fd01" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c5b9b09-4216-4f39-a714-c82000c1fd01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0c5b9b09-4216-4f39-a714-c82000c1fd01" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember_907e6fe5-d3da-4394-a59a-32331d773e60" xlink:href="arvn-20220331.xsd#arvn_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_CollaborationAgreementMember_907e6fe5-d3da-4394-a59a-32331d773e60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_ba151a75-b6ed-4817-b155-1ba713a49db2" xlink:href="arvn-20220331.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_ba151a75-b6ed-4817-b155-1ba713a49db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember_b5499dcb-5514-468e-9ba1-ee94453a3d98" xlink:href="arvn-20220331.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_RegulatoryMilestonePaymentsMember_b5499dcb-5514-468e-9ba1-ee94453a3d98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember_09946049-1cf6-4f12-a7d7-2dc58fd217dc" xlink:href="arvn-20220331.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_SalesBasedMilestonesMember_09946049-1cf6-4f12-a7d7-2dc58fd217dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember_9880bde3-a85f-451f-aa6f-2dfb272f64f6" xlink:href="arvn-20220331.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_ResearchFundingPaymentsMember_9880bde3-a85f-451f-aa6f-2dfb272f64f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember_30979c1f-8ff8-4974-b278-539ab2d8cefa" xlink:href="arvn-20220331.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_DevelopmentMilestonePaymentsMember_30979c1f-8ff8-4974-b278-539ab2d8cefa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember_0affe667-25b9-4e54-adda-fecf44125cce" xlink:href="arvn-20220331.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_SalesBasedMilestonePaymentsMember_0affe667-25b9-4e54-adda-fecf44125cce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember_c890308f-03d0-4eae-9f71-ada971a4aec0" xlink:href="arvn-20220331.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_OptionPaymentsToLicenseAgreementMember_c890308f-03d0-4eae-9f71-ada971a4aec0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember_5e609d8e-53ec-43a8-b397-6a347ff16b99" xlink:href="arvn-20220331.xsd#arvn_CommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_CommercialMilestonesMember_5e609d8e-53ec-43a8-b397-6a347ff16b99" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_776468c9-b3b8-4bfb-b91d-2234e3dcd802" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:to="loc_srt_RangeAxis_776468c9-b3b8-4bfb-b91d-2234e3dcd802" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_776468c9-b3b8-4bfb-b91d-2234e3dcd802_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_776468c9-b3b8-4bfb-b91d-2234e3dcd802" xlink:to="loc_srt_RangeMember_776468c9-b3b8-4bfb-b91d-2234e3dcd802_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5ad9e13-d945-4644-9755-f05ba0401fff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_776468c9-b3b8-4bfb-b91d-2234e3dcd802" xlink:to="loc_srt_RangeMember_e5ad9e13-d945-4644-9755-f05ba0401fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b34c3061-d061-45d1-bc12-5e1d75a6bd3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5ad9e13-d945-4644-9755-f05ba0401fff" xlink:to="loc_srt_MaximumMember_b34c3061-d061-45d1-bc12-5e1d75a6bd3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c112ec46-0036-4700-bbac-be2d4d448e2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:to="loc_srt_StatementScenarioAxis_c112ec46-0036-4700-bbac-be2d4d448e2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c112ec46-0036-4700-bbac-be2d4d448e2b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c112ec46-0036-4700-bbac-be2d4d448e2b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c112ec46-0036-4700-bbac-be2d4d448e2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c81042e1-1e92-4816-8f93-8151752ced1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c112ec46-0036-4700-bbac-be2d4d448e2b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c81042e1-1e92-4816-8f93-8151752ced1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1a308fa6-da2c-4c0b-8434-f0044e9415ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_c81042e1-1e92-4816-8f93-8151752ced1b" xlink:to="loc_srt_ScenarioForecastMember_1a308fa6-da2c-4c0b-8434-f0044e9415ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="extended" id="i98f9e2b33cc340359ab7a1e71ba8335d_ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_002d7404-3811-4f4e-9949-effec13973cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_002d7404-3811-4f4e-9949-effec13973cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_851f354e-068a-4e44-81b3-225da9709c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_851f354e-068a-4e44-81b3-225da9709c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e07673d5-4242-4906-b694-b1fb1ee861c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e07673d5-4242-4906-b694-b1fb1ee861c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_adf8933a-94cd-4ae5-9fb2-22d526b6a698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e07673d5-4242-4906-b694-b1fb1ee861c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_adf8933a-94cd-4ae5-9fb2-22d526b6a698" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="arvn-20220331.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="extended" id="idec9a9bc3be241ef81853bf7461fed85_ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_002d7404-3811-4f4e-9949-effec13973cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_002d7404-3811-4f4e-9949-effec13973cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_851f354e-068a-4e44-81b3-225da9709c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_851f354e-068a-4e44-81b3-225da9709c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e07673d5-4242-4906-b694-b1fb1ee861c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e07673d5-4242-4906-b694-b1fb1ee861c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="extended" id="if2b2b1c339b04160a98126a77261fbf9_MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ff728029-92ba-4352-850e-1b8261071a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ff728029-92ba-4352-850e-1b8261071a81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3c9ca09-b9a4-4fa8-8b60-75b941d9b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3c9ca09-b9a4-4fa8-8b60-75b941d9b61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d21a48e9-a434-48fb-b017-29f2eb2dff80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d21a48e9-a434-48fb-b017-29f2eb2dff80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d608f-7b79-43ac-92f9-6ee7d83e8bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d608f-7b79-43ac-92f9-6ee7d83e8bc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5b4210a-55ac-48a5-98f6-900ee87a542d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5b4210a-55ac-48a5-98f6-900ee87a542d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5b4210a-55ac-48a5-98f6-900ee87a542d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5b4210a-55ac-48a5-98f6-900ee87a542d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5b4210a-55ac-48a5-98f6-900ee87a542d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd4a11d-2462-433b-9c17-c127bafe9b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5b4210a-55ac-48a5-98f6-900ee87a542d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd4a11d-2462-433b-9c17-c127bafe9b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_091c255c-512b-4752-9b3f-7a0f87dc9510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd4a11d-2462-433b-9c17-c127bafe9b87" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_091c255c-512b-4752-9b3f-7a0f87dc9510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95265b2b-efde-4a4d-8573-5d873c00794e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95265b2b-efde-4a4d-8573-5d873c00794e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_95265b2b-efde-4a4d-8573-5d873c00794e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95265b2b-efde-4a4d-8573-5d873c00794e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_95265b2b-efde-4a4d-8573-5d873c00794e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_90fb1cb6-6dfe-4fe1-957f-31015cbf9d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95265b2b-efde-4a4d-8573-5d873c00794e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_90fb1cb6-6dfe-4fe1-957f-31015cbf9d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d8a1ab5e-2774-4dc5-badc-d691534d83d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_90fb1cb6-6dfe-4fe1-957f-31015cbf9d1f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d8a1ab5e-2774-4dc5-badc-d691534d83d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_7185e6fb-07d5-42c9-88cb-7e9464159f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:to="loc_us-gaap_InvestmentTypeAxis_7185e6fb-07d5-42c9-88cb-7e9464159f63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7185e6fb-07d5-42c9-88cb-7e9464159f63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_7185e6fb-07d5-42c9-88cb-7e9464159f63" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7185e6fb-07d5-42c9-88cb-7e9464159f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_7185e6fb-07d5-42c9-88cb-7e9464159f63" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_ee384f05-37aa-4307-b0d9-c888e0dc20f1" xlink:href="arvn-20220331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_ee384f05-37aa-4307-b0d9-c888e0dc20f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_359f9af2-1fc8-447e-8831-b61b567ad0aa" xlink:href="arvn-20220331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_359f9af2-1fc8-447e-8831-b61b567ad0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_07043736-9133-4dc6-ae76-020f2ac3e0f7" xlink:href="arvn-20220331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_07043736-9133-4dc6-ae76-020f2ac3e0f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_c9ad54e9-60b0-4a7e-a8a1-5e8f1805ced7" xlink:href="arvn-20220331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_c9ad54e9-60b0-4a7e-a8a1-5e8f1805ced7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_37fa89d5-3306-4a74-a6ec-6ea13ba53d62" xlink:href="arvn-20220331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_37fa89d5-3306-4a74-a6ec-6ea13ba53d62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_218dc3e9-8c4b-4ebe-9833-3258658e117b" xlink:href="arvn-20220331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_218dc3e9-8c4b-4ebe-9833-3258658e117b" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended" id="i9c77bd24773c454588f4d072f4063ee5_PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9d858674-d6a3-4dea-b557-f84dd005dcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9581e9d2-c4ab-45d3-96f5-19ea57431498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9d858674-d6a3-4dea-b557-f84dd005dcc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9581e9d2-c4ab-45d3-96f5-19ea57431498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0403eee4-0e09-4e97-a5cf-1f4d153b18f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9d858674-d6a3-4dea-b557-f84dd005dcc3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0403eee4-0e09-4e97-a5cf-1f4d153b18f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a447483e-b976-4d2f-b9df-cdf7c3eaf158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9d858674-d6a3-4dea-b557-f84dd005dcc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a447483e-b976-4d2f-b9df-cdf7c3eaf158" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3e5082e-583a-45c9-8e42-16022069da5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9d858674-d6a3-4dea-b557-f84dd005dcc3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3e5082e-583a-45c9-8e42-16022069da5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deac42a2-80d5-4d76-8946-00b7f1b9d95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3e5082e-583a-45c9-8e42-16022069da5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deac42a2-80d5-4d76-8946-00b7f1b9d95e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_deac42a2-80d5-4d76-8946-00b7f1b9d95e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deac42a2-80d5-4d76-8946-00b7f1b9d95e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_deac42a2-80d5-4d76-8946-00b7f1b9d95e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a19270b-1e0e-4068-90e9-729a24a23e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deac42a2-80d5-4d76-8946-00b7f1b9d95e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a19270b-1e0e-4068-90e9-729a24a23e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_692d09cd-7f08-4fbe-8691-8b401a3871b4" xlink:href="arvn-20220331.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a19270b-1e0e-4068-90e9-729a24a23e02" xlink:to="loc_arvn_LaboratoryEquipmentMember_692d09cd-7f08-4fbe-8691-8b401a3871b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6afb8975-194a-4204-a4bf-7b5f19390010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a19270b-1e0e-4068-90e9-729a24a23e02" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6afb8975-194a-4204-a4bf-7b5f19390010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_2a0e8283-5da9-454e-bf08-813a04674a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a19270b-1e0e-4068-90e9-729a24a23e02" xlink:to="loc_us-gaap_OfficeEquipmentMember_2a0e8283-5da9-454e-bf08-813a04674a9b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#RightofUseAssetsandLiabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="extended" id="if35f42ffd2494ec5a79ef579cc9eef14_RightofUseAssetsandLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_1a86ca85-6ce2-4691-b9fd-760beac4ccf0" xlink:href="arvn-20220331.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_1a86ca85-6ce2-4691-b9fd-760beac4ccf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_3920061c-dea3-4d6f-8cfd-ae1870999110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_3920061c-dea3-4d6f-8cfd-ae1870999110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_4c5ff128-9eb8-47b5-b547-09d9bc6a840b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_4c5ff128-9eb8-47b5-b547-09d9bc6a840b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f7a3bfea-cf7f-44cf-958f-3381ab1fd00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_us-gaap_LeaseCost_f7a3bfea-cf7f-44cf-958f-3381ab1fd00e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BaseLeaseRentPeriod_0aceac49-058b-46c9-8665-a8c647f82b6c" xlink:href="arvn-20220331.xsd#arvn_BaseLeaseRentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_arvn_BaseLeaseRentPeriod_0aceac49-058b-46c9-8665-a8c647f82b6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f95e3813-f58a-471d-9f79-88645e9675fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f95e3813-f58a-471d-9f79-88645e9675fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b8e71754-9606-4b33-9401-21fc89c1eeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b8e71754-9606-4b33-9401-21fc89c1eeb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a6bd6cd-aed8-4ac0-b188-408ed4821c81" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b8e71754-9606-4b33-9401-21fc89c1eeb6" xlink:to="loc_srt_RangeAxis_3a6bd6cd-aed8-4ac0-b188-408ed4821c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a6bd6cd-aed8-4ac0-b188-408ed4821c81_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3a6bd6cd-aed8-4ac0-b188-408ed4821c81" xlink:to="loc_srt_RangeMember_3a6bd6cd-aed8-4ac0-b188-408ed4821c81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99cbaa2c-eebc-4849-b80e-1aaa0834fd51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3a6bd6cd-aed8-4ac0-b188-408ed4821c81" xlink:to="loc_srt_RangeMember_99cbaa2c-eebc-4849-b80e-1aaa0834fd51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d442111b-dcc2-495c-8de0-368b70b443b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_99cbaa2c-eebc-4849-b80e-1aaa0834fd51" xlink:to="loc_srt_MinimumMember_d442111b-dcc2-495c-8de0-368b70b443b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2683811d-9a32-4003-8643-0677383357df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_99cbaa2c-eebc-4849-b80e-1aaa0834fd51" xlink:to="loc_srt_MaximumMember_2683811d-9a32-4003-8643-0677383357df" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended" id="ib6186bbda5c84ec39d7c413802e235a7_LongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_77e41d4d-a783-445b-9594-0aa98c38011a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_77e41d4d-a783-445b-9594-0aa98c38011a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_fae5e5e2-154a-44f4-9eb0-bd2b7b2513dc" xlink:href="arvn-20220331.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_fae5e5e2-154a-44f4-9eb0-bd2b7b2513dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0fe47275-f096-43fa-b821-aaa71458416b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0fe47275-f096-43fa-b821-aaa71458416b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm_8410a407-8dad-4c77-a959-3182b7dda0ce" xlink:href="arvn-20220331.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_arvn_DebtInstrumentInterestPaymentsTerm_8410a407-8dad-4c77-a959-3182b7dda0ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages_58aaace0-930f-44b2-ac4f-9a3a40b7995c" xlink:href="arvn-20220331.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_arvn_PercentageOfLiquidatedDamages_58aaace0-930f-44b2-ac4f-9a3a40b7995c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ac997638-71d2-4356-9d23-8a1bdf6f6b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ac997638-71d2-4356-9d23-8a1bdf6f6b70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2e25b2ef-21e6-43cf-b950-93aa73a37272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_us-gaap_DebtInstrumentTable_2e25b2ef-21e6-43cf-b950-93aa73a37272" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3ffc928f-bffd-4c0a-b941-916d8bb65880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2e25b2ef-21e6-43cf-b950-93aa73a37272" xlink:to="loc_us-gaap_DebtInstrumentAxis_3ffc928f-bffd-4c0a-b941-916d8bb65880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3ffc928f-bffd-4c0a-b941-916d8bb65880_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ffc928f-bffd-4c0a-b941-916d8bb65880" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3ffc928f-bffd-4c0a-b941-916d8bb65880_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_777263fb-b477-4b77-b2dd-856dbebc3b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ffc928f-bffd-4c0a-b941-916d8bb65880" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_777263fb-b477-4b77-b2dd-856dbebc3b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_e4d8cbbd-e1fd-40ca-9375-a5fd444cff96" xlink:href="arvn-20220331.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_777263fb-b477-4b77-b2dd-856dbebc3b18" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_e4d8cbbd-e1fd-40ca-9375-a5fd444cff96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_8729bca7-21a0-41b1-9cdf-0a39547bd51b" xlink:href="arvn-20220331.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_777263fb-b477-4b77-b2dd-856dbebc3b18" xlink:to="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_8729bca7-21a0-41b1-9cdf-0a39547bd51b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_903871e6-e39a-4264-876c-001487e1dec4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2e25b2ef-21e6-43cf-b950-93aa73a37272" xlink:to="loc_srt_StatementGeographicalAxis_903871e6-e39a-4264-876c-001487e1dec4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_903871e6-e39a-4264-876c-001487e1dec4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_903871e6-e39a-4264-876c-001487e1dec4" xlink:to="loc_srt_SegmentGeographicalDomain_903871e6-e39a-4264-876c-001487e1dec4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_03b01db0-6cfc-4109-ad66-a26bce73df6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_903871e6-e39a-4264-876c-001487e1dec4" xlink:to="loc_srt_SegmentGeographicalDomain_03b01db0-6cfc-4109-ad66-a26bce73df6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_318349bb-db77-4ffe-a868-e555b0da6b86" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_03b01db0-6cfc-4109-ad66-a26bce73df6b" xlink:to="loc_stpr_CT_318349bb-db77-4ffe-a868-e555b0da6b86" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="extended" id="id1c3ff6bdee349f8956da936491c000f_EquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_0840580c-5266-4197-a209-3886b36c541c" xlink:href="arvn-20220331.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_0840580c-5266-4197-a209-3886b36c541c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2e30396b-d002-442c-8303-a6eb20a1b66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2e30396b-d002-442c-8303-a6eb20a1b66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fc04b343-2b10-4c90-9b69-57d93c764b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fc04b343-2b10-4c90-9b69-57d93c764b82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_3b2cf0b1-aa6b-49c0-8fd8-8bf03e77acb6" xlink:href="arvn-20220331.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_3b2cf0b1-aa6b-49c0-8fd8-8bf03e77acb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1a8f82cc-1557-4dde-8582-2e8cf2436c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1a8f82cc-1557-4dde-8582-2e8cf2436c4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_be477b85-0637-44d7-937d-efeaf4f60327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_be477b85-0637-44d7-937d-efeaf4f60327" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3e9be46a-f322-4527-a965-c2d181af54f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3e9be46a-f322-4527-a965-c2d181af54f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28137b9a-c20d-462b-a6be-4e3d9dbc9143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28137b9a-c20d-462b-a6be-4e3d9dbc9143" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_7962ee65-7a84-452f-94c2-19cbfa9c7927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_7962ee65-7a84-452f-94c2-19cbfa9c7927" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3164e7fd-0f24-406f-bb5d-26eb4ce69b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3164e7fd-0f24-406f-bb5d-26eb4ce69b9c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_01c6f34e-68fb-4e52-b3ba-1ff596eb9a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_01c6f34e-68fb-4e52-b3ba-1ff596eb9a8a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7c7dea86-9e68-48f3-8d08-f48e36cc0c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7c7dea86-9e68-48f3-8d08-f48e36cc0c6d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3a5cea98-5b99-4997-9107-0d387228b9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3a5cea98-5b99-4997-9107-0d387228b9b7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_913c4923-8e2d-43a3-9f01-995332e162fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_913c4923-8e2d-43a3-9f01-995332e162fa" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d45e435b-e1a0-4334-b0f1-fb900b3f7b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d45e435b-e1a0-4334-b0f1-fb900b3f7b11" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4c5aff61-a53d-4154-9002-df45209f50f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4c5aff61-a53d-4154-9002-df45209f50f4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber_08f99436-b796-4b87-bf67-bcfa21b12ee5" xlink:href="arvn-20220331.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber_08f99436-b796-4b87-bf67-bcfa21b12ee5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_58237cb9-2662-498e-9494-2918ab5e06b0" xlink:href="arvn-20220331.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_58237cb9-2662-498e-9494-2918ab5e06b0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7692b665-057e-428d-a24c-e5f588ac87ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7692b665-057e-428d-a24c-e5f588ac87ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7692b665-057e-428d-a24c-e5f588ac87ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7692b665-057e-428d-a24c-e5f588ac87ec" xlink:to="loc_us-gaap_EquityComponentDomain_7692b665-057e-428d-a24c-e5f588ac87ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47f1a9ba-ca3a-4af2-9416-4b357aa609c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7692b665-057e-428d-a24c-e5f588ac87ec" xlink:to="loc_us-gaap_EquityComponentDomain_47f1a9ba-ca3a-4af2-9416-4b357aa609c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ee325c92-dde4-4781-a46d-3b30fd010070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47f1a9ba-ca3a-4af2-9416-4b357aa609c8" xlink:to="loc_us-gaap_CommonStockMember_ee325c92-dde4-4781-a46d-3b30fd010070" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_63aa5fee-6be6-48c4-b3d9-1ccbbdee4aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_TypeOfArrangementAxis_63aa5fee-6be6-48c4-b3d9-1ccbbdee4aa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_63aa5fee-6be6-48c4-b3d9-1ccbbdee4aa4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_63aa5fee-6be6-48c4-b3d9-1ccbbdee4aa4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_63aa5fee-6be6-48c4-b3d9-1ccbbdee4aa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2175247-7995-4145-939b-587613d862b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_63aa5fee-6be6-48c4-b3d9-1ccbbdee4aa4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2175247-7995-4145-939b-587613d862b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember_1fe8229c-8cdd-4bb9-888b-110031d9bad9" xlink:href="arvn-20220331.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2175247-7995-4145-939b-587613d862b6" xlink:to="loc_arvn_EquityDistributionAgreementMember_1fe8229c-8cdd-4bb9-888b-110031d9bad9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5f6ea27d-f5e3-4ae3-9b7a-2f1171b3cbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5f6ea27d-f5e3-4ae3-9b7a-2f1171b3cbb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5f6ea27d-f5e3-4ae3-9b7a-2f1171b3cbb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5f6ea27d-f5e3-4ae3-9b7a-2f1171b3cbb9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5f6ea27d-f5e3-4ae3-9b7a-2f1171b3cbb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee2db2fd-11c8-46a3-bbde-ccf844d02e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5f6ea27d-f5e3-4ae3-9b7a-2f1171b3cbb9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee2db2fd-11c8-46a3-bbde-ccf844d02e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_baaca12e-da7a-44b9-9a3f-caac71b6dc93" xlink:href="arvn-20220331.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee2db2fd-11c8-46a3-bbde-ccf844d02e8e" xlink:to="loc_arvn_AtTheMarketOfferingMember_baaca12e-da7a-44b9-9a3f-caac71b6dc93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d90a240c-7921-4658-94e3-7232b8bf2254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee2db2fd-11c8-46a3-bbde-ccf844d02e8e" xlink:to="loc_us-gaap_EmployeeStockMember_d90a240c-7921-4658-94e3-7232b8bf2254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_be5dce12-197b-4998-acfd-c10cb91269ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_srt_CounterpartyNameAxis_be5dce12-197b-4998-acfd-c10cb91269ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be5dce12-197b-4998-acfd-c10cb91269ab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_be5dce12-197b-4998-acfd-c10cb91269ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be5dce12-197b-4998-acfd-c10cb91269ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8020fe78-1f64-48af-9849-30d47f9bc56d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_be5dce12-197b-4998-acfd-c10cb91269ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8020fe78-1f64-48af-9849-30d47f9bc56d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember_5b65c24d-60b5-40cc-9a7c-9f6c8fc72af0" xlink:href="arvn-20220331.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8020fe78-1f64-48af-9849-30d47f9bc56d" xlink:to="loc_arvn_PiperSandlerAndCantorMember_5b65c24d-60b5-40cc-9a7c-9f6c8fc72af0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d225b5b3-08e4-4640-b415-1b04169b4239" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_srt_RangeAxis_d225b5b3-08e4-4640-b415-1b04169b4239" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d225b5b3-08e4-4640-b415-1b04169b4239_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d225b5b3-08e4-4640-b415-1b04169b4239" xlink:to="loc_srt_RangeMember_d225b5b3-08e4-4640-b415-1b04169b4239_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8b3f01ad-9625-4e40-bb51-29b2bda8e1c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d225b5b3-08e4-4640-b415-1b04169b4239" xlink:to="loc_srt_RangeMember_8b3f01ad-9625-4e40-bb51-29b2bda8e1c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e59e3c14-b4dc-475d-b803-0cd9aa5fa40b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8b3f01ad-9625-4e40-bb51-29b2bda8e1c1" xlink:to="loc_srt_MinimumMember_e59e3c14-b4dc-475d-b803-0cd9aa5fa40b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_606f4f9c-cd2b-4d62-a18a-95bc1b38dd45" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8b3f01ad-9625-4e40-bb51-29b2bda8e1c1" xlink:to="loc_srt_MaximumMember_606f4f9c-cd2b-4d62-a18a-95bc1b38dd45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_545549bb-933d-4c98-a039-ed5ef022a59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_PlanNameAxis_545549bb-933d-4c98-a039-ed5ef022a59d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_545549bb-933d-4c98-a039-ed5ef022a59d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_545549bb-933d-4c98-a039-ed5ef022a59d" xlink:to="loc_us-gaap_PlanNameDomain_545549bb-933d-4c98-a039-ed5ef022a59d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c44289b5-b180-4891-9f9c-80f004d710c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_545549bb-933d-4c98-a039-ed5ef022a59d" xlink:to="loc_us-gaap_PlanNameDomain_c44289b5-b180-4891-9f9c-80f004d710c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember_225d7ecd-2fa8-4101-affe-9401b045e27a" xlink:href="arvn-20220331.xsd#arvn_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c44289b5-b180-4891-9f9c-80f004d710c4" xlink:to="loc_arvn_StockIncentivePlanMember_225d7ecd-2fa8-4101-affe-9401b045e27a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_3803dd1b-b97a-44cf-8cc1-86c7e6160d03" xlink:href="arvn-20220331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c44289b5-b180-4891-9f9c-80f004d710c4" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_3803dd1b-b97a-44cf-8cc1-86c7e6160d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9bffacda-1266-4e58-a574-0a6db3b9db0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_AwardTypeAxis_9bffacda-1266-4e58-a574-0a6db3b9db0b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bffacda-1266-4e58-a574-0a6db3b9db0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9bffacda-1266-4e58-a574-0a6db3b9db0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bffacda-1266-4e58-a574-0a6db3b9db0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29d2922c-81e9-40c0-b622-633b2791f0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9bffacda-1266-4e58-a574-0a6db3b9db0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29d2922c-81e9-40c0-b622-633b2791f0f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a8b2767f-306b-4916-a96e-7cffee01c50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29d2922c-81e9-40c0-b622-633b2791f0f7" xlink:to="loc_us-gaap_RestrictedStockMember_a8b2767f-306b-4916-a96e-7cffee01c50d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_275b93fe-c767-47dc-af7d-116fb8c0f7f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_srt_TitleOfIndividualAxis_275b93fe-c767-47dc-af7d-116fb8c0f7f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_275b93fe-c767-47dc-af7d-116fb8c0f7f0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_275b93fe-c767-47dc-af7d-116fb8c0f7f0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_275b93fe-c767-47dc-af7d-116fb8c0f7f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d51de419-6fbe-4001-adc0-6a37fa87c521" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_275b93fe-c767-47dc-af7d-116fb8c0f7f0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d51de419-6fbe-4001-adc0-6a37fa87c521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember_79a8f58a-4591-4b64-a556-cd8321ba0909" xlink:href="arvn-20220331.xsd#arvn_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d51de419-6fbe-4001-adc0-6a37fa87c521" xlink:to="loc_arvn_EmployeesMember_79a8f58a-4591-4b64-a556-cd8321ba0909" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="extended" id="i7cc20b99f0f74be8b99c16cc0e119a25_EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f5171dd8-542e-489a-b4a8-00e834d518f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f5171dd8-542e-489a-b4a8-00e834d518f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f9fb3d1e-d2a5-4a42-8edd-07627dd793ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f9fb3d1e-d2a5-4a42-8edd-07627dd793ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c1b305c0-8dc6-4159-96c6-fcc2c21d166d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c1b305c0-8dc6-4159-96c6-fcc2c21d166d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e9d2b299-9d67-4dfb-a4a1-dd537d3422dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e9d2b299-9d67-4dfb-a4a1-dd537d3422dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0b29607d-b2e6-41e2-8840-3d51687d6b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0b29607d-b2e6-41e2-8840-3d51687d6b0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_af4c54a0-f7e0-4a1e-9170-524325100845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_af4c54a0-f7e0-4a1e-9170-524325100845" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_86edee36-61f0-4483-904f-37f9484059e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_86edee36-61f0-4483-904f-37f9484059e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2db8b8-4c14-4d64-ab5e-338fb4026bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2db8b8-4c14-4d64-ab5e-338fb4026bec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_34feef95-33f4-4390-b97c-a48ad135b9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2db8b8-4c14-4d64-ab5e-338fb4026bec" xlink:to="loc_us-gaap_AwardTypeAxis_34feef95-33f4-4390-b97c-a48ad135b9e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34feef95-33f4-4390-b97c-a48ad135b9e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_34feef95-33f4-4390-b97c-a48ad135b9e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34feef95-33f4-4390-b97c-a48ad135b9e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85ac4a40-e33f-489a-b86d-5dd50ee00db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_34feef95-33f4-4390-b97c-a48ad135b9e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85ac4a40-e33f-489a-b86d-5dd50ee00db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_17b9ade0-577a-4983-976b-3b6f8202628f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85ac4a40-e33f-489a-b86d-5dd50ee00db3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_17b9ade0-577a-4983-976b-3b6f8202628f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89233cc7-03f4-4b32-bf2b-a90c6d72a985" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2db8b8-4c14-4d64-ab5e-338fb4026bec" xlink:to="loc_srt_RangeAxis_89233cc7-03f4-4b32-bf2b-a90c6d72a985" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_89233cc7-03f4-4b32-bf2b-a90c6d72a985_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_89233cc7-03f4-4b32-bf2b-a90c6d72a985" xlink:to="loc_srt_RangeMember_89233cc7-03f4-4b32-bf2b-a90c6d72a985_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36032251-0593-4cae-b939-2c026a4dd3c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_89233cc7-03f4-4b32-bf2b-a90c6d72a985" xlink:to="loc_srt_RangeMember_36032251-0593-4cae-b939-2c026a4dd3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2710f570-52df-4c41-bac3-1857e4b3dfa9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_36032251-0593-4cae-b939-2c026a4dd3c4" xlink:to="loc_srt_MinimumMember_2710f570-52df-4c41-bac3-1857e4b3dfa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6dbb06be-3f78-43fc-8f1d-266f28b4dffc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_36032251-0593-4cae-b939-2c026a4dd3c4" xlink:to="loc_srt_MaximumMember_6dbb06be-3f78-43fc-8f1d-266f28b4dffc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquitySummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="extended" id="iec56494d6a4e4160a7119b25c10fddf6_EquitySummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1be13c76-4aae-45e7-a3b7-1cb4f00f81f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1be13c76-4aae-45e7-a3b7-1cb4f00f81f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1cacf66e-451b-475e-b1a6-f144cfef9b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1cacf66e-451b-475e-b1a6-f144cfef9b7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e737eb36-3a4a-479f-ae29-fdf8b71686e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e737eb36-3a4a-479f-ae29-fdf8b71686e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3bc6f393-04ad-48cf-a0a4-6d429ec92d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3bc6f393-04ad-48cf-a0a4-6d429ec92d7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54251bd7-d09e-4bc6-8c81-c23b6b993272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4fdfaf9f-0c0c-492b-9083-7800db58b69b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4fdfaf9f-0c0c-492b-9083-7800db58b69b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b0ed7c30-b1e1-496e-b675-715c053d932e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b0ed7c30-b1e1-496e-b675-715c053d932e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2e3082c0-697b-452c-8ab2-536ef51f7c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2e3082c0-697b-452c-8ab2-536ef51f7c3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_75e3f32a-0e0f-47bd-b03f-37472c15f149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_75e3f32a-0e0f-47bd-b03f-37472c15f149" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ff39072b-4034-4471-9082-a766b9c5a77e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ff39072b-4034-4471-9082-a766b9c5a77e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_481042dd-bdf5-4984-acca-5bd3d49bbae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9d13ad93-98e4-4d14-a905-24c110648bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9d13ad93-98e4-4d14-a905-24c110648bd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_540ca022-7736-4346-97eb-967c05f79d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_540ca022-7736-4346-97eb-967c05f79d1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_357f5e2c-4c9d-4dd9-a9b1-04e9056930e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_540ca022-7736-4346-97eb-967c05f79d1b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_357f5e2c-4c9d-4dd9-a9b1-04e9056930e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_18c33db2-035c-44d7-a8cf-93e3b8165e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_18c33db2-035c-44d7-a8cf-93e3b8165e5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract_14eafda5-275e-4d34-99bf-67dc5c6be9f2" xlink:href="arvn-20220331.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_arvn_AggregateIntrinsicValueAbstract_14eafda5-275e-4d34-99bf-67dc5c6be9f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cb1a2c26-6f4c-4569-8412-7abfd1fdad84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_14eafda5-275e-4d34-99bf-67dc5c6be9f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cb1a2c26-6f4c-4569-8412-7abfd1fdad84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d1b7a6b6-ebbb-4204-b737-503b88e3730c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d1b7a6b6-ebbb-4204-b737-503b88e3730c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14bd1b32-0fc2-4f68-ae15-da5695f17fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14bd1b32-0fc2-4f68-ae15-da5695f17fc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a6632a7c-b449-47ea-b97f-7490d30221c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14bd1b32-0fc2-4f68-ae15-da5695f17fc4" xlink:to="loc_us-gaap_PlanNameAxis_a6632a7c-b449-47ea-b97f-7490d30221c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a6632a7c-b449-47ea-b97f-7490d30221c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a6632a7c-b449-47ea-b97f-7490d30221c0" xlink:to="loc_us-gaap_PlanNameDomain_a6632a7c-b449-47ea-b97f-7490d30221c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3584f83a-ef7a-44aa-818b-55a6b428d542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a6632a7c-b449-47ea-b97f-7490d30221c0" xlink:to="loc_us-gaap_PlanNameDomain_3584f83a-ef7a-44aa-818b-55a6b428d542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_f825ee58-39da-4cb8-9562-951a0d3558c2" xlink:href="arvn-20220331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3584f83a-ef7a-44aa-818b-55a6b428d542" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_f825ee58-39da-4cb8-9562-951a0d3558c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquitySummaryofRestrictedStockGrantActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="extended" id="ifc92d6a8acd04ef1bc4bd9881e0eeecd_EquitySummaryofRestrictedStockGrantActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bce7fa44-48fd-4492-afa9-0c4e466b70ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bce7fa44-48fd-4492-afa9-0c4e466b70ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80b5c852-7314-42fb-80a2-1923386168fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80b5c852-7314-42fb-80a2-1923386168fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f13f39a-acbc-406f-bf41-9b6e7bccab2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f13f39a-acbc-406f-bf41-9b6e7bccab2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fca94b53-a587-44c9-94e4-68b5650b91e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fca94b53-a587-44c9-94e4-68b5650b91e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4dcc5b0a-9eae-4cbe-b4d4-02cdb12be381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4dcc5b0a-9eae-4cbe-b4d4-02cdb12be381" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_abccc5cc-d391-45c9-867b-4fa39c493323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bce7fa44-48fd-4492-afa9-0c4e466b70ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_559a0dac-1ca6-4e74-b3fa-f7671d4658ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_559a0dac-1ca6-4e74-b3fa-f7671d4658ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8891ffb7-abe0-422c-b9c2-67b62dd61ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8891ffb7-abe0-422c-b9c2-67b62dd61ddd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_09236997-36f7-4f5c-bd4f-220f75f01b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_09236997-36f7-4f5c-bd4f-220f75f01b25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b86a5289-d0d2-481d-b797-9dcf06e026db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b86a5289-d0d2-481d-b797-9dcf06e026db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7b077e59-a198-483f-a1c4-c9e73103cfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bce7fa44-48fd-4492-afa9-0c4e466b70ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8c9842bb-a20a-47e6-bd50-68b5f3d560cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:to="loc_us-gaap_PlanNameAxis_8c9842bb-a20a-47e6-bd50-68b5f3d560cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8c9842bb-a20a-47e6-bd50-68b5f3d560cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8c9842bb-a20a-47e6-bd50-68b5f3d560cb" xlink:to="loc_us-gaap_PlanNameDomain_8c9842bb-a20a-47e6-bd50-68b5f3d560cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2bc4f5df-f88d-4a10-8934-61287ee2ee08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8c9842bb-a20a-47e6-bd50-68b5f3d560cb" xlink:to="loc_us-gaap_PlanNameDomain_2bc4f5df-f88d-4a10-8934-61287ee2ee08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember_d933915e-fde2-4662-87b9-825fe4356c4a" xlink:href="arvn-20220331.xsd#arvn_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2bc4f5df-f88d-4a10-8934-61287ee2ee08" xlink:to="loc_arvn_StockIncentivePlanMember_d933915e-fde2-4662-87b9-825fe4356c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_29f9c28d-2a55-4d3f-a559-10d39ea277ed" xlink:href="arvn-20220331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2bc4f5df-f88d-4a10-8934-61287ee2ee08" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_29f9c28d-2a55-4d3f-a559-10d39ea277ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_40805964-1f77-4086-b65f-138ef8b8ef21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:to="loc_us-gaap_AwardTypeAxis_40805964-1f77-4086-b65f-138ef8b8ef21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40805964-1f77-4086-b65f-138ef8b8ef21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_40805964-1f77-4086-b65f-138ef8b8ef21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40805964-1f77-4086-b65f-138ef8b8ef21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9756588c-2f01-48f5-b735-329b8a9e99cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_40805964-1f77-4086-b65f-138ef8b8ef21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9756588c-2f01-48f5-b735-329b8a9e99cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d4c6a71c-3a14-4547-9df5-f320ca6c623a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9756588c-2f01-48f5-b735-329b8a9e99cf" xlink:to="loc_us-gaap_RestrictedStockMember_d4c6a71c-3a14-4547-9df5-f320ca6c623a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6d828dec-981d-465f-87ef-9bc79b57a5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9756588c-2f01-48f5-b735-329b8a9e99cf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6d828dec-981d-465f-87ef-9bc79b57a5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_fb5f681c-90fa-42cc-adcd-cb42c705193b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:to="loc_srt_TitleOfIndividualAxis_fb5f681c-90fa-42cc-adcd-cb42c705193b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fb5f681c-90fa-42cc-adcd-cb42c705193b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_fb5f681c-90fa-42cc-adcd-cb42c705193b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fb5f681c-90fa-42cc-adcd-cb42c705193b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_45c78226-5957-4f7c-bb3c-fa8b02237599" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_fb5f681c-90fa-42cc-adcd-cb42c705193b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_45c78226-5957-4f7c-bb3c-fa8b02237599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesDirectorsAndConsultantsMember_bf7a1707-36a7-4821-a2cd-8fe63fe459b7" xlink:href="arvn-20220331.xsd#arvn_EmployeesDirectorsAndConsultantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_45c78226-5957-4f7c-bb3c-fa8b02237599" xlink:to="loc_arvn_EmployeesDirectorsAndConsultantsMember_bf7a1707-36a7-4821-a2cd-8fe63fe459b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember_0fef1a87-78c9-440a-aac2-a1ebe653b7de" xlink:href="arvn-20220331.xsd#arvn_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_45c78226-5957-4f7c-bb3c-fa8b02237599" xlink:to="loc_arvn_EmployeesMember_0fef1a87-78c9-440a-aac2-a1ebe653b7de" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="extended" id="i00fd8ec9a7a645d68b917a2a8e5d332e_NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a25b79e8-5a30-4fb4-82c3-4d8208738f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ecf6b086-7261-402c-b277-4d7da01c5703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a25b79e8-5a30-4fb4-82c3-4d8208738f3a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ecf6b086-7261-402c-b277-4d7da01c5703" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e157dbf9-e182-47c2-8f41-9e9ced475f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a25b79e8-5a30-4fb4-82c3-4d8208738f3a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e157dbf9-e182-47c2-8f41-9e9ced475f34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dcf9ccdd-8685-4a4c-b46c-ffe73b0f840d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e157dbf9-e182-47c2-8f41-9e9ced475f34" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dcf9ccdd-8685-4a4c-b46c-ffe73b0f840d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dcf9ccdd-8685-4a4c-b46c-ffe73b0f840d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dcf9ccdd-8685-4a4c-b46c-ffe73b0f840d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dcf9ccdd-8685-4a4c-b46c-ffe73b0f840d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9046a84-41ad-41c0-a108-d2491ca8d13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dcf9ccdd-8685-4a4c-b46c-ffe73b0f840d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9046a84-41ad-41c0-a108-d2491ca8d13c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1aa1016d-68ee-4dee-8446-5c2faa17cfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9046a84-41ad-41c0-a108-d2491ca8d13c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1aa1016d-68ee-4dee-8446-5c2faa17cfcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0d24fa86-c1d5-4551-9f7a-6be91f20d2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9046a84-41ad-41c0-a108-d2491ca8d13c" xlink:to="loc_us-gaap_RestrictedStockMember_0d24fa86-c1d5-4551-9f7a-6be91f20d2b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_245a46e2-723a-45a0-8f6f-fbc762708021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9046a84-41ad-41c0-a108-d2491ca8d13c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_245a46e2-723a-45a0-8f6f-fbc762708021" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="extended" id="i62a4d994fe44459e8d98cdae4322f456_EquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3f59d389-dbf5-4235-aa2a-1c0980c0ffb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3f59d389-dbf5-4235-aa2a-1c0980c0ffb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_14143b1c-65bb-4746-b781-9a735101192f" xlink:href="arvn-20220331.xsd#arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_14143b1c-65bb-4746-b781-9a735101192f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d9e7508f-89e9-40b0-bc11-e6d8bbea06e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_us-gaap_ProfitLoss_d9e7508f-89e9-40b0-bc11-e6d8bbea06e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_def04372-3d76-4f55-9118-ea724546a8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_us-gaap_EquityMethodInvestments_def04372-3d76-4f55-9118-ea724546a8a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b793ff41-f75e-43fb-92aa-f01e3e9c224e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b793ff41-f75e-43fb-92aa-f01e3e9c224e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0b182c77-dd4e-4388-b941-346fe8c4e091" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:to="loc_srt_CounterpartyNameAxis_0b182c77-dd4e-4388-b941-346fe8c4e091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b182c77-dd4e-4388-b941-346fe8c4e091_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0b182c77-dd4e-4388-b941-346fe8c4e091" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b182c77-dd4e-4388-b941-346fe8c4e091_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcf53772-af77-4e8c-8d5a-8fac21ffde1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0b182c77-dd4e-4388-b941-346fe8c4e091" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcf53772-af77-4e8c-8d5a-8fac21ffde1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember_a2a09f60-a569-43b5-8e19-e213ab5cbe14" xlink:href="arvn-20220331.xsd#arvn_BayerCropScienceLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcf53772-af77-4e8c-8d5a-8fac21ffde1a" xlink:to="loc_arvn_BayerCropScienceLPMember_a2a09f60-a569-43b5-8e19-e213ab5cbe14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4257bbc0-0d64-4c4f-8f11-cc63e355afd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4257bbc0-0d64-4c4f-8f11-cc63e355afd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4257bbc0-0d64-4c4f-8f11-cc63e355afd0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4257bbc0-0d64-4c4f-8f11-cc63e355afd0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4257bbc0-0d64-4c4f-8f11-cc63e355afd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5f0b2883-4949-4987-8435-8a89d760099e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4257bbc0-0d64-4c4f-8f11-cc63e355afd0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5f0b2883-4949-4987-8435-8a89d760099e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_f0e2e4fc-de67-4ec6-add3-7c7e6947f8c2" xlink:href="arvn-20220331.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5f0b2883-4949-4987-8435-8a89d760099e" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_f0e2e4fc-de67-4ec6-add3-7c7e6947f8c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b6ef5758-71bb-4215-9c0f-54aa9fdedd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b6ef5758-71bb-4215-9c0f-54aa9fdedd80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b6ef5758-71bb-4215-9c0f-54aa9fdedd80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b6ef5758-71bb-4215-9c0f-54aa9fdedd80" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b6ef5758-71bb-4215-9c0f-54aa9fdedd80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_9a9647b6-6113-4705-bd21-aa498d23196e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b6ef5758-71bb-4215-9c0f-54aa9fdedd80" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_9a9647b6-6113-4705-bd21-aa498d23196e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_75f95a10-19ee-42ee-8541-5d15c7f5d6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_9a9647b6-6113-4705-bd21-aa498d23196e" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_75f95a10-19ee-42ee-8541-5d15c7f5d6db" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>arvn-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:966c8cdd-8d85-475a-b79b-8010015adf33,g:b9593e04-7343-4e88-918f-c5a2cc011d89-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b7f86f0f-1323-49b1-a6dc-9c562df26b10_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5b4f3c4c-bbc1-4983-8c96-40559df5fe89_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory rate, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_8cef71c8-66c7-4de0-9d52-63539928fed0_terseLabel_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="arvn-20220331.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_394966ce-73e4-4a93-900d-57d50180603b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_d51ea442-d2f5-4993-b098-e8343ee0ad7e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76e86166-1b59-4b7e-a956-6452aa8da032_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_eec68059-d691-463b-9473-24a4b951b2d1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3d019793-312f-4378-8c80-1203cb9aaebb_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5112bc81-800a-4003-84da-a8f6264c5d48_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8fe01681-330d-4a22-9878-4fbde8508456_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a481eaae-6f15-46be-91d7-ca73cf67baa1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_646edde0-8ed7-48c9-a46c-c9f0461dfd97_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing 2023-2024</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:href="arvn-20220331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a9b9ff6a-5a5f-47eb-864d-76620eeec15c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_16245b38-5a1c-4da8-9993-d4d6030d533c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Minimum Future Payments on Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8308b87e-4c4a-4a8a-8711-e21773260cc7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ba0dcfd5-98c8-4884-a172-7e8693cf7cf2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9880dc18-62ab-4a1f-b6b4-7f0d6adab4d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_0679a52a-e562-4d07-9913-ea1d42fa9d1d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contract Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c87d13a1-96cb-4058-90ea-86e1102e4f87_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_409aa743-bf98-4d30-9b3c-d5682db1c63e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ba1cd322-bfa7-480b-8ec7-6ff00b32b908_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d5f70bb-b5a3-46b0-8694-35e4ef496963_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_documentation_en-US" xlink:label="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:href="arvn-20220331.xsd#arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:to="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_82da4302-f45b-473f-a25c-0e48d5d6dd05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e7a34c22-22be-4f20-9ee9-acbc0ee84de9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares remained available for purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_91f9fdbe-dd65-45c2-af50-72cd499cef81_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5462bf3b-b5d8-41dd-a092-e04ca646b7a0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4be294e7-91f3-4370-a0bb-4b4aaae6a959_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9ee3327d-dee7-40de-89ef-7f46b4a0a53a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6f027f14-bc17-4ec0-942e-eb966d337e2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0309ce11-f64c-47c1-9f11-b45bfffc6790_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_c16d3e27-4e83-412e-bae8-513c0ece62da_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22feaefc-8adf-4bd0-bdbd-856ab6fee2bd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_15a392c9-49a6-4150-a536-060ac4acd499_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease_c9638379-3767-4f5f-b209-e5180ae14f7d_terseLabel_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease_label_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Period Increase (Decrease)</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease_documentation_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease" xlink:href="arvn-20220331.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease" xlink:to="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_372d3f94-9543-42df-b014-725325e0ad14_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from balances held at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2b9e1ca9-e421-48e0-bacb-bc483072bd53_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_62ab723d-7017-41f6-9ca9-5d818265e063_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f93ee52-55f8-48db-8513-4f97cc629ada_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2d37600d-f846-4ee8-9579-46c75895d644_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_791de51c-cb60-4c0c-8efb-c34b21c0242a_terseLabel_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestone Payments</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember" xlink:href="arvn-20220331.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SalesBasedMilestonePaymentsMember" xlink:to="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e255bee5-c6a0-4ae2-b30a-e718314ae7a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_32364ab8-226e-474f-acb8-78235b8c4c82_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e07ff2ef-e8fe-4524-a9da-c581ff5661e7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_43eefe34-cc3a-4185-98d5-fe4b9c547f69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1ec64d53-6ee7-4bbe-a524-3e0ba45185ce_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6b600124-4532-4e60-aa64-04c9a8955740_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f33e3623-5eca-4457-8a95-529b707ff533_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8387c6f8-3f21-4132-a00f-5533d0145eb0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3c70f9ee-3670-478e-b13f-289693e66060_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_79367f6e-b23a-4273-866e-7baa6464e5d2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_bf3e28c8-cec4-4baa-9a51-3366fd206a73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65b1fdbb-e0c7-4774-873f-dc50f5f5ee44_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_d767e28e-008b-4ef0-b752-2c1d76dc3268_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing 2022</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:href="arvn-20220331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3cbbf14f-f2ae-44ba-bfba-8653bfec1a46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_989bf017-4f72-4718-9783-a6a2828104f1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront non-refundable payment and certain additional payments received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_45aee2b0-c347-4c61-ad9f-535bcde1bb9b_terseLabel_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oerth</link:label>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_label_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oerth Bio Limited Liability Corporation [Member]</link:label>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_documentation_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oerth Bio LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:href="arvn-20220331.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:to="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a7f89717-90e8-4dba-93c2-39faa65135b6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6eb5f38-e891-40c9-9d5e-c6b5a5926295_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and leasehold improvements unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_55ec0bdf-68c4-4540-b9c8-9da3ee8577c4_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_0b1cd294-3acf-4b0a-9be1-cd29f4284054_terseLabel_en-US" xlink:label="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional upfront non-refundable amount received under previous agreement</link:label>
    <link:label id="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_label_en-US" xlink:label="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Upfront Non Refundable Amount Received Under Previous Agreement</link:label>
    <link:label id="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_documentation_en-US" xlink:label="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional upfront non-refundable amount received under previous agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:href="arvn-20220331.xsd#arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:to="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e7b103e1-f219-4ca7-b446-66c0f06a3a51_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_edd49ef2-d9b5-4816-bdd9-402e13cd77e4_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest payments term (in months)</link:label>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_label_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Payments Term</link:label>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest payments term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm" xlink:href="arvn-20220331.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentInterestPaymentsTerm" xlink:to="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_318bbf39-32e5-409c-aa73-3d5cfeba2c1d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_be40ca75-c6c0-4154-9f3e-7bf242bc5059_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_13ebaaf7-9bcd-4179-a820-a298f043c4ea_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_ef8baf58-253f-4e19-95f8-4a874aeeebec_terseLabel_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember" xlink:href="arvn-20220331.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DevelopmentMilestonePaymentsMember" xlink:to="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc3e5793-cc0b-4d5f-a964-cab2d85d4e4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_88ea9236-b5f5-478b-bad9-f6575a4a3b9d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_70761d99-7f16-4b09-b3bc-2444ee000ffd_terseLabel_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_label_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity distribution agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember" xlink:href="arvn-20220331.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EquityDistributionAgreementMember" xlink:to="lab_arvn_EquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fbe844a2-a092-4052-8a52-142bfff25e0f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_ddba3829-60fa-4325-9674-6ba41082f552_terseLabel_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities: Deferred revenue</link:label>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="arvn-20220331.xsd#arvn_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_db8ad6df-9fa0-484c-85e6-da008f649b83_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BaseLeaseRentPeriod_08f99b14-9542-40f5-bf39-3fc9297fb07a_terseLabel_en-US" xlink:label="lab_arvn_BaseLeaseRentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent lease term (in years)</link:label>
    <link:label id="lab_arvn_BaseLeaseRentPeriod_label_en-US" xlink:label="lab_arvn_BaseLeaseRentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Lease Rent Period</link:label>
    <link:label id="lab_arvn_BaseLeaseRentPeriod_documentation_en-US" xlink:label="lab_arvn_BaseLeaseRentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base lease rent period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BaseLeaseRentPeriod" xlink:href="arvn-20220331.xsd#arvn_BaseLeaseRentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BaseLeaseRentPeriod" xlink:to="lab_arvn_BaseLeaseRentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8f13efcd-9129-45d6-ac70-32556df490f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_0ce50cdc-b74a-4aa9-95de-6ebb5bb263b0_terseLabel_en-US" xlink:label="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label id="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="arvn-20220331.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_645390db-d654-4a09-9374-cce5172683ea_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Grant Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b2637705-ee29-451f-8336-0f5b4d2a0b94_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_56dcd944-4544-457c-a703-5c6302d574ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive units authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_12006dcc-3a5f-4ce6-899b-8f567580e47c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LongTermDebtMaturityYearSix_baa62711-1d4c-4862-8a09-abc62e9c3662_terseLabel_en-US" xlink:label="lab_arvn_LongTermDebtMaturityYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_arvn_LongTermDebtMaturityYearSix_label_en-US" xlink:label="lab_arvn_LongTermDebtMaturityYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Six</link:label>
    <link:label id="lab_arvn_LongTermDebtMaturityYearSix_documentation_en-US" xlink:label="lab_arvn_LongTermDebtMaturityYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LongTermDebtMaturityYearSix" xlink:href="arvn-20220331.xsd#arvn_LongTermDebtMaturityYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LongTermDebtMaturityYearSix" xlink:to="lab_arvn_LongTermDebtMaturityYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8fa16a3f-50e9-4f11-b59f-fccdca9bc16a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_790aecca-e09e-426e-be20-379ab5f2bc52_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_1a80970b-e5f1-4801-8f9f-7d98935907ac_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ab1e0c2b-61d0-447d-a949-4ae9f841b21d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_79f48c59-702d-4f03-b8d3-c28d068f1580_terseLabel_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Piper Sandler and Cantor</link:label>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_label_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Piper Sandler And Cantor [Member]</link:label>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_documentation_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Piper sandler and cantor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember" xlink:href="arvn-20220331.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PiperSandlerAndCantorMember" xlink:to="lab_arvn_PiperSandlerAndCantorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2620b33a-08f4-4472-9fff-625c2e74c480_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_70dcfdc4-483a-43f9-bd0b-cd6bc0c63e58_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_559e3819-ac6f-43a1-a005-3aef40fe657b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_39766c3f-90f5-4f37-99cf-1ab62746522e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_a5e59c24-a80b-4136-a353-424b84268546_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_19aeb701-1fca-4e87-a0df-a180218ebcbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d5974591-df0c-4cef-b368-a151c9106edf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_f1ebb95c-ba9d-4c32-8678-532d39ea0ff5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_225ad537-68d7-446a-a724-fd5de478bdb2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4937de86-b12a-44c2-9331-9212c92af0b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_bf833c08-02f5-4a5e-95b9-a36a5dc4ca33_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_b832454f-e367-489a-963a-62d404c63a29_terseLabel_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing 2023-2024</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:href="arvn-20220331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:to="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_9e13e19b-0053-4b7a-aabd-df9a7ed65825_terseLabel_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement direct and incremental costs incurred</link:label>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_label_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct And Incremental Costs Incurred To Obtain The Contract</link:label>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_documentation_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct and incremental costs incurred to obtain the contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:href="arvn-20220331.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:to="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_041609e1-3282-4db2-925d-78b1898ce0ac_terseLabel_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract" xlink:href="arvn-20220331.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract" xlink:to="lab_arvn_AggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_cb1de7f5-f7ff-4ffc-94ad-53e6123dbeb5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EmployeesDirectorsAndConsultantsMember_b1ea86e1-d009-4c5c-9d32-3f840dc6351d_terseLabel_en-US" xlink:label="lab_arvn_EmployeesDirectorsAndConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees, Directors and Consultants</link:label>
    <link:label id="lab_arvn_EmployeesDirectorsAndConsultantsMember_label_en-US" xlink:label="lab_arvn_EmployeesDirectorsAndConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees Directors And Consultants [Member]</link:label>
    <link:label id="lab_arvn_EmployeesDirectorsAndConsultantsMember_documentation_en-US" xlink:label="lab_arvn_EmployeesDirectorsAndConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees, directors and consultants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesDirectorsAndConsultantsMember" xlink:href="arvn-20220331.xsd#arvn_EmployeesDirectorsAndConsultantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EmployeesDirectorsAndConsultantsMember" xlink:to="lab_arvn_EmployeesDirectorsAndConsultantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2ad88520-8123-4574-b35a-3c1ad4c185e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_04e9684f-efc4-4598-b917-1734eddd0875_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in joint venture</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6c47683f-6b75-4399-89da-1656dac29cea_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_bbea4370-379e-4d1c-b7d2-bdf1f25f57d9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0daf140a-65f7-4cc2-9b30-82beadaa1859_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_e4bc4d8a-c03b-4434-b477-bfe07138b98e_terseLabel_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and marketable securities</link:label>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_label_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:href="arvn-20220331.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:to="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_9f0a4720-bab5-4d85-90b8-3c0c687f2fd6_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6821cfe7-91b4-4ae4-918c-551b52860980_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_83b7b550-f605-4b73-8991-43164efce0af_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_22f2ab96-6338-40cc-8f93-920ef9184c2b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c39158c9-195f-4075-bfd8-993ea3bcc648_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3b441879-7d99-4eba-a62c-12a00fed79a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1c94e666-bde7-44f4-8226-f19d3386aa91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_53b68b86-b810-4afc-9181-b1cedf983ed9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0baaec5a-ba57-4d3e-bf56-5da20293877a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_439dfe2c-978d-4dd5-abe0-dad7275629cf_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a79a4a45-c716-49e4-99e5-94637303c7a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5534ff60-4454-43cf-80d1-bca47df8dbae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3b28f0ad-cdfb-4a64-982c-68f975ad853f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0e4fd6db-5a0f-411f-8122-a6a328f0484b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_906a64ee-cf2e-407c-95e1-e08e7ea9282c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e34442c-ce86-4f4f-8d64-0a805f1791bb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued and sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_9dc95e1c-4fa3-4828-8d50-0bbc8a5850cb_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Assistance Agreement</link:label>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_label_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Eighteen Assistance Agreement [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and eighteen assistance agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:href="arvn-20220331.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:to="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_4b228ba0-4a5c-4a0d-a2e5-d1f8c22da386_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees and other</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a0ec0846-7b45-4e81-af5a-c1076e6cc1f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7f87b3b5-bbb6-42fe-b519-918f0eaa544e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6a971979-605e-40d2-99a8-5f4395b95d49_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 53.1 and 53.0 shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_773d28df-3bf2-42c2-b351-a361f5002017_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5cb9734a-4a19-4d41-a359-ca9af30072b4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense not yet recognized, period of recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1b4a6eca-b83c-462d-975c-97e39fae28e0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_036cfeac-aa0b-4aa6-93fe-36042542a3e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_48cc257e-fd50-48e1-a76c-3901b9d927e0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_2f392016-dae1-40ba-9bcb-653673fd7868_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bff44685-5893-4080-a392-6da2c1b66844_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_27562fc6-585c-41a4-8a6a-d39eb138ee27_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c8975e12-6f40-4cc1-b490-6e23c02d3afb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_298bf1a2-d87e-4ba4-a279-1e331d773785_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommercialMilestonesMember_081b986a-db51-4824-97ae-aa8fd1a07b0f_terseLabel_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones</link:label>
    <link:label id="lab_arvn_CommercialMilestonesMember_label_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_arvn_CommercialMilestonesMember_documentation_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember" xlink:href="arvn-20220331.xsd#arvn_CommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommercialMilestonesMember" xlink:to="lab_arvn_CommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_5aa39d3e-3b6e-4cb3-8277-6e5963eb9a89_terseLabel_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration contract asset and other assets</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_cb864dbc-1514-4a5c-9c71-244697671302_periodStartLabel_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_1a11f867-64a7-4819-ac26-f0a057d11868_periodEndLabel_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_label_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Contract Asset And Other Assets</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_documentation_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration contract asset and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets" xlink:href="arvn-20220331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationContractAssetAndOtherAssets" xlink:to="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2ad8e15a-71a1-496e-a7ed-73f184269563_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CT_cff74b0e-e4a1-4649-bb0a-f9da2248bbeb_terseLabel_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State of Connecticut</link:label>
    <link:label id="lab_stpr_CT_label_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONNECTICUT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CT" xlink:to="lab_stpr_CT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_39b169bb-6a26-4966-8d3a-3fbff5446a49_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7ee2a74e-4115-48f0-bb23-0457b6d6e218_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_ce097054-d7a9-47ec-88b2-1a4fd1fd70a4_terseLabel_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing 2022-2023</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Two Through Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Two Through Two Thousand Twenty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:href="arvn-20220331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:to="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_503e5f83-3dec-4044-8202-3d1edb399523_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_3f35e1a1-91b5-48e0-91b9-3cd1099acfb8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_521e822d-51e1-42bd-9adb-ded4096ecc96_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_86824de4-9d91-43b9-9750-a751542ab75b_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_e6c0c011-4a77-465d-b44c-53011191e26d_verboseLabel_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_label_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand eighteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:href="arvn-20220331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:to="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_027a3e6d-2cdf-4949-8172-89a1fb34504f_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to collaboration agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_label_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:href="arvn-20220331.xsd#arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:to="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0ff67f8e-3e07-4b2d-9569-9c0456d388c0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d455c865-9696-4508-a373-60cc492a04e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0bf8ecb4-c18f-4e0d-a0c6-aa8db2016626_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_d056a887-7fd3-46ff-9710-4568669860f7_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_61b95012-88cb-4a7e-90fb-b70fb914463e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0485212-ecf3-4ef8-aea3-8f8720f6ceca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2c187f0f-13d6-4384-a138-78a1571a5bb7_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber_0155ff38-64ba-482f-a843-33262339479f_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares expected to vest (in shares)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Restricted Shares Expected To Vest Exercisable Number</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, restricted shares expected to vest, exercisable number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber" xlink:href="arvn-20220331.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6666d2a5-7f45-4ca6-b63e-6cf82d0e6fce_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_6ef8b6be-7266-4581-9a6b-c22d4781ff8e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expenses)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_512e1194-823c-4cb7-9954-bdbb58c53898_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_90e63ab2-112e-4b6a-8d84-ec04dff03954_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_838f7b1b-f0f7-4f19-b69a-78c88e0d7cc0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ab6f7590-e6da-4d9f-8b21-3d95b6b97e84_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b8d0d709-cb53-4963-8e33-df31af71c93f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3643cc60-0b0a-4cb6-ac0f-55f979c3f1d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_844ba397-f9f2-4f91-a4d1-61babdb4cb19_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_3cda9a8a-2a42-498c-8ba3-1b0964f9cc8e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d6d38cda-1cbc-4ad8-be22-e7bb6bf1e71e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_b886f905-750b-4cb1-8956-ce2c55af621b_terseLabel_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash information:</link:label>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_label_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Non Cash Information Related To Leases [Abstract]</link:label>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_documentation_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:href="arvn-20220331.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:to="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease_5491c382-0280-49b3-85ca-40f75a674e18_verboseLabel_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Contract Asset And Other Assets, Period Increase (Decrease)</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease_documentation_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Contract Asset And Other Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease" xlink:href="arvn-20220331.xsd#arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease" xlink:to="lab_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_83bc497b-3f67-4081-9145-0f6a6b9d5409_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c36377a3-215d-456e-a114-7f5725ea3035_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_71b79b93-d9b1-48a9-b7f2-0b136ccbf6c2_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds One Maturing 2022-2023</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Two Through Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Two Through Two Thousand Twenty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:href="arvn-20220331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_75b16882-253e-4454-a91b-f5c10023e289_terseLabel_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Funding Payments</link:label>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_label_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Funding Payments [Member]</link:label>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_documentation_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research funding payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember" xlink:href="arvn-20220331.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchFundingPaymentsMember" xlink:to="lab_arvn_ResearchFundingPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_7ac6cf46-434b-4087-ab51-61a8b25d9850_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_acda4193-1208-42df-9902-51725259472c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_001aaee7-0816-4455-99bd-cf5e05c7c996_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cf4010a-bb92-4581-afa2-f13a5b44d08c_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_11a0206f-50c4-48cb-bbf6-925358dbed83_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_label_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturities Of Marketable Securities</link:label>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:href="arvn-20220331.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:to="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_54a9ae45-19d9-4be4-a867-772062245175_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_StockIncentivePlanMember_951b00c3-8d0a-45d1-87a4-4e6d48c0bc1e_terseLabel_en-US" xlink:label="lab_arvn_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Plan</link:label>
    <link:label id="lab_arvn_StockIncentivePlanMember_label_en-US" xlink:label="lab_arvn_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_arvn_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_arvn_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember" xlink:href="arvn-20220331.xsd#arvn_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_StockIncentivePlanMember" xlink:to="lab_arvn_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_e6ec7464-8acc-4cf2-a687-4dfbd8dd63d1_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested and expected to vest (in shares)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Vested And Expected To Vest Exercisable Number</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award restricted stock units vested and expected to vest exercisable number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:href="arvn-20220331.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_47229f93-ddde-491c-8129-f080a02b61cf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bbd7f07d-82f1-46c6-a47c-fcad3f72e92f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_ce3b945a-3a37-42b0-9eee-11087045d58d_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decc248-18a5-4e6c-bcc3-eca85f6acf85_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c3c73243-cfa7-4797-b133-b5159e1935e7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d2f5775d-ab30-4af0-a8bb-f0c382838154_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_05a0b529-c07d-42bb-9e55-73ebb2470103_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0629edc3-ac4c-4f5f-a7fb-58406f3df575_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0901cd96-f853-44b5-a2d2-86d1708f7f3c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_53c26ce5-3511-4ef5-a3f2-732101a560c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b4b52fdd-6a8a-46f8-b6b6-cfb66275089b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_066f3052-4b80-419b-bf02-2d2bff426cfb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_98409034-a9d3-4fdc-87b5-3f13cc4ddc4b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7fec9580-0fce-42d8-bcfa-e2647744788e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9edff2e8-dea9-4439-8e81-8efd6859f5b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5c7e3313-ad77-44f8-93f6-2b5b75917e0e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_07c63467-a43c-4577-978a-7132701f5ae0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_856925d9-320f-4d9a-9e4b-2e2cf63d3b29_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_3f4b5470-4d77-42dc-a77c-b63749832679_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan forgiveness</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_label_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Loan Forgiveness</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument loan forgiveness.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness" xlink:href="arvn-20220331.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentLoanForgiveness" xlink:to="lab_arvn_DebtInstrumentLoanForgiveness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_502cd68d-c5ba-43f4-beee-dd1978390b51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in reserved shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_2cecd640-62fa-4ec9-9ccf-b0d0dd8f0e29_terseLabel_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc. and F. Hoffman-La Roche Ltd.</link:label>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_label_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech Incorporation And F Hoffman La Roche Limited [Member]</link:label>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_documentation_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Incorporation. and F. Hoffman-La Roche Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:href="arvn-20220331.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:to="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_fb827c12-835e-4a3e-9582-b5566d09e014_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_1802365e-ed33-4c45-872f-7d33950ec20c_terseLabel_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of liquidated damages</link:label>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_label_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Liquidated Damages</link:label>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_documentation_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of liquidated damages.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages" xlink:href="arvn-20220331.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PercentageOfLiquidatedDamages" xlink:to="lab_arvn_PercentageOfLiquidatedDamages" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2e15c3f7-f57e-43cf-9fcd-d3ac934f63c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1b06cd12-3104-4a29-811b-934adefe3120_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bc9f2da9-88f6-4f8e-91e1-1503709ca8e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_fb0a7af7-0efd-461d-bbf3-4d90d6886b43_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_78e856a2-3f20-4814-af46-9a43d1242af5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_e915fc41-5119-400c-a43b-140a538682f6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_340d7d19-8578-4c1d-ac76-0b32adc862d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_005f3c24-e622-44e6-9926-cb59d3a2117c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of collaboration contract asset</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_89f91b7c-6ac5-43cb-a0ad-68414c6ed407_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e794f62d-3ef9-4c88-8084-b375d1385399_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f0fdfb22-e2b7-480b-b7c9-98aa76fcb89a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d4f6af45-dfa6-4588-a339-d8c8ee4b7c85_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5a10800b-ce5e-4f17-8f5b-190116254c91_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationAgreementMember_1fb2f0e5-d3c8-403d-803d-cc1fff66f2dd_terseLabel_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_arvn_CollaborationAgreementMember_label_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arvn_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember" xlink:href="arvn-20220331.xsd#arvn_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationAgreementMember" xlink:to="lab_arvn_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_72067807-7b94-4f9c-9a7d-52acff2d86ec_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_10c5c25f-7edc-48d7-bea7-c49ccb5028c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9c5b82fd-ae9c-4d29-b55d-0ec770984bad_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7c45b9cf-98f2-4a05-a396-a54d786586cc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_b2cf8069-1826-4dbf-ba08-9e72a0e06ae0_terseLabel_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock aggregate offering price</link:label>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_label_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Common Stock</link:label>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_documentation_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:href="arvn-20220331.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:to="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6804f421-4322-4ee6-ad5d-bf516badc19e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dd39f2f8-8534-4960-be0f-14dcfec907fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a4f02c58-4697-48b8-ae6a-0f2ab6aa0929_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b4419f2f-9fbd-4dee-a443-ea0a74e45f35_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_44e6dfd9-4aff-4503-b1e5-17dc82fcff15_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_33266a0c-5b04-4761-932d-2b2b8847ffdb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8ef8c331-2ac2-4529-a5de-96c8e5ee333d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3a21827c-83e2-4da3-b73e-ade3ed53c256_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ee1852b0-54fb-42cb-8aa6-5df18d4f5e69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2372bbfe-cc50-49c9-a5eb-fdb0e0e88373_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_ff7ff470-22ce-476c-8666-c9c7d6fb07a5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_690dbeac-09f7-4d5f-a662-e1f250b1ddde_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d7c1ec29-019c-4d4d-a569-51aa8df66a33_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_6426cbd7-f304-439f-9cc1-411df5a877ef_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e1bd3804-8cad-424e-a0ad-59c49d0da7a9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b7e15563-dd94-4cda-be61-f4f7a8658a17_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_cdcf4027-19bd-4fe6-94f8-1b2c1a2f60d5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_dd1e75e1-1f0f-4e98-b81b-c105a6b09ca0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c6860fa-9c53-456b-b099-3f17a8f82696_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9e81f804-1c29-48f7-9950-6497c3ef88b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_a0fa718f-c3f2-477f-95dd-94e8c0cc8236_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10801cf0-39a3-4d00-bc9c-f82d565cba96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_97a5d78a-dbe0-484f-94a0-095f875d4cba_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4f84dfab-7361-46cc-b58c-e51fe54354df_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b3a00f2a-e413-4573-8d59-1051ae249b16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_6fca2021-33e6-417e-bbff-df12858cddc9_terseLabel_en-US" xlink:label="lab_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit for collateralized by certificate of deposit</link:label>
    <link:label id="lab_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_label_en-US" xlink:label="lab_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledged Financial Instruments, Not Separately Reported, Securities for Letter of Credit Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" xlink:to="lab_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e55cdecd-0523-42d5-aacd-941c0a577bad_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0637050c-62a4-4bbe-9312-373de417dc2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_cb04b5f5-56d1-428a-9fba-45bb7c0d2be2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_dfbf1ce0-9eda-4692-95b5-6c483d1280c1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e13d0cc5-abc4-4cbe-8f1c-ab619a894c1b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_77ce230b-f9f3-4b6f-ae40-4e203c6bfbfc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of equity compensation valuation allowance recorded against net deferred tax assets, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_389ec2b6-9f6f-4634-b3b0-7ff2811dbc31_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_960bbe79-f280-4c30-902a-9560a8c2b703_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_f52e6b10-da28-46ec-82c1-1110ff07e30a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_50f37093-addf-4f83-bf9a-d5702bdf5667_verboseLabel_en-US" xlink:label="lab_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_label_en-US" xlink:label="lab_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment Summarized Financial Information Operating Expenses</link:label>
    <link:label id="lab_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_documentation_en-US" xlink:label="lab_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, summarized financial information, operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" xlink:href="arvn-20220331.xsd#arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" xlink:to="lab_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_e894c95e-f2cb-4206-8aa2-934b41529602_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_044f6ceb-a07b-4dec-8f80-a5d16c3ecf84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_506e67a5-cdeb-458c-8cec-59d3677c0ecd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_9343e401-98a7-43f4-967e-b3e69e1968e9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_834b4143-c2d9-4b1b-942f-f128c84022fd_terseLabel_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets: Collaboration contract asset</link:label>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_label_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Collaboration Contract Asset And Other Assets [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Collaboration Contract Asset And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:href="arvn-20220331.xsd#arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:to="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7753f97c-034c-43ee-972e-ddebe59d6580_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1c7eb735-294f-451f-8cab-109ebca289d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_618c3fc8-3494-4e81-8ef1-7061c9570c96_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_268fbc6c-4401-44b3-ae77-b276e875aff7_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bbdbb412-c0a8-4186-9fc3-5a1bd0afefd2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a0166be3-1384-4de2-8dff-f3dc45ffb4b3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_b80e12d9-0700-49ac-adae-1573c8017c19_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_aebc343e-8626-4dab-82c1-ba6faf82c215_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3d548fa0-3f1d-4821-9b8a-000518142a45_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BayerCropScienceLPMember_5d4e1900-4044-4dca-b1df-c60ba7eed208_terseLabel_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer LP</link:label>
    <link:label id="lab_arvn_BayerCropScienceLPMember_label_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Crop Science L P [Member]</link:label>
    <link:label id="lab_arvn_BayerCropScienceLPMember_documentation_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer CropScience LP.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember" xlink:href="arvn-20220331.xsd#arvn_BayerCropScienceLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BayerCropScienceLPMember" xlink:to="lab_arvn_BayerCropScienceLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_5863d41e-1fdd-4321-a0b3-4c188333ff49_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f66b59fe-25ad-43f7-bd2a-950825d0d25e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_b1c696b2-1d56-4072-8808-bad7008b6bae_terseLabel_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense Current</link:label>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="arvn-20220331.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_f013495b-0dd7-4a98-9b5a-d6c17b353ff8_terseLabel_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Payments To License Agreement</link:label>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_label_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Payments To License Agreement [Member]</link:label>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_documentation_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option payments to license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember" xlink:href="arvn-20220331.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OptionPaymentsToLicenseAgreementMember" xlink:to="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b5683513-e252-4c7e-938b-bd6b9b8f2ae3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_7c7ce895-5594-49a4-a425-9ba0771fe3df_terseLabel_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:href="arvn-20220331.xsd#arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:to="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_a45d5b40-5d8c-424d-89d8-ce3a61883d53_terseLabel_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and Sales-Based Milestones</link:label>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_label_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory And Sales Based Milestones [Member]</link:label>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and sales-based milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:href="arvn-20220331.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:to="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_1da20a3d-b428-4c17-aa63-e1cdcce5c959_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_4bd7f54c-40f4-4790-bb4f-202d1e38ad2a_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1b461f8b-003e-44cc-b793-1617cfe9a2c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument bearing interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_285c0391-bf9d-4d11-b019-baf9b0bc9abe_terseLabel_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block]</link:label>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:href="arvn-20220331.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NumberOfMaximumDesignatedTargets_47966dc9-89ed-48b2-8c73-35f614d4c4b1_terseLabel_en-US" xlink:label="lab_arvn_NumberOfMaximumDesignatedTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of designated targets</link:label>
    <link:label id="lab_arvn_NumberOfMaximumDesignatedTargets_label_en-US" xlink:label="lab_arvn_NumberOfMaximumDesignatedTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Maximum Designated Targets</link:label>
    <link:label id="lab_arvn_NumberOfMaximumDesignatedTargets_documentation_en-US" xlink:label="lab_arvn_NumberOfMaximumDesignatedTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of maximum designated targets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfMaximumDesignatedTargets" xlink:href="arvn-20220331.xsd#arvn_NumberOfMaximumDesignatedTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NumberOfMaximumDesignatedTargets" xlink:to="lab_arvn_NumberOfMaximumDesignatedTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d47d8952-82c5-4348-a80e-a325846de668_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BayerAGMember_91ecadcb-0bbc-49ac-a1d1-76c903bdba19_terseLabel_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Collaboration Agreement</link:label>
    <link:label id="lab_arvn_BayerAGMember_label_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer A G [Member]</link:label>
    <link:label id="lab_arvn_BayerAGMember_documentation_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember" xlink:href="arvn-20220331.xsd#arvn_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BayerAGMember" xlink:to="lab_arvn_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EmployeesMember_bf4f7f26-15ef-42ad-825c-7d7c1e54cdef_verboseLabel_en-US" xlink:label="lab_arvn_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_arvn_EmployeesMember_0d448e28-939e-4803-9e70-a0fc2585b7b4_terseLabel_en-US" xlink:label="lab_arvn_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_arvn_EmployeesMember_label_en-US" xlink:label="lab_arvn_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_arvn_EmployeesMember_documentation_en-US" xlink:label="lab_arvn_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember" xlink:href="arvn-20220331.xsd#arvn_EmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EmployeesMember" xlink:to="lab_arvn_EmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0be40d50-a29d-4043-912b-0bdea4b2736a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Pronouncements and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_06eec310-8c66-4dcd-9a9b-2e181e201756_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_59c68955-48e1-41d9-ab36-1492b3ee1d1f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_14f514c7-5930-4cd1-9da2-0af79d51ecba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_addf2630-89b2-42b8-9e06-45e19f5f96b1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_21e7f0b0-1c6c-4d35-a275-9f644f899a70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_05d7b096-bbee-4dca-8ac9-fe219a358ae6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_df052eba-fc99-4c5f-ac20-d52fd3b406b4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_829bef0f-9be4-4ec7-84bd-097d739dc263_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2ce0794c-13fe-4df4-8ab1-9d8f82dffa44_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e2bb7148-4f62-4606-8259-d32a1dfa44c7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f24e4c49-4e0a-43e4-b49c-494445a675cf_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e45043a9-c292-4cd7-943b-8c1f09be3892_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a32bc154-ea9c-4132-b31b-fc1fc47bee59_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4ceb3aec-4177-452b-9518-49e3cfb7f867_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4c83b618-2315-49b8-878b-497672781f16_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_da442966-9871-4bef-b868-946f3638fc6a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_6621b502-26a9-412e-a3ab-875cb7742b68_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a575b53e-2329-4b0d-8590-c12ab36b6b60_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2f743c69-ca99-42b1-99d7-3eaa289303ba_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based award, vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_0752aca1-eec3-4b1b-9e6d-ff704927ab3a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_86a4290b-f0ad-4eee-95b8-cc54e5292fea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_aafcd557-b423-485c-9c60-3e8da1bbfcec_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6ca8fe5f-d393-463a-bcbd-00b09114f150_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45fb154c-71ab-466d-ae0b-811ba8d1bb55_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_fe5a6546-5bc7-4f4a-86d8-f9eaaf2f183b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue receivable if milestones achieved or options for all targets exercised</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bf88fe4b-47ad-4527-9707-6eb78f605fbb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_59e3e0ab-fdf4-4dd3-bd4d-c0a74a7a59da_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8caf57cf-0d6f-4438-afd7-9746b111e2e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_f34cfff1-dcdd-4068-9371-00349653f25d_terseLabel_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestones [Member]</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember" xlink:href="arvn-20220331.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SalesBasedMilestonesMember" xlink:to="lab_arvn_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_eba165a1-f018-4c8d-9258-f5d3daddf4b3_terseLabel_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance represented as percentage on outstanding common stock</link:label>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_label_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock</link:label>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_documentation_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:href="arvn-20220331.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:to="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7dde229c-0bb3-45c5-9d23-fbfe4014bb5c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e220037b-a3b0-4fdc-afae-c912b793012a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b9621eee-5a9d-41df-be7e-0950b9f15c23_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6b5e94b1-c51d-4a48-acfa-d7745f7fae3b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_bcb4ff09-9c50-4738-8f7b-e3ffbc64edbb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Price Allocated to Performance Obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4e03ef5-a3f0-42f7-bf8b-c7e3930a7779_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_48ec3c39-ded2-44b7-b1a9-371192ef1be2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ff43f20b-4a75-4710-8e34-0cc5cfeff0ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Equipment and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b70ab512-155d-4afd-ba04-4371fd6cb345_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and leasehold improvements, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5fb66085-94d3-4d5c-8da9-de0fee548899_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and leasehold improvements, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bf291769-7ed1-4fdc-8d98-f348de21897c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_31680f7f-2388-4906-b250-60d8da9f5d13_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_bb112ba8-0bdb-4348-96e9-eff2b8e2994e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1c7edc9f-c5d9-4b0f-b84b-e9f8d51771f2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6ac2dc75-0c38-437f-a9ea-5f6ed2843eee_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PfizerIncorporationMember_27135065-1df8-4431-a5b3-fce09828eeda_terseLabel_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, Inc.</link:label>
    <link:label id="lab_arvn_PfizerIncorporationMember_label_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Incorporation [Member]</link:label>
    <link:label id="lab_arvn_PfizerIncorporationMember_documentation_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember" xlink:href="arvn-20220331.xsd#arvn_PfizerIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PfizerIncorporationMember" xlink:to="lab_arvn_PfizerIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e07a0d5a-b82f-4ef8-b2d8-2373773eede0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and leasehold improvements, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d5e8d32d-5e15-49fa-9528-c26a3c691aa2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_b4cd2b43-b60c-4718-ae56-38a5c9dfaca6_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_40144ef5-93cd-412d-80e9-f336f7a6f00f_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Table]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Table]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1e9319b6-787c-4ff4-9f39-f7d942679cd7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e079f149-5b50-40a6-a2d3-579c0197be10_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b112c0ab-4730-46e2-9bb9-0777b00df4c5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_db5c1729-908d-49c4-8303-b3f4ded3e2f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_089456d0-94a0-47ee-9357-43f850b2678d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f75abe0-7f7e-4383-82cc-b43f546cb780_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61f75c57-019e-4ab1-9831-253e3b353611_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9f402d53-0497-474c-af7e-ac704061661f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f771b71b-af88-4ab6-a517-e43403a11048_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ed8e927b-41e4-44a3-a94f-6dccc1c6c1a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f8bae4b6-22f9-4657-8012-15546a7d211e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_298dc104-084a-4973-8fc6-5432bd6b8b77_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0d4a6ef7-64ad-49bd-b828-249456b06952_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_6cfc6916-36c7-4ac6-8825-8a1964516a75_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2c633931-272a-4c16-b649-691896ce7a11_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net accretion of bond discounts/premiums</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_3a3de534-276c-4df3-b730-082024ffcf07_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5575d808-868c-44eb-8d7b-2ec3d2520a43_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_68972cbb-af92-4b2d-82da-11fbb98fec3b_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a4c3875-6f5f-4f9e-b715-d242b4142f4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef72c497-d771-436a-b6e4-d8887b8dc27c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5510bebb-ac99-4263-b7d3-39c72b03a050_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_00603de2-7a3d-4cd8-9818-dbfb381bb899_terseLabel_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing 2022</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:href="arvn-20220331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:to="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4b264884-b2c0-4497-bfce-62a03874a8c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_91f46fca-f3d2-4f85-acc7-d9abc74c6740_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_dd28390e-9a6d-42c5-a98e-9ab04f44fae6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_53c4f877-1e40-4053-84ed-54b9761e8a23_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_634a72fa-3b75-4ba2-8089-db6e11cf4b56_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6fc8fb9c-33d6-44cd-92ad-7049e6804afa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_156fab2f-10f7-403a-9efb-c850d27461ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fe62ce49-fc42-4a60-b18a-08ccc393a7db_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d0450496-8cb5-478e-ac4c-907ebdd5d81f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c15ee6cf-7e20-4611-bef4-775feb504658_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_772dd252-f273-4af8-bff7-8f85ab72f222_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e9164802-5005-4520-8b4a-b324f58cc59c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6e6c8197-a74e-4519-8e56-84122dde625d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_6ff4f544-02b2-4744-b31c-45c32cc350ec_terseLabel_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone Related to Marketing Approvals</link:label>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember" xlink:href="arvn-20220331.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RegulatoryMilestonePaymentsMember" xlink:to="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c5357442-7741-497a-b3e8-3d3556e1ee25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded From Computation of Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9e62fb69-01c7-4988-bdc0-4384bcbde45a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_54c10a4d-223d-4ff4-a0e6-7c3fcbfbcc8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a2d8ea89-2354-41ca-a27a-aa803ba4a4c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_751a62d9-dc6b-4c24-a48c-921681404bde_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_9a228cc0-5641-4c74-9d6d-96b592542959_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_289ad589-680d-4302-b190-5c2a777e2aaf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_988bc195-a311-4a99-bac7-62f8196b6935_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_da32b0cd-2e6a-482d-a010-eaf8c474f413_terseLabel_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of incremental borrowing for lease payments</link:label>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_label_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Incremental Borrowing For Lease Payments</link:label>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_documentation_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of incremental borrowing for lease payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:href="arvn-20220331.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:to="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_c2edb736-79d1-4abe-949b-b223c6dee094_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_70b6352e-4c1a-41c0-9f2c-f66f9e7f256e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_257ae3f0-d217-46ff-bc70-64bcb3e5b402_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6e68d80d-aed1-4c08-a148-36ed66c2e5f9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4b615bd4-84ae-4042-8f3f-fc3e5e9b09cb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f6e491bf-16b7-493e-af17-37d51aa7a417_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_f0e8858a-3483-4c23-8eff-4f751f2b2dfd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_24635e11-b02c-4dd6-b850-383d3495cd3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in reserved shares as percentage of outstanding common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4dcb452c-c02a-43dc-bb17-7a32cc5c2b66_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember_64d1f056-c977-418c-907e-0fb882d65048_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Assistance Agreement</link:label>
    <link:label id="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember_label_en-US" xlink:label="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Assistance Agreement [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen assistance agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:href="arvn-20220331.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:to="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_88ca074d-3e48-4112-a430-7e7a27e317e6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_4520a2a5-79fc-465d-b05b-47954342feb9_terseLabel_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember" xlink:href="arvn-20220331.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LaboratoryEquipmentMember" xlink:to="lab_arvn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_b5c7031b-8fd2-45b5-82b6-6c7c51dabeb2_terseLabel_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Offering</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember" xlink:href="arvn-20220331.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AtTheMarketOfferingMember" xlink:to="lab_arvn_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_df338783-d65f-4418-94f5-b3b1f059f15e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b6003845-1617-4d4a-9d87-ec692ec6fb50_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e0432ea2-06dc-4ab1-857f-29200e1433d2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_fa32c907-7f49-41a1-86b8-3b3395d10003_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_81245995-4473-4f40-a1eb-0bdd1e117dcc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_90712bfc-e851-4707-9314-ffa426ccbcee_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb7896c5-0aed-442d-bdf4-64f11f1a027a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a5b5ff53-ca92-4c86-951c-c969e2fe65e0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_8381a513-4cc1-4f63-bf43-5bc8fbe18d71_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease for laboratory and office space</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>arvn-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:966c8cdd-8d85-475a-b79b-8010015adf33,g:b9593e04-7343-4e88-918f-c5a2cc011d89-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/CoverPage" xlink:type="simple" xlink:href="arvn-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_57e09723-25cc-4690-a9c0-e1b472ab348a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_DocumentType_57e09723-25cc-4690-a9c0-e1b472ab348a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0167eefc-97b5-4cfb-bd82-231b64580b4d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_DocumentQuarterlyReport_0167eefc-97b5-4cfb-bd82-231b64580b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9ce442d6-7629-4ce5-9019-e1458533b77e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_DocumentPeriodEndDate_9ce442d6-7629-4ce5-9019-e1458533b77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_24aee7b2-d927-4af3-a000-d0d62bc39bf8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_DocumentTransitionReport_24aee7b2-d927-4af3-a000-d0d62bc39bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c53ac32d-6dc5-454b-8a45-6e863b478ba2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityFileNumber_c53ac32d-6dc5-454b-8a45-6e863b478ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_db2cef09-3b81-4a85-86e4-5160824b2f38" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityRegistrantName_db2cef09-3b81-4a85-86e4-5160824b2f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e57d2812-747c-4aee-ba42-8efe0cd2338c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e57d2812-747c-4aee-ba42-8efe0cd2338c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1d06b260-fb1f-4cee-9b65-75fa50161cbe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityTaxIdentificationNumber_1d06b260-fb1f-4cee-9b65-75fa50161cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_851cdbbe-1c9c-4c42-acba-67f51da23217" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityAddressAddressLine1_851cdbbe-1c9c-4c42-acba-67f51da23217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_3b4b37d4-8405-4cbc-911c-e479a1edd3ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityAddressAddressLine2_3b4b37d4-8405-4cbc-911c-e479a1edd3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_adb44a62-256a-4b09-b840-89eb41f47777" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityAddressCityOrTown_adb44a62-256a-4b09-b840-89eb41f47777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fea9b460-387d-4492-b812-bbe96bf8187f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityAddressStateOrProvince_fea9b460-387d-4492-b812-bbe96bf8187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_99d06260-4523-4849-888e-2717c6313829" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityAddressPostalZipCode_99d06260-4523-4849-888e-2717c6313829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ef62de1e-8414-4047-aca2-e572fbe80e8d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_CityAreaCode_ef62de1e-8414-4047-aca2-e572fbe80e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_47903638-3670-4a43-b8b6-5309fb0d8c2b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_LocalPhoneNumber_47903638-3670-4a43-b8b6-5309fb0d8c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_21979bac-6cb1-4aff-8a79-9b1c1b0de837" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_Security12bTitle_21979bac-6cb1-4aff-8a79-9b1c1b0de837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b671abf8-1868-44d0-b6ba-9f43faa47533" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_TradingSymbol_b671abf8-1868-44d0-b6ba-9f43faa47533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_08b2978d-b9f1-4a80-8382-e7954b3ce530" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_SecurityExchangeName_08b2978d-b9f1-4a80-8382-e7954b3ce530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3c191766-a6bc-440b-aa61-1873d9ee46f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityCurrentReportingStatus_3c191766-a6bc-440b-aa61-1873d9ee46f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f164083e-b21a-45bb-8fbb-8b6faa7014e7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityInteractiveDataCurrent_f164083e-b21a-45bb-8fbb-8b6faa7014e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9ae0597e-5709-42bc-878f-3dc08fcc344a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityFilerCategory_9ae0597e-5709-42bc-878f-3dc08fcc344a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_72613b33-57ef-45ec-8499-d9358815982a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntitySmallBusiness_72613b33-57ef-45ec-8499-d9358815982a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3ded04f6-d9fe-49c4-a595-9b6cf5a01cfb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityEmergingGrowthCompany_3ded04f6-d9fe-49c4-a595-9b6cf5a01cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b154c7c6-f208-41b4-b8ad-02c389b1d445" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityShellCompany_b154c7c6-f208-41b4-b8ad-02c389b1d445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_93cef37a-c3e8-4964-8c53-22f0115be91a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_93cef37a-c3e8-4964-8c53-22f0115be91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_40afec81-6664-41e1-bdd3-35a2e85a51d0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_AmendmentFlag_40afec81-6664-41e1-bdd3-35a2e85a51d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a9fb6315-b6e8-4284-ada5-551577e92221" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_DocumentFiscalYearFocus_a9fb6315-b6e8-4284-ada5-551577e92221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5666d304-3971-4e18-95e0-b6a35efe0d79" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5666d304-3971-4e18-95e0-b6a35efe0d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dade914b-cc42-4f6d-8b38-2ad8fd36579d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_EntityCentralIndexKey_dade914b-cc42-4f6d-8b38-2ad8fd36579d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_25e5c45b-cb21-4294-8a3f-39796679c66d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a50bc84-4741-42f8-b389-55a606b5b6ed" xlink:to="loc_dei_CurrentFiscalYearEndDate_25e5c45b-cb21-4294-8a3f-39796679c66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="arvn-20220331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c2e96397-91fc-4909-948c-40ef88e2c097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e9c9f141-63fc-4bae-8fb6-fd96a5c1881c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2e96397-91fc-4909-948c-40ef88e2c097" xlink:to="loc_us-gaap_AssetsAbstract_e9c9f141-63fc-4bae-8fb6-fd96a5c1881c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3d9ef654-38c0-4946-b902-0902638e0496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9c9f141-63fc-4bae-8fb6-fd96a5c1881c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3d9ef654-38c0-4946-b902-0902638e0496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_afc14a15-66b9-4e2f-ae2c-d6a71f736919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d9ef654-38c0-4946-b902-0902638e0496" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_afc14a15-66b9-4e2f-ae2c-d6a71f736919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7f3e02bd-e5b7-4a2a-8b2a-90d3c972c455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d9ef654-38c0-4946-b902-0902638e0496" xlink:to="loc_us-gaap_RestrictedCashCurrent_7f3e02bd-e5b7-4a2a-8b2a-90d3c972c455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_020b569c-812e-46bf-9271-9edc9c7dd5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d9ef654-38c0-4946-b902-0902638e0496" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_020b569c-812e-46bf-9271-9edc9c7dd5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fb912ed8-f75b-4f98-926d-9953e9a14341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d9ef654-38c0-4946-b902-0902638e0496" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fb912ed8-f75b-4f98-926d-9953e9a14341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_d24f40a7-f3ff-4fa8-a4b8-a65b1cdc8753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d9ef654-38c0-4946-b902-0902638e0496" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_d24f40a7-f3ff-4fa8-a4b8-a65b1cdc8753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5297f7fb-c73b-4028-b5d6-82c668eb0b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d9ef654-38c0-4946-b902-0902638e0496" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5297f7fb-c73b-4028-b5d6-82c668eb0b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c964ea4d-b245-49a8-9612-450c3a822e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d9ef654-38c0-4946-b902-0902638e0496" xlink:to="loc_us-gaap_AssetsCurrent_c964ea4d-b245-49a8-9612-450c3a822e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ea07d4c9-1607-4da8-bf88-8520edbca950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9c9f141-63fc-4bae-8fb6-fd96a5c1881c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ea07d4c9-1607-4da8-bf88-8520edbca950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b5309fd4-4953-4feb-839d-317c47c9b75e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9c9f141-63fc-4bae-8fb6-fd96a5c1881c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b5309fd4-4953-4feb-839d-317c47c9b75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_2a4dc1e0-6a23-4321-bf29-fb976c29f60b" xlink:href="arvn-20220331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9c9f141-63fc-4bae-8fb6-fd96a5c1881c" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_2a4dc1e0-6a23-4321-bf29-fb976c29f60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_de8bcfde-fc54-4974-bd42-984c738947f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9c9f141-63fc-4bae-8fb6-fd96a5c1881c" xlink:to="loc_us-gaap_Assets_de8bcfde-fc54-4974-bd42-984c738947f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fcafe01-3ae0-4803-9819-9e717df2e736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2e96397-91fc-4909-948c-40ef88e2c097" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fcafe01-3ae0-4803-9819-9e717df2e736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_69dbf8ee-91ac-4dbc-9297-73e10fdf1c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fcafe01-3ae0-4803-9819-9e717df2e736" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_69dbf8ee-91ac-4dbc-9297-73e10fdf1c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f3d2ddcc-e3d4-46fc-a5bd-f759e3ce7477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69dbf8ee-91ac-4dbc-9297-73e10fdf1c5b" xlink:to="loc_us-gaap_AccountsPayableCurrent_f3d2ddcc-e3d4-46fc-a5bd-f759e3ce7477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d605ec7f-c5e4-418c-9fa9-3483aac76a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69dbf8ee-91ac-4dbc-9297-73e10fdf1c5b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d605ec7f-c5e4-418c-9fa9-3483aac76a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6383a172-d5af-4daf-a6eb-e67fef459402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69dbf8ee-91ac-4dbc-9297-73e10fdf1c5b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6383a172-d5af-4daf-a6eb-e67fef459402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_995581ca-8e9c-4a22-bfe6-599d56deda89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69dbf8ee-91ac-4dbc-9297-73e10fdf1c5b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_995581ca-8e9c-4a22-bfe6-599d56deda89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7c3e4e06-992c-4b6f-9f3c-0e39e907097c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69dbf8ee-91ac-4dbc-9297-73e10fdf1c5b" xlink:to="loc_us-gaap_LiabilitiesCurrent_7c3e4e06-992c-4b6f-9f3c-0e39e907097c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fd7adc5c-07c7-46e2-ba39-80eec50a56c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fcafe01-3ae0-4803-9819-9e717df2e736" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fd7adc5c-07c7-46e2-ba39-80eec50a56c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a71efbd9-5386-4e36-b4ea-133562227097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fcafe01-3ae0-4803-9819-9e717df2e736" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a71efbd9-5386-4e36-b4ea-133562227097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cf11b985-2e38-44d1-b28f-ecce68c6ab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fcafe01-3ae0-4803-9819-9e717df2e736" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cf11b985-2e38-44d1-b28f-ecce68c6ab7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_022aa2f8-d623-4f73-9e50-dba87c992c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fcafe01-3ae0-4803-9819-9e717df2e736" xlink:to="loc_us-gaap_Liabilities_022aa2f8-d623-4f73-9e50-dba87c992c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4ce083b0-7075-479f-b368-7b910e27e08c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fcafe01-3ae0-4803-9819-9e717df2e736" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4ce083b0-7075-479f-b368-7b910e27e08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_abe5b875-9b77-4a21-b8e7-f3c90f1bfc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fcafe01-3ae0-4803-9819-9e717df2e736" xlink:to="loc_us-gaap_StockholdersEquityAbstract_abe5b875-9b77-4a21-b8e7-f3c90f1bfc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9eaa5f55-5d80-4f57-8e14-fd5e38894420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abe5b875-9b77-4a21-b8e7-f3c90f1bfc4f" xlink:to="loc_us-gaap_CommonStockValue_9eaa5f55-5d80-4f57-8e14-fd5e38894420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b7be8b39-e1fc-4d4b-8514-c910108db0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abe5b875-9b77-4a21-b8e7-f3c90f1bfc4f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b7be8b39-e1fc-4d4b-8514-c910108db0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_93f94239-6ac7-4d16-9f4d-1ca65c2e4d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abe5b875-9b77-4a21-b8e7-f3c90f1bfc4f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_93f94239-6ac7-4d16-9f4d-1ca65c2e4d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96bc4ab7-3f94-44c9-9067-3a9bda01b810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abe5b875-9b77-4a21-b8e7-f3c90f1bfc4f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96bc4ab7-3f94-44c9-9067-3a9bda01b810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4848a06e-5b9f-44c6-bd4f-13d55caf3657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abe5b875-9b77-4a21-b8e7-f3c90f1bfc4f" xlink:to="loc_us-gaap_StockholdersEquity_4848a06e-5b9f-44c6-bd4f-13d55caf3657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3a46ceb6-8104-48b3-8e93-da458f281aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fcafe01-3ae0-4803-9819-9e717df2e736" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3a46ceb6-8104-48b3-8e93-da458f281aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="arvn-20220331.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a394a81b-69f0-44eb-998f-0dabcdb4b86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0e210126-8f7e-4a63-834b-63fc8ef23139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a394a81b-69f0-44eb-998f-0dabcdb4b86f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0e210126-8f7e-4a63-834b-63fc8ef23139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_899796f9-218d-4ebb-9ba7-2aad7280e98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a394a81b-69f0-44eb-998f-0dabcdb4b86f" xlink:to="loc_us-gaap_CommonStockSharesIssued_899796f9-218d-4ebb-9ba7-2aad7280e98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6b8f7017-f8ba-40e1-aaf9-195bebfe64bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a394a81b-69f0-44eb-998f-0dabcdb4b86f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6b8f7017-f8ba-40e1-aaf9-195bebfe64bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="arvn-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_4971d8d7-abbb-48c1-b311-20d6d66bdcfb" xlink:href="arvn-20220331.xsd#arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_4971d8d7-abbb-48c1-b311-20d6d66bdcfb" xlink:to="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cc5dbe45-08c1-4737-8e48-022f79882ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_Revenues_cc5dbe45-08c1-4737-8e48-022f79882ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f2ec509f-a627-46db-809a-8a4257da5564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f2ec509f-a627-46db-809a-8a4257da5564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_53bb7aae-231a-4889-9c91-f84e2cf020ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f2ec509f-a627-46db-809a-8a4257da5564" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_53bb7aae-231a-4889-9c91-f84e2cf020ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_85a856b7-0ed7-4e23-9f46-5aae8b01b8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f2ec509f-a627-46db-809a-8a4257da5564" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_85a856b7-0ed7-4e23-9f46-5aae8b01b8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c5c2b73e-7196-44ee-857a-8d6985f46a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f2ec509f-a627-46db-809a-8a4257da5564" xlink:to="loc_us-gaap_OperatingExpenses_c5c2b73e-7196-44ee-857a-8d6985f46a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d06590bf-5d83-4410-8914-d7cc58d1f7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_OperatingIncomeLoss_d06590bf-5d83-4410-8914-d7cc58d1f7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_234c7e73-0a19-441a-9300-d28e41691f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_234c7e73-0a19-441a-9300-d28e41691f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_27ad3d42-6feb-473d-bb1f-9ad84b417217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_234c7e73-0a19-441a-9300-d28e41691f9e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_27ad3d42-6feb-473d-bb1f-9ad84b417217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_cc2d377a-f001-456a-8628-40bbd7da8685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_234c7e73-0a19-441a-9300-d28e41691f9e" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_cc2d377a-f001-456a-8628-40bbd7da8685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e2bd16c9-2485-4535-9a32-3a06f2cf53db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_234c7e73-0a19-441a-9300-d28e41691f9e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e2bd16c9-2485-4535-9a32-3a06f2cf53db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_4185fa75-13b4-40c4-a81c-e9c21d9c1843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_4185fa75-13b4-40c4-a81c-e9c21d9c1843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_018711e4-093e-42f0-91b7-0ec8d63793ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_018711e4-093e-42f0-91b7-0ec8d63793ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d3713498-671f-4892-939f-60534e21e9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_NetIncomeLoss_d3713498-671f-4892-939f-60534e21e9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6a48d45d-8c39-4879-b10f-1933daa84529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_EarningsPerShareBasic_6a48d45d-8c39-4879-b10f-1933daa84529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0c8c0aa6-9f53-4404-9f4e-1c54294bd6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0c8c0aa6-9f53-4404-9f4e-1c54294bd6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4c64edeb-a73d-434c-849c-93b011784ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4c64edeb-a73d-434c-849c-93b011784ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0d4a2858-00e9-47fd-8f74-75bda2512084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ca4b6cc-778a-4514-996f-75fb5268c93a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0d4a2858-00e9-47fd-8f74-75bda2512084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ee1d182-6424-4913-a68a-8444a41f7062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_4971d8d7-abbb-48c1-b311-20d6d66bdcfb" xlink:to="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ee1d182-6424-4913-a68a-8444a41f7062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5de856c5-ef99-476e-96c8-cf0b1447644c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ee1d182-6424-4913-a68a-8444a41f7062" xlink:to="loc_us-gaap_NetIncomeLoss_5de856c5-ef99-476e-96c8-cf0b1447644c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74796ac1-8217-4894-b67b-4ab97b5a48e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ee1d182-6424-4913-a68a-8444a41f7062" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74796ac1-8217-4894-b67b-4ab97b5a48e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bb7e0ee2-9c6a-4692-9122-4c9c02bae0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74796ac1-8217-4894-b67b-4ab97b5a48e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bb7e0ee2-9c6a-4692-9122-4c9c02bae0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d6206ec2-ac38-429d-993f-56c3e4f6a9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ee1d182-6424-4913-a68a-8444a41f7062" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d6206ec2-ac38-429d-993f-56c3e4f6a9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="simple" xlink:href="arvn-20220331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9b2e91fc-56aa-4a37-af31-881c6e42a2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8f333f3-0156-4a30-b401-7984eeff89e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9b2e91fc-56aa-4a37-af31-881c6e42a2fc" xlink:to="loc_us-gaap_StatementTable_e8f333f3-0156-4a30-b401-7984eeff89e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aec2afde-3618-4eb3-8e2b-7a6097f22eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8f333f3-0156-4a30-b401-7984eeff89e5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aec2afde-3618-4eb3-8e2b-7a6097f22eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aec2afde-3618-4eb3-8e2b-7a6097f22eca" xlink:to="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_17618fd2-45fc-479c-9fec-7ffa0a44177e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:to="loc_us-gaap_CommonStockMember_17618fd2-45fc-479c-9fec-7ffa0a44177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_73a5e86c-ddb4-4c2f-ace2-d9bb020c7371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:to="loc_us-gaap_RetainedEarningsMember_73a5e86c-ddb4-4c2f-ace2-d9bb020c7371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1a416517-88c6-468f-a78a-15af70368116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1a416517-88c6-468f-a78a-15af70368116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb1e033e-e188-499b-a86d-717269ac474f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05dd7533-73d7-4677-9ea9-c8bbff27aa7e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb1e033e-e188-499b-a86d-717269ac474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a713aa9-ea9f-4bc7-b018-8d54dea5f5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8f333f3-0156-4a30-b401-7984eeff89e5" xlink:to="loc_us-gaap_StatementLineItems_4a713aa9-ea9f-4bc7-b018-8d54dea5f5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a713aa9-ea9f-4bc7-b018-8d54dea5f5e3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_33955c3c-83e5-493c-8c32-81507ae2e8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_33955c3c-83e5-493c-8c32-81507ae2e8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4efdd1d0-d213-46d2-82d8-ad8ebd356dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockholdersEquity_4efdd1d0-d213-46d2-82d8-ad8ebd356dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_180900f7-b035-4e6f-9ff6-af2773cf07b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_180900f7-b035-4e6f-9ff6-af2773cf07b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_571be89a-09ba-4242-bd4e-2431b71f198e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_NetIncomeLoss_571be89a-09ba-4242-bd4e-2431b71f198e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_bdcad23c-0faa-451d-bbdd-c214b6403d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_bdcad23c-0faa-451d-bbdd-c214b6403d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ef8a6e0d-6077-48a6-bf21-d54423bbd97f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ef8a6e0d-6077-48a6-bf21-d54423bbd97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49150edb-f386-46e0-bbc7-6b0c78198aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49150edb-f386-46e0-bbc7-6b0c78198aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e6316e5-68ec-4bd6-8dd3-e11f99493a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e6316e5-68ec-4bd6-8dd3-e11f99493a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f9ab21ef-667b-407a-bad8-2c6e55c30d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f9ab21ef-667b-407a-bad8-2c6e55c30d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c0fd553a-65a7-4ea7-b7b8-fe9555b47a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c0fd553a-65a7-4ea7-b7b8-fe9555b47a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8a99f9d4-c0e0-4ad1-b5eb-28b6c2ef4a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_932143c9-a1be-419e-99a8-4374ed65e5bb" xlink:to="loc_us-gaap_StockholdersEquity_8a99f9d4-c0e0-4ad1-b5eb-28b6c2ef4a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="arvn-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c392a195-9fca-4db0-8c39-2ff8678e4af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f063bf5-26f8-477d-b78b-defbf2aa60b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c392a195-9fca-4db0-8c39-2ff8678e4af7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f063bf5-26f8-477d-b78b-defbf2aa60b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ff4eecc7-5543-4840-b80a-84d3e303415c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f063bf5-26f8-477d-b78b-defbf2aa60b6" xlink:to="loc_us-gaap_ProfitLoss_ff4eecc7-5543-4840-b80a-84d3e303415c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d6d77ce1-9575-4d50-91a5-6f682bbd6dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f063bf5-26f8-477d-b78b-defbf2aa60b6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d6d77ce1-9575-4d50-91a5-6f682bbd6dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_c66ba2d8-aa2e-42c9-99ab-40424b599acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d6d77ce1-9575-4d50-91a5-6f682bbd6dc1" xlink:to="loc_us-gaap_DepreciationAndAmortization_c66ba2d8-aa2e-42c9-99ab-40424b599acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a89714dd-d63b-48d1-aa75-dd26b2b4c34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d6d77ce1-9575-4d50-91a5-6f682bbd6dc1" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a89714dd-d63b-48d1-aa75-dd26b2b4c34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a4a1b019-8964-4700-bdda-1774b96d51f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d6d77ce1-9575-4d50-91a5-6f682bbd6dc1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a4a1b019-8964-4700-bdda-1774b96d51f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_eb60259d-3747-46e6-9713-878b30db9b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d6d77ce1-9575-4d50-91a5-6f682bbd6dc1" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_eb60259d-3747-46e6-9713-878b30db9b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_988f0271-fbfe-4045-babb-34507d6c5717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d6d77ce1-9575-4d50-91a5-6f682bbd6dc1" xlink:to="loc_us-gaap_ShareBasedCompensation_988f0271-fbfe-4045-babb-34507d6c5717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ec440f05-bf41-4ea6-90d1-763f49531ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d6d77ce1-9575-4d50-91a5-6f682bbd6dc1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ec440f05-bf41-4ea6-90d1-763f49531ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_88a8d189-7fed-43f7-8126-570042aa052c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ec440f05-bf41-4ea6-90d1-763f49531ff5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_88a8d189-7fed-43f7-8126-570042aa052c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_efe091b0-fcad-41f8-b597-f7f4932fea3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ec440f05-bf41-4ea6-90d1-763f49531ff5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_efe091b0-fcad-41f8-b597-f7f4932fea3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_91ec6036-a157-48cb-9c43-9a97492077fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ec440f05-bf41-4ea6-90d1-763f49531ff5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_91ec6036-a157-48cb-9c43-9a97492077fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b7aeed12-28a4-44c5-81a6-4865419b0221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ec440f05-bf41-4ea6-90d1-763f49531ff5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b7aeed12-28a4-44c5-81a6-4865419b0221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1d055608-7714-4b25-82ed-627025504ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ec440f05-bf41-4ea6-90d1-763f49531ff5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1d055608-7714-4b25-82ed-627025504ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_f021f61a-1676-4a9e-8005-697b6fbb709b" xlink:href="arvn-20220331.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ec440f05-bf41-4ea6-90d1-763f49531ff5" xlink:to="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_f021f61a-1676-4a9e-8005-697b6fbb709b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4a8ff9eb-de7b-493d-8843-28ca7d34b6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ec440f05-bf41-4ea6-90d1-763f49531ff5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4a8ff9eb-de7b-493d-8843-28ca7d34b6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13ef79f7-6ef8-4c14-ba5b-9607eaac3577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f063bf5-26f8-477d-b78b-defbf2aa60b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13ef79f7-6ef8-4c14-ba5b-9607eaac3577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f966fa4-68a2-43a2-9b12-e110cec48d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c392a195-9fca-4db0-8c39-2ff8678e4af7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f966fa4-68a2-43a2-9b12-e110cec48d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2f2a0e1a-57ef-4558-a4d2-30c6bc613f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f966fa4-68a2-43a2-9b12-e110cec48d7f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2f2a0e1a-57ef-4558-a4d2-30c6bc613f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_6ff88e2a-8717-4265-a492-54ccefb37278" xlink:href="arvn-20220331.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f966fa4-68a2-43a2-9b12-e110cec48d7f" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_6ff88e2a-8717-4265-a492-54ccefb37278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86f13d7a-b174-4152-89fd-8f46462619c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f966fa4-68a2-43a2-9b12-e110cec48d7f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86f13d7a-b174-4152-89fd-8f46462619c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f265bda-eb35-4041-9a07-ec042ece2da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f966fa4-68a2-43a2-9b12-e110cec48d7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f265bda-eb35-4041-9a07-ec042ece2da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3e1e0283-d412-458d-9e1c-e2d915589ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c392a195-9fca-4db0-8c39-2ff8678e4af7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3e1e0283-d412-458d-9e1c-e2d915589ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_86982468-532c-4c79-abb8-5aba805a2109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3e1e0283-d412-458d-9e1c-e2d915589ac0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_86982468-532c-4c79-abb8-5aba805a2109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54960690-0f8c-4327-bc68-0d4a28e220a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3e1e0283-d412-458d-9e1c-e2d915589ac0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54960690-0f8c-4327-bc68-0d4a28e220a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aac9b2bf-a879-4f13-bcb9-de544b6e40cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c392a195-9fca-4db0-8c39-2ff8678e4af7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aac9b2bf-a879-4f13-bcb9-de544b6e40cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18bbfe3d-e901-4da4-b4d6-85c8c1b96abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c392a195-9fca-4db0-8c39-2ff8678e4af7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18bbfe3d-e901-4da4-b4d6-85c8c1b96abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fee28cf9-89c5-4a47-a3f2-7448f88f4d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c392a195-9fca-4db0-8c39-2ff8678e4af7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fee28cf9-89c5-4a47-a3f2-7448f88f4d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c0b59fa0-4ef2-4b22-975d-7f01dcdfff1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c392a195-9fca-4db0-8c39-2ff8678e4af7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c0b59fa0-4ef2-4b22-975d-7f01dcdfff1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e4bd270b-fe9b-4a4b-9439-b61e07c9618a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c0b59fa0-4ef2-4b22-975d-7f01dcdfff1a" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e4bd270b-fe9b-4a4b-9439-b61e07c9618a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="arvn-20220331.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b496cb0d-6990-4acf-9ec2-ed64b8e63b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_639214ea-eb68-48f6-b838-6d24b7588047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b496cb0d-6990-4acf-9ec2-ed64b8e63b4c" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_639214ea-eb68-48f6-b838-6d24b7588047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5421cc20-fd06-4915-9fd6-21f88ada8252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_1f4067bf-5bb6-4c40-9ae8-055d4aa378f0" xlink:href="arvn-20220331.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5421cc20-fd06-4915-9fd6-21f88ada8252" xlink:to="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_1f4067bf-5bb6-4c40-9ae8-055d4aa378f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arvn-20220331.xsd#AccountingPronouncementsandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e0d63ff9-c54e-4fd8-9e4a-ac6831dc42d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4260ba00-5556-4649-b0ed-02846fd5095c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e0d63ff9-c54e-4fd8-9e4a-ac6831dc42d0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4260ba00-5556-4649-b0ed-02846fd5095c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arvn-20220331.xsd#ResearchCollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_48262192-c0b3-4506-9dcf-6e9b9cbf94fd" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_cc1fd893-1f8b-4840-b54e-e0a899d443ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_48262192-c0b3-4506-9dcf-6e9b9cbf94fd" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_cc1fd893-1f8b-4840-b54e-e0a899d443ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="arvn-20220331.xsd#ResearchCollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_b39cfbf7-b1d6-4a00-b62a-8648ad6fa63b" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ad2538b8-df2b-404a-8583-3dc0e567ad74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_b39cfbf7-b1d6-4a00-b62a-8648ad6fa63b" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ad2538b8-df2b-404a-8583-3dc0e567ad74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_a340cd4a-7088-4c1a-af6c-1d8dc8527d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_b39cfbf7-b1d6-4a00-b62a-8648ad6fa63b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_a340cd4a-7088-4c1a-af6c-1d8dc8527d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_b06568b6-b5a5-4389-ab58-a4268b2ca60d" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_b06568b6-b5a5-4389-ab58-a4268b2ca60d" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_304c0e19-0341-4a14-8b38-fa62a3beb4df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:to="loc_srt_CounterpartyNameAxis_304c0e19-0341-4a14-8b38-fa62a3beb4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65858c4d-80ab-4132-ba40-511a1f4328c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_304c0e19-0341-4a14-8b38-fa62a3beb4df" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65858c4d-80ab-4132-ba40-511a1f4328c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_48cdd76e-ef63-42af-9c4e-99d856337755" xlink:href="arvn-20220331.xsd#arvn_PfizerIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65858c4d-80ab-4132-ba40-511a1f4328c1" xlink:to="loc_arvn_PfizerIncorporationMember_48cdd76e-ef63-42af-9c4e-99d856337755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember_5c0886c9-90f3-412f-b66b-988673721af6" xlink:href="arvn-20220331.xsd#arvn_BayerAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65858c4d-80ab-4132-ba40-511a1f4328c1" xlink:to="loc_arvn_BayerAGMember_5c0886c9-90f3-412f-b66b-988673721af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_e4e9fcaf-0832-4450-8f20-4d777f57eddf" xlink:href="arvn-20220331.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65858c4d-80ab-4132-ba40-511a1f4328c1" xlink:to="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_e4e9fcaf-0832-4450-8f20-4d777f57eddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0c5b9b09-4216-4f39-a714-c82000c1fd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0c5b9b09-4216-4f39-a714-c82000c1fd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0c5b9b09-4216-4f39-a714-c82000c1fd01" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember_907e6fe5-d3da-4394-a59a-32331d773e60" xlink:href="arvn-20220331.xsd#arvn_CollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_CollaborationAgreementMember_907e6fe5-d3da-4394-a59a-32331d773e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_ba151a75-b6ed-4817-b155-1ba713a49db2" xlink:href="arvn-20220331.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_ba151a75-b6ed-4817-b155-1ba713a49db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember_b5499dcb-5514-468e-9ba1-ee94453a3d98" xlink:href="arvn-20220331.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_RegulatoryMilestonePaymentsMember_b5499dcb-5514-468e-9ba1-ee94453a3d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember_09946049-1cf6-4f12-a7d7-2dc58fd217dc" xlink:href="arvn-20220331.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_SalesBasedMilestonesMember_09946049-1cf6-4f12-a7d7-2dc58fd217dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember_9880bde3-a85f-451f-aa6f-2dfb272f64f6" xlink:href="arvn-20220331.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_ResearchFundingPaymentsMember_9880bde3-a85f-451f-aa6f-2dfb272f64f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember_30979c1f-8ff8-4974-b278-539ab2d8cefa" xlink:href="arvn-20220331.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_DevelopmentMilestonePaymentsMember_30979c1f-8ff8-4974-b278-539ab2d8cefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember_0affe667-25b9-4e54-adda-fecf44125cce" xlink:href="arvn-20220331.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_SalesBasedMilestonePaymentsMember_0affe667-25b9-4e54-adda-fecf44125cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember_c890308f-03d0-4eae-9f71-ada971a4aec0" xlink:href="arvn-20220331.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_OptionPaymentsToLicenseAgreementMember_c890308f-03d0-4eae-9f71-ada971a4aec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember_5e609d8e-53ec-43a8-b397-6a347ff16b99" xlink:href="arvn-20220331.xsd#arvn_CommercialMilestonesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9cd502c4-c910-4b8f-8307-ef559827c8fb" xlink:to="loc_arvn_CommercialMilestonesMember_5e609d8e-53ec-43a8-b397-6a347ff16b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_776468c9-b3b8-4bfb-b91d-2234e3dcd802" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:to="loc_srt_RangeAxis_776468c9-b3b8-4bfb-b91d-2234e3dcd802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5ad9e13-d945-4644-9755-f05ba0401fff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_776468c9-b3b8-4bfb-b91d-2234e3dcd802" xlink:to="loc_srt_RangeMember_e5ad9e13-d945-4644-9755-f05ba0401fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b34c3061-d061-45d1-bc12-5e1d75a6bd3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5ad9e13-d945-4644-9755-f05ba0401fff" xlink:to="loc_srt_MaximumMember_b34c3061-d061-45d1-bc12-5e1d75a6bd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c112ec46-0036-4700-bbac-be2d4d448e2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:to="loc_srt_StatementScenarioAxis_c112ec46-0036-4700-bbac-be2d4d448e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c81042e1-1e92-4816-8f93-8151752ced1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c112ec46-0036-4700-bbac-be2d4d448e2b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c81042e1-1e92-4816-8f93-8151752ced1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1a308fa6-da2c-4c0b-8434-f0044e9415ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_c81042e1-1e92-4816-8f93-8151752ced1b" xlink:to="loc_srt_ScenarioForecastMember_1a308fa6-da2c-4c0b-8434-f0044e9415ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_e24c5dc0-e6a3-44a5-b1e0-fbc772ba5b20" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_e63c6bae-3b66-4420-be10-5ff981ea1809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_e63c6bae-3b66-4420-be10-5ff981ea1809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_9324058e-d9ff-4d61-8dfe-90d05edd6c7d" xlink:href="arvn-20220331.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_9324058e-d9ff-4d61-8dfe-90d05edd6c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_8424c9a7-0df8-40c4-b6ee-b19bce991fe3" xlink:href="arvn-20220331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_8424c9a7-0df8-40c4-b6ee-b19bce991fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_650ece53-194a-4831-b10d-445e154a8226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_us-gaap_ProceedsFromCollaborators_650ece53-194a-4831-b10d-445e154a8226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_55c0a050-131f-40f1-8496-8210c85184c6" xlink:href="arvn-20220331.xsd#arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_55c0a050-131f-40f1-8496-8210c85184c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfMaximumDesignatedTargets_2919f95c-ae04-4707-af23-40cd07b2ea53" xlink:href="arvn-20220331.xsd#arvn_NumberOfMaximumDesignatedTargets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_02108e44-b358-4d59-a1d5-70e770f1db65" xlink:to="loc_arvn_NumberOfMaximumDesignatedTargets_2919f95c-ae04-4707-af23-40cd07b2ea53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_a4ffc86a-5970-41f2-916e-49ea2a118d95" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_fdea4e05-c7ad-4410-be00-899d920b192b" xlink:href="arvn-20220331.xsd#arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_a4ffc86a-5970-41f2-916e-49ea2a118d95" xlink:to="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_fdea4e05-c7ad-4410-be00-899d920b192b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b188ac87-bd81-40f1-96f9-dd6f5ced2c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_fdea4e05-c7ad-4410-be00-899d920b192b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b188ac87-bd81-40f1-96f9-dd6f5ced2c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease_051dfc26-a1b1-4b98-8cc9-682805cc7e4f" xlink:href="arvn-20220331.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_fdea4e05-c7ad-4410-be00-899d920b192b" xlink:to="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease_051dfc26-a1b1-4b98-8cc9-682805cc7e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_77f0c061-8882-4587-a909-030394767005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_fdea4e05-c7ad-4410-be00-899d920b192b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_77f0c061-8882-4587-a909-030394767005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_e024e8b5-16d7-4745-a937-21369b40a223" xlink:href="arvn-20220331.xsd#arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_a4ffc86a-5970-41f2-916e-49ea2a118d95" xlink:to="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_e024e8b5-16d7-4745-a937-21369b40a223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_992952f8-814a-4a0c-9dd1-bb75b03771ed" xlink:href="arvn-20220331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_e024e8b5-16d7-4745-a937-21369b40a223" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_992952f8-814a-4a0c-9dd1-bb75b03771ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease_cb16076c-3e2e-4156-9aa3-072b4f0ec640" xlink:href="arvn-20220331.xsd#arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_e024e8b5-16d7-4745-a937-21369b40a223" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease_cb16076c-3e2e-4156-9aa3-072b4f0ec640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_a5c4762b-0008-451b-ba0a-d552be22c276" xlink:href="arvn-20220331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_e024e8b5-16d7-4745-a937-21369b40a223" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_a5c4762b-0008-451b-ba0a-d552be22c276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_36aee85f-2f3d-4645-a0fd-7dfb9c7cfc11" xlink:href="arvn-20220331.xsd#arvn_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_a4ffc86a-5970-41f2-916e-49ea2a118d95" xlink:to="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_36aee85f-2f3d-4645-a0fd-7dfb9c7cfc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_854af8cf-cc76-49f3-93da-0034c7d79b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_36aee85f-2f3d-4645-a0fd-7dfb9c7cfc11" xlink:to="loc_us-gaap_ContractWithCustomerLiability_854af8cf-cc76-49f3-93da-0034c7d79b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f2610b6-db31-4283-a934-d4a695121190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_36aee85f-2f3d-4645-a0fd-7dfb9c7cfc11" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f2610b6-db31-4283-a934-d4a695121190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_9c629f7a-1a9c-48b4-88e3-632f4c176f9b" xlink:href="arvn-20220331.xsd#arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_36aee85f-2f3d-4645-a0fd-7dfb9c7cfc11" xlink:to="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_9c629f7a-1a9c-48b4-88e3-632f4c176f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0a98273c-8983-4d51-a2cb-8dfd8374cd20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_36aee85f-2f3d-4645-a0fd-7dfb9c7cfc11" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0a98273c-8983-4d51-a2cb-8dfd8374cd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_e498115e-b255-4baf-af41-db9f90c37fc9" xlink:href="arvn-20220331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e07673d5-4242-4906-b694-b1fb1ee861c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_e498115e-b255-4baf-af41-db9f90c37fc9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e07673d5-4242-4906-b694-b1fb1ee861c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_adf8933a-94cd-4ae5-9fb2-22d526b6a698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e07673d5-4242-4906-b694-b1fb1ee861c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_adf8933a-94cd-4ae5-9fb2-22d526b6a698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e07673d5-4242-4906-b694-b1fb1ee861c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_002d7404-3811-4f4e-9949-effec13973cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_002d7404-3811-4f4e-9949-effec13973cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_851f354e-068a-4e44-81b3-225da9709c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_31f6cd19-fcda-489c-a404-46f0fb4ab259" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_851f354e-068a-4e44-81b3-225da9709c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="arvn-20220331.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="simple" xlink:href="arvn-20220331.xsd#MarketableSecuritiesandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dfc18ab9-8d4e-4764-a339-b7707c033e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c41666f5-d972-427e-a513-a9054ae7290c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dfc18ab9-8d4e-4764-a339-b7707c033e57" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c41666f5-d972-427e-a513-a9054ae7290c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="arvn-20220331.xsd#MarketableSecuritiesandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_975ed590-9568-43fc-8c61-9e699e77cb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ad159a70-33ee-469e-b815-55b766138043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_975ed590-9568-43fc-8c61-9e699e77cb2d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ad159a70-33ee-469e-b815-55b766138043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_45471414-bcdc-4ab9-85b4-d06eb8e58f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_45471414-bcdc-4ab9-85b4-d06eb8e58f16" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5b4210a-55ac-48a5-98f6-900ee87a542d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5b4210a-55ac-48a5-98f6-900ee87a542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd4a11d-2462-433b-9c17-c127bafe9b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5b4210a-55ac-48a5-98f6-900ee87a542d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd4a11d-2462-433b-9c17-c127bafe9b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_091c255c-512b-4752-9b3f-7a0f87dc9510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd4a11d-2462-433b-9c17-c127bafe9b87" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_091c255c-512b-4752-9b3f-7a0f87dc9510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95265b2b-efde-4a4d-8573-5d873c00794e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95265b2b-efde-4a4d-8573-5d873c00794e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_90fb1cb6-6dfe-4fe1-957f-31015cbf9d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95265b2b-efde-4a4d-8573-5d873c00794e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_90fb1cb6-6dfe-4fe1-957f-31015cbf9d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d8a1ab5e-2774-4dc5-badc-d691534d83d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_90fb1cb6-6dfe-4fe1-957f-31015cbf9d1f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d8a1ab5e-2774-4dc5-badc-d691534d83d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_7185e6fb-07d5-42c9-88cb-7e9464159f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:to="loc_us-gaap_InvestmentTypeAxis_7185e6fb-07d5-42c9-88cb-7e9464159f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_7185e6fb-07d5-42c9-88cb-7e9464159f63" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_ee384f05-37aa-4307-b0d9-c888e0dc20f1" xlink:href="arvn-20220331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_ee384f05-37aa-4307-b0d9-c888e0dc20f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_359f9af2-1fc8-447e-8831-b61b567ad0aa" xlink:href="arvn-20220331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_359f9af2-1fc8-447e-8831-b61b567ad0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_07043736-9133-4dc6-ae76-020f2ac3e0f7" xlink:href="arvn-20220331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember_07043736-9133-4dc6-ae76-020f2ac3e0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_c9ad54e9-60b0-4a7e-a8a1-5e8f1805ced7" xlink:href="arvn-20220331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_c9ad54e9-60b0-4a7e-a8a1-5e8f1805ced7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_37fa89d5-3306-4a74-a6ec-6ea13ba53d62" xlink:href="arvn-20220331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_37fa89d5-3306-4a74-a6ec-6ea13ba53d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_218dc3e9-8c4b-4ebe-9833-3258658e117b" xlink:href="arvn-20220331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29af1db0-9490-4489-89e5-f63d8fcb9aed" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_218dc3e9-8c4b-4ebe-9833-3258658e117b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a44527f2-eaf8-4143-a088-c111c84eb9e5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ff728029-92ba-4352-850e-1b8261071a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ff728029-92ba-4352-850e-1b8261071a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3c9ca09-b9a4-4fa8-8b60-75b941d9b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3c9ca09-b9a4-4fa8-8b60-75b941d9b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d21a48e9-a434-48fb-b017-29f2eb2dff80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d21a48e9-a434-48fb-b017-29f2eb2dff80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d608f-7b79-43ac-92f9-6ee7d83e8bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2589606d-9505-47e2-a475-5fa5d235b6e9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d608f-7b79-43ac-92f9-6ee7d83e8bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements" xlink:type="simple" xlink:href="arvn-20220331.xsd#PropertyEquipmentandLeaseholdImprovements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dbc55fc3-655b-49f8-b1a1-41da74471da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c5731223-086f-431f-b371-bacd0ddc1a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dbc55fc3-655b-49f8-b1a1-41da74471da1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c5731223-086f-431f-b371-bacd0ddc1a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables" xlink:type="simple" xlink:href="arvn-20220331.xsd#PropertyEquipmentandLeaseholdImprovementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5d5218c5-0d61-47fc-be57-930eda52b946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6c0b93b1-5fc1-4da5-99f7-02f88d289272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5d5218c5-0d61-47fc-be57-930eda52b946" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6c0b93b1-5fc1-4da5-99f7-02f88d289272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_90af33ba-98cc-4b5b-8cf4-311d66dd0542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3e5082e-583a-45c9-8e42-16022069da5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_90af33ba-98cc-4b5b-8cf4-311d66dd0542" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3e5082e-583a-45c9-8e42-16022069da5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deac42a2-80d5-4d76-8946-00b7f1b9d95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3e5082e-583a-45c9-8e42-16022069da5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deac42a2-80d5-4d76-8946-00b7f1b9d95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a19270b-1e0e-4068-90e9-729a24a23e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deac42a2-80d5-4d76-8946-00b7f1b9d95e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a19270b-1e0e-4068-90e9-729a24a23e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_692d09cd-7f08-4fbe-8691-8b401a3871b4" xlink:href="arvn-20220331.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a19270b-1e0e-4068-90e9-729a24a23e02" xlink:to="loc_arvn_LaboratoryEquipmentMember_692d09cd-7f08-4fbe-8691-8b401a3871b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6afb8975-194a-4204-a4bf-7b5f19390010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a19270b-1e0e-4068-90e9-729a24a23e02" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6afb8975-194a-4204-a4bf-7b5f19390010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_2a0e8283-5da9-454e-bf08-813a04674a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a19270b-1e0e-4068-90e9-729a24a23e02" xlink:to="loc_us-gaap_OfficeEquipmentMember_2a0e8283-5da9-454e-bf08-813a04674a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9d858674-d6a3-4dea-b557-f84dd005dcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3e5082e-583a-45c9-8e42-16022069da5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9d858674-d6a3-4dea-b557-f84dd005dcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9581e9d2-c4ab-45d3-96f5-19ea57431498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9d858674-d6a3-4dea-b557-f84dd005dcc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9581e9d2-c4ab-45d3-96f5-19ea57431498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0403eee4-0e09-4e97-a5cf-1f4d153b18f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9d858674-d6a3-4dea-b557-f84dd005dcc3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0403eee4-0e09-4e97-a5cf-1f4d153b18f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a447483e-b976-4d2f-b9df-cdf7c3eaf158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9d858674-d6a3-4dea-b557-f84dd005dcc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a447483e-b976-4d2f-b9df-cdf7c3eaf158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ada304df-4cbd-4b79-8f32-539304039d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_8bcacd19-e46f-4d8b-be1e-120dc68f2b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ada304df-4cbd-4b79-8f32-539304039d92" xlink:to="loc_us-gaap_DepreciationAndAmortization_8bcacd19-e46f-4d8b-be1e-120dc68f2b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilities" xlink:type="simple" xlink:href="arvn-20220331.xsd#RightofUseAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_603003d2-2651-45ba-be1a-5635d488dbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c03fed8e-64a1-4f38-983f-4b08cdce4c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_603003d2-2651-45ba-be1a-5635d488dbc9" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c03fed8e-64a1-4f38-983f-4b08cdce4c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="arvn-20220331.xsd#RightofUseAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a0b55558-9e3c-464a-8771-15b8a82fbe75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_66ba9b88-3555-466e-bd78-77435022d736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a0b55558-9e3c-464a-8771-15b8a82fbe75" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_66ba9b88-3555-466e-bd78-77435022d736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_4a6d1e97-2790-4239-9dfa-da655707cc60" xlink:href="arvn-20220331.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a0b55558-9e3c-464a-8771-15b8a82fbe75" xlink:to="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_4a6d1e97-2790-4239-9dfa-da655707cc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f1bf0566-d280-4338-906d-173ccfc97bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a0b55558-9e3c-464a-8771-15b8a82fbe75" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f1bf0566-d280-4338-906d-173ccfc97bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#RightofUseAssetsandLiabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a63c6608-b800-4b2d-b43e-75a6764b5a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b8e71754-9606-4b33-9401-21fc89c1eeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a63c6608-b800-4b2d-b43e-75a6764b5a54" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b8e71754-9606-4b33-9401-21fc89c1eeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a6bd6cd-aed8-4ac0-b188-408ed4821c81" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b8e71754-9606-4b33-9401-21fc89c1eeb6" xlink:to="loc_srt_RangeAxis_3a6bd6cd-aed8-4ac0-b188-408ed4821c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99cbaa2c-eebc-4849-b80e-1aaa0834fd51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3a6bd6cd-aed8-4ac0-b188-408ed4821c81" xlink:to="loc_srt_RangeMember_99cbaa2c-eebc-4849-b80e-1aaa0834fd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d442111b-dcc2-495c-8de0-368b70b443b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_99cbaa2c-eebc-4849-b80e-1aaa0834fd51" xlink:to="loc_srt_MinimumMember_d442111b-dcc2-495c-8de0-368b70b443b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2683811d-9a32-4003-8643-0677383357df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_99cbaa2c-eebc-4849-b80e-1aaa0834fd51" xlink:to="loc_srt_MaximumMember_2683811d-9a32-4003-8643-0677383357df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b8e71754-9606-4b33-9401-21fc89c1eeb6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_1a86ca85-6ce2-4691-b9fd-760beac4ccf0" xlink:href="arvn-20220331.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_1a86ca85-6ce2-4691-b9fd-760beac4ccf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_3920061c-dea3-4d6f-8cfd-ae1870999110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_3920061c-dea3-4d6f-8cfd-ae1870999110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_4c5ff128-9eb8-47b5-b547-09d9bc6a840b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_4c5ff128-9eb8-47b5-b547-09d9bc6a840b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f7a3bfea-cf7f-44cf-958f-3381ab1fd00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_us-gaap_LeaseCost_f7a3bfea-cf7f-44cf-958f-3381ab1fd00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BaseLeaseRentPeriod_0aceac49-058b-46c9-8665-a8c647f82b6c" xlink:href="arvn-20220331.xsd#arvn_BaseLeaseRentPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_arvn_BaseLeaseRentPeriod_0aceac49-058b-46c9-8665-a8c647f82b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f95e3813-f58a-471d-9f79-88645e9675fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ec33634-94e1-481b-b8ba-bd129ebb58fe" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f95e3813-f58a-471d-9f79-88645e9675fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b5b17346-374e-448f-85b5-e5ddc9e92d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_feb2ac6e-5902-4412-9e72-566db2107cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b5b17346-374e-448f-85b5-e5ddc9e92d02" xlink:to="loc_us-gaap_OperatingLeaseCost_feb2ac6e-5902-4412-9e72-566db2107cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4d9b2cd7-e6b1-49d2-a9d9-00db2fa6581c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_105b5a0d-fda1-410d-a478-a3f8e3d25118" xlink:href="arvn-20220331.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4d9b2cd7-e6b1-49d2-a9d9-00db2fa6581c" xlink:to="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_105b5a0d-fda1-410d-a478-a3f8e3d25118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4515d7e4-b661-491c-a751-b582205ed4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_105b5a0d-fda1-410d-a478-a3f8e3d25118" xlink:to="loc_us-gaap_OperatingLeasePayments_4515d7e4-b661-491c-a751-b582205ed4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_15059822-47b8-4320-969e-74dcdc0999c1" xlink:href="arvn-20220331.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4d9b2cd7-e6b1-49d2-a9d9-00db2fa6581c" xlink:to="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_15059822-47b8-4320-969e-74dcdc0999c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5a1375de-bdd8-408c-a02b-ed93fb2435c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_15059822-47b8-4320-969e-74dcdc0999c1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5a1375de-bdd8-408c-a02b-ed93fb2435c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1a16f7c9-a264-474d-bb52-23c66c63c265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8869c6ae-ca1d-4dfa-8ca1-783335a98269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a16f7c9-a264-474d-bb52-23c66c63c265" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8869c6ae-ca1d-4dfa-8ca1-783335a98269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a0100f19-4a82-4187-b1d4-d8634f87446b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a16f7c9-a264-474d-bb52-23c66c63c265" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a0100f19-4a82-4187-b1d4-d8634f87446b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2f89fe12-4160-41a9-a4a7-6dc29305c215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a16f7c9-a264-474d-bb52-23c66c63c265" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2f89fe12-4160-41a9-a4a7-6dc29305c215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b5bcfa82-afdb-4f16-9c89-bbab97118146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a16f7c9-a264-474d-bb52-23c66c63c265" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b5bcfa82-afdb-4f16-9c89-bbab97118146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d434a3ef-a0e4-4a66-a1bb-3f59eb3e6b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a16f7c9-a264-474d-bb52-23c66c63c265" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d434a3ef-a0e4-4a66-a1bb-3f59eb3e6b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b1373c3a-ccaa-4880-b535-58d0409bec32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a16f7c9-a264-474d-bb52-23c66c63c265" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b1373c3a-ccaa-4880-b535-58d0409bec32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4cb5db72-006d-4730-8377-698203c30ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a16f7c9-a264-474d-bb52-23c66c63c265" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4cb5db72-006d-4730-8377-698203c30ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b434f7f4-8282-477b-a2fc-d97576067ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a16f7c9-a264-474d-bb52-23c66c63c265" xlink:to="loc_us-gaap_OperatingLeaseLiability_b434f7f4-8282-477b-a2fc-d97576067ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="arvn-20220331.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccruedExpenses" xlink:type="simple" xlink:href="arvn-20220331.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b1b90732-5367-4dd9-9978-a88b5f4b7ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_161747ff-4d75-4798-83d7-6386409f2c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b1b90732-5367-4dd9-9978-a88b5f4b7ec6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_161747ff-4d75-4798-83d7-6386409f2c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="arvn-20220331.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ca93660b-bb04-44eb-9022-b57913a80d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e15749a9-dae9-4c97-9490-e1abfa764844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ca93660b-bb04-44eb-9022-b57913a80d74" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e15749a9-dae9-4c97-9490-e1abfa764844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_33909cc7-d964-488b-839d-8307600aa716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_a2c41654-f5c7-4330-a893-6e6954949c7a" xlink:href="arvn-20220331.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_33909cc7-d964-488b-839d-8307600aa716" xlink:to="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_a2c41654-f5c7-4330-a893-6e6954949c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5947c959-e56c-45d4-be91-0b5344a643e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_33909cc7-d964-488b-839d-8307600aa716" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5947c959-e56c-45d4-be91-0b5344a643e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_49c8f667-fdd7-49f3-8792-3c16155defce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_33909cc7-d964-488b-839d-8307600aa716" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_49c8f667-fdd7-49f3-8792-3c16155defce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_faf9c123-7e31-43c2-90b8-0cdcdc980f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_33909cc7-d964-488b-839d-8307600aa716" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_faf9c123-7e31-43c2-90b8-0cdcdc980f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_67e4e9e7-dd85-4981-9e5e-9a976b1f6dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_33909cc7-d964-488b-839d-8307600aa716" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_67e4e9e7-dd85-4981-9e5e-9a976b1f6dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebt" xlink:type="simple" xlink:href="arvn-20220331.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_465eb314-9a09-43db-8e98-08a2d765c90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_824ae950-2677-494a-9ef9-de4b2aff28bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_465eb314-9a09-43db-8e98-08a2d765c90e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_824ae950-2677-494a-9ef9-de4b2aff28bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="arvn-20220331.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8e8dcda6-0f3c-4491-9440-2844e0fc1a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4ae68bd4-5bcb-418f-b4aa-c91f9ad0b354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8e8dcda6-0f3c-4491-9440-2844e0fc1a0e" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4ae68bd4-5bcb-418f-b4aa-c91f9ad0b354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0b3e0c69-da51-49ef-a69e-cd16e24aab1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2e25b2ef-21e6-43cf-b950-93aa73a37272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0b3e0c69-da51-49ef-a69e-cd16e24aab1f" xlink:to="loc_us-gaap_DebtInstrumentTable_2e25b2ef-21e6-43cf-b950-93aa73a37272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3ffc928f-bffd-4c0a-b941-916d8bb65880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e25b2ef-21e6-43cf-b950-93aa73a37272" xlink:to="loc_us-gaap_DebtInstrumentAxis_3ffc928f-bffd-4c0a-b941-916d8bb65880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_777263fb-b477-4b77-b2dd-856dbebc3b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ffc928f-bffd-4c0a-b941-916d8bb65880" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_777263fb-b477-4b77-b2dd-856dbebc3b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_e4d8cbbd-e1fd-40ca-9375-a5fd444cff96" xlink:href="arvn-20220331.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_777263fb-b477-4b77-b2dd-856dbebc3b18" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_e4d8cbbd-e1fd-40ca-9375-a5fd444cff96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_8729bca7-21a0-41b1-9cdf-0a39547bd51b" xlink:href="arvn-20220331.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_777263fb-b477-4b77-b2dd-856dbebc3b18" xlink:to="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_8729bca7-21a0-41b1-9cdf-0a39547bd51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_903871e6-e39a-4264-876c-001487e1dec4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e25b2ef-21e6-43cf-b950-93aa73a37272" xlink:to="loc_srt_StatementGeographicalAxis_903871e6-e39a-4264-876c-001487e1dec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_03b01db0-6cfc-4109-ad66-a26bce73df6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_903871e6-e39a-4264-876c-001487e1dec4" xlink:to="loc_srt_SegmentGeographicalDomain_03b01db0-6cfc-4109-ad66-a26bce73df6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_318349bb-db77-4ffe-a868-e555b0da6b86" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CT"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_03b01db0-6cfc-4109-ad66-a26bce73df6b" xlink:to="loc_stpr_CT_318349bb-db77-4ffe-a868-e555b0da6b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e25b2ef-21e6-43cf-b950-93aa73a37272" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_77e41d4d-a783-445b-9594-0aa98c38011a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_77e41d4d-a783-445b-9594-0aa98c38011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_fae5e5e2-154a-44f4-9eb0-bd2b7b2513dc" xlink:href="arvn-20220331.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_fae5e5e2-154a-44f4-9eb0-bd2b7b2513dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0fe47275-f096-43fa-b821-aaa71458416b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0fe47275-f096-43fa-b821-aaa71458416b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm_8410a407-8dad-4c77-a959-3182b7dda0ce" xlink:href="arvn-20220331.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_arvn_DebtInstrumentInterestPaymentsTerm_8410a407-8dad-4c77-a959-3182b7dda0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages_58aaace0-930f-44b2-ac4f-9a3a40b7995c" xlink:href="arvn-20220331.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_arvn_PercentageOfLiquidatedDamages_58aaace0-930f-44b2-ac4f-9a3a40b7995c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ac997638-71d2-4356-9d23-8a1bdf6f6b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a042b67-e917-4f71-990e-5e641b8cfe51" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ac997638-71d2-4356-9d23-8a1bdf6f6b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e0235a22-9d16-48cc-ab1f-807cfd7cd391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e9593a4a-a49c-4aa0-bfb0-57494e35531e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0235a22-9d16-48cc-ab1f-807cfd7cd391" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e9593a4a-a49c-4aa0-bfb0-57494e35531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e96e50c0-6ffc-4f81-8a98-728e8d2ea16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0235a22-9d16-48cc-ab1f-807cfd7cd391" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e96e50c0-6ffc-4f81-8a98-728e8d2ea16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8a62cd63-ba63-44e7-b4a4-3c04b27d9a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0235a22-9d16-48cc-ab1f-807cfd7cd391" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8a62cd63-ba63-44e7-b4a4-3c04b27d9a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9d88674b-f5ea-4566-b4f3-3b1881fbd5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0235a22-9d16-48cc-ab1f-807cfd7cd391" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9d88674b-f5ea-4566-b4f3-3b1881fbd5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_135c015b-1ae3-4cdd-a08a-f65d2e353f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0235a22-9d16-48cc-ab1f-807cfd7cd391" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_135c015b-1ae3-4cdd-a08a-f65d2e353f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LongTermDebtMaturityYearSix_4c84347f-888c-474e-b6ba-8a27c172fcfa" xlink:href="arvn-20220331.xsd#arvn_LongTermDebtMaturityYearSix"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0235a22-9d16-48cc-ab1f-807cfd7cd391" xlink:to="loc_arvn_LongTermDebtMaturityYearSix_4c84347f-888c-474e-b6ba-8a27c172fcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1a3dec4f-3eb2-4efd-be93-ddf95a157856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0235a22-9d16-48cc-ab1f-807cfd7cd391" xlink:to="loc_us-gaap_LongTermDebt_1a3dec4f-3eb2-4efd-be93-ddf95a157856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/Equity" xlink:type="simple" xlink:href="arvn-20220331.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25ad9276-6819-46ad-a66c-17a775822672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f81ea607-691d-4a36-aade-2c590ee7f1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25ad9276-6819-46ad-a66c-17a775822672" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f81ea607-691d-4a36-aade-2c590ee7f1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityTables" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b0a5a29-2d3f-458b-8965-580aeca9cecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4548374f-132a-4205-8536-b1a6bf22f4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b0a5a29-2d3f-458b-8965-580aeca9cecb" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4548374f-132a-4205-8536-b1a6bf22f4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4748ed8e-822f-4ab5-83ae-860542e1b849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b0a5a29-2d3f-458b-8965-580aeca9cecb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4748ed8e-822f-4ab5-83ae-860542e1b849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2f75e186-50ed-4cee-a19f-a0957efc0221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b0a5a29-2d3f-458b-8965-580aeca9cecb" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2f75e186-50ed-4cee-a19f-a0957efc0221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7608382-fb76-4f28-8cb9-db50d10fb2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7608382-fb76-4f28-8cb9-db50d10fb2ba" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7692b665-057e-428d-a24c-e5f588ac87ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7692b665-057e-428d-a24c-e5f588ac87ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47f1a9ba-ca3a-4af2-9416-4b357aa609c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7692b665-057e-428d-a24c-e5f588ac87ec" xlink:to="loc_us-gaap_EquityComponentDomain_47f1a9ba-ca3a-4af2-9416-4b357aa609c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ee325c92-dde4-4781-a46d-3b30fd010070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47f1a9ba-ca3a-4af2-9416-4b357aa609c8" xlink:to="loc_us-gaap_CommonStockMember_ee325c92-dde4-4781-a46d-3b30fd010070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_63aa5fee-6be6-48c4-b3d9-1ccbbdee4aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_TypeOfArrangementAxis_63aa5fee-6be6-48c4-b3d9-1ccbbdee4aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2175247-7995-4145-939b-587613d862b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_63aa5fee-6be6-48c4-b3d9-1ccbbdee4aa4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2175247-7995-4145-939b-587613d862b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember_1fe8229c-8cdd-4bb9-888b-110031d9bad9" xlink:href="arvn-20220331.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2175247-7995-4145-939b-587613d862b6" xlink:to="loc_arvn_EquityDistributionAgreementMember_1fe8229c-8cdd-4bb9-888b-110031d9bad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5f6ea27d-f5e3-4ae3-9b7a-2f1171b3cbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5f6ea27d-f5e3-4ae3-9b7a-2f1171b3cbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee2db2fd-11c8-46a3-bbde-ccf844d02e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5f6ea27d-f5e3-4ae3-9b7a-2f1171b3cbb9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee2db2fd-11c8-46a3-bbde-ccf844d02e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_baaca12e-da7a-44b9-9a3f-caac71b6dc93" xlink:href="arvn-20220331.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee2db2fd-11c8-46a3-bbde-ccf844d02e8e" xlink:to="loc_arvn_AtTheMarketOfferingMember_baaca12e-da7a-44b9-9a3f-caac71b6dc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d90a240c-7921-4658-94e3-7232b8bf2254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee2db2fd-11c8-46a3-bbde-ccf844d02e8e" xlink:to="loc_us-gaap_EmployeeStockMember_d90a240c-7921-4658-94e3-7232b8bf2254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_be5dce12-197b-4998-acfd-c10cb91269ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_srt_CounterpartyNameAxis_be5dce12-197b-4998-acfd-c10cb91269ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8020fe78-1f64-48af-9849-30d47f9bc56d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_be5dce12-197b-4998-acfd-c10cb91269ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8020fe78-1f64-48af-9849-30d47f9bc56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember_5b65c24d-60b5-40cc-9a7c-9f6c8fc72af0" xlink:href="arvn-20220331.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8020fe78-1f64-48af-9849-30d47f9bc56d" xlink:to="loc_arvn_PiperSandlerAndCantorMember_5b65c24d-60b5-40cc-9a7c-9f6c8fc72af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d225b5b3-08e4-4640-b415-1b04169b4239" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_srt_RangeAxis_d225b5b3-08e4-4640-b415-1b04169b4239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8b3f01ad-9625-4e40-bb51-29b2bda8e1c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d225b5b3-08e4-4640-b415-1b04169b4239" xlink:to="loc_srt_RangeMember_8b3f01ad-9625-4e40-bb51-29b2bda8e1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e59e3c14-b4dc-475d-b803-0cd9aa5fa40b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8b3f01ad-9625-4e40-bb51-29b2bda8e1c1" xlink:to="loc_srt_MinimumMember_e59e3c14-b4dc-475d-b803-0cd9aa5fa40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_606f4f9c-cd2b-4d62-a18a-95bc1b38dd45" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8b3f01ad-9625-4e40-bb51-29b2bda8e1c1" xlink:to="loc_srt_MaximumMember_606f4f9c-cd2b-4d62-a18a-95bc1b38dd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_545549bb-933d-4c98-a039-ed5ef022a59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_PlanNameAxis_545549bb-933d-4c98-a039-ed5ef022a59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c44289b5-b180-4891-9f9c-80f004d710c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_545549bb-933d-4c98-a039-ed5ef022a59d" xlink:to="loc_us-gaap_PlanNameDomain_c44289b5-b180-4891-9f9c-80f004d710c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember_225d7ecd-2fa8-4101-affe-9401b045e27a" xlink:href="arvn-20220331.xsd#arvn_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c44289b5-b180-4891-9f9c-80f004d710c4" xlink:to="loc_arvn_StockIncentivePlanMember_225d7ecd-2fa8-4101-affe-9401b045e27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_3803dd1b-b97a-44cf-8cc1-86c7e6160d03" xlink:href="arvn-20220331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c44289b5-b180-4891-9f9c-80f004d710c4" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_3803dd1b-b97a-44cf-8cc1-86c7e6160d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9bffacda-1266-4e58-a574-0a6db3b9db0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_AwardTypeAxis_9bffacda-1266-4e58-a574-0a6db3b9db0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29d2922c-81e9-40c0-b622-633b2791f0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9bffacda-1266-4e58-a574-0a6db3b9db0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29d2922c-81e9-40c0-b622-633b2791f0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a8b2767f-306b-4916-a96e-7cffee01c50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29d2922c-81e9-40c0-b622-633b2791f0f7" xlink:to="loc_us-gaap_RestrictedStockMember_a8b2767f-306b-4916-a96e-7cffee01c50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_275b93fe-c767-47dc-af7d-116fb8c0f7f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_srt_TitleOfIndividualAxis_275b93fe-c767-47dc-af7d-116fb8c0f7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d51de419-6fbe-4001-adc0-6a37fa87c521" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_275b93fe-c767-47dc-af7d-116fb8c0f7f0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d51de419-6fbe-4001-adc0-6a37fa87c521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember_79a8f58a-4591-4b64-a556-cd8321ba0909" xlink:href="arvn-20220331.xsd#arvn_EmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d51de419-6fbe-4001-adc0-6a37fa87c521" xlink:to="loc_arvn_EmployeesMember_79a8f58a-4591-4b64-a556-cd8321ba0909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4e825e8-94fd-43cd-8256-8f4beaca91fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_0840580c-5266-4197-a209-3886b36c541c" xlink:href="arvn-20220331.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_0840580c-5266-4197-a209-3886b36c541c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2e30396b-d002-442c-8303-a6eb20a1b66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2e30396b-d002-442c-8303-a6eb20a1b66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fc04b343-2b10-4c90-9b69-57d93c764b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fc04b343-2b10-4c90-9b69-57d93c764b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_3b2cf0b1-aa6b-49c0-8fd8-8bf03e77acb6" xlink:href="arvn-20220331.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_3b2cf0b1-aa6b-49c0-8fd8-8bf03e77acb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1a8f82cc-1557-4dde-8582-2e8cf2436c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1a8f82cc-1557-4dde-8582-2e8cf2436c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_be477b85-0637-44d7-937d-efeaf4f60327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_be477b85-0637-44d7-937d-efeaf4f60327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3e9be46a-f322-4527-a965-c2d181af54f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3e9be46a-f322-4527-a965-c2d181af54f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28137b9a-c20d-462b-a6be-4e3d9dbc9143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28137b9a-c20d-462b-a6be-4e3d9dbc9143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_7962ee65-7a84-452f-94c2-19cbfa9c7927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_7962ee65-7a84-452f-94c2-19cbfa9c7927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3164e7fd-0f24-406f-bb5d-26eb4ce69b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3164e7fd-0f24-406f-bb5d-26eb4ce69b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_01c6f34e-68fb-4e52-b3ba-1ff596eb9a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_01c6f34e-68fb-4e52-b3ba-1ff596eb9a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7c7dea86-9e68-48f3-8d08-f48e36cc0c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7c7dea86-9e68-48f3-8d08-f48e36cc0c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3a5cea98-5b99-4997-9107-0d387228b9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3a5cea98-5b99-4997-9107-0d387228b9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_913c4923-8e2d-43a3-9f01-995332e162fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_913c4923-8e2d-43a3-9f01-995332e162fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d45e435b-e1a0-4334-b0f1-fb900b3f7b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d45e435b-e1a0-4334-b0f1-fb900b3f7b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4c5aff61-a53d-4154-9002-df45209f50f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4c5aff61-a53d-4154-9002-df45209f50f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber_08f99436-b796-4b87-bf67-bcfa21b12ee5" xlink:href="arvn-20220331.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber_08f99436-b796-4b87-bf67-bcfa21b12ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_58237cb9-2662-498e-9494-2918ab5e06b0" xlink:href="arvn-20220331.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fc08d36-5f54-4336-b8f2-031572009a2f" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_58237cb9-2662-498e-9494-2918ab5e06b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_554d65b5-9a6c-41b1-9273-bfa427a3564e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2db8b8-4c14-4d64-ab5e-338fb4026bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_554d65b5-9a6c-41b1-9273-bfa427a3564e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2db8b8-4c14-4d64-ab5e-338fb4026bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_34feef95-33f4-4390-b97c-a48ad135b9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2db8b8-4c14-4d64-ab5e-338fb4026bec" xlink:to="loc_us-gaap_AwardTypeAxis_34feef95-33f4-4390-b97c-a48ad135b9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85ac4a40-e33f-489a-b86d-5dd50ee00db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_34feef95-33f4-4390-b97c-a48ad135b9e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85ac4a40-e33f-489a-b86d-5dd50ee00db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_17b9ade0-577a-4983-976b-3b6f8202628f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85ac4a40-e33f-489a-b86d-5dd50ee00db3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_17b9ade0-577a-4983-976b-3b6f8202628f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89233cc7-03f4-4b32-bf2b-a90c6d72a985" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2db8b8-4c14-4d64-ab5e-338fb4026bec" xlink:to="loc_srt_RangeAxis_89233cc7-03f4-4b32-bf2b-a90c6d72a985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36032251-0593-4cae-b939-2c026a4dd3c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_89233cc7-03f4-4b32-bf2b-a90c6d72a985" xlink:to="loc_srt_RangeMember_36032251-0593-4cae-b939-2c026a4dd3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2710f570-52df-4c41-bac3-1857e4b3dfa9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_36032251-0593-4cae-b939-2c026a4dd3c4" xlink:to="loc_srt_MinimumMember_2710f570-52df-4c41-bac3-1857e4b3dfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6dbb06be-3f78-43fc-8f1d-266f28b4dffc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_36032251-0593-4cae-b939-2c026a4dd3c4" xlink:to="loc_srt_MaximumMember_6dbb06be-3f78-43fc-8f1d-266f28b4dffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2db8b8-4c14-4d64-ab5e-338fb4026bec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f5171dd8-542e-489a-b4a8-00e834d518f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f5171dd8-542e-489a-b4a8-00e834d518f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f9fb3d1e-d2a5-4a42-8edd-07627dd793ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f9fb3d1e-d2a5-4a42-8edd-07627dd793ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c1b305c0-8dc6-4159-96c6-fcc2c21d166d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c1b305c0-8dc6-4159-96c6-fcc2c21d166d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e9d2b299-9d67-4dfb-a4a1-dd537d3422dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e9d2b299-9d67-4dfb-a4a1-dd537d3422dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0b29607d-b2e6-41e2-8840-3d51687d6b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0b29607d-b2e6-41e2-8840-3d51687d6b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_af4c54a0-f7e0-4a1e-9170-524325100845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_af4c54a0-f7e0-4a1e-9170-524325100845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_86edee36-61f0-4483-904f-37f9484059e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e4b8b2-3368-4efd-b8dc-2a2ba142638b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_86edee36-61f0-4483-904f-37f9484059e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquitySummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82103ce2-ffe1-4b03-b52a-8ce3e78baf18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14bd1b32-0fc2-4f68-ae15-da5695f17fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82103ce2-ffe1-4b03-b52a-8ce3e78baf18" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14bd1b32-0fc2-4f68-ae15-da5695f17fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a6632a7c-b449-47ea-b97f-7490d30221c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14bd1b32-0fc2-4f68-ae15-da5695f17fc4" xlink:to="loc_us-gaap_PlanNameAxis_a6632a7c-b449-47ea-b97f-7490d30221c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3584f83a-ef7a-44aa-818b-55a6b428d542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a6632a7c-b449-47ea-b97f-7490d30221c0" xlink:to="loc_us-gaap_PlanNameDomain_3584f83a-ef7a-44aa-818b-55a6b428d542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_f825ee58-39da-4cb8-9562-951a0d3558c2" xlink:href="arvn-20220331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3584f83a-ef7a-44aa-818b-55a6b428d542" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_f825ee58-39da-4cb8-9562-951a0d3558c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14bd1b32-0fc2-4f68-ae15-da5695f17fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1be13c76-4aae-45e7-a3b7-1cb4f00f81f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1be13c76-4aae-45e7-a3b7-1cb4f00f81f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1cacf66e-451b-475e-b1a6-f144cfef9b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1cacf66e-451b-475e-b1a6-f144cfef9b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e737eb36-3a4a-479f-ae29-fdf8b71686e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e737eb36-3a4a-479f-ae29-fdf8b71686e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3bc6f393-04ad-48cf-a0a4-6d429ec92d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3bc6f393-04ad-48cf-a0a4-6d429ec92d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54251bd7-d09e-4bc6-8c81-c23b6b993272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c52427b0-396d-4ab0-8cbb-501c07f345db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54251bd7-d09e-4bc6-8c81-c23b6b993272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4fdfaf9f-0c0c-492b-9083-7800db58b69b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4fdfaf9f-0c0c-492b-9083-7800db58b69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b0ed7c30-b1e1-496e-b675-715c053d932e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b0ed7c30-b1e1-496e-b675-715c053d932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2e3082c0-697b-452c-8ab2-536ef51f7c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2e3082c0-697b-452c-8ab2-536ef51f7c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_75e3f32a-0e0f-47bd-b03f-37472c15f149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_75e3f32a-0e0f-47bd-b03f-37472c15f149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ff39072b-4034-4471-9082-a766b9c5a77e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ff39072b-4034-4471-9082-a766b9c5a77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_481042dd-bdf5-4984-acca-5bd3d49bbae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f8c0033d-356a-4b68-922e-3e8c8eca8d0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_481042dd-bdf5-4984-acca-5bd3d49bbae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9d13ad93-98e4-4d14-a905-24c110648bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9d13ad93-98e4-4d14-a905-24c110648bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_540ca022-7736-4346-97eb-967c05f79d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_540ca022-7736-4346-97eb-967c05f79d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_357f5e2c-4c9d-4dd9-a9b1-04e9056930e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_540ca022-7736-4346-97eb-967c05f79d1b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_357f5e2c-4c9d-4dd9-a9b1-04e9056930e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_18c33db2-035c-44d7-a8cf-93e3b8165e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_18c33db2-035c-44d7-a8cf-93e3b8165e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract_14eafda5-275e-4d34-99bf-67dc5c6be9f2" xlink:href="arvn-20220331.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_arvn_AggregateIntrinsicValueAbstract_14eafda5-275e-4d34-99bf-67dc5c6be9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cb1a2c26-6f4c-4569-8412-7abfd1fdad84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_14eafda5-275e-4d34-99bf-67dc5c6be9f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cb1a2c26-6f4c-4569-8412-7abfd1fdad84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d1b7a6b6-ebbb-4204-b737-503b88e3730c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aef343a9-f448-4eaf-ab97-a6d7b0dd6991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d1b7a6b6-ebbb-4204-b737-503b88e3730c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquitySummaryofRestrictedStockGrantActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1bf95719-c5c4-4c6d-aaca-82631d5ef42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1bf95719-c5c4-4c6d-aaca-82631d5ef42c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8c9842bb-a20a-47e6-bd50-68b5f3d560cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:to="loc_us-gaap_PlanNameAxis_8c9842bb-a20a-47e6-bd50-68b5f3d560cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2bc4f5df-f88d-4a10-8934-61287ee2ee08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8c9842bb-a20a-47e6-bd50-68b5f3d560cb" xlink:to="loc_us-gaap_PlanNameDomain_2bc4f5df-f88d-4a10-8934-61287ee2ee08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember_d933915e-fde2-4662-87b9-825fe4356c4a" xlink:href="arvn-20220331.xsd#arvn_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2bc4f5df-f88d-4a10-8934-61287ee2ee08" xlink:to="loc_arvn_StockIncentivePlanMember_d933915e-fde2-4662-87b9-825fe4356c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_29f9c28d-2a55-4d3f-a559-10d39ea277ed" xlink:href="arvn-20220331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2bc4f5df-f88d-4a10-8934-61287ee2ee08" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_29f9c28d-2a55-4d3f-a559-10d39ea277ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_40805964-1f77-4086-b65f-138ef8b8ef21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:to="loc_us-gaap_AwardTypeAxis_40805964-1f77-4086-b65f-138ef8b8ef21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9756588c-2f01-48f5-b735-329b8a9e99cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_40805964-1f77-4086-b65f-138ef8b8ef21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9756588c-2f01-48f5-b735-329b8a9e99cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d4c6a71c-3a14-4547-9df5-f320ca6c623a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9756588c-2f01-48f5-b735-329b8a9e99cf" xlink:to="loc_us-gaap_RestrictedStockMember_d4c6a71c-3a14-4547-9df5-f320ca6c623a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6d828dec-981d-465f-87ef-9bc79b57a5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9756588c-2f01-48f5-b735-329b8a9e99cf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6d828dec-981d-465f-87ef-9bc79b57a5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_fb5f681c-90fa-42cc-adcd-cb42c705193b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:to="loc_srt_TitleOfIndividualAxis_fb5f681c-90fa-42cc-adcd-cb42c705193b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_45c78226-5957-4f7c-bb3c-fa8b02237599" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_fb5f681c-90fa-42cc-adcd-cb42c705193b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_45c78226-5957-4f7c-bb3c-fa8b02237599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesDirectorsAndConsultantsMember_bf7a1707-36a7-4821-a2cd-8fe63fe459b7" xlink:href="arvn-20220331.xsd#arvn_EmployeesDirectorsAndConsultantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_45c78226-5957-4f7c-bb3c-fa8b02237599" xlink:to="loc_arvn_EmployeesDirectorsAndConsultantsMember_bf7a1707-36a7-4821-a2cd-8fe63fe459b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember_0fef1a87-78c9-440a-aac2-a1ebe653b7de" xlink:href="arvn-20220331.xsd#arvn_EmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_45c78226-5957-4f7c-bb3c-fa8b02237599" xlink:to="loc_arvn_EmployeesMember_0fef1a87-78c9-440a-aac2-a1ebe653b7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bce7fa44-48fd-4492-afa9-0c4e466b70ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68c28ac9-80d3-4d71-9a1d-7972f8cde18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bce7fa44-48fd-4492-afa9-0c4e466b70ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bce7fa44-48fd-4492-afa9-0c4e466b70ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80b5c852-7314-42fb-80a2-1923386168fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80b5c852-7314-42fb-80a2-1923386168fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f13f39a-acbc-406f-bf41-9b6e7bccab2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f13f39a-acbc-406f-bf41-9b6e7bccab2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fca94b53-a587-44c9-94e4-68b5650b91e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fca94b53-a587-44c9-94e4-68b5650b91e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4dcc5b0a-9eae-4cbe-b4d4-02cdb12be381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4dcc5b0a-9eae-4cbe-b4d4-02cdb12be381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_abccc5cc-d391-45c9-867b-4fa39c493323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca9472e4-a86b-49a6-b578-e9941c1d0e86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_abccc5cc-d391-45c9-867b-4fa39c493323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bce7fa44-48fd-4492-afa9-0c4e466b70ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_559a0dac-1ca6-4e74-b3fa-f7671d4658ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_559a0dac-1ca6-4e74-b3fa-f7671d4658ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8891ffb7-abe0-422c-b9c2-67b62dd61ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8891ffb7-abe0-422c-b9c2-67b62dd61ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_09236997-36f7-4f5c-bd4f-220f75f01b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_09236997-36f7-4f5c-bd4f-220f75f01b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b86a5289-d0d2-481d-b797-9dcf06e026db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b86a5289-d0d2-481d-b797-9dcf06e026db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7b077e59-a198-483f-a1c4-c9e73103cfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d71c2c8-94c3-4717-974b-e5d89c770758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7b077e59-a198-483f-a1c4-c9e73103cfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxes" xlink:type="simple" xlink:href="arvn-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ec226bef-6fa8-4268-9740-fc5a16b63014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1bd29503-7bc2-4dab-b00e-5989851adc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec226bef-6fa8-4268-9740-fc5a16b63014" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1bd29503-7bc2-4dab-b00e-5989851adc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4dac935e-bcbe-4d20-99ff-9190af537d24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_89ece90f-e9d1-48f0-a6ab-4abbdfb406f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4dac935e-bcbe-4d20-99ff-9190af537d24" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_89ece90f-e9d1-48f0-a6ab-4abbdfb406f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a8d5515a-596b-434a-aa5c-d3a87c616111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4dac935e-bcbe-4d20-99ff-9190af537d24" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a8d5515a-596b-434a-aa5c-d3a87c616111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a0ab2b82-2508-499d-8f51-75543dc8d338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4dac935e-bcbe-4d20-99ff-9190af537d24" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a0ab2b82-2508-499d-8f51-75543dc8d338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShare" xlink:type="simple" xlink:href="arvn-20220331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7f3c3699-280c-4e58-87f6-949042bd89cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_09ffe76a-9a14-4834-bd83-67318816cf73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7f3c3699-280c-4e58-87f6-949042bd89cf" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_09ffe76a-9a14-4834-bd83-67318816cf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="arvn-20220331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_09a8e6b8-7344-4327-8f0d-432bdd76c968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0c3979a6-314d-4e19-b481-fb93cc980be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_09a8e6b8-7344-4327-8f0d-432bdd76c968" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0c3979a6-314d-4e19-b481-fb93cc980be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_eedb0e78-f9d0-4408-87c7-3e20c358a48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_09a8e6b8-7344-4327-8f0d-432bdd76c968" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_eedb0e78-f9d0-4408-87c7-3e20c358a48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#NetLossPerShareBasicandDilutedLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_22029e70-60d9-470b-bd97-4ff154effbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8b476fbd-154d-470e-a9f1-afcf5f9c8386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_22029e70-60d9-470b-bd97-4ff154effbe5" xlink:to="loc_us-gaap_NetIncomeLoss_8b476fbd-154d-470e-a9f1-afcf5f9c8386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_acbea855-f83d-4059-94a8-f8bf210caebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_22029e70-60d9-470b-bd97-4ff154effbe5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_acbea855-f83d-4059-94a8-f8bf210caebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9c3f732c-ffed-440a-bc64-f3e9280bcc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_22029e70-60d9-470b-bd97-4ff154effbe5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9c3f732c-ffed-440a-bc64-f3e9280bcc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_119f5f94-f160-4c08-9eef-ebac1457b931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_22029e70-60d9-470b-bd97-4ff154effbe5" xlink:to="loc_us-gaap_EarningsPerShareBasic_119f5f94-f160-4c08-9eef-ebac1457b931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_719e4c03-4c68-4a06-b1ab-f9ee64b2059e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_22029e70-60d9-470b-bd97-4ff154effbe5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_719e4c03-4c68-4a06-b1ab-f9ee64b2059e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9b167d13-7aa8-42f5-923d-3501d8ae3a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e157dbf9-e182-47c2-8f41-9e9ced475f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9b167d13-7aa8-42f5-923d-3501d8ae3a5b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e157dbf9-e182-47c2-8f41-9e9ced475f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dcf9ccdd-8685-4a4c-b46c-ffe73b0f840d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e157dbf9-e182-47c2-8f41-9e9ced475f34" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dcf9ccdd-8685-4a4c-b46c-ffe73b0f840d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9046a84-41ad-41c0-a108-d2491ca8d13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dcf9ccdd-8685-4a4c-b46c-ffe73b0f840d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9046a84-41ad-41c0-a108-d2491ca8d13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1aa1016d-68ee-4dee-8446-5c2faa17cfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9046a84-41ad-41c0-a108-d2491ca8d13c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1aa1016d-68ee-4dee-8446-5c2faa17cfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0d24fa86-c1d5-4551-9f7a-6be91f20d2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9046a84-41ad-41c0-a108-d2491ca8d13c" xlink:to="loc_us-gaap_RestrictedStockMember_0d24fa86-c1d5-4551-9f7a-6be91f20d2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_245a46e2-723a-45a0-8f6f-fbc762708021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9046a84-41ad-41c0-a108-d2491ca8d13c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_245a46e2-723a-45a0-8f6f-fbc762708021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a25b79e8-5a30-4fb4-82c3-4d8208738f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e157dbf9-e182-47c2-8f41-9e9ced475f34" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a25b79e8-5a30-4fb4-82c3-4d8208738f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ecf6b086-7261-402c-b277-4d7da01c5703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a25b79e8-5a30-4fb4-82c3-4d8208738f3a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ecf6b086-7261-402c-b277-4d7da01c5703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestments" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquityMethodInvestments"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_06ce6c3f-bc59-49db-8e46-7f54c577674d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_98e75f91-2bf8-47fb-858d-a39e045ec615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_06ce6c3f-bc59-49db-8e46-7f54c577674d" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_98e75f91-2bf8-47fb-858d-a39e045ec615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="arvn-20220331.xsd#EquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e29702eb-cddd-47fc-b26c-1e32188e571e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e29702eb-cddd-47fc-b26c-1e32188e571e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0b182c77-dd4e-4388-b941-346fe8c4e091" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:to="loc_srt_CounterpartyNameAxis_0b182c77-dd4e-4388-b941-346fe8c4e091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcf53772-af77-4e8c-8d5a-8fac21ffde1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0b182c77-dd4e-4388-b941-346fe8c4e091" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcf53772-af77-4e8c-8d5a-8fac21ffde1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember_a2a09f60-a569-43b5-8e19-e213ab5cbe14" xlink:href="arvn-20220331.xsd#arvn_BayerCropScienceLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcf53772-af77-4e8c-8d5a-8fac21ffde1a" xlink:to="loc_arvn_BayerCropScienceLPMember_a2a09f60-a569-43b5-8e19-e213ab5cbe14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4257bbc0-0d64-4c4f-8f11-cc63e355afd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4257bbc0-0d64-4c4f-8f11-cc63e355afd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5f0b2883-4949-4987-8435-8a89d760099e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4257bbc0-0d64-4c4f-8f11-cc63e355afd0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5f0b2883-4949-4987-8435-8a89d760099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_f0e2e4fc-de67-4ec6-add3-7c7e6947f8c2" xlink:href="arvn-20220331.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5f0b2883-4949-4987-8435-8a89d760099e" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_f0e2e4fc-de67-4ec6-add3-7c7e6947f8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b6ef5758-71bb-4215-9c0f-54aa9fdedd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b6ef5758-71bb-4215-9c0f-54aa9fdedd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_9a9647b6-6113-4705-bd21-aa498d23196e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b6ef5758-71bb-4215-9c0f-54aa9fdedd80" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_9a9647b6-6113-4705-bd21-aa498d23196e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_75f95a10-19ee-42ee-8541-5d15c7f5d6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_9a9647b6-6113-4705-bd21-aa498d23196e" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_75f95a10-19ee-42ee-8541-5d15c7f5d6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_013daf50-fa6c-4705-8888-fa66e8454da9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3f59d389-dbf5-4235-aa2a-1c0980c0ffb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3f59d389-dbf5-4235-aa2a-1c0980c0ffb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_14143b1c-65bb-4746-b781-9a735101192f" xlink:href="arvn-20220331.xsd#arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_14143b1c-65bb-4746-b781-9a735101192f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d9e7508f-89e9-40b0-bc11-e6d8bbea06e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_us-gaap_ProfitLoss_d9e7508f-89e9-40b0-bc11-e6d8bbea06e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_def04372-3d76-4f55-9118-ea724546a8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_us-gaap_EquityMethodInvestments_def04372-3d76-4f55-9118-ea724546a8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b793ff41-f75e-43fb-92aa-f01e3e9c224e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fc0f354-4fda-4825-96f3-067570f235cd" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b793ff41-f75e-43fb-92aa-f01e3e9c224e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840851902392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARVINAS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2566120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Science Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">395 Winchester Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">535-1456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARVN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,165,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001655759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840854125832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62.3<span></span>
</td>
<td class="nump">$ 108.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,366.1<span></span>
</td>
<td class="nump">1,394.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,457.0<span></span>
</td>
<td class="nump">1,552.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,488.3<span></span>
</td>
<td class="nump">1,581.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">30.2<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">197.5<span></span>
</td>
<td class="nump">206.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">238.0<span></span>
</td>
<td class="nump">261.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">521.9<span></span>
</td>
<td class="nump">534.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">765.0<span></span>
</td>
<td class="nump">799.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 53.1 and 53.0 shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(746.3)<span></span>
</td>
<td class="num">(682.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,488.3<span></span>
</td>
<td class="nump">1,469.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(18.7)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">723.3<span></span>
</td>
<td class="nump">781.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,488.3<span></span>
</td>
<td class="nump">$ 1,581.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration contract asset and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840856552184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840854144872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 24.2<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="nump">34.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">84.2<span></span>
</td>
<td class="nump">47.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(60.0)<span></span>
</td>
<td class="num">(41.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income taxes</a></td>
<td class="num">(58.9)<span></span>
</td>
<td class="num">(41.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (63.4)<span></span>
</td>
<td class="num">$ (41.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (1.20)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.20)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">53.0<span></span>
</td>
<td class="nump">48.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">53.0<span></span>
</td>
<td class="nump">48.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (63.4)<span></span>
</td>
<td class="num">$ (41.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(14.1)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (77.5)<span></span>
</td>
<td class="num">$ (41.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855957704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 642.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (491.9)<span></span>
</td>
<td class="nump">$ 1,133.5<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 615.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(532.9)<span></span>
</td>
<td class="nump">1,148.3<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">53.0<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 781.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(682.9)<span></span>
</td>
<td class="nump">1,469.2<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(63.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">$ (14.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">53.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 723.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (746.3)<span></span>
</td>
<td class="nump">$ 1,488.3<span></span>
</td>
<td class="num">$ (18.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840851784136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (63.4)<span></span>
</td>
<td class="num">$ (41.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of bond discounts/premiums</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of collaboration contract asset</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(22.6)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liability</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(21.2)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57.1)<span></span>
</td>
<td class="num">(39.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(263.2)<span></span>
</td>
<td class="num">(240.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">273.9<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and leasehold improvements</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="num">(207.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(46.0)<span></span>
</td>
<td class="num">(242.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="nump">112.8<span></span>
</td>
<td class="nump">588.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">66.8<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, equipment and leasehold improvements unpaid at period end</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturities of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromMaturitiesOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840854944824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and subsidiaries (&#8220;Arvinas&#8221; or &#8220;the Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (&#8220;SEC&#8221;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from Arvinas&#8217; audited consolidated financial statements at that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, forming part of Arvinas&#8217; 2021 Annual Report on Form 10-K filed with the SEC on February&#160;28, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products, and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future.  The Company has financed its operations primarily through sales of equity interests, proceeds from collaborations, grant funding and debt financing. The Company had cash, cash equivalents, restricted cash and marketable securities totaling $1.4 billion as of March&#160;31, 2022.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of the Coronavirus (&#8220;COVID-19&#8221;) Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, many companies have experienced disruptions in their operations and in the markets they serve. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company&#8217;s financial position and results of operations as of and for the three months ended March&#160;31, 2022. The full extent of the future impacts of COVID-19 on the Company&#8217;s operations remains uncertain. A prolonged outbreak could have a material adverse impact on the Company's financial results and business operations, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance its preclinical pipeline.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855161944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Pronouncements and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Accounting Pronouncements and Significant Accounting Policies</a></td>
<td class="text">Accounting Pronouncements and Significant Accounting Policies<div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviews</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new accounting standards as issued. As of March&#160;31, 2022, the Company has not identified any new standards that it believes will have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840854956840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreements</a></td>
<td class="text">Research Collaboration and License Agreements  <div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARV-471 Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) (the &#8220;ARV-471 Collaboration Agreement&#8221;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#8217;s proprietary compound ARV-471 (the &#8220;Licensed Products&#8221;). Under the ARV-471 Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0 million. In addition, the Company will be eligible to receive up to an additional $1.4 billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Pfizer will share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the ARV-471 Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9 million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $12.9 million in collaboration contract asset and other assets on the condensed consolidated balance sheet at inception of the agreement, which is being amortized as general and administrative expense over the total estimated period of performance under the ARV-471 Collaboration Agreement.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the &#8220;Bayer Collaboration Agreement&#8221;) setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC&#174; targeted protein degraders, that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company&#8217;s technology license. Bayer is committed to fund an additional $12.0 million through 2023, of which of $10.5&#160;million was received through March&#160;31, 2022. These payments are being recognized over the total estimated period of performance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no development or sales-based milestone payments or royalties received as of March&#160;31, 2022.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Research Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the &#8220;Pfizer Research Collaboration Agreement&#8221;). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. During the three months ended March&#160;31, 2022, the Company received payments totaling $3.5 million, which was included in accounts receivable at December 31, 2021, for an additional target and additional services which are being recognized as revenue over the total period of performance. There were no sales-based milestone payments or royalties received as of March&#160;31, 2022.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genentech Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the &#8220;Genentech Modification&#8221;) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement. Under the Genentech Modification, the Company received additional upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement) to fund Genentech-related research. Under the Genentech Modification, Genentech has the right to designate up to ten targets. The Company is eligible to receive up to $27.5 million in additional expansion target payments if Genentech exercises its options on all remaining targets. Upfront non-refundable payments are recognized as revenue over the total estimated period of performance. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $44.0 million per target in development milestone payments, $52.5 million in regulatory milestone payments and $60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received as of March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about changes in the Company's contract balances for the three months ended March&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">719.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of March&#160;31, 2022 was $719.4 million, which is expected to be recognized in the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">150.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">190.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">719.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration And License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855123656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Marketable Securities and Fair Value Measurements</a></td>
<td class="text">Marketable Securities and Fair Value Measurements <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities consist of corporate bonds and government securities which are adjusted to fair value at each balance sheet date based on quoted prices, which are considered Level 2 inputs. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities measured at fair value on a recurring basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 - 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">797.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.9)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">793.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">525.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">511.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 - 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,384.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,366.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">784.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.7)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">783.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">582.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">578.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,398.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,394.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts receivable, accounts payable and accrued expenses approximate their </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values due to the short-term nature of these assets and liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840854958760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Leasehold Improvements</a></td>
<td class="text">Property, Equipment and Leasehold Improvements <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following at:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $1.5 million and $1.1 million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855115880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Right-of-Use Assets and Liabilities</a></td>
<td class="text">Right-of-Use Assets and Liabilities<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate ranges from 3.0% - 4.1%. Lease expense is recognized on a straight-line basis over the lease term. Some of the Company&#8217;s leases include options to extend or terminate the lease. The Company includes these options in the recognition of the Company&#8217;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise such options.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a lease for approximately 160,000 square feet of laboratory and office space to be occupied in 2024. In connection with the signing of the lease, and at the Company&#8217;s election to increase the landlord&#8217;s contribution to the tenant improvement allowance, the Company issued a letter of credit for $4.5 million, collateralized by a certificate of deposit in the same amount, which is presented as restricted cash at March&#160;31, 2022. Once occupied, the base rent will range from $7.7 million to $8.8 million annually over a ten-year lease term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than January&#160;31, 2026. The leases have a weighted average remaining term of 3.1 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for operating leases as of March&#160;31, 2022, are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840854983320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855117272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into an additional Assistance Agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through 2028, with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received. At March&#160;31, 2022, $1.0 million remains outstanding under the 2018 Assistance Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an Assistance Agreement with the State of Connecticut entered into in 2014 (the &#8220;2014 Assistant Agreement&#8221;) under which all the borrowings by the Company were forgiven, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $2.5 million plus liquidated damages of 7.5%. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt for the years ending December&#160;31 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, interest expense was immaterial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840854985752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Distribution Agreements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp; Company (&#8220;Piper Sandler&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $300.0 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the common stock registered under the Company's universal shelf registration statement pursuant to one or more &#8220;at-the-market" offering. During the quarter ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March&#160;31, 2022, no shares have been issued under this agreement.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the &#8220;2018 ESPP&#8221;), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company&#8217;s common stock. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2018 ESPP increase, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company&#8217;s then-outstanding common stock, effective as of January 1 of each year. As of March&#160;31, 2022, 2,005,714 shares remained available for purchase. During the three months ended March&#160;31, 2022 and 2021, the Company issued 5,749 and 12,050 shares, respectively, of common stock under the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incentive Share Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Fourth Amendment to the Company&#8217;s Incentive Share Plan (the &#8220;Incentive Plan&#8221;) adopted in March 2018, the Company was authorized to issue up to an aggregate of 6,199,477 incentive units pursuant to the terms of the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNDkwNA_c8db3740-5782-4c3e-b75d-6ff6aad14517">one</span> to four years. The Incentive Plan was terminated in September 2018. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Stock Incentive Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s board of directors adopted, and the Company&#8217;s stockholders approved, the 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s initial public offering. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement expired, terminated or were otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and including, the fiscal year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company&#8217;s common stock, 4% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the year or an amount determined by the Company&#8217;s board of directors. As of March&#160;31, 2022, 2,849,537 shares remained available for issuance under the 2018 Plan. Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or canceled without having been fully exercised or are forfeited in whole or in part shall be available for future grants of awards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, the Company recognized compensation expense of $16.6 million and $10.3 million, respectively, relating to the issuance of incentive awards. At March&#160;31, 2022, there was $93.1 million of unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately two years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during the three months ended March&#160;31, 2022 and 2021 was determined using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.2 - 76.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">77.4 - 78.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.6 - 7.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.6 - 7.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5% - 2.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5% - 1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$64.19 - $78.91</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$77.51 - $82.21</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the Company&#8217;s common stock has not been trading for a sufficient period of time, the Company calculates volatility of its common stock by utilizing a weighted average of a collection of peer company volatilities and its own common stock volatility. The expected term is calculated utilizing the simplified method. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Term (Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,343,254&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.98&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,234,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(117,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(101,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,359,174&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">137.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exercisable at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,739,009&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">103.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2022 was $43.02. The total intrinsic value of options exercised during the three months ended March&#160;31, 2022 was $5.9 million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there were 5,995,790 stock options under the 2018 Plan that have vested or are expected to vest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock award activity under the Incentive Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include restricted stock granted to employees, directors and consultants.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,625&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,929&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there were 5,810 restricted shares under the Incentive Plan that are expected to vest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity under the 2018 Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include restricted stock units granted to employees. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock units at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">88,307&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.02&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">167,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock units at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">214,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there were 174,335 restricted stock units under the 2018 Plan that have vested or are expected to vest.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855008840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate was 7.6% and 0.0% for the three months ended March&#160;31, 2022 and 2021, respectively. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended March&#160;31, 2022 and the Company&#8217;s overall effective tax rate of 7.6% was the effect of equity compensation, deferred state income taxes and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended March&#160;31, 2021 and the Company&#8217;s overall effective tax rate of 0.0% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company is expecting to have net taxable income for the current year, resulting in current income tax expense for the period, and </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expects to fully utilize its net operating loss and credit carryforwards during the year. This is primarily due to revenue recognition for tax purposes from the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ARV-471 Collaboration Agreement</span> and the capitalization of qualified research and development expenses incurred on or after January 1, 2022. Under the Tax Cuts and Jobs Act of 2017, qualified research expenses incurred after 2021 are no longer immediately deductible for tax purposes and instead must be amortized over at least five years for tax purposes. A valuation allowance has been established against the Company&#8217;s net deferred tax assets, including the deferred tax liabilities resulting from the deferred revenue and deferred tax assets associated with the capitalization of research and development expenses for tax, since the Company expects to incur tax losses again after the current year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855120072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(63.4)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41.0)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average number of common shares outstanding</span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;- basic and diluted</span></div></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53.0&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48.6&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net loss per common share </span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">-  basic and diluted</span></div></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.20)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.84)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the three months ended March&#160;31, 2022 and 2021, and therefore excluded all stock options, restricted stock awards and restricted stock units from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855008840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments</a></td>
<td class="text">Equity Method Investments<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company and Bayer CropScience LP (&#8220;Bayer LP&#8221;) formed a joint venture, Oerth Bio LLC (&#8220;Oerth&#8221;), to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. As Oerth is jointly controlled by the Company and Bayer LP, the Company accounts for its 50% interest using the equity method of accounting.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides to Oerth compensated research and development services and administrative services through a separate agreement. The services rendered by the Company during the three months ended March&#160;31, 2022 and 2021 were immaterial.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses and net loss of Oerth for the three months ended March&#160;31, 2022 and 2021 totaled $4.9 million</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $2.6 million, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he investment has been reduced to zero and, as a result, no additional losses were recorded against the carrying value of the investment during the three months ended March&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855074648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Contract Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about changes in the Company's contract balances for the three months ended March&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">719.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Transaction Price Allocated to Performance Obligations</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of March&#160;31, 2022 was $719.4 million, which is expected to be recognized in the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">150.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">190.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">719.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration And License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855134248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available-for-Sale Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities measured at fair value on a recurring basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 - 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">797.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.9)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">793.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">525.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">511.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 - 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,384.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,366.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">784.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.7)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">783.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">582.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">578.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,398.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,394.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855177096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Equipment and Leasehold Improvements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following at:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840857965432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for operating leases as of March&#160;31, 2022, are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855008120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840856063256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Minimum Future Payments on Long-Term Debt</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt for the years ending December&#160;31 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840857888456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during the three months ended March&#160;31, 2022 and 2021 was determined using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.2 - 76.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">77.4 - 78.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.6 - 7.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.6 - 7.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5% - 2.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5% - 1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$64.19 - $78.91</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$77.51 - $82.21</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Term (Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,343,254&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.98&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,234,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(117,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(101,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,359,174&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">137.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exercisable at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,739,009&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">103.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Restricted Stock Grant Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock award activity under the Incentive Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include restricted stock granted to employees, directors and consultants.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,625&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,929&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity under the 2018 Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include restricted stock units granted to employees. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock units at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">88,307&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.02&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">167,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested restricted stock units at March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">214,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840852951256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Loss per Common Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(63.4)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41.0)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average number of common shares outstanding</span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;- basic and diluted</span></div></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53.0&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48.6&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net loss per common share </span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">-  basic and diluted</span></div></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.20)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.84)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Securities Excluded From Computation of Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the three months ended March&#160;31, 2022 and 2021, and therefore excluded all stock options, restricted stock awards and restricted stock units from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855162504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details)<br> $ in Billions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities', window );">Cash, cash equivalents, restricted cash and marketable securities</a></td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash and Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840847297464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>Target</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront non-refundable payment and certain additional payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract', window );">Collaboration agreement direct and incremental costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Regulatory and Sales-Based Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Regulatory Milestone Related to Marketing Approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales Based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront non-refundable payment and certain additional payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales Based Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Option Payments To License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Research Funding Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Research Funding Payments | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Development Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront non-refundable payment and certain additional payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Sales Based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront non-refundable payment and certain additional payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Sales Based Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront non-refundable payment and certain additional payments received</a></td>
<td class="nump">$ 34,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement', window );">Additional upfront non-refundable amount received under previous agreement</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NumberOfMaximumDesignatedTargets', window );">Number of designated targets | Target</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Regulatory Milestone Related to Marketing Approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Option Payments To License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront non-refundable payment and certain additional payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional upfront non-refundable amount received under previous agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration contract asset and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct and incremental costs incurred to obtain the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DirectAndIncrementalCostsIncurredToObtainTheContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfMaximumDesignatedTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of maximum designated targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfMaximumDesignatedTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_RegulatoryAndSalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_RegulatoryAndSalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855258136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Summary of Contract Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward', window );"><strong>Accounts receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease', window );">Payments received</a></td>
<td class="num">(15.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward', window );"><strong>Contract assets: Collaboration contract asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Beginning balance</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease', window );">Amortization</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Ending balance</a></td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities: Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">740.6<span></span>
</td>
<td class="nump">45.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from balances held at the beginning of the period</a></td>
<td class="num">(24.2)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements', window );">Additions to collaboration agreements</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 719.4<span></span>
</td>
<td class="nump">$ 42.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, After Allowance For Credit Loss, Current, Period Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Accounts Receivable, after Allowance for Credit Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Collaboration Contract Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration contract asset and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Contract Asset And Other Assets, Period Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840853085096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 719.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 150.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 190.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 136.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 100.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 63.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2027-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 34.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2028-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 44.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840848390824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details) - Level 2 - Fair Value, Measurements, Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,384.8<span></span>
</td>
<td class="nump">$ 1,398.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(18.7)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,366.1<span></span>
</td>
<td class="nump">1,394.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Corporate Bonds One Maturing 2022-2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">797.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">793.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Corporate Bonds Maturing 2023-2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">525.7<span></span>
</td>
<td class="nump">582.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(14.2)<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">511.5<span></span>
</td>
<td class="nump">578.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Government Securities Maturing 2022-2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">41.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">41.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Government Securities Maturing 2023-2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Corporate Bonds Maturing 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">784.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">783.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Government Securities Maturing 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840851725448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">$ 25.6<span></span>
</td>
<td class="nump">$ 23.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(12.2)<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840854002360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840851699768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Additional Information (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Lease for laboratory and office space | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities', window );">Letter of credit for collateralized by certificate of deposit</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_BaseLeaseRentPeriod', window );">Base rent lease term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments', window );">Percentage of incremental borrowing for lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Base rent</a></td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments', window );">Percentage of incremental borrowing for lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Base rent</a></td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_BaseLeaseRentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base lease rent period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_BaseLeaseRentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of incremental borrowing for lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfIncrementalBorrowingForLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the date of the latest financial statement presented of securities which are owned but transferred to serve as collateral for letter of credit arrangements, and for which the transferee does not have the right by contract or custom to sell or re-pledge them to an unrelated party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855236312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840854128648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract', window );"><strong>Supplemental non-cash information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new lease obligations</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental non-cash information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SupplementalNonCashInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840852720504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840847222440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 18.4<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee expenses</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and other</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 30.2<span></span>
</td>
<td class="nump">$ 23.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840851966376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember', window );">2018 Assistance Agreement | State of Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_DebtInstrumentLoanForgiveness', window );">Loan forgiveness</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument bearing interest rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_DebtInstrumentInterestPaymentsTerm', window );">Debt instrument interest payments term (in months)</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PercentageOfLiquidatedDamages', window );">Percentage of liquidated damages</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember', window );">2014 Assistance Agreement | State of Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PercentageOfLiquidatedDamages', window );">Percentage of liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentInterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest payments term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentInterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfLiquidatedDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of liquidated damages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfLiquidatedDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840852615576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_LongTermDebtMaturityYearSix', window );">2028</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_LongTermDebtMaturityYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, Year Six</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_LongTermDebtMaturityYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840848295224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Incentive units authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,199,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">$ 10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan | Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber', window );">Restricted shares expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,067,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,849,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase in reserved shares as percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock options vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,995,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber', window );">Restricted stock units vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based award, vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Annual increase in reserved shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,989,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based award, vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2018 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock', window );">Common stock reserved for issuance represented as percentage on outstanding common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,005,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,749<span></span>
</td>
<td class="nump">12,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common | Equity Distribution Agreement | At-the-Market Offering | Piper Sandler and Cantor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_MaximumAggregateOfferingPriceOfCommonStock', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_MaximumAggregateOfferingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate offering price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_MaximumAggregateOfferingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, restricted shares expected to vest, exercisable number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award restricted stock units vested and expected to vest exercisable number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PiperSandlerAndCantorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PiperSandlerAndCantorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840848238168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">73.20%<span></span>
</td>
<td class="nump">77.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 64.19<span></span>
</td>
<td class="nump">$ 77.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 78.91<span></span>
</td>
<td class="nump">$ 82.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840853163272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Stock Option Activity (Details) - 2018 Plan<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">5,343,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,234,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(117,399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(101,525)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">6,359,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, ending balance (in shares) | shares</a></td>
<td class="nump">2,739,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 44.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">65.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">17.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">57.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">49.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 31.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (in years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding | $</a></td>
<td class="nump">$ 137.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable | $</a></td>
<td class="nump">$ 103.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840848206136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Restricted Stock Grant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan | Restricted stock awards | Employees, Directors and Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">30,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(23,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(1,320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">5,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">16.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">16.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | Restricted stock units | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">88,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">167,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(38,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(3,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">214,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">64.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">19.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">21.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 55.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_EmployeesDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_EmployeesDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840853984744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate, percentage</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effect of equity compensation valuation allowance recorded against net deferred tax assets, percentage</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855196440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Loss per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (63.4)<span></span>
</td>
<td class="num">$ (41.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic (in shares)</a></td>
<td class="nump">53.0<span></span>
</td>
<td class="nump">48.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted (in shares)</a></td>
<td class="nump">53.0<span></span>
</td>
<td class="nump">48.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (1.20)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.20)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840848193368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139840855987352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 63,400,000<span></span>
</td>
<td class="nump">$ 41,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth | Equity Method Investment, Nonconsolidated Investee or Group of Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">4,900,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember', window );">Bayer LP | Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, summarized financial information, operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>arvn-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arvn="http://www.arvinas.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arvn-20220331.xsd" xlink:type="simple"/>
    <context id="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i298bddf478094dbe96ea9820c24d31b6_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i25a3253dc54e4eac92fd34e0a563037a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9805af17bb1e4148957b4b787a17b462_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i325b2c55e24f4d3085397ec2a20a3663_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia371b6c494bd486eba4eb8f874aac24d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic08ce866c4b94f27be498b6f213dedf4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibdded53975a5429895fe70fedb812866_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64cdb93492594796ae0fafa8520ff6ef_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8e87a608f4fe4e9fba87219c47ddd422_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i466a50b5c0114bcea592e1b1334a0324_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie9ab3a4e1902404387845f936fedb097_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a3d030a19ea49da95e47ac71dec2969_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib69f4662e8e8448abec08c5f3b291024_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1a46859c40274bc9b50db4b08d11374e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib4c768bfb30f454d8c3b8dedd536434c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ife15238ba3aa438e92145e6ce7fce7e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79edb451b83c41328adf8b4f80baea6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i695ecd5938c4493b80a441194c7f13f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41e39a8922e54876b257e31ace35e9dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6bd9ddc02dc48188e9e3137a9f8178d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id5dd562c52e04ac296e9718c72c905ce_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i99c6e27ac8b742a493910e355bca12b4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8e38918aafc24219a8eb691051421674_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6bc3521706e841c982eab94aeac4cc7b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia234f753bb3e4302ab5a9e1282401b5e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6b8bae6e224e4a98adadcf7e3210eb8f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4f6edb80919d4576ac9bb041310aa949_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i431cda9cb00645c88fdbc954baf2ad13_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia2998b237d8c4cc5b5cfbfbbe55bd80a_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="if8cc818798e540e78ab7b7c156e4fbc2_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryAndSalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="icf1b8a28931b4231b16a210b71e519f8_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="iaa2e9fa2922c461da7d579a31613e064_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i4532b7b853b44517abe2e4b76db69a39_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i68c017139446444892ba5b5141397092_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0da6cc0567c949ee99cc3823d7769be9_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i961fd92786d94a7bb50d58b8ec7d663f_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="if8f6a7fb4f9d4e3dba2515d41bb60d59_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7429a91425d84698be06a86197d0ffc8_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ibb8bc2b78c234516bd399c4cb1c0fb36_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id06d955e966b4215b1e8175bf00c3521_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i18bd65fbf8f4463899c17a0bdfe66d8d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i179e7109d53d425a903964aede9fad1f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ieae46787668d404b9768ffd8422cf730_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9ff207795b444585941a6e4f1d28bb9b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7b01340ddf614d96910de55cc1e88eab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i489172a8ff124366a130239025bbf1c6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3b0348777d704a5a973250876179db45_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e203cfdd5884e8d9b9a0ab5f0fabd0d_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i06908e112e7d405b9415d441e9bdb200_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iab85607423a442d5a33914e00073dd49_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i36dff9a96749481b9449da6624996bb1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if28802bd397f467aaea1a72ce7ce0c76_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0638c95ee09d4cd68aeefe4b785026d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1a386ef91f34522865c79b14ea0b285_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie20688dc77174b7f82b8e1f0419169f7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2aa7f1a0cfca4e97964f782ad3f98919_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i102061bc526443889b82c4150e2f488c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i882466d699264682b0f4ba252c12d5e5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4345a91c389b4360afb19c57116d7ac2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i310b023a39314b88848d936e4457d7e7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3ed48a9634a74706aa50054bf2177c4f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic25cf701d1374c4c9ab79f7036a6ab1e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i95d305fe2172466ab61fdf2e1b9c22b3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2ca9825bcc0c4b3cba9688ebc7c3599c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i57a0f6dd7ca44f28ac6939f93d4228da_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ife24052b16484996b2ccebc986eefddf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i248d829d7548451dae53a9e40b3985ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic556a60245544ecf94e8f539795821fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e68c26befb7440a88ac95a1480a49a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e17a2a0dd9d408188b1eea507950135_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idd25500d0c7946cab2bb104a0d38fbdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c11d105fc7e43e8abf3b8464ed2b242_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2432c4a5e7ba4d1ea0e0080e009e226b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e050c23b5444aae82eec5a8826e74b9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iea03b274b37a4adb984dd693b64b3f6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d23fd19f97f40e78883b6aa5fea051f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib57b0b1255a54112b386652ff3e4aa50_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i209db759fd014857b8ce446bc1b613a2_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i3ea0fe2f906848acb4fdf90217135445_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i44a11df340c6411ab9d44c8a5bdca3b6_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ie80d3e8623984738bd827627643f522d_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ib76a16c4b82e4fc1afb937c6900e150c_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i4935b90c90e34bf6b3aed0f1df6f02ee_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i73790ff93f1f4e57acc10cab17dc2e89_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i0dd70cc9b901409ab550af0ec999338f_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i060bd9cd585847318e2f9ad13a0d80e6_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i5cddce78d1d948c5b583d717cd77e28a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45363eaf411f4c0fa67bd782a95bcb4c_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ib22a7c97a95649208e3e16626fb046fa_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="i102371b1a4f74f1989575feb5349c7e8_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i9d11b00f18034e2faf571d32e08733be_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i6baa8537a2484bdcbd212331111a5ab2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i283e92babacf44249b5ac15c0401dae2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2fcf33d6545f49979c8996508f1dafdc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic72afe64f6d942ceaec3f2bcea014191_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ibc8c5780bba44a3ea641915dda767963_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i49ed2e413afc4936a46c5ae2d54150a8_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i135de9f10c6a4846ba8e3bd9311c3aaf_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i6380e9eea75f4e87923e1958591b5177_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="if4075817b88149f4ad4be9a0e24f00bd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i671442cf18e9459a9ae011753dc2baf4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i676daf315860494fae1a0db23d870397_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2a028511c76147dfa9eea3ef963d7391_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i22436d4d6b37470dae576ae029c13e17_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i433048cb8a22434c9c966ee4a08d5783_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i61acd713861543de9a324e7901c946b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i89b128b20436420eb6e8f593916c4d49_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic0183429203148f5b51f86ce4175b9db_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i671f93d65ec949f6a09add626b9cc77d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idfe72e9e1d7f4ef38b63abc9e9247aa6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4067c8a18e3a462ab80648a7b2f71e05_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id6884606b15a4b1c92ccbbd8551ca251_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i649860d7edd84bfdb3be6ff127c824e6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i98d32989f98049b98b156c00b715a0f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i28d56097cbd64f55a89cefb5e23f4fdd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a949a59544846bea32da66debdc0f5c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id20769d0f7ab420fb3b232e6d0b967fe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8e513085eec343c4b787da47473ad4c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i70ebb09ff5e84d1aa19beee9d199a829_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i726c996b1f294aea83f7646f6c212dd2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i07f988855484455ab096cd4c3443153c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icf87072bef5a4f5cbbe0ef6ae8aee71b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0b1f35859d641bd8934d7229fc923b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1a02298ba683464096a7a075d1fbb1bb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0e55da3f43bb49b19eed56be6d2f98be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i834d98020bdd4bcca28aae792703f6b0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i870a90a229974cd0bf199bf46c04b252_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i300ed13406744d99b22892681909ed10_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i32f56e3363e742a0b334906ca508739d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4c01ec64eb01468487ce85da6539107d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i333e000cdba54a2482be61ecd1dd9dbb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3073ab7967df4bf8a4f22af60b4b3306_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia7f17d29e95941cbb2f7dfbf46b84035_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="target">
        <measure>arvn:Target</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80L2ZyYWc6NzVlYmYxOWE1ODA2NGJjOTkxMTU2YTk1Njc5NTIzY2QvdGFibGU6NzdhNWMyZTllYWRkNGI2MGIxZmY1M2NhMDEzZWRjMWMvdGFibGVyYW5nZTo3N2E1YzJlOWVhZGQ0YjYwYjFmZjUzY2EwMTNlZGMxY18yLTEtMS0xLTIwODM3_8a648472-c68f-4329-925b-6864536a481a">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80L2ZyYWc6NzVlYmYxOWE1ODA2NGJjOTkxMTU2YTk1Njc5NTIzY2QvdGFibGU6NzdhNWMyZTllYWRkNGI2MGIxZmY1M2NhMDEzZWRjMWMvdGFibGVyYW5nZTo3N2E1YzJlOWVhZGQ0YjYwYjFmZjUzY2EwMTNlZGMxY18zLTEtMS0xLTIwODM3_afe56cf2-48de-4d16-91fc-d561ad737fd9">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80L2ZyYWc6NzVlYmYxOWE1ODA2NGJjOTkxMTU2YTk1Njc5NTIzY2QvdGFibGU6NzdhNWMyZTllYWRkNGI2MGIxZmY1M2NhMDEzZWRjMWMvdGFibGVyYW5nZTo3N2E1YzJlOWVhZGQ0YjYwYjFmZjUzY2EwMTNlZGMxY180LTEtMS0xLTIwODM3_f5342113-e18b-4bf8-8e78-c5589c497420">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80L2ZyYWc6NzVlYmYxOWE1ODA2NGJjOTkxMTU2YTk1Njc5NTIzY2QvdGFibGU6NzdhNWMyZTllYWRkNGI2MGIxZmY1M2NhMDEzZWRjMWMvdGFibGVyYW5nZTo3N2E1YzJlOWVhZGQ0YjYwYjFmZjUzY2EwMTNlZGMxY181LTEtMS0xLTIwODM3_5f3c7dbd-6fff-42ac-8690-1d951f52a660">0001655759</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80L2ZyYWc6NzVlYmYxOWE1ODA2NGJjOTkxMTU2YTk1Njc5NTIzY2QvdGFibGU6NzdhNWMyZTllYWRkNGI2MGIxZmY1M2NhMDEzZWRjMWMvdGFibGVyYW5nZTo3N2E1YzJlOWVhZGQ0YjYwYjFmZjUzY2EwMTNlZGMxY182LTEtMS0xLTIwODM3_cd6e7184-9a7f-440a-bdd1-0c48da238327">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="id1a386ef91f34522865c79b14ea0b285_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfMS0xLTEtMS0yMDgzNw_6375aae0-27d1-4f54-8417-90e64372bcae">P9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ie20688dc77174b7f82b8e1f0419169f7_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfMi0xLTEtMS0yMDgzNw_bab45435-a7df-450e-a878-2d14b023e52b">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i2aa7f1a0cfca4e97964f782ad3f98919_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfMy0xLTEtMS0yMDgzNw_d6b795df-ed92-42e6-a514-11678be91fca">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i102061bc526443889b82c4150e2f488c_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfNC0xLTEtMS0yMDgzNw_b8f8c67d-b006-4032-b917-2cd9ca2ab2e7">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i882466d699264682b0f4ba252c12d5e5_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfNS0xLTEtMS0yMDgzNw_9032550b-3bca-4f78-95c7-1474270b4f02">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i4345a91c389b4360afb19c57116d7ac2_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfNi0xLTEtMS0yMDgzNw_33cd66c6-0f27-41f6-bfae-768ad3b8aff5">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i310b023a39314b88848d936e4457d7e7_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80Ni9mcmFnOjBmOThhNTA2MjRkYzQ2NzdhMDEwNmI5NmFmZDRmZTNlL3RhYmxlOjMxMWFmZWQxMTNkNTQ4YmI4YTI0NGIxM2M1MTdkY2I5L3RhYmxlcmFuZ2U6MzExYWZlZDExM2Q1NDhiYjhhMjQ0YjEzYzUxN2RjYjlfNy0xLTEtMS0yMDgzNw_d4fea663-e22f-4a4a-9e2e-3bea1e3d6421"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibc8c5780bba44a3ea641915dda767963_D20180301-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNDkwNA_c8db3740-5782-4c3e-b75d-6ff6aad14517">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTUx_4064c2f0-c694-4691-a96b-2b321ff9e870">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6OWQ1OGRmZTY4YzcwNGQ2NDk4NmEwOWFkMzA4MjczN2IvdGFibGVyYW5nZTo5ZDU4ZGZlNjhjNzA0ZDY0OTg2YTA5YWQzMDgyNzM3Yl8wLTAtMS0xLTIwODM3_0d5f0a45-abc7-4004-938a-8ec8b79b9a81">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8xNjQ5MjY3NDQzODU1_95d2c6b1-de55-49ff-9cfb-304e1b36d8d9">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NjZkMzc3OGQ5MTAzNGJjMmFiNWFiYmRkYzJmOTg2YzIvdGFibGVyYW5nZTo2NmQzNzc4ZDkxMDM0YmMyYWI1YWJiZGRjMmY5ODZjMl8wLTAtMS0xLTIwODM3_173628a6-ea0f-42f5-abae-73cfd3303494">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTQ2_4ea6d77d-b805-4212-842a-8579e8cc59c1">001-38672</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTUy_9ef89422-2c2c-402c-9401-bbd6ad0ebf38">ARVINAS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8wLTAtMS0xLTIwODM3_64c4369b-adfe-43e0-9d86-a581f2dcb64e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8wLTEtMS0xLTIwODM3_adafb64f-6abc-4426-8809-383fd364e195">47-2566120</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8yLTAtMS0xLTIwODM3L3RleHRyZWdpb246NDA1MDc2ZjVhMDFhNDUzYzllNjViYTA0ZTE1ZmViMTNfNQ_7e42c30c-979f-4f2c-b9f7-e194064d039e">5 Science Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8yLTAtMS0xLTIwODM3L3RleHRyZWdpb246NDA1MDc2ZjVhMDFhNDUzYzllNjViYTA0ZTE1ZmViMTNfOQ_a225eef4-c23d-4d0e-9db4-49e130fd6bbb">395 Winchester Ave</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8yLTAtMS0xLTIwODM3L3RleHRyZWdpb246NDA1MDc2ZjVhMDFhNDUzYzllNjViYTA0ZTE1ZmViMTNfMTQ_b4e33654-40b8-4dae-9145-f8c14bde3edd">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8yLTAtMS0xLTIwODM3L3RleHRyZWdpb246NDA1MDc2ZjVhMDFhNDUzYzllNjViYTA0ZTE1ZmViMTNfMTg_35e28594-2939-407e-b9cf-14b5ef04b530">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6NzE5YjllMzliNGZhNGY0N2IyMDc2MmFjNGYxMTcyNTIvdGFibGVyYW5nZTo3MTliOWUzOWI0ZmE0ZjQ3YjIwNzYyYWM0ZjExNzI1Ml8yLTEtMS0xLTIwODM3_42c9aff9-8a27-4376-9d1f-6b93afcbb9f7">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTUz_cfcc814c-423d-45da-951f-edb3bd46b64e">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTQ3_d5225101-d1eb-4853-a598-e2b18374af3e">535-1456</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ODQ0NjJjZDA2Nzg4NDY2NzlhYzE1NDg3OTAxYjI3MWMvdGFibGVyYW5nZTo4NDQ2MmNkMDY3ODg0NjY3OWFjMTU0ODc5MDFiMjcxY18xLTAtMS0xLTIwODM3_9cb9a92c-6d52-4391-8f00-671b5e507bee">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ODQ0NjJjZDA2Nzg4NDY2NzlhYzE1NDg3OTAxYjI3MWMvdGFibGVyYW5nZTo4NDQ2MmNkMDY3ODg0NjY3OWFjMTU0ODc5MDFiMjcxY18xLTItMS0xLTIwODM3_5b9395b0-b9fb-4634-a782-4ea1e8135524">ARVN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ODQ0NjJjZDA2Nzg4NDY2NzlhYzE1NDg3OTAxYjI3MWMvdGFibGVyYW5nZTo4NDQ2MmNkMDY3ODg0NjY3OWFjMTU0ODc5MDFiMjcxY18xLTQtMS0xLTIwODM3_f2257590-e464-4715-8307-2f2ebdba96df">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8xNjQ5MjY3NDQzOTI0_21f1838f-c0fb-412b-ba3a-ae652c519fc0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8xNjQ5MjY3NDQzOTI1_11233275-596c-4a51-bea7-75ab7b3c9373">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ZmJkNGNjNjBmMzFlNDM1NDlkNmI2MTc2NTk4ZjMzMTEvdGFibGVyYW5nZTpmYmQ0Y2M2MGYzMWU0MzU0OWQ2YjYxNzY1OThmMzMxMV8wLTAtMS0xLTIwODYy_3cfe9a70-9de1-47ab-8613-17b6b4438d0f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ZmJkNGNjNjBmMzFlNDM1NDlkNmI2MTc2NTk4ZjMzMTEvdGFibGVyYW5nZTpmYmQ0Y2M2MGYzMWU0MzU0OWQ2YjYxNzY1OThmMzMxMV8xLTMtMS0xLTIwODM3_1509dbb4-c00b-4684-bae3-e6ad032476f4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGFibGU6ZmJkNGNjNjBmMzFlNDM1NDlkNmI2MTc2NTk4ZjMzMTEvdGFibGVyYW5nZTpmYmQ0Y2M2MGYzMWU0MzU0OWQ2YjYxNzY1OThmMzMxMV8yLTMtMS0xLTIwODM3_2dd5e6cb-733a-4710-892d-0daf2f9ba23c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8yMTQ4_75e801ca-41e2-4b90-b14d-dba9e143a26c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i298bddf478094dbe96ea9820c24d31b6_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xL2ZyYWc6YmZmMTA3NjVkNTFlNDAxODkyNTAxMzhkOGU5NmVhZWEvdGV4dHJlZ2lvbjpiZmYxMDc2NWQ1MWU0MDE4OTI1MDEzOGQ4ZTk2ZWFlYV8xNjQ5MjY3NDQzODcz_8cad88b1-afe9-4529-8046-c19312a2bfa5"
      unitRef="shares">53165962</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMy0xLTEtMS0yMDgzNw_19556ade-b602-4295-8b3b-ab93d651b845"
      unitRef="usd">62300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMy0zLTEtMS0yMDgzNw_0f75a892-8622-49c6-993f-26a4dac23f60"
      unitRef="usd">108300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNC0xLTEtMS0yMDgzNw_8245f05f-1f1d-45eb-954a-50782d57e913"
      unitRef="usd">4500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNC0zLTEtMS0yMDgzNw_d4a69809-c777-428e-9c71-fe3cb9e6e393"
      unitRef="usd">4500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNS0xLTEtMS0yMDgzNw_51fd8a4b-8a0a-4205-a29a-10bdfd17277a"
      unitRef="usd">1366100000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNS0zLTEtMS0yMDgzNw_c0271a52-c991-4b2c-8465-e2196f2f5c47"
      unitRef="usd">1394300000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNi0xLTEtMS0yMDgzNw_4683b266-5f18-4237-9130-8897efdb2f94"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNi0zLTEtMS0yMDgzNw_d783c23c-bdec-41f4-891a-f4ec92cf89d4"
      unitRef="usd">15000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNy0xLTEtMS0yMDgzNw_206d05a6-bbc3-4720-87bd-d9f73ac8974f"
      unitRef="usd">6700000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfNy0zLTEtMS0yMDgzNw_0b7f3516-56fd-40a3-a128-b7cab1d80c89"
      unitRef="usd">10700000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfOC0xLTEtMS0yMDgzNw_c1428128-cbdb-40f4-861d-c41098766a56"
      unitRef="usd">17400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfOC0zLTEtMS0yMDgzNw_e1c74dcd-62a7-4961-8e2d-ba9a1652303d"
      unitRef="usd">19700000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfOS0xLTEtMS0yMDgzNw_350668d2-d6ab-4679-b6c7-6703e735c56f"
      unitRef="usd">1457000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfOS0zLTEtMS0yMDgzNw_07413802-a565-47de-815c-9c2e946ec85f"
      unitRef="usd">1552500000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTAtMS0xLTEtMjA4Mzc_6b764d39-be0e-472d-9064-86dab06866a7"
      unitRef="usd">13400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTAtMy0xLTEtMjA4Mzc_ac618b18-9c7e-4aca-816f-ac399ee46871"
      unitRef="usd">12700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTEtMS0xLTEtMjA4Mzc_78470bc0-96cd-43fb-b3d3-4af95397f6ef"
      unitRef="usd">5800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTEtMy0xLTEtMjA4Mzc_1742eeae-2042-4853-ae60-5ca8a923c26b"
      unitRef="usd">3900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTItMS0xLTEtMjA4Mzc_670f9d1f-9ad1-41ac-b924-e79525a3dc06"
      unitRef="usd">12100000</arvn:CollaborationContractAssetAndOtherAssets>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTItMy0xLTEtMjA4Mzc_ee7a8cd7-e210-4520-99fd-b8459cca364d"
      unitRef="usd">12500000</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:Assets
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTMtMS0xLTEtMjA4Mzc_44bba137-60bd-4f45-944b-2dae958981f7"
      unitRef="usd">1488300000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTMtMy0xLTEtMjA4Mzc_6d7f4884-b0f4-4c1d-b5ba-569a4ac9cf13"
      unitRef="usd">1581600000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTYtMS0xLTEtMjA4Mzc_436ec88c-2c64-42cd-904f-f158cb2fb933"
      unitRef="usd">8600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTYtMy0xLTEtMjA4Mzc_5dc4c07f-9673-464a-bbd8-d3b74870c381"
      unitRef="usd">31300000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTctMS0xLTEtMjA4Mzc_b79def8e-8370-4e8f-86c0-51eef9e112c1"
      unitRef="usd">30200000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTctMy0xLTEtMjA4Mzc_6e0f3ec2-1d3a-47aa-8bcc-dfd2c99cc480"
      unitRef="usd">23100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTgtMS0xLTEtMjA4Mzc_de8936c0-3845-4af9-aa3c-d08b38d2476d"
      unitRef="usd">197500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTgtMy0xLTEtMjA4Mzc_84f8a1a1-65d3-4dd6-bbbb-471003026439"
      unitRef="usd">206200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTktMS0xLTEtMjA4Mzc_fa513f25-756f-4a55-9880-f169181d35b8"
      unitRef="usd">1700000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMTktMy0xLTEtMjA4Mzc_d1d791f0-5b70-474f-8a01-233861bb5d8b"
      unitRef="usd">1100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjAtMS0xLTEtMjA4Mzc_33aac8a4-358b-496b-9191-4081e0c17e96"
      unitRef="usd">238000000.0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjAtMy0xLTEtMjA4Mzc_5398c1ca-9e75-427e-a7fb-2d04d05b51c1"
      unitRef="usd">261700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjEtMS0xLTEtMjA4Mzc_8bb82385-acb9-45a1-94e6-7f3849e9255a"
      unitRef="usd">521900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjEtMy0xLTEtMjA4Mzc_b8ed97a8-8d77-4ed5-bc9c-c1bfcf58435d"
      unitRef="usd">534300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjItMS0xLTEtMjA4Mzc_edcfd2cc-0b69-4cbb-8472-08737ff750ff"
      unitRef="usd">1000000.0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjItMy0xLTEtMjA4Mzc_16d2dc54-6b8f-42e8-8ac5-a66ad3146dd0"
      unitRef="usd">1000000.0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjMtMS0xLTEtMjA4Mzc_7e4c11b4-a2b1-4d17-9aae-1dc926f88833"
      unitRef="usd">4100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjMtMy0xLTEtMjA4Mzc_abfa783c-59ff-4a44-b044-b9da61e9f958"
      unitRef="usd">2900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjQtMS0xLTEtMjA4Mzc_6d72adc0-f72c-4f7e-ad29-e3b8a0513223"
      unitRef="usd">765000000.0</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjQtMy0xLTEtMjA4Mzc_4ea89b10-21d8-4619-a78a-1ee10521f902"
      unitRef="usd">799900000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjUtMS0xLTEtMjA4Mzc_57f32fd3-2ace-4b9d-80c8-bdbe42aa7baa"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjUtMy0xLTEtMjA4Mzc_55231700-288f-47b3-8726-8d6a4ad4bde1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl8xOQ_06f810a6-c1f1-46dd-94aa-9a3589976d4b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl8xOQ_2513f3c0-3dc5-4dd6-b55e-e42266508b21"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl85MzQ1ODQ4ODM2MjI2_423cf8bf-0e8e-46ad-bf31-61897b665563"
      unitRef="shares">53100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl85MzQ1ODQ4ODM2MjI2_a814da7d-4e13-4c44-af54-d20616e21d29"
      unitRef="shares">53100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl85MzQ1ODQ4ODM2MjIy_a0b920a3-834f-4d88-9b90-4c5ad251c483"
      unitRef="shares">53000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMC0xLTEtMjA4MzcvdGV4dHJlZ2lvbjpmZWIyMDE0ZTBkMGU0Mzc4ODIwMDY2ODY1YjcwODE5Yl85MzQ1ODQ4ODM2MjIy_f79464a7-a5b9-4d87-bd8f-83ec4dbf3f64"
      unitRef="shares">53000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMS0xLTEtMjA4Mzc_0e5001df-e6b9-4a9e-949a-2c080a3658ec"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjctMy0xLTEtMjA4Mzc_8dce893e-11f5-4ad8-8844-2a5456db4ebe"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjgtMS0xLTEtMjA4Mzc_2e502757-d5d9-4e0b-a47a-3ea0c962aee5"
      unitRef="usd">-746300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjgtMy0xLTEtMjA4Mzc_565423bd-faca-4258-976b-157b3d495c1d"
      unitRef="usd">-682900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjktMS0xLTEtMjA4Mzc_f82f4eff-7ce1-439a-83c7-4ac31b566011"
      unitRef="usd">1488300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMjktMy0xLTEtMjA4Mzc_f8031ed5-98ce-464c-9e71-84307cc84916"
      unitRef="usd">1469200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzAtMS0xLTEtMjA4Mzc_d814cece-6acd-4d67-b887-4b3cb6583176"
      unitRef="usd">-18700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzAtMy0xLTEtMjA4Mzc_7f2a267a-f7f2-463c-a04f-33e1fc803190"
      unitRef="usd">-4600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzEtMS0xLTEtMjA4Mzc_7a048b3d-bd6a-40f7-8833-37b9c4f46314"
      unitRef="usd">723300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzEtMy0xLTEtMjA4Mzc_d19d032d-b140-4940-9f1f-cf6714dba1c1"
      unitRef="usd">781700000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzItMS0xLTEtMjA4Mzc_267865d6-b093-442a-be45-c1b64773d52a"
      unitRef="usd">1488300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8xOS9mcmFnOmRmYzhiNzgwMTFkZTQ1NGFiZWMxN2JlODk5MmE0Mjk3L3RhYmxlOmZjZDNkZGQ5NGIwOTQ0MzNiYTNmMzdiZWQzZGRlYjRmL3RhYmxlcmFuZ2U6ZmNkM2RkZDk0YjA5NDQzM2JhM2YzN2JlZDNkZGViNGZfMzItMy0xLTEtMjA4Mzc_09096e78-fa91-4185-ad39-47ca8de0c658"
      unitRef="usd">1581600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMi0xLTEtMS0yMDgzNw_d5891d75-b3f5-44cb-9c3f-900839b52016"
      unitRef="usd">24200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMi0zLTEtMS0yMDgzNw_3ed0d905-e673-4ea7-a3d0-2c5ac51fbf30"
      unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNC0xLTEtMS0yMDgzNw_b3992245-996b-434e-aba8-1a0548fa2477"
      unitRef="usd">64000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNC0zLTEtMS0yMDgzNw_6652b330-fc7d-4e5c-9d00-c9e929ecae41"
      unitRef="usd">34900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNS0xLTEtMS0yMDgzNw_ff343dd6-4ee3-46ff-8db2-07fdf61c90ae"
      unitRef="usd">20200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNS0zLTEtMS0yMDgzNw_554ae67c-a508-4744-a34b-ea7865d5cccb"
      unitRef="usd">12300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNi0xLTEtMS0yMDgzNw_d8fe1056-3445-426f-9fd6-931e21146646"
      unitRef="usd">84200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNi0zLTEtMS0yMDgzNw_78930013-8617-4197-8338-e8939bda5436"
      unitRef="usd">47200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNy0xLTEtMS0yMDgzNw_660e54a8-b7cc-4658-9fb9-2f2a556eb24b"
      unitRef="usd">-60000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfNy0zLTEtMS0yMDgzNw_abc6e002-071e-4050-9f3d-7da55185ebb4"
      unitRef="usd">-41700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfOS0xLTEtMS0yMDgzNw_4db02d9e-6444-41d3-a446-8735fc0609d2"
      unitRef="usd">-100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfOS0zLTEtMS0yMDgzNw_df24ca16-ff53-4482-98ec-c3ed252a7131"
      unitRef="usd">200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTAtMS0xLTEtMjA4Mzc_7983560f-9cef-4d0b-9782-147d050ccfbd"
      unitRef="usd">1200000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTAtMy0xLTEtMjA4Mzc_3ef3a033-c824-4298-a1bf-c3077e81a532"
      unitRef="usd">500000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTItMS0xLTEtMjA4Mzc_56a5c81d-4e43-4643-a175-8871cd5fd0d0"
      unitRef="usd">1100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTItMy0xLTEtMjA4Mzc_458890d1-1040-4bbe-bf13-ec109d8eba3a"
      unitRef="usd">700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTMtMS0xLTEtMjU1NTA_a5c006d8-0f94-4b7b-b864-4a563bbfd4e5"
      unitRef="usd">-58900000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTMtMy0xLTEtMjU1NTA_722841dc-24d0-4a0d-a173-2c35dce1dfe4"
      unitRef="usd">-41000000.0</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMS0xLTEtMjU1NTA_337b7fbc-8f9f-4001-8e3b-ec42f2ef993c"
      unitRef="usd">4500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMy0xLTEtMjU1NTA_9a593ea8-6f3c-4a70-a780-2237775d41db"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTMtMS0xLTEtMjA4Mzc_f00d7240-6f2d-4b28-aaba-ff9889341130"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTMtMy0xLTEtMjA4Mzc_aad210f9-10b6-432d-87fd-d7adb57d59a0"
      unitRef="usd">-41000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMS0xLTEtMjA4Mzc_89df1570-a9cd-4bca-9ddd-c7dbd0486877"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMS0xLTEtMjA4Mzc_b2979a19-9b0e-43d8-9981-ed56442e5a05"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMy0xLTEtMjA4Mzc_99d3f1aa-cea6-4cd3-841a-1e607dd0195f"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTQtMy0xLTEtMjA4Mzc_f7079a8d-1643-4de1-96f9-a02611f53a60"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTUtMS0xLTEtMjA4Mzc_85ac847a-f618-4930-8c8c-a0f7e26d9e23"
      unitRef="shares">53000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTUtMS0xLTEtMjA4Mzc_e95a855f-fe3b-4271-a553-308a1750f667"
      unitRef="shares">53000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTUtMy0xLTEtMjA4Mzc_2b21cf41-e740-4d03-9902-9258e56b0341"
      unitRef="shares">48600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yMi9mcmFnOmJkMWQ2NTIxMzMzNzQ3ZDhiYTU2N2Q4NjZiYTZhNTc3L3RhYmxlOjAwMGMzODllZTc5MjQyOTBiM2Y3NmY5MjA5NGFjYjE2L3RhYmxlcmFuZ2U6MDAwYzM4OWVlNzkyNDI5MGIzZjc2ZjkyMDk0YWNiMTZfMTUtMy0xLTEtMjA4Mzc_37ba2093-ab35-4d99-8c26-e1cb56e5880c"
      unitRef="shares">48600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfMi0xLTEtMS0yMDgzNw_e275535b-0ab7-433f-96cb-63b54baa6ba5"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfMi0zLTEtMS0yMDgzNw_0be15ac7-4b2e-4e03-b65f-6404384bd4a2"
      unitRef="usd">-41000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfNC0xLTEtMS0yMDgzNw_3d870d01-203d-4d03-b0ed-bc98eae205aa"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfNC0zLTEtMS0yMDgzNw_31856354-8d36-4c68-9912-569994269636"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfNS0xLTEtMS0yMDgzNw_e72f7f7b-eeb1-498c-8d5d-528d2e5ba9ad"
      unitRef="usd">-77500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yNS9mcmFnOjFkNzU1ZTgzMWJkZTQzYWFhOWJlNWQ3ZTEyNWRiOGU0L3RhYmxlOmM3MzczMDgzMzYwNzQ4MmQ4MThhYzk3OWZlMjEzODg3L3RhYmxlcmFuZ2U6YzczNzMwODMzNjA3NDgyZDgxOGFjOTc5ZmUyMTM4ODdfNS0zLTEtMS0yMDgzNw_e43ab475-9bad-4f28-bebb-c5f269701dad"
      unitRef="usd">-41800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i325b2c55e24f4d3085397ec2a20a3663_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi0xLTEtMS0yMDgzNw_61f86174-d022-444b-816b-d082a98a3e1a"
      unitRef="shares">53000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i325b2c55e24f4d3085397ec2a20a3663_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi0zLTEtMS0yMDgzNw_6e793bd8-01c6-426b-ad2c-4da3c252d3f2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia371b6c494bd486eba4eb8f874aac24d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi01LTEtMS0yMDgzNw_474d2488-ebb9-4293-a282-eb535aaa4e8b"
      unitRef="usd">-682900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic08ce866c4b94f27be498b6f213dedf4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi03LTEtMS0yMDgzNw_44644f1c-376d-41de-b5ae-a93bb9a89450"
      unitRef="usd">1469200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdded53975a5429895fe70fedb812866_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi05LTEtMS0yMDgzNw_2fae3b10-f489-4460-986d-315447e8a4ef"
      unitRef="usd">-4600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMi0xMS0xLTEtMjA4Mzc_9d04acc3-b9e0-4599-bb99-e80d6f43a864"
      unitRef="usd">781700000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i64cdb93492594796ae0fafa8520ff6ef_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMy03LTEtMS0yMDgzNw_2a9d7ebf-0d1f-4448-a64f-7e70dc98ff49"
      unitRef="usd">16600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMy0xMS0xLTEtMjA4Mzc_839103b6-528c-4d73-877d-b884733e216e"
      unitRef="usd">16600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i8e87a608f4fe4e9fba87219c47ddd422_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfNC01LTEtMS0yMDgzNw_4bc50ddd-6a17-4db0-bb0d-986cb8d969b2"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfNC0xMS0xLTEtMjA4Mzc_3f5160a9-2560-4984-9b1e-efe9a698b421"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i466a50b5c0114bcea592e1b1334a0324_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfNi0xLTEtMS0yMDgzNw_c8914daa-b23c-45d9-b4e9-ffe8a8dab473"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i64cdb93492594796ae0fafa8520ff6ef_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfNi03LTEtMS0yMDgzNw_67a3e8c8-4f15-4b7b-b3e1-32aa52ada126"
      unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfNi0xMS0xLTEtMjA4Mzc_ddab3603-2567-41a8-841b-83a6769c5b87"
      unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie9ab3a4e1902404387845f936fedb097_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOC05LTEtMS0yMDgzNw_909c9b69-53b4-4293-a21a-25dab4e24345"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOC0xMS0xLTEtMjA4Mzc_f13428c1-4949-468a-b6ea-9c4c976f39aa"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3a3d030a19ea49da95e47ac71dec2969_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS0xLTEtMS0yMDgzNw_69e8a440-cb53-49d4-9f7b-262c61c99d56"
      unitRef="shares">53100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3a3d030a19ea49da95e47ac71dec2969_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS0zLTEtMS0yMDgzNw_03447c35-668f-440c-853f-e2395828de68"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib69f4662e8e8448abec08c5f3b291024_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS01LTEtMS0yMDgzNw_39e2caca-f27f-4ec6-b964-fc846784ae7b"
      unitRef="usd">-746300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a46859c40274bc9b50db4b08d11374e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS03LTEtMS0yMDgzNw_0293485e-a039-4af1-be92-1ca0d7f13334"
      unitRef="usd">1488300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4c768bfb30f454d8c3b8dedd536434c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS05LTEtMS0yMDgzNw_6d3275d9-4c9c-4861-b403-3c9d406a56f1"
      unitRef="usd">-18700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfOS0xMS0xLTEtMjA4Mzc_fdb9e445-e724-4fe7-a561-c3ce211dca10"
      unitRef="usd">723300000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ife15238ba3aa438e92145e6ce7fce7e7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTAtMS0xLTEtMjA4Mzc_3a544740-500f-4f04-a5e1-db2a6daa85a1"
      unitRef="shares">48500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i79edb451b83c41328adf8b4f80baea6f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTAtNS0xLTEtMjA4Mzc_7ce559d7-d163-485c-8975-137041629b12"
      unitRef="usd">-491900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i695ecd5938c4493b80a441194c7f13f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTAtNy0xLTEtMjA4Mzc_e945a221-c555-410b-866d-197330a426bd"
      unitRef="usd">1133500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41e39a8922e54876b257e31ace35e9dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTAtOS0xLTEtMjA4Mzc_9b3556bb-fc1a-4d4e-ae9a-5464b21109f0"
      unitRef="usd">600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTAtMTEtMS0xLTIwODM3_f3d9e4dd-c079-4da2-b222-1d7346f3ef54"
      unitRef="usd">642200000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if6bd9ddc02dc48188e9e3137a9f8178d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTEtNy0xLTEtMjA4Mzc_6179b880-a732-4d99-b11f-ec9d1fa4ab7a"
      unitRef="usd">10300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTEtMTEtMS0xLTIwODM3_fbd9df9e-9424-4f45-b43e-829e42bec6e7"
      unitRef="usd">10300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="id5dd562c52e04ac296e9718c72c905ce_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTItNS0xLTEtMjA4Mzc_36fcf1a1-decd-4287-a82f-a4b0f3ce1672"
      unitRef="usd">-41000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTItMTEtMS0xLTIwODM3_d7f676a6-7dbb-4a3f-8266-e9a5b45782a9"
      unitRef="usd">-41000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i99c6e27ac8b742a493910e355bca12b4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTMtMS0xLTEtMjA4Mzc_fe3724d8-b6ef-4d4e-9f17-c1e8c3572d63"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTMtMTEtMS0xLTIwODM3_8376ce46-169a-4187-ab04-b7f54d75ef6f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i99c6e27ac8b742a493910e355bca12b4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTQtMS0xLTEtMjA4Mzc_8f071e93-a1bd-417e-b852-4489e9eae8b6"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if6bd9ddc02dc48188e9e3137a9f8178d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTQtNy0xLTEtMjA4Mzc_14901a27-a665-42a1-83d3-aaeb270e6a83"
      unitRef="usd">4500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTQtMTEtMS0xLTIwODM3_e5b370ce-7427-4295-b1cf-0e1cd3d8a8a9"
      unitRef="usd">4500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8e38918aafc24219a8eb691051421674_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTYtOS0xLTEtMjA4Mzc_f9559f71-9087-46bb-a78a-00814c8de891"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTYtMTEtMS0xLTIwODM3_4fb6ef44-84f7-47eb-8fa9-7519c8a25fbf"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6bc3521706e841c982eab94aeac4cc7b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctMS0xLTEtMjA4Mzc_fa7f0508-8afa-448c-b8d0-1260afab85e6"
      unitRef="shares">48800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6bc3521706e841c982eab94aeac4cc7b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctMy0xLTEtMjA4Mzc_599bcc6e-d028-4892-9ac5-03a12aca55b1"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia234f753bb3e4302ab5a9e1282401b5e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctNS0xLTEtMjA4Mzc_7c14911c-995b-477d-ac88-640c6cab799e"
      unitRef="usd">-532900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b8bae6e224e4a98adadcf7e3210eb8f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctNy0xLTEtMjA4Mzc_eb70b3d8-a6c7-4fda-8af1-dcee2a8d85aa"
      unitRef="usd">1148300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f6edb80919d4576ac9bb041310aa949_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctOS0xLTEtMjA4Mzc_26e222c0-b316-46c4-857a-806fb649bbd8"
      unitRef="usd">-200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i431cda9cb00645c88fdbc954baf2ad13_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8yOC9mcmFnOjc3NWI3NzRkNTVhYjQ1ZDA4NWI4OGRhM2NlNWIwZGI5L3RhYmxlOmE1NGJjZjcwYmY3ZDQ5ZWY4OWNiYTczNzc2NjMzYTcwL3RhYmxlcmFuZ2U6YTU0YmNmNzBiZjdkNDllZjg5Y2JhNzM3NzY2MzNhNzBfMTctMTEtMS0xLTIwODM3_5a97c28b-a5e4-4e63-93f0-32c9d3a8bc71"
      unitRef="usd">615200000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMy0xLTEtMS0yMDgzNw_79e45f39-7137-48c5-8702-23405a946a0e"
      unitRef="usd">-63400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMy0zLTEtMS0yMDgzNw_a3d7de30-3fb5-40e9-9de2-b493966f4631"
      unitRef="usd">-41000000.0</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfNS0xLTEtMS0yMDgzNw_89bc87b8-4432-4d96-9820-56aba0381c90"
      unitRef="usd">1500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfNS0zLTEtMS0yMDgzNw_36cb332c-39ee-4f74-8fbe-bac40994c908"
      unitRef="usd">1100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfNi0xLTEtMS0yMDgzNw_196b766d-833c-4633-9f21-5122357f4d30"
      unitRef="usd">-3300000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfNi0zLTEtMS0yMDgzNw_52aa1c23-0df9-4ff7-bc1c-e3d2f44db8ee"
      unitRef="usd">-1000000.0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfOS0xLTEtMS0yMDgzNw_3683cb03-b5c3-442b-ab60-539c4ce5c8d7"
      unitRef="usd">600000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfOS0zLTEtMS0yMDgzNw_b4aff522-66a3-4844-8807-e086efa2963d"
      unitRef="usd">300000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTAtMS0xLTEtMjA4Mzc_f10b934e-f183-41d2-b118-ad0e8fca4e0e"
      unitRef="usd">300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTAtMy0xLTEtMjA4Mzc_af9cc870-ae5b-4a7a-8659-66f7167547ca"
      unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTEtMS0xLTEtMjA4Mzc_a1b4c41f-f98c-4bd7-aa56-20e31c3c4b91"
      unitRef="usd">16600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTEtMy0xLTEtMjA4Mzc_ff750bdf-5364-44c1-8626-264201e78fcc"
      unitRef="usd">10300000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTMtMS0xLTEtMjA4Mzc_c8552dab-56e1-480c-850c-2bdf4887fc58"
      unitRef="usd">-15000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTMtMy0xLTEtMjA4Mzc_8cbd306e-21f5-4320-8a12-795896b9f3c8"
      unitRef="usd">-1000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTQtMS0xLTEtMjA4Mzc_ea02efa9-91e4-436a-be3d-9fcef5543f84"
      unitRef="usd">-4100000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTQtMy0xLTEtMjA4Mzc_a39fa2b8-1809-4a37-86e1-51d65dedd1dd"
      unitRef="usd">-2300000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTUtMS0xLTEtMjA4Mzc_b36375f4-03cb-4b37-9e3d-aa92c8402c25"
      unitRef="usd">-2300000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTUtMy0xLTEtMjA4Mzc_e44a2d06-e07d-44ab-b88a-e950f936067b"
      unitRef="usd">2100000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTctMS0xLTEtMjA4Mzc_81dabe16-fd47-4815-bfe8-29c88f681aef"
      unitRef="usd">-22600000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTctMy0xLTEtMjA4Mzc_1439129d-153a-4c8c-9010-817bd84418f8"
      unitRef="usd">1800000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTgtMS0xLTEtMjA4Mzc_3742d2e9-d488-4550-90a0-a2294efa4477"
      unitRef="usd">7000000.0</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTgtMy0xLTEtMjA4Mzc_b4c7d91a-05a2-43a8-99ae-84977569ec42"
      unitRef="usd">-10900000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <arvn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTktMS0xLTEtMjA4Mzc_8ee22207-8b8c-44c0-86e1-fd547d88cbe6"
      unitRef="usd">-600000</arvn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <arvn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMTktMy0xLTEtMjA4Mzc_d1e96950-72f1-497d-b878-8925632945e7"
      unitRef="usd">-300000</arvn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjAtMS0xLTEtMjA4Mzc_64c1f53a-316f-4958-a329-7bfcade8398b"
      unitRef="usd">-21200000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjAtMy0xLTEtMjA4Mzc_f9d87955-6431-416c-bb56-3f05f90d5277"
      unitRef="usd">-2500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjEtMS0xLTEtMjA4Mzc_94ec76d1-299f-4f16-af28-d41d0bdc81b0"
      unitRef="usd">-57100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjEtMy0xLTEtMjA4Mzc_52fcb070-de2d-4608-92f9-1ffca6f94ed6"
      unitRef="usd">-39000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjMtMS0xLTEtMjA4Mzc_22c8830d-2772-4d0e-b966-1a387cdb0321"
      unitRef="usd">263200000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjMtMy0xLTEtMjA4Mzc_f50c0fbe-c000-4f1a-a3cb-a06830ce371f"
      unitRef="usd">240500000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjQtMS0xLTEtMjA4Mzc_ae7658f1-e679-4a1f-9233-ec3ca8406cf9"
      unitRef="usd">273900000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjQtMy0xLTEtMjA4Mzc_240c3bec-691c-4419-ac86-479c52ff98b6"
      unitRef="usd">33700000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjYtMS0xLTEtMjA4Mzc_8327ec0c-adde-4ab8-987a-69fd476bf3d6"
      unitRef="usd">2100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjYtMy0xLTEtMjA4Mzc_935245e1-13cf-4fd9-9315-79f7c3097197"
      unitRef="usd">1000000.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjctMS0xLTEtMjA4Mzc_52607cd7-a790-40c6-96f5-b618dc7ac2b3"
      unitRef="usd">8600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMjctMy0xLTEtMjA4Mzc_09fd6629-8078-4721-a0b6-795ea59afc8f"
      unitRef="usd">-207800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzEtMS0xLTEtMjA4Mzc_e75a7107-c55b-425e-b855-9769776b921b"
      unitRef="usd">2500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzEtMy0xLTEtMjA4Mzc_412819bf-9e20-4bf4-b6c2-28a348db0199"
      unitRef="usd">4500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzItMS0xLTEtMjA4Mzc_41d9e580-6967-4e8d-8260-732bfe86186e"
      unitRef="usd">2500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzItMy0xLTEtMjA4Mzc_e796d469-ed16-4507-85ad-8b0b2a55d3d9"
      unitRef="usd">4500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzMtMS0xLTEtMjA4Mzc_8f41d036-cf91-49a5-9740-f5a647be61d5"
      unitRef="usd">-46000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzMtMy0xLTEtMjA4Mzc_c2c6a69c-d89b-4e2a-b75c-b86d247fa36b"
      unitRef="usd">-242300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzQtMS0xLTEtMjA4Mzc_816ec28b-b124-4080-a83d-e7f210b5d260"
      unitRef="usd">112800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzQtMy0xLTEtMjA4Mzc_ac970c30-7c8c-47f9-ba04-a86621f23efc"
      unitRef="usd">588400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzUtMS0xLTEtMjA4Mzc_49881344-93b3-4bb3-8d0b-87e751ea024c"
      unitRef="usd">66800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i431cda9cb00645c88fdbc954baf2ad13_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzUtMy0xLTEtMjA4Mzc_3e904089-c704-4d8e-8154-6772188a1742"
      unitRef="usd">346100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzctMS0xLTEtMjA4Mzc_19e1d7f8-bf01-40dd-ba9a-9f3a6aed1734"
      unitRef="usd">100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zMS9mcmFnOmM3OGJkN2M2OTFkYTQ1NDg5OWVkOWViMTJkY2MyMzlkL3RhYmxlOjE2ZWY5OTMwMTk5OTRkZDZhZGU4MmQzNzQ2YmY4NzJkL3RhYmxlcmFuZ2U6MTZlZjk5MzAxOTk5NGRkNmFkZTgyZDM3NDZiZjg3MmRfMzctMy0xLTEtMjA4Mzc_41b14733-0e09-4b5b-9316-35ec84fa29c0"
      unitRef="usd">100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zNy9mcmFnOmM2NDk3NGFkNDlmMjQ5NmQ4NDVjNDg5MDllODhiYjZhL3RleHRyZWdpb246YzY0OTc0YWQ0OWYyNDk2ZDg0NWM0ODkwOWU4OGJiNmFfMjk3Ng_e2ba13bc-833d-4e37-8021-d6f8991bd19c">Nature of Business and Basis of Presentation&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arvinas, Inc. and subsidiaries (&#x201c;Arvinas&#x201d; or &#x201c;the Company&#x201d;) is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#x201c;Exchange Act&#x201d;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (&#x201c;SEC&#x201d;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from Arvinas&#x2019; audited consolidated financial statements at that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, forming part of Arvinas&#x2019; 2021 Annual Report on Form 10-K filed with the SEC on February&#160;28, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products, and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future.  The Company has financed its operations primarily through sales of equity interests, proceeds from collaborations, grant funding and debt financing. The Company had cash, cash equivalents, restricted cash and marketable securities totaling $1.4 billion as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impact of the Coronavirus (&#x201c;COVID-19&#x201d;) Pandemic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the COVID-19 pandemic, many companies have experienced disruptions in their operations and in the markets they serve. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company&#x2019;s financial position and results of operations as of and for the three months ended March&#160;31, 2022. The full extent of the future impacts of COVID-19 on the Company&#x2019;s operations remains uncertain. A prolonged outbreak could have a material adverse impact on the Company's financial results and business operations, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance its preclinical pipeline.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF8zNy9mcmFnOmM2NDk3NGFkNDlmMjQ5NmQ4NDVjNDg5MDllODhiYjZhL3RleHRyZWdpb246YzY0OTc0YWQ0OWYyNDk2ZDg0NWM0ODkwOWU4OGJiNmFfOTM0NTg0ODg0MDYyMQ_19d04983-0691-4d1a-a453-4491019363b4"
      unitRef="usd">1400000000</arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80MC9mcmFnOjk4ZjdiMTRjZWU2NTQ4NDU5OTViYzBlZTAwNGM3YWQwL3RleHRyZWdpb246OThmN2IxNGNlZTY1NDg0NTk5NWJjMGVlMDA0YzdhZDBfMzY5_97db9182-1aba-4123-a236-7b7ade6c2c6b">Accounting Pronouncements and Significant Accounting Policies&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reviews&lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;new accounting standards as issued. As of March&#160;31, 2022, the Company has not identified any new standards that it believes will have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no changes to the Company&#x2019;s significant accounting policies during the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzYwNA_c912e438-ed6f-45fb-8d2b-249e8c5bc4ba">Research Collaboration and License Agreements  &lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ARV-471 Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;) (the &#x201c;ARV-471 Collaboration Agreement&#x201d;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#x2019;s proprietary compound ARV-471 (the &#x201c;Licensed Products&#x201d;). Under the ARV-471 Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0 million. In addition, the Company will be eligible to receive up to an additional $1.4 billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Pfizer will share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a direct result of the Company&#x2019;s entry into the ARV-471 Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9 million. In accordance with ASC 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized an asset of $12.9 million in collaboration contract asset and other assets on the condensed consolidated balance sheet at inception of the agreement, which is being amortized as general and administrative expense over the total estimated period of performance under the ARV-471 Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bayer Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the &#x201c;Bayer Collaboration Agreement&#x201d;) setting forth the Company&#x2019;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC&#xae; targeted protein degraders, that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company&#x2019;s technology license. Bayer is committed to fund an additional $12.0 million through 2023, of which of $10.5&#160;million was received through March&#160;31, 2022. These payments are being recognized over the total estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There were no development or sales-based milestone payments or royalties received as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pfizer Research Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the &#x201c;Pfizer Research Collaboration Agreement&#x201d;). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#x2019;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. During the three months ended March&#160;31, 2022, the Company received payments totaling $3.5 million, which was included in accounts receivable at December 31, 2021, for an additional target and additional services which are being recognized as revenue over the total period of performance. There were no sales-based milestone payments or royalties received as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Genentech Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the &#x201c;Genentech Modification&#x201d;) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement. Under the Genentech Modification, the Company received additional upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement) to fund Genentech-related research. Under the Genentech Modification, Genentech has the right to designate up to ten targets. The Company is eligible to receive up to $27.5 million in additional expansion target payments if Genentech exercises its options on all remaining targets. Upfront non-refundable payments are recognized as revenue over the total estimated period of performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is eligible to receive up to $44.0 million per target in development milestone payments, $52.5 million in regulatory milestone payments and $60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about changes in the Company's contract balances for the three months ended March&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract assets: Collaboration contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract liabilities: Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;740.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions to collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;719.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of March&#160;31, 2022 was $719.4 million, which is expected to be recognized in the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;150.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;190.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;719.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ia2998b237d8c4cc5b5cfbfbbe55bd80a_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNTEw_697c860d-0322-4998-8e19-56d7b12bbf37"
      unitRef="usd">650000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="if8cc818798e540e78ab7b7c156e4fbc2_I20210731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNTg3_04f2f260-f838-4555-b192-12fad2199185"
      unitRef="usd">1400000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="icf1b8a28931b4231b16a210b71e519f8_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzMw_a2cb6b97-f19d-48b4-9c8d-f4db0d300e36"
      unitRef="usd">400000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="iaa2e9fa2922c461da7d579a31613e064_I20210731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzk3_f56bfbe3-da59-4f5b-885d-fcc15320c97d"
      unitRef="usd">1000000000</us-gaap:ContractWithCustomerAssetNet>
    <arvn:DirectAndIncrementalCostsIncurredToObtainTheContract
      contextRef="i4532b7b853b44517abe2e4b76db69a39_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfMzU2OQ_87933076-fbd3-49f8-af37-5693e11f05cc"
      unitRef="usd">12900000</arvn:DirectAndIncrementalCostsIncurredToObtainTheContract>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="i68c017139446444892ba5b5141397092_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfMzY2OQ_474f6617-45f7-4170-b21f-2beda1f8827b"
      unitRef="usd">12900000</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i0da6cc0567c949ee99cc3823d7769be9_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNDQ4Nw_08f72825-a3e0-4241-bcf2-c99d68d6556c"
      unitRef="usd">17500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i961fd92786d94a7bb50d58b8ec7d663f_I20231231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNDYzOA_dc124a69-cc30-48f6-8109-637736108095"
      unitRef="usd">12000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="if8f6a7fb4f9d4e3dba2515d41bb60d59_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzODc1Mw_bccdeee7-de2d-4518-84ab-145c13635d75"
      unitRef="usd">10500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i7429a91425d84698be06a86197d0ffc8_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzMDg0MQ_ccbaa29b-0310-4bb7-9ce2-a279133affc4"
      unitRef="usd">197500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ibb8bc2b78c234516bd399c4cb1c0fb36_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzMDg4OQ_f5de40aa-e6d7-4aee-9651-71290ac614a0"
      unitRef="usd">490000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="id06d955e966b4215b1e8175bf00c3521_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzMTE3Mw_0f8e8b3b-c77f-4ea9-8b8c-0c1a55f4ac17"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i18bd65fbf8f4463899c17a0bdfe66d8d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzMTE3Mw_b1933677-45fc-4879-b008-12b357fdc8e4"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i179e7109d53d425a903964aede9fad1f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNTkyNA_7977e394-1d1b-4d76-8095-74c2e1b2f30e"
      unitRef="usd">28000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ieae46787668d404b9768ffd8422cf730_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNTkyOA_38ab3c76-fe74-4ff5-a5d8-3b3fe4fa78df"
      unitRef="usd">37500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i9ff207795b444585941a6e4f1d28bb9b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNjExMQ_5e390f24-165e-4f66-af39-42912e820ed7"
      unitRef="usd">225000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i7b01340ddf614d96910de55cc1e88eab_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNjE1OQ_c7f1273f-c2bc-4687-91f1-7c3e6b84adeb"
      unitRef="usd">550000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i489172a8ff124366a130239025bbf1c6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNjkzNw_0635062f-e757-417f-8b45-ea8ba0dccc57"
      unitRef="usd">3500000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i3b0348777d704a5a973250876179db45_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNTE1Mw_d7b8006d-fcb9-4718-84bf-fefe6a4353db"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i9e203cfdd5884e8d9b9a0ab5f0fabd0d_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNjgzOQ_e80410e2-2b22-4da3-87ef-6882c5262128"
      unitRef="usd">34500000</us-gaap:ProceedsFromCollaborators>
    <arvn:AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement
      contextRef="i9e203cfdd5884e8d9b9a0ab5f0fabd0d_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNjg1OA_c1884c27-e5e0-4419-b507-32078149c41c"
      unitRef="usd">11000000</arvn:AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement>
    <arvn:NumberOfMaximumDesignatedTargets
      contextRef="i9e203cfdd5884e8d9b9a0ab5f0fabd0d_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzAxMw_10921100-830d-4b0e-a079-3ff7e7b72a8e"
      unitRef="target">10</arvn:NumberOfMaximumDesignatedTargets>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i06908e112e7d405b9415d441e9bdb200_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNzU4NQ_8ac610db-61c7-4344-b46d-9cf48ea364d8"
      unitRef="usd">27500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="iab85607423a442d5a33914e00073dd49_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNzgzOA_85603980-5305-42d0-b98f-0e1e226598ed"
      unitRef="usd">44000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i36dff9a96749481b9449da6624996bb1_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNzg4OA_22bf7b8f-fe39-49e0-ae33-5139f3463d80"
      unitRef="usd">52500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="if28802bd397f467aaea1a72ce7ce0c76_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzNzkyOQ_a88c370c-5567-4526-9fe9-2ea6c9381ded"
      unitRef="usd">60000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i0638c95ee09d4cd68aeefe4b785026d6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzAzODAzNg_20c4b72e-a630-4865-b2d0-d00161e4acc4"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzYwMg_24969c73-7936-4dca-834a-c6ca7f82b6cb">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about changes in the Company's contract balances for the three months ended March&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract assets: Collaboration contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract liabilities: Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;740.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions to collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;719.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMi0xLTEtMS0zNDc1Mw_d783c23c-bdec-41f4-891a-f4ec92cf89d4"
      unitRef="usd">15000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMi0zLTEtMS0zNDk3MA_b339aebe-fb9e-41a1-8a22-cb6607b94b18"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMy0xLTEtMS0zNDk3Mw_237790ad-1743-46ad-929b-05bbe8e6c892"
      unitRef="usd">-15000000.0</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMy0zLTEtMS0zNDk3MA_5bda23ff-24e0-4291-906f-ac44e83d43a1"
      unitRef="usd">0</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNC0xLTEtMS0zNDk3Mw_2c4d387f-4683-4576-b48b-a7ac35cc040f"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i431cda9cb00645c88fdbc954baf2ad13_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNC0zLTEtMS0zNDk3MA_79e204a6-7d44-4d5a-8d44-f245aa88997d"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNi0xLTEtMS0zNDk3NQ_0828d1e8-0791-4550-9802-c440736234bc"
      unitRef="usd">12500000</arvn:CollaborationContractAssetAndOtherAssets>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNi0zLTEtMS0zNDk3NQ_542f575d-c98e-4cd8-8c2c-9bed31589a04"
      unitRef="usd">0</arvn:CollaborationContractAssetAndOtherAssets>
    <arvn:CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNy0xLTEtMS0zNDc4Ng_801555be-405c-4542-ae44-a1158fb08054"
      unitRef="usd">-400000</arvn:CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease>
    <arvn:CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNy0zLTEtMS0zNDk3NQ_57a8ea7e-18ef-4e25-8f43-2145797a77d3"
      unitRef="usd">0</arvn:CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfOC0xLTEtMS0zNDk3NQ_6038fc88-93d9-45c1-8100-d0d138e94cab"
      unitRef="usd">12100000</arvn:CollaborationContractAssetAndOtherAssets>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="i431cda9cb00645c88fdbc954baf2ad13_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfOC0zLTEtMS0zNDk3NQ_a97151b5-b4a4-468a-9372-16783d80a851"
      unitRef="usd">0</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMS0xLTEtMS0zNDY3Nw_556827c7-58ff-453f-81c7-500368045f2f"
      unitRef="usd">740600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4c69f145e8d24e459c482e4c3e4b4d45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMTAtMy0xLTEtMzQ5Nzc_ec258c9b-40b1-42a0-9b51-9743fc1ab6e9"
      unitRef="usd">45100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMi0xLTEtMS0zNDY4MA_e4111376-01c6-4749-b27a-2c46fb0325b6"
      unitRef="usd">-24200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMTEtMy0xLTEtMzQ5Nzc_67fc0d73-ac4d-47f8-991a-cba18c77315c"
      unitRef="usd">-5500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMy0xLTEtMS0zNDY4Ng_73bdf976-88d8-4224-b8c1-14e3cd197829"
      unitRef="usd">3000000.0</arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMTItMy0xLTEtMzQ5Nzc_b75eb012-c869-41a8-9f97-1cf490effbe7"
      unitRef="usd">3000000.0</arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfNC0xLTEtMS0zNDY5Ng_e955cef7-b32d-4ecb-9b19-28e3f76dcc7c"
      unitRef="usd">719400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i431cda9cb00645c88fdbc954baf2ad13_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmJiMTcwY2RlZjgxYjQ4OTliNzI4ZjMyODRkMTk3NzQ1L3RhYmxlcmFuZ2U6YmIxNzBjZGVmODFiNDg5OWI3MjhmMzI4NGQxOTc3NDVfMTMtMy0xLTEtMzQ5Nzc_c7efa5eb-8510-448b-81f7-f623ad88559a"
      unitRef="usd">42600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfNzYwMw_75d2d12e-7370-434b-8683-066580fc3f9a">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of March&#160;31, 2022 was $719.4 million, which is expected to be recognized in the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;150.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;190.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;719.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RleHRyZWdpb246NGEwOWQyOTZjZTQ5NDFkY2I0YjhkNTFlNjJmNWI1NjFfODc5NjA5MzA0MDY3MQ_537dec3d-b734-400e-bacb-2a51515db046"
      unitRef="usd">719400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="id1a386ef91f34522865c79b14ea0b285_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfMC0xLTEtMS0yMDgzNw_aa98d425-f892-443e-b1fe-0a5a1bbe2858"
      unitRef="usd">150100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ie20688dc77174b7f82b8e1f0419169f7_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfMS0xLTEtMS0yMDgzNw_c4b16414-d34f-4297-989c-db9413a593af"
      unitRef="usd">190000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i2aa7f1a0cfca4e97964f782ad3f98919_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfMi0xLTEtMS0yMDgzNw_0631c054-128f-4e85-b9df-565d1b5c8143"
      unitRef="usd">136500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i102061bc526443889b82c4150e2f488c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfMy0xLTEtMS0yMDgzNw_752bc1e8-b42b-4270-8e93-863718c5f35a"
      unitRef="usd">100400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i882466d699264682b0f4ba252c12d5e5_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfNC0xLTEtMS0yMDgzNw_90a382c7-5187-4ab2-a589-b6a89b4415d1"
      unitRef="usd">63400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i4345a91c389b4360afb19c57116d7ac2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfNS0xLTEtMS0yMDgzNw_8ed69761-4350-44fb-8b15-36ead46c6403"
      unitRef="usd">34100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i310b023a39314b88848d936e4457d7e7_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfNi0xLTEtMS0yMDgzNw_8c5e8898-96af-4ae9-837e-24ab44fd0ef7"
      unitRef="usd">44900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80My9mcmFnOjRhMDlkMjk2Y2U0OTQxZGNiNGI4ZDUxZTYyZjViNTYxL3RhYmxlOmMwYzAxYjFmYjNiYTQyOTlhOWM0MGNhNmU2YTEyMjliL3RhYmxlcmFuZ2U6YzBjMDFiMWZiM2JhNDI5OWE5YzQwY2E2ZTZhMTIyOWJfNy0xLTEtMS0yMDgzNw_fd473969-e6ca-4848-9492-f50d5cc3f028"
      unitRef="usd">719400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RleHRyZWdpb246MWJiNWNmMjFkZmNlNDMyMWJkNjkxM2M2MGY0MmM3NzZfMzEzNg_c21f88eb-a8d9-4bd4-92bf-a140f82c7ee0">Marketable Securities and Fair Value Measurements &lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable securities consist of corporate bonds and government securities which are adjusted to fair value at each balance sheet date based on quoted prices, which are considered Level 2 inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities measured at fair value on a recurring basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Maturity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;797.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;793.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 - 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;525.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;511.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 - 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(18.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,366.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Maturity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;784.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;783.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 - 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;582.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;578.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,398.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of accounts receivable, accounts payable and accrued expenses approximate their &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RleHRyZWdpb246MWJiNWNmMjFkZmNlNDMyMWJkNjkxM2M2MGY0MmM3NzZfMzEzNw_f6de12f4-0836-436a-87e7-7f019cc090ae">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities measured at fair value on a recurring basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Maturity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;797.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;793.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 - 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;525.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;511.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 - 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(18.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,366.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Maturity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;784.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;783.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 - 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;582.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;578.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,398.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3ed48a9634a74706aa50054bf2177c4f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMi00LTEtMS0yMDgzNw_7d77eb7a-8d38-4b80-af3c-ba896436dc95"
      unitRef="usd">797800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3ed48a9634a74706aa50054bf2177c4f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMi02LTEtMS0yMDgzNw_9760dae9-b5ff-4b38-9674-dfdca6fcc17e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3ed48a9634a74706aa50054bf2177c4f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMi04LTEtMS0yMDgzNw_2a62743f-bc17-4665-8116-4cc427368801"
      unitRef="usd">3900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ed48a9634a74706aa50054bf2177c4f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMi0xMC0xLTEtMjA4Mzc_98247007-1e86-4f50-88f3-a4c70ed57c75"
      unitRef="usd">793900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic25cf701d1374c4c9ab79f7036a6ab1e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMy00LTEtMS0yMDgzNw_c599ab41-405d-4de3-8e4c-0b9dc99f2d49"
      unitRef="usd">525700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic25cf701d1374c4c9ab79f7036a6ab1e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMy02LTEtMS0yMDgzNw_1d70262d-b462-4bb4-8d7a-46880cdf3bde"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic25cf701d1374c4c9ab79f7036a6ab1e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMy04LTEtMS0yMDgzNw_b3c8d716-ca27-461c-9c14-21de951ec45e"
      unitRef="usd">14200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic25cf701d1374c4c9ab79f7036a6ab1e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfMy0xMC0xLTEtMjA4Mzc_63499a26-2b2e-434d-9dc2-bf047bc3330d"
      unitRef="usd">511500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i95d305fe2172466ab61fdf2e1b9c22b3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC02LTEtMS0yOTQ5MA_8ad598c5-36fe-4efd-be27-8d39e4611d87"
      unitRef="usd">41900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i95d305fe2172466ab61fdf2e1b9c22b3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC04LTEtMS0yOTQ5MA_058110fd-a070-44e5-b32f-3ae93ae54be5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i95d305fe2172466ab61fdf2e1b9c22b3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC0xMC0xLTEtMjk0OTA_01260710-407f-466c-875a-56bc0e701ed1"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95d305fe2172466ab61fdf2e1b9c22b3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC0xMi0xLTEtMjk0OTA_7238106e-d19f-47cc-99de-7e72d4e30487"
      unitRef="usd">41500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2ca9825bcc0c4b3cba9688ebc7c3599c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC00LTEtMS0yMDgzNw_61f2013b-3b6e-4c38-95e7-913b4d124eb6"
      unitRef="usd">19400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2ca9825bcc0c4b3cba9688ebc7c3599c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC02LTEtMS0yMDgzNw_f9edea6d-2711-44da-af6f-2469f5c713f2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2ca9825bcc0c4b3cba9688ebc7c3599c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC04LTEtMS0yMDgzNw_bc4e0bb7-24dd-4de2-be09-2458931cda18"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ca9825bcc0c4b3cba9688ebc7c3599c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNC0xMC0xLTEtMjA4Mzc_06c119ad-9ec8-4579-88df-1762e5f94842"
      unitRef="usd">19200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i57a0f6dd7ca44f28ac6939f93d4228da_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNS00LTEtMS0yMDgzNw_faa3ecaa-160a-42dd-a1c3-19450a644161"
      unitRef="usd">1384800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i57a0f6dd7ca44f28ac6939f93d4228da_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNS02LTEtMS0yMDgzNw_dc30ddb9-d54c-4e13-a077-47eb496a1de4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i57a0f6dd7ca44f28ac6939f93d4228da_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNS04LTEtMS0yMDgzNw_0ffea319-dd1b-44dc-afa0-953b7516e839"
      unitRef="usd">18700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57a0f6dd7ca44f28ac6939f93d4228da_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjYyMWNjZWFmMGRiNTQ3ZGY4N2NlZWY1ZDhiYzhlMDZlL3RhYmxlcmFuZ2U6NjIxY2NlYWYwZGI1NDdkZjg3Y2VlZjVkOGJjOGUwNmVfNS0xMC0xLTEtMjA4Mzc_d3d4410e-8ece-45df-b74b-1939aa472502"
      unitRef="usd">1366100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ife24052b16484996b2ccebc986eefddf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMi00LTEtMS0yMDgzNw_fbe1e186-e43f-4572-82eb-0344d8d528c6"
      unitRef="usd">784000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ife24052b16484996b2ccebc986eefddf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMi02LTEtMS0yMDgzNw_62117d34-d7fb-4989-b6e8-16b6a389d04f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ife24052b16484996b2ccebc986eefddf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMi04LTEtMS0yMDgzNw_d17f55d8-5063-48e1-bd11-c586d3512db6"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife24052b16484996b2ccebc986eefddf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMi0xMC0xLTEtMjA4Mzc_eaf5e57b-666b-4502-85a3-2f4a6960f554"
      unitRef="usd">783300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i248d829d7548451dae53a9e40b3985ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy02LTEtMS0yNzA4NQ_216f16fd-a410-4016-98fa-34d36cfbb9ab"
      unitRef="usd">582500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i248d829d7548451dae53a9e40b3985ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy04LTEtMS0yNzA4NQ_4591feb6-7162-4ce0-9772-d47c47b3ddfc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i248d829d7548451dae53a9e40b3985ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy0xMC0xLTEtMjcwODU_dc7e8b1a-ab31-4c4a-88f7-22a3508600f1"
      unitRef="usd">3800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i248d829d7548451dae53a9e40b3985ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy0xMi0xLTEtMjcwODU_e292948a-c11e-448e-a10f-a9bd44d63f26"
      unitRef="usd">578700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic556a60245544ecf94e8f539795821fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfNC02LTEtMS0yNzA4NQ_3fd59dc6-e6cc-4219-9bca-31e1163ffd1e"
      unitRef="usd">32400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic556a60245544ecf94e8f539795821fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfNC04LTEtMS0yNzA4NQ_4e8cb840-9855-4bc5-bd13-95eda2ade568"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic556a60245544ecf94e8f539795821fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfNC0xMC0xLTEtMjcwODU_547bebba-e9fc-44d1-8c7e-bb018f07fb3c"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic556a60245544ecf94e8f539795821fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfNC0xMi0xLTEtMjcwODU_5cc8fcb7-b7bf-4cab-8119-80bb8c5bdb89"
      unitRef="usd">32300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4e68c26befb7440a88ac95a1480a49a3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy00LTEtMS0yMDgzNw_c4682c15-2391-4ca6-818b-d14471275007"
      unitRef="usd">1398900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4e68c26befb7440a88ac95a1480a49a3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy02LTEtMS0yMDgzNw_1ec7b02c-b5e8-4ae2-98a0-c33e35b06c92"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4e68c26befb7440a88ac95a1480a49a3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy04LTEtMS0yMDgzNw_6cd375dc-9702-4bce-9f58-5144f82988cb"
      unitRef="usd">4600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e68c26befb7440a88ac95a1480a49a3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF80OS9mcmFnOjFiYjVjZjIxZGZjZTQzMjFiZDY5MTNjNjBmNDJjNzc2L3RhYmxlOjc3YWYzOGRkYThiYTQ2Njg4NzVmMWY3ODUxOGJiNmY3L3RhYmxlcmFuZ2U6NzdhZjM4ZGRhOGJhNDY2ODg3NWYxZjc4NTE4YmI2ZjdfMy0xMC0xLTEtMjA4Mzc_3c25aa33-4b88-40f3-b75a-67676f05a3c1"
      unitRef="usd">1394300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RleHRyZWdpb246MWIwMmIzYTk1NDBhNDllYjg0NjFmNzRlM2YxZTQ3ZDJfMzAz_c2d95188-bb3c-48ef-ab3c-e4295f908e48">Property, Equipment and Leasehold Improvements &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements consist of the following at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Property, equipment and leasehold improvements, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense totaled $1.5 million and $1.1 million for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RleHRyZWdpb246MWIwMmIzYTk1NDBhNDllYjg0NjFmNzRlM2YxZTQ3ZDJfMzA0_009cfa53-13dc-416c-ab0b-e4e894711280">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements consist of the following at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Property, equipment and leasehold improvements, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9e17a2a0dd9d408188b1eea507950135_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMS0xLTEtMS0yMDgzNw_b14b0320-8af4-49d5-9526-0749e02d0fdf"
      unitRef="usd">14900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idd25500d0c7946cab2bb104a0d38fbdb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMS0zLTEtMS0yMDgzNw_2fbb42c8-522b-4be9-812e-d5f64e331bc2"
      unitRef="usd">13600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5c11d105fc7e43e8abf3b8464ed2b242_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMi0xLTEtMS0yOTQ1OQ_6df727c6-1bf8-4cdd-af0c-5b4dbe04408e"
      unitRef="usd">9200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2432c4a5e7ba4d1ea0e0080e009e226b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMi0zLTEtMS0yOTQ1OQ_a74b0332-91e7-47c8-859f-3737300c6edf"
      unitRef="usd">8400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6e050c23b5444aae82eec5a8826e74b9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMi0xLTEtMS0yMDgzNw_9fa1dfa2-7b2e-46d5-b477-24fb1a51caed"
      unitRef="usd">1500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iea03b274b37a4adb984dd693b64b3f6c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfMi0zLTEtMS0yMDgzNw_15e6b4bb-48fa-40b1-ad94-92d88a7e7e78"
      unitRef="usd">1400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNC0xLTEtMS0yMDgzNw_59dff922-3f65-49ca-8715-5281f284c291"
      unitRef="usd">25600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNC0zLTEtMS0yMDgzNw_516516f8-7b52-48bd-9db3-a38e8fc66068"
      unitRef="usd">23400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNS0xLTEtMS0yMDgzNw_c32ca116-dae6-4ff6-8096-de6085ac7ed2"
      unitRef="usd">12200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNS0zLTEtMS0yMDgzNw_fad593b8-8e1d-4eac-ab1b-f26f627a780e"
      unitRef="usd">10700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNi0xLTEtMS0yMDgzNw_68e8405b-02da-4050-8f3b-2715c27e39d0"
      unitRef="usd">13400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RhYmxlOjE5OTE5ZDcxNmE1YTRlMGU4NTBlYmU4OWZjYjU4OTQxL3RhYmxlcmFuZ2U6MTk5MTlkNzE2YTVhNGUwZTg1MGViZTg5ZmNiNTg5NDFfNi0zLTEtMS0yMDgzNw_ac2d5422-c583-425a-89d0-605ad2db15b6"
      unitRef="usd">12700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RleHRyZWdpb246MWIwMmIzYTk1NDBhNDllYjg0NjFmNzRlM2YxZTQ3ZDJfMTgw_dbb33da8-bad2-41db-97f5-d061a862de0b"
      unitRef="usd">1500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81Mi9mcmFnOjFiMDJiM2E5NTQwYTQ5ZWI4NDYxZjc0ZTNmMWU0N2QyL3RleHRyZWdpb246MWIwMmIzYTk1NDBhNDllYjg0NjFmNzRlM2YxZTQ3ZDJfMTg3_35a8ff41-781f-40ed-9bcf-d87affaeed11"
      unitRef="usd">1100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjEwOQ_7b0681fa-2edb-4d98-8e6f-0a99961f69f1">Right-of-Use Assets and Liabilities&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate ranges from 3.0% - 4.1%. Lease expense is recognized on a straight-line basis over the lease term. Some of the Company&#x2019;s leases include options to extend or terminate the lease. The Company includes these options in the recognition of the Company&#x2019;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a lease for approximately 160,000 square feet of laboratory and office space to be occupied in 2024. In connection with the signing of the lease, and at the Company&#x2019;s election to increase the landlord&#x2019;s contribution to the tenant improvement allowance, the Company issued a letter of credit for $4.5 million, collateralized by a certificate of deposit in the same amount, which is presented as restricted cash at March&#160;31, 2022. Once occupied, the base rent will range from $7.7 million to $8.8 million annually over a ten-year lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than January&#160;31, 2026. The leases have a weighted average remaining term of 3.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Supplemental non-cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets obtained in exchange for new lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities for operating leases as of March&#160;31, 2022, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <arvn:PercentageOfIncrementalBorrowingForLeasePayments
      contextRef="i5d23fd19f97f40e78883b6aa5fea051f_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfODY2_6891fada-a55c-4d52-89cc-ccd29a9a1f27"
      unitRef="number">0.030</arvn:PercentageOfIncrementalBorrowingForLeasePayments>
    <arvn:PercentageOfIncrementalBorrowingForLeasePayments
      contextRef="ib57b0b1255a54112b386652ff3e4aa50_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfODcw_8849e24f-ef6f-4fcb-988d-f6b2a5654ef4"
      unitRef="number">0.041</arvn:PercentageOfIncrementalBorrowingForLeasePayments>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i209db759fd014857b8ce446bc1b613a2_I20210531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjE5OTAyMzI1NzcyMw_7bee4d18-1be9-45e6-b66c-c31b73f5b819"
      unitRef="sqft">160000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities
      contextRef="i209db759fd014857b8ce446bc1b613a2_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMTUyNg_fc6eec26-af89-4a56-84b4-d148d11e9232"
      unitRef="usd">4500000</us-gaap:PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities>
    <us-gaap:LeaseCost
      contextRef="i3ea0fe2f906848acb4fdf90217135445_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMTY4Mw_eba7eeae-6498-4a2d-a800-f329e1275208"
      unitRef="usd">7700000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i44a11df340c6411ab9d44c8a5bdca3b6_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMTY4OQ_17684a47-91e2-48e9-a403-3295c42ede89"
      unitRef="usd">8800000</us-gaap:LeaseCost>
    <arvn:BaseLeaseRentPeriod
      contextRef="ie80d3e8623984738bd827627643f522d_D20210501-20210531"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjExMA_2aceb46a-781b-47f0-b6c0-0d7edb294139">P10Y</arvn:BaseLeaseRentPeriod>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMTkwMQ_6c779a8f-590a-43fb-9eed-7d420ef239ca">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjEwNg_7969f479-3215-4af2-bd81-33a72ef28883">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOmM1ODdmY2RiYjNmODQ5M2Y5YjVhOGFiZjM3ZTEyNzc2L3RhYmxlcmFuZ2U6YzU4N2ZjZGJiM2Y4NDkzZjliNWE4YWJmMzdlMTI3NzZfMi0xLTEtMS0yMDgzNw_3ece09da-9f9b-4ae8-82f4-4f60037697bd"
      unitRef="usd">600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOmM1ODdmY2RiYjNmODQ5M2Y5YjVhOGFiZjM3ZTEyNzc2L3RhYmxlcmFuZ2U6YzU4N2ZjZGJiM2Y4NDkzZjliNWE4YWJmMzdlMTI3NzZfMi0zLTEtMS0yMDgzNw_a26050f5-99b6-496c-a045-a9e69b164480"
      unitRef="usd">300000</us-gaap:OperatingLeaseCost>
    <arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjEwNw_79ad83ad-e705-4306-ba95-d0d06a8a9d2d">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Supplemental non-cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets obtained in exchange for new lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjU4NTdjODE4N2UwZjRmZjI4OThjMDc1NjFlZWZjZmFmL3RhYmxlcmFuZ2U6NTg1N2M4MTg3ZTBmNGZmMjg5OGMwNzU2MWVlZmNmYWZfMy0xLTEtMS0yMDgzNw_c051f1f4-e303-4279-bbac-27b45ee55fa7"
      unitRef="usd">600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjU4NTdjODE4N2UwZjRmZjI4OThjMDc1NjFlZWZjZmFmL3RhYmxlcmFuZ2U6NTg1N2M4MTg3ZTBmNGZmMjg5OGMwNzU2MWVlZmNmYWZfMy0zLTEtMS0yMDgzNw_de5eecbf-c400-4061-8595-af393798e9c5"
      unitRef="usd">300000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjU4NTdjODE4N2UwZjRmZjI4OThjMDc1NjFlZWZjZmFmL3RhYmxlcmFuZ2U6NTg1N2M4MTg3ZTBmNGZmMjg5OGMwNzU2MWVlZmNmYWZfNS0xLTEtMS0yMDgzNw_bb4fed26-97e9-47c4-abbb-318e97ce67ec"
      unitRef="usd">2400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjU4NTdjODE4N2UwZjRmZjI4OThjMDc1NjFlZWZjZmFmL3RhYmxlcmFuZ2U6NTg1N2M4MTg3ZTBmNGZmMjg5OGMwNzU2MWVlZmNmYWZfNS0zLTEtMS0yMDgzNw_e7d01a7a-ebeb-45c9-9935-b4383fb847ab"
      unitRef="usd">3200000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RleHRyZWdpb246ZWQ3N2Y2MGNhZDBlNDlmOWIyODM2MmVhZTBmNDI5NmJfMjEwOA_d3a990dc-0154-4a29-aa23-ab303bfa31d5">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities for operating leases as of March&#160;31, 2022, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfMC0xLTEtMS0yMDgzNw_3e14dc75-737b-4db8-9c3a-fa9be4a90e73"
      unitRef="usd">1300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfMS0xLTEtMS0yMDgzNw_29878eac-c58b-497b-92ce-ee220f2351f9"
      unitRef="usd">2100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfMi0xLTEtMS0yMDgzNw_0a8bb6b2-a054-4208-b7c6-0779d41b4335"
      unitRef="usd">2100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfMy0xLTEtMS0yMDgzNw_f8248cc8-2c04-46be-8c21-8a9219fd5e8f"
      unitRef="usd">600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfNS0xLTEtMS0yNjcyMw_f70c1561-2bed-42f3-9947-6eb0efdda9c9"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfNC0xLTEtMS0yMDgzNw_cc01028a-de0f-4ee1-8cf4-e5106ae59d72"
      unitRef="usd">6100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfNS0xLTEtMS0yMDgzNw_0b1fb4cc-c9c5-4521-9f60-ce98a62822e8"
      unitRef="usd">300000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF81NS9mcmFnOmVkNzdmNjBjYWQwZTQ5ZjliMjgzNjJlYWUwZjQyOTZiL3RhYmxlOjcyNTcxM2U5YjU2ZDRlNDk4M2IwMjk3NzU1MDNlZmZmL3RhYmxlcmFuZ2U6NzI1NzEzZTliNTZkNGU0OTgzYjAyOTc3NTUwM2VmZmZfNi0xLTEtMS0yMDgzNw_2ea4b78b-e579-4ec4-9a3b-77f1485faa89"
      unitRef="usd">5800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RleHRyZWdpb246MmZmOTUwODRkOTdiNDk1MDlkOTFkOGMyOWZlZWU3MjNfNzE_3e42d362-682b-474a-8dde-34a490c046c3">Accrued Expenses &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RleHRyZWdpb246MmZmOTUwODRkOTdiNDk1MDlkOTFkOGMyOWZlZWU3MjNfNzI_dbb7865b-16f2-4622-9331-ac729ecc42e9">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMi0xLTEtMS0yMDgzNw_f4a56a51-4650-4a62-bd9c-180aa60197c5"
      unitRef="usd">18400000</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMi0zLTEtMS0yMDgzNw_23bcf969-9988-4492-b4d2-23b201bcc5ae"
      unitRef="usd">9500000</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0xLTEtMS0zMTE4NA_0d06b265-3fa3-4588-8557-94fc0f046644"
      unitRef="usd">5100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0zLTEtMS0zMTE4NA_47eeee58-805c-45e4-b0de-fdef6a7b7d1a"
      unitRef="usd">12400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0xLTEtMS0zMzQ5Ng_9a2b52ad-a981-4be7-ae0d-9bc90a127391"
      unitRef="usd">4500000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0zLTEtMS0zMzQ5Ng_fc801133-54f8-42ab-b41e-3df0b836ea3a"
      unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0xLTEtMS0yMDgzNw_20439d2e-b730-45c5-b0b0-2320147a9b98"
      unitRef="usd">2200000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfMy0zLTEtMS0yMDgzNw_26634b13-7c22-4e27-9187-850c018ee89b"
      unitRef="usd">1200000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfNC0xLTEtMS0yMDgzNw_041f3859-0ed7-4867-9d22-86be5abb082a"
      unitRef="usd">30200000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9805af17bb1e4148957b4b787a17b462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82MS9mcmFnOjJmZjk1MDg0ZDk3YjQ5NTA5ZDkxZDhjMjlmZWVlNzIzL3RhYmxlOmQyMWI1YjdiZmVlMTRmMzBiYjMwZDc1NDdjN2Q2MTA3L3RhYmxlcmFuZ2U6ZDIxYjViN2JmZWUxNGYzMGJiMzBkNzU0N2M3ZDYxMDdfNC0zLTEtMS0yMDgzNw_65a010d5-642d-47ac-ab76-e10a8213852e"
      unitRef="usd">23100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfMjA0Mw_27fac540-037e-4ed9-a749-901760420e1e">Long-Term Debt&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into an additional Assistance Agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through 2028, with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received. At March&#160;31, 2022, $1.0 million remains outstanding under the 2018 Assistance Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with an Assistance Agreement with the State of Connecticut entered into in 2014 (the &#x201c;2014 Assistant Agreement&#x201d;) under which all the borrowings by the Company were forgiven, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $2.5 million plus liquidated damages of 7.5%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum future principal payments on long-term debt for the years ending December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, interest expense was immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib76a16c4b82e4fc1afb937c6900e150c_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDE4MA_a9df2d12-179c-4dbf-a812-2a2ddf4701d8"
      unitRef="usd">2000000</us-gaap:DebtInstrumentFaceAmount>
    <arvn:DebtInstrumentLoanForgiveness
      contextRef="i4935b90c90e34bf6b3aed0f1df6f02ee_D20180901-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDE5Ng_1eb4fa51-85f6-4598-a09a-082a30ef0ece"
      unitRef="usd">1000000</arvn:DebtInstrumentLoanForgiveness>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib76a16c4b82e4fc1afb937c6900e150c_I20180930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDIwNQ_d033ab47-3736-4846-8490-fa89b2d2442d"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <arvn:DebtInstrumentInterestPaymentsTerm
      contextRef="i4935b90c90e34bf6b3aed0f1df6f02ee_D20180901-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDIxNw_b3b79ff8-b1b8-4088-a582-5e3995971573">P60M</arvn:DebtInstrumentInterestPaymentsTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib76a16c4b82e4fc1afb937c6900e150c_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDIzMw_6bc352db-8c11-4dc4-9b0e-971df28895c2"
      unitRef="usd">2000000</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfLiquidatedDamages
      contextRef="i4935b90c90e34bf6b3aed0f1df6f02ee_D20180901-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MDI0MA_96c5b243-c7be-4cfa-b011-51385ba86d8e"
      unitRef="number">0.075</arvn:PercentageOfLiquidatedDamages>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MTcyMw_edcfd2cc-0b69-4cbb-8472-08737ff750ff"
      unitRef="usd">1000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i73790ff93f1f4e57acc10cab17dc2e89_I20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MjE0Mw_08aa2143-5f62-43ef-8e22-b3841d760be0"
      unitRef="usd">2500000</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfLiquidatedDamages
      contextRef="i0dd70cc9b901409ab550af0ec999338f_D20140101-20141231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfOTM0NTg0ODg0MjE3NA_67b052a9-13b0-42b0-b2c0-d4d685925441"
      unitRef="number">0.075</arvn:PercentageOfLiquidatedDamages>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RleHRyZWdpb246NGI1MzFmOTExZjI1NDM1OGFjNzQyY2VjYjJlYWM5MTJfMjA0NA_e49eda8d-86ec-4c4c-af25-f662be915399">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum future principal payments on long-term debt for the years ending December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMC0xLTEtMS0yNjUyNA_85f4ba4c-8ec2-4b47-bc28-869c7a87256b"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMC0xLTEtMS0yMDgzNw_3f4cb524-aac1-43a2-8986-5293f0ffa1c8"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMS0xLTEtMS0yMDgzNw_d63be136-a011-41b1-a836-21bdeb2e09e9"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMy0xLTEtMS0yNjUyNA_57ca97b5-07de-4114-8e8b-a8f5de5b4d5a"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfNC0xLTEtMS0yNjUyNA_312c940a-5602-4437-98e4-7fc14bcae32c"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <arvn:LongTermDebtMaturityYearSix
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMi0xLTEtMS0yMDgzNw_6fb6e77c-f670-4978-87be-84783560eb73"
      unitRef="usd">200000</arvn:LongTermDebtMaturityYearSix>
    <us-gaap:LongTermDebt
      contextRef="i25a3253dc54e4eac92fd34e0a563037a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82NC9mcmFnOjRiNTMxZjkxMWYyNTQzNThhYzc0MmNlY2IyZWFjOTEyL3RhYmxlOjFhMjIwZGEyMWY4ZDQ5MzBhMDU5Zjg3MzVjOGNlMTAwL3RhYmxlcmFuZ2U6MWEyMjBkYTIxZjhkNDkzMGEwNTlmODczNWM4Y2UxMDBfMy0xLTEtMS0yMDgzNw_da44f74e-0171-4bc0-b6a9-9fbeb7941794"
      unitRef="usd">1000000.0</us-gaap:LongTermDebt>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODE3Mg_3fbd2812-f2c3-4410-92ff-d3c401bff37f">Equity&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Distribution Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp;amp; Company (&#x201c;Piper Sandler&#x201d;) and Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $300.0 million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the common stock registered under the Company's universal shelf registration statement pursuant to one or more &#x201c;at-the-market" offering. During the quarter ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; March&#160;31, 2022, no shares have been issued under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the &#x201c;2018 ESPP&#x201d;), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company&#x2019;s common stock. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2018 ESPP increase, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company&#x2019;s then-outstanding common stock, effective as of January 1 of each year. As of March&#160;31, 2022, 2,005,714 shares remained available for purchase. During the three months ended March&#160;31, 2022 and 2021, the Company issued 5,749 and 12,050 shares, respectively, of common stock under the 2018 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incentive Share Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Fourth Amendment to the Company&#x2019;s Incentive Share Plan (the &#x201c;Incentive Plan&#x201d;) adopted in March 2018, the Company was authorized to issue up to an aggregate of 6,199,477 incentive units pursuant to the terms of the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNDkwNA_c8db3740-5782-4c3e-b75d-6ff6aad14517"&gt;one&lt;/span&gt; to four years. The Incentive Plan was terminated in September 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s stockholders approved, the 2018 Stock Incentive Plan (the &#x201c;2018 Plan&#x201d;), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#x2019;s initial public offering. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement expired, terminated or were otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and including, the fiscal year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company&#x2019;s common stock, 4% of the number of shares of the Company&#x2019;s common stock outstanding on the first day of the year or an amount determined by the Company&#x2019;s board of directors. As of March&#160;31, 2022, 2,849,537 shares remained available for issuance under the 2018 Plan. Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or canceled without having been fully exercised or are forfeited in whole or in part shall be available for future grants of awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, the Company recognized compensation expense of $16.6 million and $10.3 million, respectively, relating to the issuance of incentive awards. At March&#160;31, 2022, there was $93.1 million of unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted during the three months ended March&#160;31, 2022 and 2021 was determined using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.2 - 76.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;77.4 - 78.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.6 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.6 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5% - 2.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5% - 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$64.19 - $78.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$77.51 - $82.21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the Company&#x2019;s common stock has not been trading for a sufficient period of time, the Company calculates volatility of its common stock by utilizing a weighted average of a collection of peer company volatilities and its own common stock volatility. The expected term is calculated utilizing the simplified method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the 2018 Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;br/&gt;except weighted average exercise price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,343,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,234,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(117,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(101,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,359,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;137.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Exercisable at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,739,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2022 was $43.02. The total intrinsic value of options exercised during the three months ended March&#160;31, 2022 was $5.9 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, there were 5,995,790 stock options under the 2018 Plan that have vested or are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock award activity under the Incentive Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include restricted stock granted to employees, directors and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested restricted stock at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested restricted stock at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, there were 5,810 restricted shares under the Incentive Plan that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock unit activity under the 2018 Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include restricted stock units granted to employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested restricted stock units at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;88,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;167,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested restricted stock units at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;214,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, there were 174,335 restricted stock units under the 2018 Plan that have vested or are expected to vest.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <arvn:MaximumAggregateOfferingPriceOfCommonStock
      contextRef="i060bd9cd585847318e2f9ad13a0d80e6_I20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzMDU0Mg_bfbe808b-0855-4728-9707-939a0e556c5b"
      unitRef="usd">300000000</arvn:MaximumAggregateOfferingPriceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5cddce78d1d948c5b583d717cd77e28a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfMTU1NQ_7e2103ab-eee1-412d-8979-8dc3a703b59c"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i45363eaf411f4c0fa67bd782a95bcb4c_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfMjYyMA_01a8d0c8-453b-4506-afac-16f1ab7b0191"
      unitRef="shares">311850</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock
      contextRef="ib22a7c97a95649208e3e16626fb046fa_D20200101-20200101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfMjgzMQ_3face9f5-16f6-4a10-8563-fde84bf18f01"
      unitRef="number">0.01</arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock>
    <arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock
      contextRef="i102371b1a4f74f1989575feb5349c7e8_D20220101-20220101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfMjgzMQ_4c78b31c-d150-4728-94c2-de0878a2b28e"
      unitRef="number">0.01</arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock>
    <arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock
      contextRef="i9d11b00f18034e2faf571d32e08733be_D20210101-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfMjgzMQ_99079aa0-b239-4179-9bff-2641f34b99df"
      unitRef="number">0.01</arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6baa8537a2484bdcbd212331111a5ab2_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzMjA3Nw_b1723404-4997-45c0-a84e-14de6c3ad014"
      unitRef="shares">2005714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i283e92babacf44249b5ac15c0401dae2_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzMjMyOQ_284b57c6-ddc2-4d27-bdbd-322631512c26"
      unitRef="shares">5749</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2fcf33d6545f49979c8996508f1dafdc_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzOTE3MQ_cf452139-469e-4d61-a322-2d7615560743"
      unitRef="shares">12050</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic72afe64f6d942ceaec3f2bcea014191_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNDY5Nw_2748640b-53a0-4beb-9620-7e33392bd5db"
      unitRef="shares">6199477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i49ed2e413afc4936a46c5ae2d54150a8_D20180301-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNDkxMA_beda9855-ee29-4ad6-ba95-da6b73e14174">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i135de9f10c6a4846ba8e3bd9311c3aaf_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNTMyMg_c0edac75-03f3-4d1f-8dce-8ff6b5857f04"
      unitRef="shares">4067007</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6380e9eea75f4e87923e1958591b5177_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNTQwMg_f5377291-84f3-455e-a0ed-aae48fb487d6"
      unitRef="shares">1277181</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="if4075817b88149f4ad4be9a0e24f00bd_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNTk1Nw_ed2bead3-6e50-47df-bbe7-c98ad0a34330"
      unitRef="shares">4989593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i671442cf18e9459a9ae011753dc2baf4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNTk5OA_cbb5ad14-28ca-4776-b182-2c6d83e861da"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i676daf315860494fae1a0db23d870397_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzNDcwMw_c89d250c-e8dd-4903-a6ef-ba2bd22c17b5"
      unitRef="shares">2849537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a028511c76147dfa9eea3ef963d7391_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNjU4NA_6ac96fb8-2c09-48e5-b67e-f553fa914054"
      unitRef="usd">16600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i22436d4d6b37470dae576ae029c13e17_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNjU5MQ_322ecf09-2968-4edb-a16e-f2a9a822c29f"
      unitRef="usd">10300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i433048cb8a22434c9c966ee4a08d5783_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNjc4Mg_e5506459-e027-44ed-9183-0b40528a7668"
      unitRef="usd">93100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2a028511c76147dfa9eea3ef963d7391_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfNjkwMw_55ecd2fa-82ae-4364-9247-da9738979e5d">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODE3Mw_50452851-08f7-47e7-a8b9-3b9e6d79d87a">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted during the three months ended March&#160;31, 2022 and 2021 was determined using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.2 - 76.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;77.4 - 78.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.6 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.6 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5% - 2.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5% - 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$64.19 - $78.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$77.51 - $82.21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMS0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmM5MTFlY2ZlYjJhNzRhNGFhMGI0ZTgzNjZmODdlOGY4XzQ_4b3a2696-536e-46ad-8aff-55085677380f"
      unitRef="number">0.732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMS0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmM5MTFlY2ZlYjJhNzRhNGFhMGI0ZTgzNjZmODdlOGY4Xzk_a815f8d2-9f0d-45bc-8b21-140ff8e98f59"
      unitRef="number">0.760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMS0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjcwMjFhY2RhNjE3MjRiN2JhYjBhMDUwZmFjZjYzYTc4XzQ_f56098d9-68a9-4f7c-b9b3-45b9ab332ecf"
      unitRef="number">0.774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMS0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjcwMjFhY2RhNjE3MjRiN2JhYjBhMDUwZmFjZjYzYTc4Xzk_cd0bc2a2-3dda-405d-a53a-7e19d6449ad0"
      unitRef="number">0.780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i61acd713861543de9a324e7901c946b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMi0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjJlNDUyZDk5NmM4MTQ1MTdiYmNmNjA5Yjg4MjM0Y2RhXzQ_39ad28a4-8441-480b-8246-6b1da62e4bdb">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i89b128b20436420eb6e8f593916c4d49_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMi0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjJlNDUyZDk5NmM4MTQ1MTdiYmNmNjA5Yjg4MjM0Y2RhXzk_10ae2479-0937-497c-ab12-8fabc2389094">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic0183429203148f5b51f86ce4175b9db_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMi0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmFjOThiZjdmMWViMTRhYzQ5NDE2YTFmM2E4Y2JhMjk2XzQ_a4c1510a-4e32-4a6f-8053-d54182688c16">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i671f93d65ec949f6a09add626b9cc77d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMi0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmFjOThiZjdmMWViMTRhYzQ5NDE2YTFmM2E4Y2JhMjk2Xzk_e383f357-1965-4289-831d-bb7c36566f03">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMy0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmFjNmY1NTU0NmUzYzQ5YjFiYzM1NWNlYzkyYjc1YTdmXzQ_08c98ea6-0e16-4a49-83be-138dd2b2bff3"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMy0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmFjNmY1NTU0NmUzYzQ5YjFiYzM1NWNlYzkyYjc1YTdmXzk_5a0b15e6-61e6-4f31-b757-6c7811d8d284"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMy0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjhjZjliMmY2ZTYxODRkYjQ5NTYwMjRhOGU0MTY4YzliXzQ_1b25f2e9-15da-4690-aacc-2040d0478aed"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfMy0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjhjZjliMmY2ZTYxODRkYjQ5NTYwMjRhOGU0MTY4YzliXzk_31e1e481-7e88-4efe-9ada-0d8b1d6b8fc8"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNC0xLTEtMS0yMDgzNw_19344529-b014-4224-bd1e-b4b1f9a15529"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iee2aac495ced47c0b6128a17ecb50c31_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNC0zLTEtMS0yMDgzNw_afc0ca15-7e14-4684-bb0b-7723c2da4608"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="idfe72e9e1d7f4ef38b63abc9e9247aa6_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNS0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmZmYjdkODVjNTU4MjRhMjdhYTM4ZTIzNjA2OGNhNzRjXzQ_718f5640-a28e-4bc6-a661-cef2df58b98e"
      unitRef="usdPerShare">64.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i4067c8a18e3a462ab80648a7b2f71e05_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNS0xLTEtMS0yMDgzNy90ZXh0cmVnaW9uOmZmYjdkODVjNTU4MjRhMjdhYTM4ZTIzNjA2OGNhNzRjXzk_4eea3042-83b2-445a-9c87-70be83e2e830"
      unitRef="usdPerShare">78.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="id6884606b15a4b1c92ccbbd8551ca251_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNS0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjc3NTc1NjY3Nzc1MDQ4YWI4NThjZGEyYTQ5OWZmNTcxXzQ_308567c7-0c50-4210-98f9-142df61f68de"
      unitRef="usdPerShare">77.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i649860d7edd84bfdb3be6ff127c824e6_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmFkOTcxNTZhN2UxOTQ1MmI4MDk2Yjk0MDEwZTA3NGY5L3RhYmxlcmFuZ2U6YWQ5NzE1NmE3ZTE5NDUyYjgwOTZiOTQwMTBlMDc0ZjlfNS0zLTEtMS0yMDgzNy90ZXh0cmVnaW9uOjc3NTc1NjY3Nzc1MDQ4YWI4NThjZGEyYTQ5OWZmNTcxXzk_0890b9b4-a7d4-43ca-9136-004bdd3b078f"
      unitRef="usdPerShare">82.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODE2OQ_b043fc85-09ed-43b8-bd05-23f169bd8756">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the 2018 Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;br/&gt;except weighted average exercise price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,343,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,234,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(117,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(101,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,359,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;137.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Exercisable at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,739,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i98d32989f98049b98b156c00b715a0f0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMS0yLTEtMS0yMDgzNw_d1d15104-b152-48eb-a4c9-26017efdc710"
      unitRef="shares">5343254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i98d32989f98049b98b156c00b715a0f0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMS00LTEtMS0yMDgzNw_c2fea9be-ab77-4c5e-9ded-da4e268af4bb"
      unitRef="usdPerShare">44.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMi0yLTEtMS0yMDgzNw_cf209888-8e07-4d5a-b93a-4d4b1aa34328"
      unitRef="shares">1234844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMi00LTEtMS0yMDgzNw_d72c4de3-5923-41e4-906f-4ca86136ad7a"
      unitRef="usdPerShare">65.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMy0yLTEtMS0yMDgzNw_16ed894b-8e57-45cf-bdf2-fd3915a6c100"
      unitRef="shares">117399</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfMy00LTEtMS0yMDgzNw_1bbcd5e9-e316-4a5c-ae86-a6626ffdac8f"
      unitRef="usdPerShare">17.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNC0yLTEtMS0yMDgzNw_61d37977-c064-4dfb-b2ba-60fafd7a93dd"
      unitRef="shares">101525</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNC00LTEtMS0yMDgzNw_f0ca702e-9ccd-43fd-9f78-5f6e35df7496"
      unitRef="usdPerShare">57.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i676daf315860494fae1a0db23d870397_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNS0yLTEtMS0yMDgzNw_6ffa6281-92f0-4292-a403-6583cb05dd4b"
      unitRef="shares">6359174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i676daf315860494fae1a0db23d870397_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNS00LTEtMS0yMDgzNw_9336cb0a-3324-4b30-9d58-2b7a1539967e"
      unitRef="usdPerShare">49.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNS02LTEtMS0yMDgzNw_065181d2-c4d7-4f28-a00a-54f10f90852d">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i676daf315860494fae1a0db23d870397_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNS04LTEtMS0yMDgzNw_6685627e-cd09-4024-8714-46b24f850b3f"
      unitRef="usd">137200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i676daf315860494fae1a0db23d870397_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNi0yLTEtMS0yMDgzNw_09b0e345-ab0c-4aaa-8501-2e9ccd78953c"
      unitRef="shares">2739009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i676daf315860494fae1a0db23d870397_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNi00LTEtMS0yMDgzNw_b1a9e251-5d13-4e6c-84d7-9d38a2f68011"
      unitRef="usdPerShare">31.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia6e451d8d2324034a526c5df542af0eb_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNi02LTEtMS0yMDgzNw_c79329b6-0013-44ca-8413-d389adc3fba9">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i676daf315860494fae1a0db23d870397_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOmNjYTVkMGJmOGI2YTQ5MzliMDQwNjQyNWQ5NDJiNmVkL3RhYmxlcmFuZ2U6Y2NhNWQwYmY4YjZhNDkzOWIwNDA2NDI1ZDk0MmI2ZWRfNi04LTEtMS0yMDgzNw_827e12b6-1b5b-44d2-b345-4195ecec2d68"
      unitRef="usd">103100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzNzEzMg_76a6f1ce-04b9-4e92-9e3d-11994f2afd4c"
      unitRef="usdPerShare">43.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzNzIwNg_9cb6ebd0-4110-42c2-8a23-6c7eb6f5fbc5"
      unitRef="usd">5900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i676daf315860494fae1a0db23d870397_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzNjE3Mg_9c2adfde-6d0b-4c8e-bedb-32efed6f6cbd"
      unitRef="shares">5995790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODE3MA_389ccf2a-7982-49f2-b9a1-01b6ad82c79b">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock award activity under the Incentive Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include restricted stock granted to employees, directors and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested restricted stock at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested restricted stock at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock unit activity under the 2018 Plan during the three months ended March&#160;31, 2022 is presented below. These amounts include restricted stock units granted to employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested restricted stock units at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;88,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;167,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested restricted stock units at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;214,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i28d56097cbd64f55a89cefb5e23f4fdd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMS0yLTEtMS0yMDgzNw_cd6a2cea-34fd-4a8e-b88b-c298bab507e7"
      unitRef="shares">30625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i28d56097cbd64f55a89cefb5e23f4fdd_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMS00LTEtMS0yMDgzNw_bd60f215-b36d-46ca-b1e7-b67ab9d396d1"
      unitRef="usdPerShare">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3a949a59544846bea32da66debdc0f5c_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMi0yLTEtMS0yMDgzNw_f54c02d0-c92b-42f5-bb5e-cc56cacf7fdc"
      unitRef="shares">23376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3a949a59544846bea32da66debdc0f5c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMi00LTEtMS0yMDgzNw_b31da503-4b33-495b-bb59-3b8d02cb72d0"
      unitRef="usdPerShare">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3a949a59544846bea32da66debdc0f5c_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMy0yLTEtMS0yODExMQ_b677f457-2ce0-4c14-9df8-9137836e6a72"
      unitRef="shares">1320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i3a949a59544846bea32da66debdc0f5c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMy00LTEtMS0yODExMQ_4ae194a8-06b1-4101-9173-004613b957fd"
      unitRef="usdPerShare">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id20769d0f7ab420fb3b232e6d0b967fe_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMy0yLTEtMS0yMDgzNw_0c3f6a67-04ea-4672-bf3f-00f3306f2547"
      unitRef="shares">5929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id20769d0f7ab420fb3b232e6d0b967fe_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjFjZjEyZDkxMjlhMjQ3OWJiZTgzOTljMTM5NWM0YTRmL3RhYmxlcmFuZ2U6MWNmMTJkOTEyOWEyNDc5YmJlODM5OWMxMzk1YzRhNGZfMy00LTEtMS0yMDgzNw_34ff549e-a0e7-414f-ba0c-ad5f7a3f7687"
      unitRef="usdPerShare">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber
      contextRef="i8e513085eec343c4b787da47473ad4c0_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODc5NjA5MzAzNTkyNA_35ce34fa-fb37-4889-9931-c6fd636a9e44"
      unitRef="shares">5810</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i70ebb09ff5e84d1aa19beee9d199a829_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMS0yLTEtMS0yMDgzNw_fc05b851-c223-4bbb-b08f-91ce6391b366"
      unitRef="shares">88307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i70ebb09ff5e84d1aa19beee9d199a829_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMS00LTEtMS0yMDgzNw_8fe25adc-08fb-40cd-aff7-b258f74944f8"
      unitRef="usdPerShare">20.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMi0yLTEtMS0yODE3MQ_38482701-d4e5-435b-bb95-c16bb50d536b"
      unitRef="shares">167811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMi00LTEtMS0yODE3MQ_848954f0-2304-4039-b778-9d8295f74a2e"
      unitRef="usdPerShare">64.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMi0yLTEtMS0yMDgzNw_95357865-8d1a-46e8-807d-e4c8b876721f"
      unitRef="shares">38490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMi00LTEtMS0yMDgzNw_9338a975-1c63-4a6e-b59c-b3eab7baf09d"
      unitRef="usdPerShare">19.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMy0yLTEtMS0yMDgzNw_d2e553ed-3b04-493d-b8c8-4baae3871724"
      unitRef="shares">3434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i40ac2b1bfa434f3992c4ca5d10e9a133_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfMy00LTEtMS0yMDgzNw_b1610d51-395d-45e9-8349-34c22ab65cf4"
      unitRef="usdPerShare">21.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i726c996b1f294aea83f7646f6c212dd2_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfNC0yLTEtMS0yMDgzNw_55afa567-2633-45e6-be52-a95326e65776"
      unitRef="shares">214194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i726c996b1f294aea83f7646f6c212dd2_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RhYmxlOjIxZDQyYWRkMzExZjRkZWI5YTZmN2U0MmE3YmVjYTJkL3RhYmxlcmFuZ2U6MjFkNDJhZGQzMTFmNGRlYjlhNmY3ZTQyYTdiZWNhMmRfNC00LTEtMS0yMDgzNw_8290b76e-b9a1-4cf5-b789-197fc080493f"
      unitRef="usdPerShare">55.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber
      contextRef="i676daf315860494fae1a0db23d870397_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF82Ny9mcmFnOjQ3MWNhZjk3MDcxNjQxYThhZjE1MGY2YTk3MGJiNWVkL3RleHRyZWdpb246NDcxY2FmOTcwNzE2NDFhOGFmMTUwZjZhOTcwYmI1ZWRfODA4OQ_9b6ad4cc-2638-4220-8f4a-0c5f4e84e6cf"
      unitRef="shares">174335</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfMTAwMQ_f9a8e097-eb96-44e0-a183-7fca7239aad1">Income Taxes &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective tax rate was 7.6% and 0.0% for the three months ended March&#160;31, 2022 and 2021, respectively. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended March&#160;31, 2022 and the Company&#x2019;s overall effective tax rate of 7.6% was the effect of equity compensation, deferred state income taxes and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended March&#160;31, 2021 and the Company&#x2019;s overall effective tax rate of 0.0% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company is expecting to have net taxable income for the current year, resulting in current income tax expense for the period, and &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;expects to fully utilize its net operating loss and credit carryforwards during the year. This is primarily due to revenue recognition for tax purposes from the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ARV-471 Collaboration Agreement&lt;/span&gt; and the capitalization of qualified research and development expenses incurred on or after January 1, 2022. Under the Tax Cuts and Jobs Act of 2017, qualified research expenses incurred after 2021 are no longer immediately deductible for tax purposes and instead must be amortized over at least five years for tax purposes. A valuation allowance has been established against the Company&#x2019;s net deferred tax assets, including the deferred tax liabilities resulting from the deferred revenue and deferred tax assets associated with the capitalization of research and development expenses for tax, since the Company expects to incur tax losses again after the current year.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfOTM0NTg0ODgzNzEwMQ_4ed53fb9-70a6-47ae-88b2-b2f6560c66aa"
      unitRef="number">0.076</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfNjA_00df6d9b-942b-4fb6-8768-e5441ac02fe2"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfOTM0NTg0ODgzNzYxOA_09457a69-0270-4df8-bba7-79d8b726dc2e"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfODc5NjA5MzAyNDA5Ng_2bf39c95-f074-4617-aae0-6524d1297d38"
      unitRef="number">0.076</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfOTM0NTg0ODgzNzUyOQ_559862ba-0586-40cb-9922-3cb3c6b7516d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83My9mcmFnOjA2NzIxMmVjMzY3YzQwNzNiY2EyM2M2ZDI1N2RiZGI2L3RleHRyZWdpb246MDY3MjEyZWMzNjdjNDA3M2JjYTIzYzZkMjU3ZGJkYjZfODc5NjA5MzAyNDEwNA_58d7c678-089e-4c8e-92b5-8e2dd63823ea"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RleHRyZWdpb246ZWYxYWE4ZmEwMTQ5NGVlYThiODViZmVmMTBjZjUyODVfMTA2_13b09cf3-0757-4de0-9af7-55193d638ba6">Net Loss Per Share &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars and shares in millions, except per common share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(63.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net loss per common share &lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;-  basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported net losses for each of the three months ended March&#160;31, 2022 and 2021, and therefore excluded all stock options, restricted stock awards and restricted stock units from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RleHRyZWdpb246ZWYxYWE4ZmEwMTQ5NGVlYThiODViZmVmMTBjZjUyODVfMTA3_4ed24ece-1d55-4f05-8640-0cbbbc265fe1">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars and shares in millions, except per common share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(63.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net loss per common share &lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;-  basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMi0xLTEtMS0yMDgzNw_4bd91451-9a29-4b35-b799-51276d67d205"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMi0zLTEtMS0yMDgzNw_c65d1faa-c3dd-4dc6-a548-d1a93e5ef1aa"
      unitRef="usd">-41000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMy0xLTEtMS0yMDgzNw_2a941460-aeeb-409f-9b39-3a027cff81e0"
      unitRef="shares">53000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMy0xLTEtMS0yMDgzNw_f61c4c1b-5862-4ee8-94e3-8391c4d5b33f"
      unitRef="shares">53000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMy0zLTEtMS0yMDgzNw_c60912e3-2467-4d1d-add7-57bbaf71edc3"
      unitRef="shares">48600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfMy0zLTEtMS0yMDgzNw_e46a9766-55cc-42ef-b162-bf1ecdb7abc7"
      unitRef="shares">48600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfNC0xLTEtMS0yMDgzNw_0c49f434-4cdf-4450-ab01-b5390ad8b622"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfNC0xLTEtMS0yMDgzNw_ed672c4c-e4ea-498b-b9de-79488343167c"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfNC0zLTEtMS0yMDgzNw_055e3030-ab73-4804-92bc-8c6dec52789f"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjZkYjliMTViYWQ2MjQ4OTI5OGY0MDQwM2FmMjIxMTY1L3RhYmxlcmFuZ2U6NmRiOWIxNWJhZDYyNDg5Mjk4ZjQwNDAzYWYyMjExNjVfNC0zLTEtMS0yMDgzNw_6cac20e5-71c4-46e6-8558-8c0f0fac708e"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RleHRyZWdpb246ZWYxYWE4ZmEwMTQ5NGVlYThiODViZmVmMTBjZjUyODVfMTY0OTI2NzQ0MjA5MQ_b15f0545-c36a-48d5-b935-f629b329d109">&lt;div style="margin-top:12pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported net losses for each of the three months ended March&#160;31, 2022 and 2021, and therefore excluded all stock options, restricted stock awards and restricted stock units from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i07f988855484455ab096cd4c3443153c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfMi0xLTEtMS0yNjExMg_f700e9c5-47c1-4705-9849-1ed969c02fb2"
      unitRef="shares">6400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icf87072bef5a4f5cbbe0ef6ae8aee71b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfMi0xLTEtMS0yNjAzNw_74a78d6c-47ab-4912-8e08-2ee2c9497c1b"
      unitRef="shares">5400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if0b1f35859d641bd8934d7229fc923b5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfMy0xLTEtMS0yNjExMg_70c6fef8-e3e8-4ba4-9f15-247d5654999c"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1a02298ba683464096a7a075d1fbb1bb_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfMy0xLTEtMS0yNjAzNw_8e1a026b-6f24-4c1a-9693-69a0ef37c0ec"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0e55da3f43bb49b19eed56be6d2f98be_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfNC0xLTEtMS0yNjExMg_16e93b7c-0a70-4bb6-9173-f7466aaa508a"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i834d98020bdd4bcca28aae792703f6b0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfNC0xLTEtMS0yNjAzNw_19dcadd0-7d70-4637-9cd1-aeda1773edaa"
      unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfNS0xLTEtMS0yNjExMg_ae737539-3875-41ea-be6e-68a7b7d2712c"
      unitRef="shares">6600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib7acf637e21448fbadef08ad0d4b4523_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83Ni9mcmFnOmVmMWFhOGZhMDE0OTRlZWE4Yjg1YmZlZjEwY2Y1Mjg1L3RhYmxlOjVkMDFmZjJjZDAyOTRkN2E4ZmEyODEzNjU4MjUxMmJlL3RhYmxlcmFuZ2U6NWQwMWZmMmNkMDI5NGQ3YThmYTI4MTM2NTgyNTEyYmVfNS0zLTEtMS0yNjExMg_724725e8-6338-4efb-a609-228b1a74e9c7"
      unitRef="shares">5700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i7ade8388a569462b86955ec5835b56e4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfMTA2MQ_f5fcb2a0-6e01-47ba-a3a8-7be42878b4bd">Equity Method Investments&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company and Bayer CropScience LP (&#x201c;Bayer LP&#x201d;) formed a joint venture, Oerth Bio LLC (&#x201c;Oerth&#x201d;), to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. As Oerth is jointly controlled by the Company and Bayer LP, the Company accounts for its 50% interest using the equity method of accounting.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also provides to Oerth compensated research and development services and administrative services through a separate agreement. The services rendered by the Company during the three months ended March&#160;31, 2022 and 2021 were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses and net loss of Oerth for the three months ended March&#160;31, 2022 and 2021 totaled $4.9 million&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $2.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he investment has been reduced to zero and, as a result, no additional losses were recorded against the carrying value of the investment during the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i870a90a229974cd0bf199bf46c04b252_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfMzY3_a27b8ec8-ef27-4904-bcef-15cd0802e18c"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProfitLoss
      contextRef="i300ed13406744d99b22892681909ed10_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfNzM0_97888492-b65c-480a-8d96-22cd82b30f0e"
      unitRef="usd">-4900000</us-gaap:ProfitLoss>
    <arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
      contextRef="i300ed13406744d99b22892681909ed10_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfNzM0_f0429ecf-fca1-41f0-94ea-b758dabb1414"
      unitRef="usd">4900000</arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses>
    <us-gaap:ProfitLoss
      contextRef="i32f56e3363e742a0b334906ca508739d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfNzQx_3012a966-cc73-4648-a823-9215b62bf3a7"
      unitRef="usd">-2600000</us-gaap:ProfitLoss>
    <arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
      contextRef="i32f56e3363e742a0b334906ca508739d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfNzQx_6a6efdc5-7301-48d5-8765-8678fb8d4311"
      unitRef="usd">2600000</arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses>
    <us-gaap:EquityMethodInvestments
      contextRef="i4c01ec64eb01468487ce85da6539107d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfOTI0_0fe1a905-d8f6-4cd0-9cc3-c132d7165e83"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i333e000cdba54a2482be61ecd1dd9dbb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfOTI0_5a28484b-f626-4673-8441-e20d7fcdaea1"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3073ab7967df4bf8a4f22af60b4b3306_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfOTQ1_1d001570-6d65-4a24-9ca7-432474c2d39e"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia7f17d29e95941cbb2f7dfbf46b84035_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmOGQ0MDZhYjNhYTQ1YmU4MjU5MDc4MmIwZmUyZTFkL3NlYzo1ZjhkNDA2YWIzYWE0NWJlODI1OTA3ODJiMGZlMmUxZF83OS9mcmFnOmUzMjgxYTQxNDY3ZTQzNTg5NjYwYTA5MWU1ZDM2MmQyL3RleHRyZWdpb246ZTMyODFhNDE0NjdlNDM1ODk2NjBhMDkxZTVkMzYyZDJfOTQ1_9434cf96-8155-415a-b699-9ccfc8f70872"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MQ"7]LX!\CP7T43DX)1FML<_7:^J ASOY1]*Q.8/Y^"PWPDJ)RSU X_2%K;G
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M4;FOYS2/5]NC]\SX5TX2OH!0]_@$/C55[3A6)UIFY:;=7&HMT_)PQ5G$E7D
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M9:E#^&%%/1RU2Z#UC5+V$+@V,?PKY/\ 4$L#!!0    ( +>$I52[088>U 0
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M6QO \Y40ZF6@/R-57S(7_P)02P,$%     @ MX2E5$6?Y20%!@  PQ<  !@
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6RE6-MNVS@0_17"Z$,+Q)9$^9;
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MD1:E.](V50QQ-,+G"%UB'58_1=AR2N0GE6_O.<0X8=MT,IS,[-*W&648]V0
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M4+.BNC&N7A0_F$O7#5>*Y^9Q3TE*A1: W[><J]<7O4%S;[_\#U!+ P04
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M%+Y:&=]N-4JLHIQX757E%,JKQG.B6B6O3-,&#U4;Q8(MBED@MP K88AYO:;
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M&TP^:X]1081]G>: ,ZR]?_CT97'WXP_CR]F;8@UYG@B14J' I 9W&_(/LH#
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M$G0*0 OP?*64+;^0@.IW&K?_!E!+ P04    " "WA*54KRZMM 8$   *"@
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M0_(<Q3/[%\,;&$_&?DK_+D/1.QJ=Q/YDX'9H\!)*W*(D,(I&_KA#. D3/QK
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MT-O!#0MZK*&R!VA_)4E/]Q/KH'O^S7\ 4$L#!!0    ( +>$I50VL>N?T@(
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M#D3>A.BJ=C$05-JF?WG?\M!;<#Q^9L&T73!EW,D1H_Q)1GEQYMU:>)H-:_3
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M<%3@45%HHH=UI-(5N!JATH)XUJCM%%Z5M.?&0J/HY@A!)+"O@:9;U&&\'[%
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M4*H4NJ[;D=F:O-I%UA=CO--VP)O.Z"@(9^)=4>7F3BEQPTZX;J$-4\5U#LP
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M82R#RB \Y[BW+KJ">AP[T.497!RV6&3++8<@M?I,5<I>&B4^L#[#&7/0IH+
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MV7QI35N0,RTU@JS(RB R0J32;[5(Q6G_*T?>VE->A(8(5:QEWI[#3>!V*L7
MA09C.! 4*'K.21PZU2'<-LCD" D?.+F.>$W=11OG6*68/&O[E<&\\8(/\MED
M^)R>0JW#JT[69]GPZK0P8"D;#&^]/L;DI;#VR)SV0K?('#S0LNIK!TKA8(O(
M;29O)<6@0_J(UC#\ ,@H&)8NV@!J6LQSQ?=1Z) 4Y1ATL"B-Y01$0<V0KHK_
M<NS/0W^3\,,OO4GI61>@,BM"KW,0[F1L"/UJWTX7L8M\VAY[,84M* 70N"/7
MT?#GRP1L[&]QXDT3>LK6>.I085@B%RUO(/O.4"UW$P[0_\F8_P-02P,$%
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M4%D%NB^D-(>#==#^SYC^!E!+ P04    " "WA*54-.O'M;L"  !"!@  &0
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M0.LO\/?2&+<_>(+N%V;U+U!+ P04    " "WA*54$5:];Y "  !B!0  &0
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M(9O(<>4OY<$9VN64YY;?M2H_/Z*1<(V9@]-'E@FT9_/8$;@/B?,=T*H%2@\
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M:4>""V9%+QP:'T#[&ZU=Y_@"_9NY_ =02P,$%     @ MX2E5*VET^H1!0
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M>I:^[B$:4C\S4__/ =8H!QDR.&OAQ(4A>[.W<N)RR:K/0]V^<3_(EAZ,FJO
M)Y& ?T0P*;:$6<B=[9-S.1K%/-F[XN16!A-!KO30].24(8^S%@Y<&#(W:^O
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M@UF_NH76R5GQA6[U_<Y75&3F-%H]QAZU#2&KN,B_P*)$5I.16Y/W%R7:E>(
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MBZ-7L= BS4\O2Z'A+)1?KN&X2J4)@.>1$/II80Y$U0%X\@]02P,$%     @
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M+_UGZ>><-F5_;\*OX=)8C:_\]QE7_=95W[OJGW U 1SQ@H56.3]4*&W96U#
M"^X$ \<Z%&AO/:U;"-N\U[G)XNUAU8[9]%J;$&]\\$(%Z+4?7$,*M9$V-+#5
MMKMAZ$?B@WZ$.R.,^#M-6#C8GC63AG!8(66W\QDG3H<A#H)5M9^#I;(X5?Y8
MX=X#[0SP?J64W0O.0;M)\S]02P,$%     @ MX2E5&__[#V& P    L  !D
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M 2@[ 9]OI#3[CCV?VK]+\A=02P,$%     @ MX2E5,-LD*%.!@  DQX  !D
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M !HP)(JJ?7!O/PK7^U2X^?]K^ M02P,$%     @ MX2E5)>*NQS     $P(
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M#?O06J' 6L:5[Y-66"P-(%\3D*_C0IZ5I6Z5PV3',',K/"Y]7W0]ZRJ ?$-
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M4$L! A0#%     @ MX2E5":@)01O @  (08  !@              ("!F1,
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( +>$I52[088>
MU 0  &T2   8              " @3X6  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "WA*54=^>4H.L$  #5%   &
M@(%(&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ MX2E
M5$6?Y20%!@  PQ<  !@              ("!:2   'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( +>$I52= C]_FP@   P5   8
M      " @:0F  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "WA*54$NX4#(X"   J!@  &               @(%U+P  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ MX2E5 (1\H"C"@  LR$  !@
M             ("!.3(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( +>$I52O+JVT!@0   H*   9              " @1(]  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ MX2E5#:QZY_2 @
MU 8  !D              ("!3T$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "WA*54Q[@#83 &   Y#P  &0              @(%8
M1   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +>$I50%
M@EIR@ (  %P%   9              " @;]*  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ MX2E5)Q2V+)9!   BPH  !D
M     ("!=DT  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +>$I50=8PA&[0,  $<)   9              "
M@9!H  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ MX2E
M5,/E+]=X P  <P@  !D              ("!M&P  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "WA*54-.O'M;L"  !"!@  &0
M        @(%C<   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( +>$I53U6<J.A0,  ,X(   9              " @55S  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ MX2E5!%6O6^0 @  8@4
M !D              ("!$7<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "WA*54DH\:O7P"   _!0  &0              @('8>0
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +>$I52MI=/J
M$04  '0-   9              " @8M\  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ MX2E5"X380B6 P  : @  !D
M ("!TX$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "W
MA*54H>$M:RL"  !"!   &0              @(&@A0  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( +>$I50? $G 1 <  )LQ   9
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M970S,BYX;6Q02P$"% ,4    " "WA*54"[],"EH"  !5!0  &0
M    @(&2GP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M +>$I51O_^P]A@,    +   9              " @2.B  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ MX2E5%][5Y=* @  )P4  !D
M             ("!X*4  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " "WA*54EA8K7<\"  #*!@  &0              @(%AJ   >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( +>$I53G"9HUD (
M  P'   9              " @6>K  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ MX2E5*M&5%20 @  V08  !D              ("!
M+JX  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "WA*54
M4#D,05L#  #&"P  &0              @('UL   >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( +>$I515.%-34 (  &D&   9
M      " @8>T  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ MX2E5,-LD*%.!@  DQX  !D              ("!#K<  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "WA*54\1*8QK0#  #P#0
M&0              @(&3O0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( +>$I50@LU$V]0,  ) .   9              " @7[!  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ MX2E5)@I_[KR
M P  ;Q   !D              ("!JL4  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " "WA*54\-"L$(8"   %!P  &0
M@('3R0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( +>$
MI51\!\Y<[@(  (4(   9              " @9#,  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ MX2E5 L<O[0% P  <PL  !D
M         ("!M<\  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    " "WA*54%\J%-#@#  !&"P  &0              @('QT@  >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( +>$I50Z&?R7)P,   P3
M   -              "  6#6  !X;"]S='EL97,N>&UL4$L! A0#%     @
MMX2E5)>*NQS     $P(   L              ( !LMD  %]R96QS+RYR96QS
M4$L! A0#%     @ MX2E5.X$ CT0!   ,2    \              ( !F]H
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +>$I522+*"6N $  .<<   :
M              "  =C>  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( +>$I52,3^J/N@$  .X<   3              "  <C@  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     X #@ /P\  +/B      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>140</ContextCount>
  <ElementCount>238</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Accounting Pronouncements and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies</Role>
      <ShortName>Accounting Pronouncements and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Research Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements</Role>
      <ShortName>Research Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Property, Equipment and Leasehold Improvements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements</Role>
      <ShortName>Property, Equipment and Leasehold Improvements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Right-of-Use Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilities</Role>
      <ShortName>Right-of-Use Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137111 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2141112 - Disclosure - Equity Method Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestments</Role>
      <ShortName>Equity Method Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Research Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables</Role>
      <ShortName>Research Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables</Role>
      <ShortName>Property, Equipment and Leasehold Improvements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Right-of-Use Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables</Role>
      <ShortName>Right-of-Use Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/RightofUseAssetsandLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2326306 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/LongTermDebt</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2330307 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/Equity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/NetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Summary of Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Right-of-Use Assets and Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccruedExpensesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails</Role>
      <ShortName>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails</Role>
      <ShortName>Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails</Role>
      <ShortName>Equity - Summary of Restricted Stock Grant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/IncomeTaxes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Net Loss Per Share - Basic and Diluted Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arvn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestmentsDetails</Role>
      <ShortName>Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/EquityMethodInvestments</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="arvn-20220331.htm">arvn-20220331.htm</File>
    <File>arvinas-formofrsuagreement.htm</File>
    <File>arvn-20220331.xsd</File>
    <File>arvn-20220331_cal.xml</File>
    <File>arvn-20220331_def.xml</File>
    <File>arvn-20220331_lab.xml</File>
    <File>arvn-20220331_pre.xml</File>
    <File>arvn-20220331x10qex311.htm</File>
    <File>arvn-20220331x10qex312.htm</File>
    <File>arvn-20220331x10qex321.htm</File>
    <File>arvn-20220331x10qex322.htm</File>
    <File>pfizerarvinasamendmentno2r.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="446">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arvn-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 140,
   "dts": {
    "calculationLink": {
     "local": [
      "arvn-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arvn-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "arvn-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arvn-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arvn-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "arvn-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 387,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 13
   },
   "keyCustom": 23,
   "keyStandard": 215,
   "memberCustom": 30,
   "memberStandard": 18,
   "nsprefix": "arvn",
   "nsuri": "http://www.arvinas.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.arvinas.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Marketable Securities and Fair Value Measurements",
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements",
     "shortName": "Marketable Securities and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Property, Equipment and Leasehold Improvements",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements",
     "shortName": "Property, Equipment and Leasehold Improvements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Right-of-Use Assets and Liabilities",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilities",
     "shortName": "Right-of-Use Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Accrued Expenses",
     "role": "http://www.arvinas.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Long-Term Debt",
     "role": "http://www.arvinas.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Equity",
     "role": "http://www.arvinas.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - Income Taxes",
     "role": "http://www.arvinas.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137111 - Disclosure - Net Loss Per Share",
     "role": "http://www.arvinas.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141112 - Disclosure - Equity Method Investments",
     "role": "http://www.arvinas.com/role/EquityMethodInvestments",
     "shortName": "Equity Method Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Research Collaboration and License Agreements (Tables)",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables",
     "shortName": "Research Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "role": "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)",
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables",
     "shortName": "Marketable Securities and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables",
     "shortName": "Property, Equipment and Leasehold Improvements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Right-of-Use Assets and Liabilities (Tables)",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables",
     "shortName": "Right-of-Use Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.arvinas.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326306 - Disclosure - Long-Term Debt (Tables)",
     "role": "http://www.arvinas.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330307 - Disclosure - Equity (Tables)",
     "role": "http://www.arvinas.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.arvinas.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "role": "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "arvn:CollaborationContractAssetAndOtherAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Research Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i489172a8ff124366a130239025bbf1c6_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i9805af17bb1e4148957b4b787a17b462_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails",
     "shortName": "Research Collaboration and License Agreements - Summary of Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i4c69f145e8d24e459c482e4c3e4b4d45_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "role": "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails",
     "shortName": "Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i57a0f6dd7ca44f28ac6939f93d4228da_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details)",
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails",
     "shortName": "Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i57a0f6dd7ca44f28ac6939f93d4228da_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
     "shortName": "Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
     "shortName": "Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i209db759fd014857b8ce446bc1b613a2_I20210531",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LandSubjectToGroundLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Right-of-Use Assets and Liabilities - Additional Information (Details)",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
     "shortName": "Right-of-Use Assets and Liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i209db759fd014857b8ce446bc1b613a2_I20210531",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LandSubjectToGroundLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails",
     "shortName": "Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails",
     "shortName": "Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Right-of-Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "arvn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.arvinas.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "arvn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "role": "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "ib76a16c4b82e4fc1afb937c6900e150c_I20180930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "role": "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)",
     "role": "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails",
     "shortName": "Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i25a3253dc54e4eac92fd34e0a563037a_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Equity - Additional Information (Details)",
     "role": "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
     "shortName": "Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "role": "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
     "shortName": "Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i0efc5e2aed564649b1c3daccc1cb1c3d_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i98d32989f98049b98b156c00b715a0f0_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Equity - Summary of Stock Option Activity (Details)",
     "role": "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails",
     "shortName": "Equity - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i98d32989f98049b98b156c00b715a0f0_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i28d56097cbd64f55a89cefb5e23f4fdd_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)",
     "role": "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
     "shortName": "Equity - Summary of Restricted Stock Grant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i28d56097cbd64f55a89cefb5e23f4fdd_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Income Taxes (Details)",
     "role": "http://www.arvinas.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Net Loss Per Share - Basic and Diluted Loss per Common Share (Details)",
     "role": "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails",
     "shortName": "Net Loss Per Share - Basic and Diluted Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)",
     "role": "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Equity Method Investments (Details)",
     "role": "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
     "shortName": "Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EquityMethodInvestments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i333e000cdba54a2482be61ecd1dd9dbb_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "ife15238ba3aa438e92145e6ce7fce7e7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)",
     "role": "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "ife15238ba3aa438e92145e6ce7fce7e7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business and Basis of Presentation",
     "role": "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Accounting Pronouncements and Significant Accounting Policies",
     "role": "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies",
     "shortName": "Accounting Pronouncements and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Research Collaboration and License Agreements",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements",
     "shortName": "Research Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220331.htm",
      "contextRef": "i7ade8388a569462b86955ec5835b56e4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Period Increase (Decrease)",
        "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Period Increase (Decrease)",
        "terseLabel": "Payments received"
       }
      }
     },
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentPeriodIncreaseDecrease",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional upfront non-refundable amount received under previous agreement.",
        "label": "Additional Upfront Non Refundable Amount Received Under Previous Agreement",
        "terseLabel": "Additional upfront non-refundable amount received under previous agreement"
       }
      }
     },
     "localname": "AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueAbstract",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-the-Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_BaseLeaseRentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base lease rent period.",
        "label": "Base Lease Rent Period",
        "terseLabel": "Base rent lease term (in years)"
       }
      }
     },
     "localname": "BaseLeaseRentPeriod",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG.",
        "label": "Bayer A G [Member]",
        "terseLabel": "Bayer Collaboration Agreement"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_BayerCropScienceLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer CropScience LP.",
        "label": "Bayer Crop Science L P [Member]",
        "terseLabel": "Bayer LP"
       }
      }
     },
     "localname": "BayerCropScienceLPMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
        "terseLabel": "Cash, cash equivalents, restricted cash and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndMarketableSecurities",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Accounts Receivable, after Allowance for Credit Loss",
        "label": "Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Collaboration Contract Asset And Other Assets",
        "label": "Change in Collaboration Contract Asset And Other Assets [Roll Forward]",
        "terseLabel": "Contract assets: Collaboration contract asset"
       }
      }
     },
     "localname": "ChangeInCollaborationContractAssetAndOtherAssetsRollForward",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract with Customer, Liability",
        "label": "Change in Contract with Customer, Liability [Roll Forward]",
        "terseLabel": "Contract liabilities: Deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CollaborationContractAssetAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration contract asset and other assets.",
        "label": "Collaboration Contract Asset And Other Assets",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Collaboration contract asset and other assets"
       }
      }
     },
     "localname": "CollaborationContractAssetAndOtherAssets",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Contract Asset And Other Assets, Period Increase (Decrease)",
        "label": "Collaboration Contract Asset And Other Assets, Period Increase (Decrease)",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "CollaborationContractAssetAndOtherAssetsPeriodIncreaseDecrease",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements",
        "label": "Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements",
        "terseLabel": "Additions to collaboration agreements"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four [Member]",
        "terseLabel": "Corporate Bonds Maturing 2023-2024"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Two",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Two [Member]",
        "terseLabel": "Corporate Bonds Maturing 2022"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyTwoMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Two Through Two Thousand Twenty Three",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Two Through Two Thousand Twenty Three [Member]",
        "terseLabel": "Corporate Bonds One Maturing 2022-2023"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_DebtInstrumentInterestPaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest payments term.",
        "label": "Debt Instrument Interest Payments Term",
        "terseLabel": "Debt instrument interest payments term (in months)"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentsTerm",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_DebtInstrumentLoanForgiveness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument loan forgiveness.",
        "label": "Debt Instrument Loan Forgiveness",
        "terseLabel": "Loan forgiveness"
       }
      }
     },
     "localname": "DebtInstrumentLoanForgiveness",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_DevelopmentMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone payments.",
        "label": "Development Milestone Payments [Member]",
        "terseLabel": "Development Milestone Payments"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_DirectAndIncrementalCostsIncurredToObtainTheContract": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct and incremental costs incurred to obtain the contract.",
        "label": "Direct And Incremental Costs Incurred To Obtain The Contract",
        "terseLabel": "Collaboration agreement direct and incremental costs incurred"
       }
      }
     },
     "localname": "DirectAndIncrementalCostsIncurredToObtainTheContract",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_EmployeesDirectorsAndConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees, directors and consultants.",
        "label": "Employees Directors And Consultants [Member]",
        "terseLabel": "Employees, Directors and Consultants"
       }
      }
     },
     "localname": "EmployeesDirectorsAndConsultantsMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees.",
        "label": "Employees [Member]",
        "terseLabel": "Employees",
        "verboseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_EquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity distribution agreement.",
        "label": "Equity Distribution Agreement [Member]",
        "terseLabel": "Equity Distribution Agreement"
       }
      }
     },
     "localname": "EquityDistributionAgreementMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, summarized financial information, operating expenses.",
        "label": "Equity Method Investment Summarized Financial Information Operating Expenses",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech, Incorporation. and F. Hoffman-La Roche Limited.",
        "label": "Genentech Incorporation And F Hoffman La Roche Limited [Member]",
        "terseLabel": "Genentech, Inc. and F. Hoffman-La Roche Ltd."
       }
      }
     },
     "localname": "GenentechIncorporationAndFHoffmanLaRocheLimitedMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four",
        "label": "Government Securities Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four [Member]",
        "terseLabel": "Government Securities Maturing 2023-2024"
       }
      }
     },
     "localname": "GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Maturing Two Thousand Twenty Two",
        "label": "Government Securities Maturing Two Thousand Twenty Two [Member]",
        "terseLabel": "Government Securities Maturing 2022"
       }
      }
     },
     "localname": "GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Maturing Two Thousand Twenty Two Through Two Thousand Twenty Three",
        "label": "Government Securities Maturing Two Thousand Twenty Two Through Two Thousand Twenty Three [Member]",
        "terseLabel": "Government Securities Maturing 2022-2023"
       }
      }
     },
     "localname": "GovernmentSecuritiesMaturingTwoThousandTwentyTwoThroughTwoThousandTwentyThreeMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Statement And Statement Of Comprehensive Income",
        "label": "Income Statement And Statement Of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAndStatementOfComprehensiveIncomeAbstract",
     "nsuri": "http://www.arvinas.com/20220331",
     "xbrltype": "stringItemType"
    },
    "arvn_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.",
        "label": "Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock",
        "terseLabel": "Common stock reserved for issuance represented as percentage on outstanding common stock"
       }
      }
     },
     "localname": "IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_LongTermDebtMaturityYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, Year Six",
        "label": "Long-Term Debt, Maturity, Year Six",
        "terseLabel": "2028"
       }
      }
     },
     "localname": "LongTermDebtMaturityYearSix",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_MaximumAggregateOfferingPriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate offering price of common stock.",
        "label": "Maximum Aggregate Offering Price Of Common Stock",
        "terseLabel": "Common stock aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPriceOfCommonStock",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_NumberOfMaximumDesignatedTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of maximum designated targets.",
        "label": "Number Of Maximum Designated Targets",
        "terseLabel": "Number of designated targets"
       }
      }
     },
     "localname": "NumberOfMaximumDesignatedTargets",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arvn_OerthBioLimitedLiabilityCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oerth Bio LLC.",
        "label": "Oerth Bio Limited Liability Corporation [Member]",
        "terseLabel": "Oerth"
       }
      }
     },
     "localname": "OerthBioLimitedLiabilityCorporationMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_OptionPaymentsToLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option payments to license agreement.",
        "label": "Option Payments To License Agreement [Member]",
        "terseLabel": "Option Payments To License Agreement"
       }
      }
     },
     "localname": "OptionPaymentsToLicenseAgreementMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_PercentageOfIncrementalBorrowingForLeasePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of incremental borrowing for lease payments.",
        "label": "Percentage Of Incremental Borrowing For Lease Payments",
        "terseLabel": "Percentage of incremental borrowing for lease payments"
       }
      }
     },
     "localname": "PercentageOfIncrementalBorrowingForLeasePayments",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_PercentageOfLiquidatedDamages": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of liquidated damages.",
        "label": "Percentage Of Liquidated Damages",
        "terseLabel": "Percentage of liquidated damages"
       }
      }
     },
     "localname": "PercentageOfLiquidatedDamages",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_PfizerIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer, Incorporation.",
        "label": "Pfizer Incorporation [Member]",
        "terseLabel": "Pfizer, Inc."
       }
      }
     },
     "localname": "PfizerIncorporationMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_PiperSandlerAndCantorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Piper sandler and cantor.",
        "label": "Piper Sandler And Cantor [Member]",
        "terseLabel": "Piper Sandler and Cantor"
       }
      }
     },
     "localname": "PiperSandlerAndCantorMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ProceedsFromMaturitiesOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from maturities of marketable securities.",
        "label": "Proceeds From Maturities Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesOfMarketableSecurities",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_RegulatoryAndSalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory and sales-based milestones.",
        "label": "Regulatory And Sales Based Milestones [Member]",
        "terseLabel": "Regulatory and Sales-Based Milestones"
       }
      }
     },
     "localname": "RegulatoryAndSalesBasedMilestonesMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_RegulatoryMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payments.",
        "label": "Regulatory Milestone Payments [Member]",
        "terseLabel": "Regulatory Milestone Related to Marketing Approvals"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaboration And License Agreements",
        "label": "Research Collaboration And License Agreements [Abstract]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.arvinas.com/20220331",
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreements.",
        "label": "Research Collaboration And License Agreements [Line Items]",
        "terseLabel": "Research Collaboration And License Agreements [Line Items]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsLineItems",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreements.",
        "label": "Research Collaboration And License Agreements [Table]",
        "terseLabel": "Research Collaboration And License Agreements [Table]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsTable",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchFundingPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research funding payments.",
        "label": "Research Funding Payments [Member]",
        "terseLabel": "Research Funding Payments"
       }
      }
     },
     "localname": "ResearchFundingPaymentsMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SalesBasedMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestone payments.",
        "label": "Sales Based Milestone Payments [Member]",
        "terseLabel": "Sales Based Milestone Payments"
       }
      }
     },
     "localname": "SalesBasedMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestones.",
        "label": "Sales Based Milestones [Member]",
        "terseLabel": "Sales-Based Milestones"
       }
      }
     },
     "localname": "SalesBasedMilestonesMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental cash flow information related to leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, restricted shares expected to vest, exercisable number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Restricted Shares Expected To Vest Exercisable Number",
        "terseLabel": "Restricted shares expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesExpectedToVestExercisableNumber",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award restricted stock units vested and expected to vest exercisable number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Vested And Expected To Vest Exercisable Number",
        "terseLabel": "Restricted stock units vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock incentive plan.",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SupplementalNonCashInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental non-cash information related to leases.",
        "label": "Supplemental Non Cash Information Related To Leases [Abstract]",
        "terseLabel": "Supplemental non-cash information:"
       }
      }
     },
     "localname": "SupplementalNonCashInformationRelatedToLeasesAbstract",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_TwoThousandAndEighteenAssistanceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and eighteen assistance agreement.",
        "label": "Two Thousand And Eighteen Assistance Agreement [Member]",
        "terseLabel": "2018 Assistance Agreement"
       }
      }
     },
     "localname": "TwoThousandAndEighteenAssistanceAgreementMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_TwoThousandAndFourteenAssistanceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen assistance agreement.",
        "label": "Two Thousand And Fourteen Assistance Agreement [Member]",
        "terseLabel": "2014 Assistance Agreement"
       }
      }
     },
     "localname": "TwoThousandAndFourteenAssistanceAgreementMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_TwoThousandEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock incentive plan.",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Plan",
        "verboseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "nsuri": "http://www.arvinas.com/20220331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r43",
      "r45",
      "r88",
      "r89",
      "r183",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r182",
      "r213",
      "r240",
      "r242",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r399",
      "r401",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r182",
      "r213",
      "r240",
      "r242",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r399",
      "r401",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r182",
      "r213",
      "r231",
      "r240",
      "r242",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r399",
      "r401",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r182",
      "r213",
      "r231",
      "r240",
      "r242",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r399",
      "r401",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r44",
      "r45",
      "r88",
      "r89",
      "r183",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r100",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r100",
      "r105",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r227",
      "r230",
      "r400",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r227",
      "r230",
      "r400",
      "r423",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r100",
      "r105",
      "r166",
      "r241",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r141",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONNECTICUT",
        "terseLabel": "State of Connecticut"
       }
      }
     },
     "localname": "CT",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r354"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r18",
      "r142",
      "r143"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net accretion of bond discounts/premiums"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r14",
      "r372",
      "r387"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/AccruedExpensesDetails",
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r35"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees and other"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r162"
     ],
     "calculation": {
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r48",
      "r49",
      "r50",
      "r389",
      "r406",
      "r407"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r56",
      "r57",
      "r58",
      "r92",
      "r93",
      "r94",
      "r311",
      "r402",
      "r403",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r278",
      "r354"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r275",
      "r276",
      "r277",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r243",
      "r245",
      "r281",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r245",
      "r271",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per common share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r85",
      "r125",
      "r129",
      "r135",
      "r155",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r306",
      "r312",
      "r327",
      "r352",
      "r354",
      "r370",
      "r386"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r42",
      "r85",
      "r155",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r306",
      "r312",
      "r327",
      "r352",
      "r354"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r147",
      "r158"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r145",
      "r148",
      "r158",
      "r375"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r246",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r91",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, equipment and leasehold improvements unpaid at period end"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of collaboration contract asset"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r27",
      "r77"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r71",
      "r77",
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r328"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r300",
      "r301",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Research Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r39",
      "r165",
      "r376",
      "r393"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r92",
      "r93",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r354"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 53.1 and 53.0 shares issued and outstanding as of March\u00a031, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r52",
      "r54",
      "r55",
      "r62",
      "r379",
      "r396"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Contract Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r221",
      "r223",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract revenue receivable if milestones achieved or options for all targets exercised"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r221",
      "r222",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r221",
      "r222",
      "r228"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r221",
      "r222",
      "r228"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from balances held at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r196",
      "r203",
      "r204",
      "r206",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r84",
      "r90",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r208",
      "r209",
      "r210",
      "r211",
      "r337",
      "r371",
      "r373",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r179",
      "r208",
      "r209",
      "r336",
      "r337",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r37",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument bearing interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38",
      "r84",
      "r90",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r208",
      "r209",
      "r210",
      "r211",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r38",
      "r84",
      "r90",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r205",
      "r208",
      "r209",
      "r210",
      "r211",
      "r216",
      "r217",
      "r218",
      "r219",
      "r335",
      "r336",
      "r337",
      "r338",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r75",
      "r160"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r63",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r106",
      "r108",
      "r110",
      "r111",
      "r112",
      "r116",
      "r117",
      "r317",
      "r318",
      "r380",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, basic (in dollars per share)",
        "verboseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r63",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r108",
      "r110",
      "r111",
      "r112",
      "r116",
      "r117",
      "r317",
      "r318",
      "r380",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r86",
      "r286",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r286",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Effect of equity compensation valuation allowance recorded against net deferred tax assets, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation expense not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense not yet recognized, period of recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "2018 ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r56",
      "r57",
      "r58",
      "r92",
      "r93",
      "r94",
      "r96",
      "r102",
      "r104",
      "r119",
      "r157",
      "r215",
      "r220",
      "r275",
      "r276",
      "r277",
      "r290",
      "r291",
      "r316",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r402",
      "r403",
      "r404",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r1",
      "r85",
      "r155",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r1",
      "r85",
      "r155",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "auth_ref": [
      "r1",
      "r85",
      "r155",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest in joint venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r28",
      "r126",
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r194",
      "r208",
      "r209",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r320",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r319",
      "r320",
      "r322",
      "r323",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Marketable Securities and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r194",
      "r208",
      "r209",
      "r232",
      "r233",
      "r238",
      "r239",
      "r320",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r194",
      "r208",
      "r209",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r58",
      "r64"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r60",
      "r75",
      "r123",
      "r152",
      "r377",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Loss from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Condensed Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r287",
      "r288",
      "r289",
      "r292",
      "r295",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r103",
      "r104",
      "r124",
      "r285",
      "r293",
      "r296",
      "r398"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r74",
      "r367"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Lease for laboratory and office space"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r347",
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Base rent"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Right-of-Use Assets and Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r85",
      "r130",
      "r155",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r307",
      "r312",
      "r313",
      "r327",
      "r352",
      "r353"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r85",
      "r155",
      "r327",
      "r354",
      "r374",
      "r391"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r85",
      "r155",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r307",
      "r312",
      "r313",
      "r327",
      "r352",
      "r353",
      "r354"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r193",
      "r207",
      "r208",
      "r209",
      "r373",
      "r388"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r90",
      "r167",
      "r198"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r90",
      "r167",
      "r198"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r90",
      "r167",
      "r198"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r90",
      "r167",
      "r198"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r90",
      "r167",
      "r198"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r34"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r51",
      "r53",
      "r58",
      "r61",
      "r76",
      "r85",
      "r95",
      "r97",
      "r98",
      "r99",
      "r100",
      "r103",
      "r104",
      "r109",
      "r125",
      "r128",
      "r131",
      "r134",
      "r136",
      "r155",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r318",
      "r327",
      "r378",
      "r395"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Grant Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r125",
      "r128",
      "r131",
      "r134",
      "r136"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r343",
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r341",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r346",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r304",
      "r305",
      "r310"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized loss on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expenses)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and leasehold improvements"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r246",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the date of the latest financial statement presented of securities which are owned but transferred to serve as collateral for letter of credit arrangements, and for which the transferee does not have the right by contract or custom to sell or re-pledge them to an unrelated party.",
        "label": "Pledged Financial Instruments, Not Separately Reported, Securities for Letter of Credit Facilities",
        "terseLabel": "Letter of credit for collateralized by certificate of deposit"
       }
      }
     },
     "localname": "PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Upfront non-refundable payment and certain additional payments received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r274"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r51",
      "r53",
      "r58",
      "r70",
      "r85",
      "r95",
      "r103",
      "r104",
      "r125",
      "r128",
      "r131",
      "r134",
      "r136",
      "r155",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r304",
      "r308",
      "r309",
      "r314",
      "r315",
      "r318",
      "r327",
      "r382"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r164",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Equipment and Leasehold Improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r161"
     ],
     "calculation": {
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, equipment and leasehold improvements, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r163",
      "r354",
      "r383",
      "r392"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and leasehold improvements, net",
        "totalLabel": "Property, equipment and leasehold improvements, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Equipment and Leasehold Improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r284",
      "r368",
      "r438"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r3",
      "r10",
      "r81"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r220",
      "r278",
      "r354",
      "r390",
      "r405",
      "r407"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r92",
      "r93",
      "r94",
      "r96",
      "r102",
      "r104",
      "r157",
      "r275",
      "r276",
      "r277",
      "r290",
      "r291",
      "r316",
      "r402",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "terseLabel": "Transaction Price Allocated to Performance Obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r59",
      "r85",
      "r121",
      "r122",
      "r127",
      "r132",
      "r133",
      "r137",
      "r138",
      "r140",
      "r155",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r327",
      "r382"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r345",
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Components of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Securities Excluded From Computation of Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r1",
      "r85",
      "r154",
      "r155",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule Of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Minimum Future Payments on Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r246",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r251",
      "r261",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Share-based award, vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Incentive units authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock, shares remained available for purchase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable, ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period",
        "terseLabel": "Annual increase in reserved shares of common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r253",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Stock options vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Annual increase in reserved shares as percentage of outstanding common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r244",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r268",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r82",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Accounting Pronouncements and Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r41",
      "r56",
      "r57",
      "r58",
      "r92",
      "r93",
      "r94",
      "r96",
      "r102",
      "r104",
      "r119",
      "r157",
      "r215",
      "r220",
      "r275",
      "r276",
      "r277",
      "r290",
      "r291",
      "r316",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r402",
      "r403",
      "r404",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r119",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r16",
      "r17",
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued and sold (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r16",
      "r17",
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r215",
      "r220",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Proceeds from exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r215",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r215",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r85",
      "r144",
      "r155",
      "r327",
      "r354"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r107",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r106",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r439": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r440": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r441": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r442": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r443": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r444": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001655759-22-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001655759-22-000016-xbrl.zip
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MM9A%@5H(T 1?0HH1(^(0]9*:T/"[@R^QW 7.AX"1FG'_7AJ%-J!L6/ 2_K*
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MI-".9,8D=?MB2+,=^N#$!;]NBN3*]1:$/@XI%Q0XR,QJ!AZR#0R,(Q$)ICZ
MB?1BZ+/J?9Y<*=/Z8'*_V7EKCO*^:2T(F<!<#3ZA&C<<S%*P"&*0* 9O%29
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MR3HO(\;9A$LBXECDPE<L( 4L21 MHG,<J-*LNE<K).-/@"6MB@6IE+=MM(J
M-GX;VH\NSXU;A)ZZ?-=X AMNY;RNU<X;;KG?!WOP1:,=;Q<UMF*^G"6AX7D1
MFIUVY^)173MUYC^M=Z?]KSPX3(.)2'+.$2>!(<NY1%HQD3R6V 2ZMH%G])&?
M^[!>4<*]*M+ZJ/;&6D87**.3C#HDRKTE$J4D<FU"39'1T2//8J""6D5@?396
M(43B"9"8E8M[W\YIY+'7OS-[>;JAM MWK@[G_ (,-N/2].!<"23<V9MN>:,,
MK(G$"1D?$^(!.V04X"'A*F"!O4\NK&V0A;EA5M2'^@1E=.&<I9;11<GH1(U1
M%A.S,/_(:PHJ!34:6>(2T!6L5-3$"E94BD7EC-9T98D'O"J??+(^YD'\W9@-
M=4$>9G+!VOX4CYR%T\):0U[,F3-=OE](*[PF.;.*YS0"^&&)$DAK17P0"6@"
MSKQPVHQU.Q7Y9G*P0E:N9R78"^>2M6 O3+ GR"076AL<""(XMU%R+B*7"$/1
M$VR"CLXRF\GDG9LH/:)@/P$VM"J^9-#O2LOGAHNITXU#KW+?_JHS$I;'Y7<>
MC+/9[W=;[J24E][KO+/=V*X5]/DP=6>,+'TBS;W-KT"5,)9!(YP,*.A..02+
M![_EEE7.I<"C6-L0>D8N^LV=?H\>QUPG*:Q,%%XM[XN5]].+\JXHU9P$CR@/
MP*$L#EDY8HAZ)H*/)*181>3=)>KVT>7]";"HE0N0VA[1IV%>9QT7=>^NQ3SE
M>_;70,/\*[9C:M4@.1](OI\B18PIIY+S2">3$"P\03HR!XHFIXG&9 SS )(S
MO!9U(-1RB>?C.A4OD<[QIH:I]2L&=!:[G5IJYY7:"6ICK# L6HUD8AZHC<+(
M*HT1I4PI)0+0'K>V47HZTS_K\*C:$#1I"+H#OYW73KX<E.TN9<BO>N(E/ B6
MPY@%.ZU.+EN [:KR!R2,@Z(< ^#3@+BC&EGK+$K):&T8)R07))=LG2]4EWU$
M)]_BNB?4@/6$ .O^K'$U8"W&^%8!EK4!9C\91+"3B#- +:U20 %.'"=4$,;B
M>S"^U<[+IQ?*-7)>YD:1(*!'@!"E7^2+AK.]EJ\JV[=R7^YP![_WC-;M3^ZH
MF/^I5^VX>!>['_/>6"S/I9>>&J]MMPV3U1O>=ZO:AZ/S ]?GQYQVR>K\T"8D
M(K)=P_A,>+U%)@38R"JX@+F6.E?X7^:=\%?&IGH?W'$?.&J4L<0@XW $'A$T
M,D83%(.0G-,H+!8E\V6:1RRTSL8U./G(]NSZF*N/N05H1S6X/909OP(W8P)+
MQ%KDHP4ER0>&-"<6D2BQ"@$3(]*M#KD'VP<UW5G,3D@*PS&G R(YAI^'2)"1
MH#U;3"4A23 K<8[WU=/VO=4]YIZ #GU'OT]H_1A>^\AV]UOML0BBX451OD(Y
M,\I56[G!??\E,H4 /(@2+N T^J?\$4/#PK/8_7A!$>\U.B?]7A_T<!CO55HY
M/.^= @^KB9NU2^_(<);DS+\4ZJMION\@F^$B;U9KW#PY<K&[FP8@7P"_MWN^
MTK61="[4_S2MY KK-5<6)4DTXH9AI+WV@/H)CFX93*1L63?%U&ZX2 GK+7&[
M+1&-L%J(A%*.PN)4$62%8(@!?2-*X"2E6ML0;(;=?+$EN!<!M:L7V5X?,/<:
M)U8?,/>,)A-J!764^,0)BBJG$0;,D#&8(D.%CD(ZS'+[Q>7<%/4!<R];@BEG
M*38,6<<$; EC@'-0B2+QF1\(K7$.^-7K\MD=,$NJC_Y1TH*&VE-6&<O&%TD'
MCB4LH[5<N*BI,%AIZG"*-)+PE8JU\2]-ZYF$EN.R7'ZT:M7<P_@.[7$OOAS^
M\N=P>*UV.57*E_X<7&RPE%EIG9CVLBS5VW_^;(7^P4N"\3HL8SZ+!HKVX,Z#
MM]?+6Q-[J7I/JG5 KTO?QNODTO>NNBSAZUA<_M6K+GOU>[ Z]S-8=M/+KLXF
MO]SH\HCQ"7K(J<IE7K;Z< M_$]-]R%+3[35:[0;<Y3 W.+F\<+>Y4XR&C[F@
MUX/,PI4&HC>=;J-_$!M[!]T8&SOP^8->XW4[Q/ OU_UC8R>WV&XP\N(&]<N?
M[W::'0#SJI-M?KT8&O!;B6ZRV1+WL0__Y%[EO48GP5M'Q]UX )]K_8B-_\R(
M\9ZE4LV7MKAL^RY/3C9B+/!);U+6_DE,&KEW05P* _VK-V_PFU>K$^1V8S(]
M>+ [9^2OFF__-L^]A(:8.DGC<M6Z^7&@6G][\[UY]HE\V=L_V_GGW]^_[+V'
M[[XYV(7O-O\!-7OO]6GSGP^MW;>?\$BU/MIAH.:>Y1KB.V>??X(Z#N.!__<.
M#CZ??6>[_\!]OKT&U7N?3:K6G^%[S;.=G[M;H,9_VV3-K?W3+UO[OW9!%=\%
M-3T_T\X>J-Y;(>U,=T*-5 D!2X*P=0IQQA(RTCLDF1/<62N=%7?.T;C%]K]O
M*^P$Q-XX-JE&L&>#8,\M:V-%$&RRXP)VD0CK54XPBXA'S)"3(B'),6>:N\ M
MO7/2QJ,CV,JQVJ4GKU7#*']! \UD]N4-=(PY%*_[^>C*;8<9AO64</(K5$#G
M4[L;X=YG,529/7!ZV!^V=9B-RBAUNJAGLTDZ^I-NJ]^Z98W"&:K?,KMFET,C
M**)\P994':^;P^6!U<F+\W&T-IOAVTFOG^U0<!;OICW[ZUVGFQ]@J8N:K<()
MW7PUI6.PH!4.95E9J!RZ#L> G#<ZVDBQL'9M@_ [-2Z;;3-Y3!WBN<O[/78"
MKN5]F>1]DI$SHH5D@B,=6,X0D#G]B5 $N&\,I])()DM<^#*+^\HQK*4GW*^F
MJ/9EJSU'K,63M+XL]/E7_!2Y/]8XXP 9'@[U"3#/"3#=J38JFE12#L7H".)&
M>S@+1$""ZD"C<-;8L+:AU#P5&A<I%(L]*JXS(M=P5L/9_9/B&LX6!F>3A#9R
M9AU7 AE8+\03U<A%YY 7"=BLPB1D..-D'D:[O'"VI,QW.J)T=G#H=.C*8K"
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M@QPA"45O DF66Z=R.0&\L(B?6MAK('ZF:S-/A+>R/DFF(B6<Z^1LB EK&W
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M-B+*J9SF,\(8*O]G 75]4//[;7H[OM2IP'4MZ+.>OU5^[_#\(#C'6+ :.5!
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MF#U0"V9/-EHQ',;P$0"SXP$'/G< I\\*:UCKGOX=3VRO4-&O\:3;@\#E>OY
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M&UZ#SW\&_:R2W4\?F[7++Q=U^KU9+QI]JZ*ZEP>/;.,J!(@J6? 4,0+7,$*
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M8W)#.<]MF;BMRON);-Y87#NN%''0:VKS4Q]."1Y$JH5&].)8N+HY&9W"ZX,
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MD2G7X2,_ZUU;@-*/798)J+V?\6,E"4P9I9#'DB,>DD...HLD3C8%90T+ 4P
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M:N:9-IVDJ%PJQ9R+*!Z(W&%>"N<I O4"NBUB13$#28MIR+*I,%!6H]0'64_
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M,)QJ<_DF6A+&BOA6;<]>:\9V&+M@S9:('C$5 (WX?-+EE$9IO($,(Y8BW*B
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MOWIKK:O0<1-AL3A-$O#CLDB-1FIN7BP3/B=O!NTLX';,M:+G5Z7F>$QW2@(
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MCJTWP[PDZWPOA-/"LT4O\B0MOZU4G?KD)LXG$2L P9270G](1[B +53J/B^
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M6#'_)ORD?R]:>0J<-C$ +IB'-5Q1KDO!TH>9((WB#7T6 C#\4"+@/E829S3
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MQQ&OQF1,61:]CXM_8H;]?#E?X/3JS[%]^6,VC6?@(D[=0!TC5EK,C2FEQ!E
M_2FO('*#;KT-'38$.*1@JQ9'6NBFG@F<33]^@'[R L+B$A:?%1-6  'M*9&<
M&N* *V*R3>C_:8@)VIB-M7B&%&A5,QV[CWPU%KPYAAYEGWY\#7X.Z\AI15
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MI-FAO"D31X4E)J#CEZ!\#'S_C8X#3,,J<Z6Z<EKWN)UC"ER"2&C;5 93FE2
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MTJ2&7JIQY3>,'69? ".2U1+_&HE!)4&U3"3ILO<DHVJ#M4",0C.G'<U)M&D
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M=V%2"#X@QMN^?7/,Y]]%$F0_/YX-B/CF=P^*MSGQXR$5?..K!T#;?1$Y@9,
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MXS&3LZ=>2F8J<> &E.V'&0.8:'4&P /T6R%%Y#/,4"9(O_EV@B[V=(G*"*_
MZDA2"I+(R#/Q$3A)+@3*:33"L"I6OQW/4S#] )JN,.!7G.&>D=-+IA4SQ-I8
M=OLL@C/6$Z9\-E1HRUB='*$[83T%-@RG]QK9'S'.3^;'):]SU>['$B@$!E0(
M(, L+H#.!>*M3L0PP[7S41I9YU"I-\0G098J]EB9/O$?KZ[I"F/J/Q^8L/T9
MIH"/.'K='"/1FK;+!?&3]'X<2P[QP6$+B[3ABP'Q;I*;]J3[X)LR9QY/'Y*P
M/<R#-T_8KJ" :PG;P4HJLZ96"",9=R%ZF9D"'@5.&L:.AH'PL"FE&.9V  >W
M +C8O,%13RU(28)02.2DRMYM4L10,(9FEH)6]U'@@<_>W(>>S%H?9_\:SXY>
MSZ<S')WMP70*LP\P&X$640>/$4/0.+-+3DD 1HG*V5D&ON0_57*G5Z/:WARY
M#3K<]+D'LL> [G>GAS?C%N(,!>^.,XK$_OAU,YU-\?=YVT+ZVGP,Q6G\>@1G
M0I2C#$F5!700<T9-:$9LRD <351!2CJ:U&M@/.3I3Y,HVS'&@,Y[!_B*4LX0
M=;Q&(3HWH?ME.K*2R^B\(31E5 F-J!P-0 +#I0*<8_EZ8<P*QO1]XA-F216E
M5_#@/[5-!$C3MZBJ"\Q-.QUI12&"$H0YZ8FT@B$FFG#J4\"4]);S.B'=2DA/
MDR[#6F+ 5.=."1>>WA^GJ)_)[$/)T,[S22H'( <GS7PR^XSH,+Y(?Z"OV7YJ
MX=NXF4_/U3-2*E)/%25,,)S[4 W$2J>)165%JYB54?>:5C;'\C09M M##9A3
MW<'_,"]Z_)A_]]_')_.3-S ='TY*'/O5MX=EGN2.N>Q4)+XT+I"&FI+J+\J,
MF:@)'+SJMSC=]Z0GS)%!E3Q@ZO)ZBE@>O>*RJ5*D!+1'@-(K4K8T2 [1&!Z\
M"IP.&_=M)4UAZYRHJ/9=)SA,VQGZ83CO07OJV]F/#_X$NM,X066DP!RA0C(B
M/9/$!F%)]II[$2#(U&LS$A]PR:W!WZZ[-*L0;#M]H;JEFP$U/F#\4_!\AM,Y
M2NTO27@=XG+GM0_(==(;>M&C-[SMICD,8\EF6V;8&6>TLLI&F8BE/A#)!"?!
M2TH48YYE*;B-O<X_'P-75F1 [) JZVA_Z&V53WG\/]"60Y7V=#F9+L]69&G!
M9300R!IG3NXS<5&63.)DE1;"&-5O2WKE([;GHU:T1S.X,H?>=_W5_X#VX!]+
M)!@=6:NC(XYF1,)X)D'K0!R^:X3AS%_O@['"K%>^]LF9\N%*&WJ$_@/*L2K$
MHRN\0H_G[7\U.9_XR7O_N8E'\'Y\4CH-G9V,2G Y(LVH19FEQ'C89D[1IS;&
M9&4@77<.5YCY08]_<G2H;X0*NZ)?\7,?\T';EOY412O=>D:C"BY0A[,0TT1F
M@3&6P44M6DXIC2PG6B?7Z58X3S6&&,X&-1)>+N!,4>P/S<1?O/,57TU][*K3
MECSN [=JQO2:@'>32SV J:\GPFS!3C62[-:$[6)2E$?$Z1A.CL%F8@4UZ"LI
MY2PWT>8ZC9?V@E;W9&3OGE7KF*?JJ>_YO'P&C!K0&11)(GDBA9/$*^>)X.C!
MX!(K0/?;/+WK*=M/J*MJGY6GNYLH=^B(Y3,<EO2_IOV!\G_QQS#]M?17^GV,
MKV;-!,XD#YXIYHTJ9\V)2,L,+LQ*$1:Z6CCI4N"]"-#S@4^8"S54/O1D<('Q
M'-8G_Z/3S1DZ)3&BCH$HA9.AU!8C;$1, !QZW\*+Y.R:A%CQJ&=!A2'4/*#[
MVJ&[@YO4.:FI=(3%7!9%QG%13(;P%%6I.6$FQ5[6?Y8SP$"*'3IUXRQ6>SOO
MBN*O,=%92T,"0;Q5N72IRL1[G1%9#MSPK&7/W:P['_.$K3Z<>H?.I7@#W^"X
M.>U<DA7SD*#..'1VB<TEZ\P921"6)4J47A/)1@QU^B6'WONL)TR!@14]=$;%
M+?/2-734YPQ:XWR$01&1H-!53>BT9HA92L95C/?63_1[U!-FP;!J'K#S6H=N
MT2WI#-#7YOI.W1)BM(X*BC)3D6CIXX*.238,<7IGF)<>8K^(L-_SGC =*BA\
MP/YHR_#UY*0TS_+'-QP6A<&I2^B6*E%Z:0EO21#.$.V%-#DS'9SKQ8/5SWC"
MMA](L0,V*>M.>8JHW>:7,1ICCNCPT0%7HY #"8XEPKF0(%),EO;J*-8O6^'L
ML4_UI.+ANAW0U3\'<58FW@/&\$E,%P"VGZ;T0!-<-^(&^ALZ^^@2'% ^.6""
M)"<5D5I*XHQ2)%,5/)64Y3Q<JF)U,]Z1032L%==1V\#66R97GVWX"!D%U8RD
M\D.JTC<N,DX4L&24UR&).)C]KCQZRYD$#U5^,X3F!MQ&+T#.>_E\P;7"M^.F
MXV5DC$.4FE J=$F.+QUM?20!>)))RM+09S!3W@KA*2^DF^M\P&V4#M 2QQ^3
MZ2G$<1Y#6N;"] $U^!*[$L[V%]P!3-74TO/ D_D=X"RCD@,C#!POQSF:V.Q$
MN86)&<4C)#;@;+!=X]^Q3&_-]FNHMY+-WS8M1#\]"]B9+^&ZUR1YC@%<I(%8
M*22N:E1*<)*IZWME QC\*H;M+ND#&><6<V^@V94K_4YZT5S:._C4XA\/CCMJ
M09HUGZ#M.J-,(GP,Q^/#[CNFV^A3\V!06^QA,XSBKO6W<4A"G&B$B%%(*I3S
MP7@&A@5OA5"I?W^;!\/;M,?>-YB4VSS**%OT ;_YK-^^XV@L-9OC$_S(Q_P%
MWYWF!=CWY_6 @F4=$W,DQY*$8ETD7I::3IUI#M('KNJTCQE.ALT[%O9 ,J*4
M)U,T(RS#,"-WI072$<@9(A/.()MVIZCM[Y7NB(,WFR .;;PJ/3$WU-6BT3\;
M6<6R4(B>:HN:*G6\E@5!.%?E.("Z:.OT8!]*@A>>;I,"%3*/-Y9C&?U3HXU(
M:G$CGW14DZ"=)('EP "L9K'.=1##X-_6)01/A;SK&WW7/0$&$QT#X7;V!GW"
M17_OE*T3PA,G8R+2@R(N!XZC-RFN@_;Z>OKDOO#^BAR[NE9A%T0<>BP\G! K
MI_-'%=..V%Y&M2/V&.+:Z\J[%MDFB,Z[$$4 +AEDRZP2(1NI689D5?W(%@&^
MQ+8OL>U+;/L2V[[$MB\\?8EM7V+;)T[>7<>V0SK_O_OV3_3C4*"+&T?1.WSK
MQVUWK^[OX*?S13/KZ9?YR8EO?S3YX!LZ?N7?H-Y*COMM7[+!>59U3)N[_=M5
MVS6?/_/  XM"N$ ET]0[R[CVQG!T^D-VH^KH-IMUSW$L&EUW&4,^C(^[1RRQ
MI8^3S^6QY=+;16)V>_;KKWXZOM3?DBOK--6).$5Q,!K@.!48153V*G&A@H8Z
M/O^@8FS<'^+,>F\7UGL#87;I#N&3IIV5>X9+._KNP:.<#;>4.^)X*+7HBA.K
M*! 6+-*(&N9MG98UZR+=OI.U.W[>:"M1TZH50H-[\%[<0?2/MIE.+ZZ_+O=>
M_UHF'BBW6GL17?34D> \+NG96V*#IL2HX"1++NA^"51#4[,?_!>^;M/^-5KM
M/%"(<G'[A1"),R\M.%2>0"%LR56GS!#N,H? 4\ZVSK7@@\!_(?$V[5^C'=DU
M(2[[<)?%&5'FDB[5AB885ZK/(JX=V1$-8)(58$.46^'I*H0O5!S8B@.6F VI
ML454[:54W&1.P)>J>"8%\=1:$AECT4H(E^Y-WSMO?JN[*?O#TMU8?U_R!<ZE
M__7'^<O_&D-;#MU^O"]](+ICWZ""Y(QZHA0.3FF](LYF31RE -9X)7FJ2^P[
M\>WJ?']'W%G%X.%L6,$QO77_YB;>92I^'[!5&XRN!7<W[45KV'T5M:H9;>=,
MTR%)STH=KM0<G0\1B(OHZD;&3? 97+!UCC_V@&'W=!K=.X*M8ZN:Q'HW.9W/
MIIT&^'E'-!:Y4I$HQ@.Z((H3%P2ZM)YF:U)TBM6)F.\ M</@8WASKB+.AK:H
ML(]X:=A<4L/;%OY[#I/XHQLS3G&M J*#G(!(7SK0*R.(2M:(2*EQLE?5W28.
MU2IP+][4D-:KL#URVR@[![@<6WT@;MV!N@9RYV[3, ;NL:0-89TM>4HWH-(<
M6 R:Z'*QL\S ,,HV&<U-F8HAN\1Z=6IY/ 3J[Q7MCC]K&&5;'O;YO+Q<A9/U
MS <%A!LCB4Q1D>!3)$D[IH1,5J3*FV%WH-L/UV@CL_;QI#>Q207/Z-WD&TQG
M77<Z_!>+KDC,*M Y$&JZ;*3HB+4Q$ -.:LF4RUI48<E-+,_;[]G0-A7VY:\B
M>NUG<-BTX_^Y?(M:'X15O9S[,>[&R=G4FG>28S!35%B:>B#ESI>+@REQTE$B
MI46D.# ( DPVQ^ \U-G,WA59[G%HML^5=2PP_ 4RB]O:X-=FDJ:_^]F\3*)?
M_VJ^'C7SDFCX]2^$_J-[HVWFAT<W_X2D..\)!\+*3!41QI>4)6I(H,F1:*T%
MFB*G^5HBVLJ^L@/"VKYW,[31F[VPV-#7V/25I,!=)<O;9MZ>-6''<8A*Y83E
MB,N]-("C5#!24HR4-CY1WZ_;_;"XGB?[*MAL\(M#FV_03KHN9^?)%YL.)VJH
M%$9HXI@0):+0Q(/1A.(XXCX*H-GTXF %<$^+B+NVWM#W]JPG3\_A%9U/2H(C
MFJ**I<?AY3'F)0IL9I:J"*D&'9_CQ+AS^PU]L5!_/^-L+C?96X<.LA!4%["2
M> V1:/!,!*]$TOUNFUOWR4^+2%7U/O0E1.O.PF?*83;A=(HJB3(0"0&(LSCE
M"JZL5A88,Z'*,OD4";,%&ZR\LVC(\L5/;7,*[>S';_\]'W>W+97.%N"G<-0<
MIW<GIRW*N2ASBT>0YL?0Y-[_9(,*QFW VKR(<>O*N]Z5,QH3$I?&B"B55-9F
MF:CA65(M -1H&P WVRL[>]RG8S^9'4S2^6/?GV?6NF1Q<. $F[JVYPD\"4H9
MDJU,B5*58JRS/7\_MDUW"E<^H:N,&#EE&;C$290^E#[]@CB=%6$.O#)2,%FI
M]=7=N+8_DP_,DNO;A0.:H49-X$7!S!LX;2&.NQ4,7Q]#I_9)6A8R^D7OH17"
MC*BD."N )!3*)=W@#/$J9L)PUF!*!&9SI8JJ@21X<L3;B6DKG'BL!/8!9N5$
MT$@K@ 2'8;U,/..KE$E,V: OA Z8VO(LAJB>')4&,T&%9+$S[^)C7HERV1)$
M@**6 U%6>)QIRYD/2$Z8+LZA=LDK7X4J?1%NJS:I,EFJ&&1?ZHE6BO3KC_/#
M1=16E-QS8FDY7$PX*JSK+MD()C,<&T[5R7WM 6Y7.2!U2-%WFGJ@<;:YF!6
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M&CPWB60% OTY_.&"\81GQ@P+ L>#JS)YK(3TO!V>82Q5HV[_ DYI@OHQ7QI
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M[%,[CC"R&A* T$2SC)))*XBC,A-ALI,XX)6#'27C/%BF%_[OAAX5BF"&2T%
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MRB;$',3**_W!%6FRR[?+C^"G\)__]O\#4$L#!!0    ( +>$I53ZS>C+6KD
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M<IF>E49 3;: U#HI?[162OT#+!\%>-JHIAW7N58.S#?:&3JMCBQZFLO'M]/
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M_RV_?\Q7.C7H_INZXO5>F52H_^2KA\>]/WY0[WV3*T73,$ 1DE"$L5I2IIA
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MJ8[8X(=L ;AN:%.4X%D4H-3Z_FA9%F0D\YM1X02-.C"U5NI JO4!79U!1VE
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MO=2G.-6+*!KYND8.@C@A A*22NX3+Z&>44'R,^-,C0 VDH*-J!:U64X@>IH
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MK&L0:P*JRL'I>OH@>U+7O/3IR&-A(;/=,\>HCW0ZTB;K*"IOQ 8[-:!OMHM
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M$*^#'J-= */;<_L><HQ[OM\?J+TX@ L>U=,-UPDS.L-"<4E=ZW7FQ;$,O2B
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M#%CSK^-NM_I[13,P*QP"65_6-.*"G;S^+ )K:+S:!M=['=5*L ;AV%ZP?W'
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M$.51;@*\"!1I0F-A", M/Z-3[U.CAE9X0&OI 5\]/Z^68%U)#U9[\>\ ,PJ
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MX,\_K7*LU1N#F;9>:)ZA'&:,%Q I1"'.!8:*2+UK2E2,4^9"6'V=38VC=GY
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MZ'/29DD^+V'C.S&+,$%9+B)($#79J*6$),T*B%*%LX@E>8&M"GN[=3NUI>&
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M?)G/KO)WY/DP::0#:2SA-BA)-BT:T)+Y$EEV2<2#5;^]:C?UCS@->I 8!X;
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MOK;C"^,SN6^U32$/)*1<NXY1) E6(F<E%YYTFWSUXS0->WG6!@./ ^T0A8P
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MVC"]GU3\E?S>U13'Q]IJ\GTAT;Y8+G%UF_>K215!!1X9]^"\472N,?*L<@[
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M%%G#HG0@J&P#MC>]C0"$6SQLGAPK6WCP,4 *DJ+-4 0)JMZ)1*EM"(;YU*;
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MY<N15[&4D'( +HPAETV3*=6VC@XQ.<KH<^P6L>Q>CW6;C&$[U8S#8]E?+R,
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MNP4J2P7>QP+&YJ23B>C+;K?)GWG0V?>X.@2D@TN@%VL^S.[(789,4N1!)&'
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M(?5]*-RV&:IC42>G!5A9-\I$B602@P#NA93.<$/1V+GJVEF/N#D!SD^OD@>
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M83']#^:?IK,P2]-P]7I6YHN/FSJO39OXV?M7?]5Y.[B<<,65C#R!T36VLLI
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M0')AUJM\X:I:^>UNS=G[>^?_ U!+ P04    " "WA*54E<<BMG<(  #-*
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MW>9 *OI4)9*)DA..^2JAP_P$6N<DQ\>I5#,.K=.1\LQ&5V *L'IFZ@X>"_9
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M IO^G'_"UZ[*+2H17[8LNM !(#JSZUT>N5V7?_J+?N[*X=G_ %!+ P04
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M+]J]/RX[9*"'/KG\\NOY69OL%,OEFWJ[7#[MG9)/O<_GI%&J5$E/TD!QS45
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M'3!=#O/%N$!F%DKF_ZHRRBU<5C'F<8G>GOVM\ OGM%NZ8#P.SBS%YI2Y;.@
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MM\<<O3C,\YZ?SD]\]Y7\]!7%DF#7EFTM(CWC#'7G'EUQA#&[#P&?"E"L0%H
M?*",03^? .Y=GY$:H8X8L<*"EK?R(-D0JY^C8"@\6_V,:(:6?@1W82Y .K8P
M4Y<#R_9,Y3-S31!:P(02^!QR,M,)/@= 3J+M%PLS[<*! %7!4O9@(FHO>4Q4
M(#,"2\F8XG(X-_I<IC*_0$(QQC:)NV'>9,JI,);\Q4<+!5C<5%%//;#%:5<'
M]:]/FN9QF!]3]15);HL(*\ 1$AD_).VER40< UC!LOE9!&(0F6(60*$[0S_(
M#07; JTV.$],(D7[$U<!<D"WM*_DH&ABC^D #.H9F%UZA]>XEK20&,A$+$3
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MJT6?Q^2O0]IC3HFI9%;F"O$Q6.\V58I[DTU?4WKNZQ;P_U)R5!_@I6PA#O+
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M/U!+ 0(4 Q0    ( +>$I50HYH5 A!4  (*:   >              "  0
M  !A<G9I;F%S+69O<FUO9G)S=6%G<F5E;65N="YH=&U02P$"% ,4    " "W
MA*54%G@E TA: 0"3\ T $0              @ ' %0  87)V;BTR,#(R,#,S
M,2YH=&U02P$"% ,4    " "WA*54/^"<2GT0  #CIP  $0
M@ $W< $ 87)V;BTR,#(R,#,S,2YX<V102P$"% ,4    " "WA*54@\:PR:\6
M  !KUP  %0              @ 'C@ $ 87)V;BTR,#(R,#,S,5]C86PN>&UL
M4$L! A0#%     @ MX2E5(CQS$ ./   K*P" !4              ( !Q9<!
M &%R=FXM,C R,C S,S%?9&5F+GAM;%!+ 0(4 Q0    ( +>$I53ZS>C+6KD
M .C@!P 5              "  0;4 0!A<G9N+3(P,C(P,S,Q7VQA8BYX;6Q0
M2P$"% ,4    " "WA*54(])E]75I  !RV 0 %0              @ &3C0(
M87)V;BTR,#(R,#,S,5]P<F4N>&UL4$L! A0#%     @ MX2E5!+U$Y1P"
M&B@  !H              ( !._<" &%R=FXM,C R,C S,S%X,3!Q97@S,3$N
M:'1M4$L! A0#%     @ MX2E5)7'(K9W"   S2@  !H              ( !
MX_\" &%R=FXM,C R,C S,S%X,3!Q97@S,3(N:'1M4$L! A0#%     @ MX2E
M5']/57?J!   @A,  !H              ( !D@@# &%R=FXM,C R,C S,S%X
M,3!Q97@S,C$N:'1M4$L! A0#%     @ MX2E5 6DU@WE!   YQ(  !H
M         ( !M T# &%R=FXM,C R,C S,S%X,3!Q97@S,C(N:'1M4$L! A0#
M%     @ MX2E5%7!P:)Y"@  <5$  !X              ( !T1(# '!F:7IE
M<F%R=FEN87-A;65N9&UE;G1N;S)R+FAT;5!+!08     #  , $(#  "&'0,
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
